before	IN	O	O
using	VBG	O	O
this	DT	O	O
medication	NN	O	O
","	","	O	O
tell	VB	O	O
your	PRP$	O	O
doctor	NN	O	O
or	CC	O	O
pharmacist	NN	O	O
of	IN	O	O
all	DT	O	O
prescription	NN	O	O
and	CC	O	O
nonprescription	NN	O	O
products	NNS	O	O
you	PRP	O	O
may	MD	O	O
use	VB	O	O
","	","	O	O
especially	RB	O	O
of	IN	O	O
:	:	O	O
aminoglycosides	NNS	G	G
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
gentamicin	NN	D	D
","	","	O	O
amikacin	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
amphotericin	NN	O	D
b	NN	O	O
","	","	O	O
cyclosporine	NN	D	D
","	","	O	O
non-steroidal	JJ	O	O
anti-inflammatory	JJ	O	G
drugs	NNS	D	D
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
ibuprofen	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
tacrolimus	NN	D	D
","	","	O	O
vancomycin	NN	D	O
.	.	.	.

do	VB	O	O
not	RB	O	O
start	VB	O	O
or	CC	O	O
stop	VB	O	O
any	DT	O	O
medicine	NN	O	O
without	IN	O	O
doctor	NN	O	O
or	CC	O	O
pharmacist	NN	O	O
approval	NN	O	O
.	.	.	.

intravenous	JJ	O	O
adenocard	NN	B	O
-lrb-	-LRB-	O	O
adenosine	NN	D	D
-rrb-	-RRB-	O	O
has	VBZ	O	O
been	VBN	O	O
effectively	RB	O	O
administered	VBN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
other	JJ	O	O
cardioactive	JJ	O	O
drugs	NNS	D	D
","	","	O	O
such	JJ	O	O
as	IN	O	O
quinidine	NN	D	D
","	","	O	O
beta-adrenergic	JJ	O	O
blocking	VBG	O	O
agents	NNS	O	O
","	","	O	O
calcium	NN	D	D
channel	NN	O	O
blocking	VBG	O	O
agents	NNS	O	O
","	","	O	O
and	CC	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
without	IN	O	O
any	DT	O	O
change	NN	O	O
in	IN	O	O
the	DT	O	O
adverse	JJ	O	O
reaction	NN	O	O
profile	NN	O	O
.	.	.	.

digoxin	NN	D	D
and	CC	O	O
verapamil	NN	D	D
use	NN	O	O
may	MD	O	O
be	VB	O	O
rarely	RB	O	O
associated	VBN	O	O
with	IN	O	O
ventricular	JJ	O	O
fibrillation	NN	O	O
when	WRB	O	O
combined	VBN	O	O
with	IN	O	O
adenocard	NNP	B	B
.	.	.	.

because	IN	O	O
of	IN	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
additive	JJ	O	O
or	CC	O	O
synergistic	JJ	O	O
depressant	NN	O	O
effects	NNS	O	O
on	IN	O	O
the	DT	O	O
sa	NNP	O	O
and	CC	O	O
av	NNP	O	O
nodes	NNS	O	O
","	","	O	O
however	RB	O	O
","	","	O	O
adenocard	NNP	B	B
should	MD	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
caution	NN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
these	DT	O	O
agents	NNS	O	O
.	.	.	.

the	DT	O	O
use	NN	O	O
of	IN	O	O
adenocard	NNP	B	B
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
digitalis	NN	G	G
may	MD	O	O
be	VB	O	O
rarely	RB	O	O
associated	VBN	O	O
with	IN	O	O
ventricular	JJ	O	O
fibrillation	NN	O	O
.	.	.	.

the	DT	O	O
effects	NNS	O	O
of	IN	O	O
adenosine	NN	D	D
are	VBP	O	O
antagonized	VBN	O	O
by	IN	O	O
methylxanthines	NNS	G	G
such	JJ	O	O
as	IN	O	O
caffeine	NN	D	D
and	CC	O	O
theophylline	NN	D	D
.	.	.	.

in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
these	DT	O	O
methylxanthines	NNS	G	O
","	","	O	O
larger	JJR	O	O
doses	NNS	O	O
of	IN	O	O
adenosine	NN	D	D
may	MD	O	O
be	VB	O	O
required	VBN	O	O
or	CC	O	O
adenosine	NN	D	D
may	MD	O	O
not	RB	O	O
be	VB	O	O
effective	JJ	O	O
.	.	.	.

adenosine	NN	D	O
effects	NNS	O	O
are	VBP	O	O
potentiated	VBN	O	O
by	IN	O	O
dipyridamole	NN	D	D
.	.	.	.

thus	RB	O	O
","	","	O	O
smaller	JJR	O	O
doses	NNS	O	O
of	IN	O	O
adenosine	NN	D	D
may	MD	O	O
be	VB	O	O
effective	JJ	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
dipyridamole	NN	D	D
.	.	.	.

carbamazepine	NNP	D	D
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
increase	VB	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
heart	NN	O	O
block	NN	O	O
produced	VBN	O	O
by	IN	O	O
other	JJ	O	O
agents	NNS	O	O
.	.	.	.

as	IN	O	O
the	DT	O	O
primary	JJ	O	O
effect	NN	O	O
of	IN	O	O
adenosine	NN	D	D
is	VBZ	O	O
to	TO	O	O
decrease	VB	O	O
conduction	NN	O	O
through	IN	O	O
the	DT	O	O
a-v	NN	O	O
node	NN	O	O
","	","	O	O
higher	JJR	O	O
degrees	NNS	O	O
of	IN	O	O
heart	NN	O	O
block	NN	O	O
may	MD	O	O
be	VB	O	O
produced	VBN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
carbamazepine	NN	D	D
.	.	.	.

co-administration	NN	O	O
with	IN	O	O
antifungal	JJ	O	G
agents	NNS	O	O
such	JJ	O	O
as	IN	O	O
ketoconazole	NN	D	D
or	CC	O	O
itraconazole	NN	D	D
is	VBZ	O	O
not	RB	O	O
recommended	VBN	O	O
.	.	.	.

nafazodone	NNP	D	D
","	","	O	O
fluvoxamine	NN	D	D
","	","	O	O
cimetidine	NN	D	D
-lrb-	-LRB-	O	O
consider	VB	O	O
xanax	NNP	B	O
dose	NN	O	O
reduction	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

fluoxetine	NNP	D	D
","	","	O	O
ocs	NNP	G	O
","	","	O	O
sertraline	NN	D	D
","	","	O	O
diltiazem	NN	D	D
","	","	O	O
macrolide	NN	O	O
antibiotics	NNS	G	G
-lrb-	-LRB-	O	O
exercise	NN	O	O
caution	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

no	DT	O	O
drug	NN	D	O
interaction	NN	O	O
studies	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
.	.	.	.

no	DT	O	O
in	FW	O	O
vitro	FW	O	O
metabolism	NN	O	O
studies	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
.	.	.	.

dexamethasone	NN	D	D
:	:	O	O
steady-state	JJ	O	O
trough	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
albendazole	NN	D	O
sulfoxide	NN	O	O
were	VBD	O	O
about	IN	O	O
56	CD	O	O
%	NN	O	O
higher	JJR	O	O
when	WRB	O	O
8	CD	O	O
mg	NN	O	O
dexamethasone	NN	D	D
was	VBD	O	O
coadministered	VBN	O	O
with	IN	O	O
each	DT	O	O
dose	NN	O	O
of	IN	O	O
albendazole	NN	D	D
-lrb-	-LRB-	O	O
15	CD	O	O
mg/kg/day	NN	O	O
-rrb-	-RRB-	O	O
in	IN	O	O
eight	CD	O	O
neurocysticercosis	NN	O	O
patients	NNS	O	O
.	.	.	.

praziquantel	NNP	D	D
:	:	O	O
in	IN	O	O
the	DT	O	O
fed	NN	O	O
state	NN	O	O
","	","	O	O
praziquantel	NN	D	D
-lrb-	-LRB-	O	O
40	CD	O	O
mg/kg	NN	O	O
-rrb-	-RRB-	O	O
increased	VBD	O	O
mean	JJ	O	O
maximum	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
and	CC	O	O
area	NN	O	O
under	IN	O	O
the	DT	O	O
curve	NN	O	O
of	IN	O	O
albendazole	NN	D	O
sulfoxide	NN	O	O
by	IN	O	O
about	IN	O	O
50	CD	O	O
%	NN	O	O
in	IN	O	O
healthy	JJ	O	O
subjects	NNS	O	O
-lrb-	-LRB-	O	O
n	NN	O	O
=	JJ	O	O
10	CD	O	O
-rrb-	-RRB-	O	O
compared	VBN	O	O
with	IN	O	O
a	DT	O	O
separate	JJ	O	O
group	NN	O	O
of	IN	O	O
subjects	NNS	O	O
-lrb-	-LRB-	O	O
n	NN	O	O
=	JJ	O	O
6	CD	O	O
-rrb-	-RRB-	O	O
given	VBN	O	O
albendazole	NN	D	D
alone	RB	O	O
.	.	.	.

mean	NN	O	O
t	NN	O	O
max	NN	O	O
and	CC	O	O
mean	VB	O	O
plasma	NN	O	O
elimination	NN	O	O
half-life	NN	O	O
of	IN	O	O
albendazole	NN	D	D
sulfoxide	NN	O	O
were	VBD	O	O
unchanged	JJ	O	O
.	.	.	.

the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
praziquantel	NN	D	D
were	VBD	O	O
unchanged	JJ	O	O
following	VBG	O	O
coadministration	NN	O	O
with	IN	O	O
albendazole	NN	D	D
-lrb-	-LRB-	O	O
400	CD	O	O
mg	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

cimetidine	NNP	D	D
:	:	O	O
albendazole	NNP	O	O
sulfoxide	NN	O	O
concentrations	NNS	O	O
in	IN	O	O
bile	NN	O	O
and	CC	O	O
cystic	JJ	O	O
fluid	NN	O	O
were	VBD	O	O
increased	VBN	O	O
-lrb-	-LRB-	O	O
about	IN	O	O
2-fold	JJ	O	O
-rrb-	-RRB-	O	O
in	IN	O	O
hydatid	NN	O	O
cyst	NN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
cimetidine	NN	D	D
-lrb-	-LRB-	O	O
10	CD	O	O
mg/kg/day	NN	O	O
-rrb-	-RRB-	O	O
-lrb-	-LRB-	O	O
n	NN	O	O
=	JJ	O	O
7	CD	O	O
-rrb-	-RRB-	O	O
compared	VBN	O	O
with	IN	O	O
albendazole	NN	D	D
-lrb-	-LRB-	O	O
20	CD	O	O
mg/kg/day	NN	O	O
-rrb-	-RRB-	O	O
alone	RB	O	O
-lrb-	-LRB-	O	O
n	NN	O	O
=	JJ	O	O
12	CD	O	O
-rrb-	-RRB-	O	O
.	.	.	.

albendazole	NNP	O	O
sulfoxide	NN	O	O
plasma	NN	O	O
concentrations	NNS	O	O
were	VBD	O	O
unchanged	JJ	O	O
4	CD	O	O
hours	NNS	O	O
after	IN	O	O
dosing	NN	O	O
.	.	.	.

theophylline	NNP	D	D
:	:	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
theophylline	NN	D	D
-lrb-	-LRB-	O	O
aminophylline	NN	D	B
5.8	CD	O	O
mg/kg	NN	O	O
infused	VBD	O	O
over	IN	O	O
20	CD	O	O
minutes	NNS	O	O
-rrb-	-RRB-	O	O
were	VBD	O	O
unchanged	JJ	O	O
following	VBG	O	O
a	DT	O	O
single	JJ	O	O
oral	JJ	O	O
dose	NN	O	O
of	IN	O	O
albendazole	NN	D	D
-lrb-	-LRB-	O	O
400	CD	O	O
mg	NN	O	O
-rrb-	-RRB-	O	O
in	IN	O	O
6	CD	O	O
healthy	JJ	O	O
subjects	NNS	O	O
.	.	.	.

no	DT	O	O
information	NN	O	O
provided	VBN	O	O
.	.	.	.

proleukin	NNP	B	D
may	MD	O	O
affect	VB	O	O
central	JJ	O	O
nervous	JJ	O	O
function	NN	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
interactions	NNS	O	O
could	MD	O	O
occur	VB	O	O
following	VBG	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
psychotropic	JJ	O	O
drugs	NNS	D	D
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
narcotics	NNS	G	G
","	","	O	O
analgesics	NNS	G	G
","	","	O	O
antiemetics	NNS	G	G
","	","	O	O
sedatives	NNS	G	G
","	","	O	O
tranquilizers	NNS	G	G
-rrb-	-RRB-	O	O
.	.	.	.

concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
drugs	NNS	D	D
possessing	VBG	O	O
nephrotoxic	JJ	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
aminoglycosides	NNS	G	G
","	","	O	O
indomethacin	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
myelotoxic	JJ	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
cytotoxic	JJ	G	O
chemotherapy	NN	O	O
-rrb-	-RRB-	O	O
","	","	O	O
cardiotoxic	JJ	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
doxorubicin	NN	D	D
-rrb-	-RRB-	O	O
or	CC	O	O
hepatotoxic	JJ	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
methotrexate	NN	D	D
","	","	O	O
asparaginase	NN	D	D
-rrb-	-RRB-	O	O
effects	NNS	O	O
with	IN	O	O
proleukin	NN	B	D
may	MD	O	O
increase	VB	O	O
toxicity	NN	O	O
in	IN	O	O
these	DT	O	O
organ	NN	O	O
systems	NNS	O	O
.	.	.	.

the	DT	O	O
safety	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
proleukin	NNP	B	B
in	IN	O	O
combination	NN	O	O
with	IN	O	O
any	DT	O	O
antineoplastic	JJ	O	O
agents	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
established	VBN	O	O
.	.	.	.

in	IN	O	O
addition	NN	O	O
","	","	O	O
reduced	VBD	O	O
kidney	NN	O	O
and	CC	O	O
liver	NN	O	O
function	NN	O	O
secondary	JJ	O	O
to	TO	O	O
proleukin	NN	B	O
treatment	NN	O	O
may	MD	O	O
delay	VB	O	O
elimination	NN	O	O
of	IN	O	O
concomitant	JJ	O	O
medications	NNS	O	O
and	CC	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
adverse	JJ	O	O
events	NNS	O	O
from	IN	O	O
those	DT	O	O
drugs	NNS	D	D
.	.	.	.

hypersensitivity	NN	O	O
reactions	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
combination	NN	O	O
regimens	NNS	O	O
containing	VBG	O	O
sequential	JJ	O	O
high	JJ	O	O
dose	NN	O	O
proleukin	NN	B	O
and	CC	O	O
antineoplastic	JJ	O	O
agents	NNS	O	O
","	","	O	O
specifically	RB	O	O
","	","	O	O
dacarbazine	NN	D	O
","	","	O	O
cis-platinum	NN	D	D
","	","	O	O
tamoxifen	NN	D	O
and	CC	O	O
interferon-alfa	NN	D	O
.	.	.	.

these	DT	O	O
reactions	NNS	O	O
consisted	VBD	O	O
of	IN	O	O
erythema	NN	O	O
","	","	O	O
pruritus	NN	O	O
","	","	O	O
and	CC	O	O
hypotension	NN	O	O
and	CC	O	O
occurred	VBD	O	O
within	IN	O	O
hours	NNS	O	O
of	IN	O	O
administration	NN	O	O
of	IN	O	O
chemotherapy	NN	O	D
.	.	.	.

these	DT	O	O
events	NNS	O	O
required	VBN	O	O
medical	JJ	O	O
intervention	NN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
.	.	.	.

myocardial	JJ	O	O
injury	NN	O	O
","	","	O	O
including	VBG	O	O
myocardial	JJ	O	O
infarction	NN	O	O
","	","	O	O
myocarditis	NN	O	O
","	","	O	O
ventricular	JJ	O	O
hypokinesia	NN	O	O
","	","	O	O
and	CC	O	O
severe	JJ	O	O
rhabdomyolysis	NN	O	O
appear	VBP	O	O
to	TO	O	O
be	VB	O	O
increased	VBN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
proleukin	NNP	B	B
and	CC	O	O
interferon-alfa	JJ	D	O
concurrently	RB	O	O
.	.	.	.

exacerbation	NN	O	D
or	CC	O	O
the	DT	O	O
initial	JJ	O	O
presentation	NN	O	O
of	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
autoimmune	JJ	O	O
and	CC	O	O
inflammatory	JJ	O	O
disorders	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
observed	VBN	O	O
following	VBG	O	O
concurrent	JJ	O	O
use	NN	O	O
of	IN	O	O
interferon-alfa	NN	D	D
and	CC	O	O
proleukin	NN	B	O
","	","	O	O
including	VBG	O	O
crescentic	JJ	O	O
iga	NN	O	O
glomerulonephritis	NN	O	O
","	","	O	O
oculo-bulbar	JJ	O	O
myasthenia	NN	O	O
gravis	NN	O	O
","	","	O	O
inflammatory	JJ	O	O
arthritis	NN	O	O
","	","	O	O
thyroiditis	NN	O	O
","	","	O	O
bullous	JJ	O	O
pemphigoid	NN	O	O
","	","	O	O
and	CC	O	O
stevens-johnson	NN	O	O
syndrome	NN	O	O
.	.	.	.

although	IN	O	O
glucocorticoids	NNS	G	O
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
reduce	VB	O	O
proleukin-induced	JJ	O	O
side	JJ	O	O
effects	NNS	O	O
including	VBG	O	O
fever	NN	O	O
","	","	O	O
renal	JJ	O	O
insufficiency	NN	O	O
","	","	O	O
hyperbilirubinemia	NN	O	O
","	","	O	O
confusion	NN	O	O
","	","	O	O
and	CC	O	O
dyspnea	NN	O	O
","	","	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
these	DT	O	O
agents	NNS	O	O
with	IN	O	O
proleukin	NN	B	D
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
antitumor	NN	O	O
effectiveness	NN	O	O
of	IN	O	O
proleukin	NNP	B	B
and	CC	O	O
thus	RB	O	O
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
.	.	.	.

12	CD	O	O
beta-blockers	NNS	G	O
and	CC	O	O
other	JJ	O	O
antihypertensives	NNS	G	G
may	MD	O	O
potentiate	VB	O	O
the	DT	O	O
hypotension	NN	O	O
seen	VBN	O	O
with	IN	O	O
proleukin	NN	B	D
.	.	.	.

delayed	VBN	O	O
adverse	JJ	O	O
reactions	NNS	O	O
to	TO	O	O
iodinated	NNP	O	O
contrast	NNP	O	O
media	NNP	O	O
:	:	O	O
a	NNP	O	O
review	NN	O	O
of	IN	O	O
the	DT	O	O
literature	NN	O	O
revealed	VBD	O	O
that	IN	O	O
12.6	CD	O	O
%	NN	O	O
-lrb-	-LRB-	O	O
range	NN	O	O
28-Nov	CD	O	O
%	NN	O	O
-rrb-	-RRB-	O	O
of	IN	O	O
501	CD	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
various	JJ	O	O
interleukin-2	NN	D	O
containing	VBG	O	O
regimens	NNS	O	O
who	WP	O	O
were	VBD	O	O
subsequently	RB	O	O
administered	VBN	O	O
radiographic	JJ	O	O
iodinated	VBN	O	O
contrast	NN	O	O
media	NNS	O	O
experienced	VBD	O	O
acute	JJ	O	O
","	","	O	O
atypical	JJ	O	O
adverse	JJ	O	O
reactions	NNS	O	O
.	.	.	.

the	DT	O	O
onset	NN	O	O
of	IN	O	O
symptoms	NNS	O	O
usually	RB	O	O
occurred	VBD	O	O
within	IN	O	O
hours	NNS	O	O
-lrb-	-LRB-	O	O
most	RBS	O	O
commonly	RB	O	O
1	CD	O	O
to	TO	O	O
4	CD	O	O
hours	NNS	O	O
-rrb-	-RRB-	O	O
following	VBG	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
contrast	NN	O	O
media	NNS	O	O
.	.	.	.

these	DT	O	O
reactions	NNS	O	O
include	VBP	O	O
fever	NN	O	O
","	","	O	O
chills	NNS	O	O
","	","	O	O
nausea	NN	O	O
","	","	O	O
vomiting	VBG	O	O
","	","	O	O
pruritus	NN	O	O
","	","	O	O
rash	NN	O	O
","	","	O	O
diarrhea	NN	O	O
","	","	O	O
hypotension	NN	O	O
","	","	O	O
edema	NN	O	O
","	","	O	O
and	CC	O	O
oliguria	NN	O	D
.	.	.	.

some	DT	O	O
clinicians	NNS	O	O
have	VBP	O	O
noted	VBN	O	O
that	IN	O	O
these	DT	O	O
reactions	NNS	O	O
resemble	VBP	O	O
the	DT	O	O
immediate	JJ	O	O
side	JJ	O	O
effects	NNS	O	O
caused	VBN	O	O
by	IN	O	O
interleukin-2	NN	D	O
administration	NN	O	O
","	","	O	O
however	RB	O	O
the	DT	O	O
cause	NN	O	O
of	IN	O	O
contrast	NN	O	O
reactions	NNS	O	O
after	IN	O	O
interleukin-2	NN	D	O
therapy	NN	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	.	.

most	JJS	O	O
events	NNS	O	O
were	VBD	O	O
reported	VBN	O	O
to	TO	O	O
occur	VB	O	O
when	WRB	O	O
contrast	NN	O	O
media	NNS	O	O
was	VBD	O	O
given	VBN	O	O
within	IN	O	O
4	CD	O	O
weeks	NNS	O	O
after	IN	O	O
the	DT	O	O
last	JJ	O	O
dose	NN	O	O
of	IN	O	O
interleukin-2	NN	D	D
.	.	.	.

these	DT	O	O
events	NNS	O	O
were	VBD	O	O
also	RB	O	O
reported	VBN	O	O
to	TO	O	O
occur	VB	O	O
when	WRB	O	O
contrast	NN	O	O
media	NNS	O	O
was	VBD	O	O
given	VBN	O	O
several	JJ	O	O
months	NNS	O	O
after	IN	O	O
interleukin-2	NN	D	D
treatment	NN	O	O
.	.	.	.

no	DT	O	O
formal	JJ	O	O
interaction	NN	O	O
studies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
performed	VBN	O	O
.	.	.	.

the	DT	O	O
duration	NN	O	O
of	IN	O	O
the	DT	O	O
period	NN	O	O
following	VBG	O	O
treatment	NN	O	O
with	IN	O	O
amevive	NN	B	B
before	IN	O	O
one	CD	O	O
should	MD	O	O
consider	VB	O	O
starting	VBG	O	O
other	JJ	O	O
immunosuppressive	JJ	G	O
therapy	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
evaluated	VBN	O	O
.	.	.	.

carcinogenesis	NN	O	O
","	","	O	O
mutagenesis	NN	O	O
","	","	O	O
and	CC	O	O
fertility	NN	O	O
.	.	.	.

in	IN	O	O
a	DT	O	O
chronic	JJ	O	O
toxicity	NN	O	O
study	NN	O	O
","	","	O	O
cynomolgus	NN	O	O
monkeys	NNS	O	O
were	VBD	O	O
dosed	VBN	O	O
weekly	RB	O	O
for	IN	O	O
52	CD	O	O
weeks	NNS	O	O
with	IN	O	O
intravenous	JJ	O	O
alefacept	NN	D	D
at	IN	O	O
1	CD	O	O
mg/kg/dose	NN	O	O
or	CC	O	O
20	CD	O	O
mg/kg/dose	NN	O	O
.	.	.	.

one	CD	O	O
animal	NN	O	O
in	IN	O	O
the	DT	O	O
high	JJ	O	O
dose	NN	O	O
group	NN	O	O
developed	VBD	O	O
a	DT	O	O
b-cell	NN	O	O
lymphoma	NN	O	O
that	WDT	O	O
was	VBD	O	O
detected	VBN	O	O
after	IN	O	O
28	CD	O	O
weeks	NNS	O	O
of	IN	O	O
dosing	NN	O	O
.	.	.	.

additional	JJ	O	O
animals	NNS	O	O
in	IN	O	O
both	DT	O	O
dose	NN	O	O
groups	NNS	O	O
developed	VBD	O	O
b-cell	NN	O	O
hyperplasia	NN	O	O
of	IN	O	O
the	DT	O	O
spleen	NN	O	O
and	CC	O	O
lymph	NN	O	O
nodes	NNS	O	O
.	.	.	.

all	DT	O	O
animals	NNS	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
were	VBD	O	O
positive	JJ	O	O
for	IN	O	O
an	DT	O	O
endemic	JJ	O	O
primate	JJ	O	O
gammaherpes	NNS	O	O
virus	NN	O	O
also	RB	O	O
known	VBN	O	O
as	IN	O	O
lymphocryptovirus	NN	O	O
-lrb-	-LRB-	O	O
lcv	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

latent	JJ	O	O
lcv	NN	O	O
infection	NN	O	O
is	VBZ	O	O
generally	RB	O	O
asymptomatic	JJ	O	O
","	","	O	O
but	CC	O	O
can	MD	O	O
lead	VB	O	O
to	TO	O	O
b-cell	NN	O	O
lymphomas	NNS	O	O
when	WRB	O	O
animals	NNS	O	O
are	VBP	O	O
immune	JJ	O	O
suppressed	VBN	O	O
.	.	.	.

in	IN	O	O
a	DT	O	O
separate	JJ	O	O
study	NN	O	O
","	","	O	O
baboons	NNS	O	O
given	VBN	O	O
3	CD	O	O
doses	NNS	O	O
of	IN	O	O
alefacept	NN	D	D
at	IN	O	O
1	CD	O	O
mg/kg	NN	O	O
every	DT	O	O
8	CD	O	O
weeks	NNS	O	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
centroblast	NN	O	O
proliferation	NN	O	O
in	IN	O	O
b-cell	NN	O	O
dependent	JJ	O	O
areas	NNS	O	O
in	IN	O	O
the	DT	O	O
germinal	JJ	O	O
centers	NNS	O	O
of	IN	O	O
the	DT	O	O
spleen	NN	O	O
following	VBG	O	O
a	DT	O	O
116-day	JJ	O	O
washout	NN	O	O
period	NN	O	O
.	.	.	.

the	DT	O	O
role	NN	O	O
of	IN	O	O
amevive	NNP	B	B
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
the	DT	O	O
lymphoid	JJ	O	O
malignancy	NN	O	O
and	CC	O	O
the	DT	O	O
hyperplasia	NN	O	O
observed	VBN	O	O
in	IN	O	O
non-human	JJ	O	O
primates	NNS	O	O
and	CC	O	O
the	DT	O	O
relevance	NN	O	O
to	TO	O	O
humans	NNS	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	.	.

immunodeficiency-associated	JJ	O	O
lymphocyte	NN	O	O
disorders	NNS	O	O
-lrb-	-LRB-	O	O
plasmacytic	JJ	O	O
hyperplasia	NN	O	O
","	","	O	O
polymorphic	JJ	O	O
proliferation	NN	O	O
","	","	O	O
and	CC	O	O
b-cell	NN	O	O
lymphomas	NNS	O	O
-rrb-	-RRB-	O	O
occur	VBP	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
have	VBP	O	O
congenital	JJ	O	O
or	CC	O	O
acquired	VBN	O	O
immunodeficiencies	NNS	O	O
including	VBG	O	O
those	DT	O	O
resulting	VBG	O	O
from	IN	O	O
immunosuppressive	JJ	G	O
therapy	NN	O	O
.	.	.	.

no	DT	O	O
carcinogenicity	NN	O	O
or	CC	O	O
fertility	NN	O	O
studies	NNS	O	O
were	VBD	O	O
conducted	VBN	O	O
.	.	.	.

mutagenicity	NN	O	O
studies	NNS	O	O
were	VBD	O	O
conducted	VBN	O	O
in	FW	O	O
vitro	FW	O	O
and	CC	O	O
in	FW	O	O
vivo	FW	O	O
;	:	O	O
.	.	.	.

no	DT	O	O
evidence	NN	O	O
of	IN	O	O
mutagenicity	NN	O	O
was	VBD	O	O
observed	VBN	O	O
.	.	.	.

pregnancy	NN	O	O
-lrb-	-LRB-	O	O
category	NN	O	O
b	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

women	NNS	O	O
of	IN	O	O
childbearing	JJ	O	O
potential	JJ	O	O
make	VB	O	O
up	RP	O	O
a	DT	O	O
considerable	JJ	O	O
segment	NN	O	O
of	IN	O	O
the	DT	O	O
patient	NN	O	O
population	NN	O	O
affected	VBN	O	O
by	IN	O	O
psoriasis	NN	O	O
.	.	.	.

since	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
amevive	NNP	B	B
on	IN	O	O
pregnancy	NN	O	O
and	CC	O	O
fetal	JJ	O	O
development	NN	O	O
","	","	O	O
including	VBG	O	O
immune	JJ	O	O
system	NN	O	O
development	NN	O	O
","	","	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
","	","	O	O
health	NN	O	O
care	NN	O	O
providers	NNS	O	O
are	VBP	O	O
encouraged	VBN	O	O
to	TO	O	O
enroll	VB	O	O
patients	NNS	O	O
currently	RB	O	O
taking	VBG	O	O
amevive	NNP	B	B
who	WP	O	O
become	VBP	O	O
pregnant	JJ	O	O
into	IN	O	O
the	DT	O	O
biogen	NNP	O	O
pregnancy	NNP	O	O
registry	NNP	O	O
by	IN	O	O
calling	VBG	O	O
1-866-amevive	NN	O	O
-lrb-	-LRB-	O	O
1-866-263-8483	CD	O	O
-rrb-	-RRB-	O	O
.	.	.	.

reproductive	NNP	O	O
toxicology	NN	O	O
studies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
performed	VBN	O	O
in	IN	O	O
cynomolgus	NN	O	O
monkeys	NNS	O	O
at	IN	O	O
doses	NNS	O	O
up	RB	O	O
to	TO	O	O
5	CD	O	O
mg/kg/week	NN	O	O
-lrb-	-LRB-	O	O
about	IN	O	O
62	CD	O	O
times	NNS	O	O
the	DT	O	O
human	JJ	O	O
dose	NN	O	O
based	VBN	O	O
on	IN	O	O
body	NN	O	O
weight	NN	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
have	VBP	O	O
revealed	VBN	O	O
no	DT	O	O
evidence	NN	O	O
of	IN	O	O
impaired	JJ	O	O
fertility	NN	O	O
or	CC	O	O
harm	NN	O	O
to	TO	O	O
the	DT	O	O
fetus	NN	O	O
due	JJ	O	O
to	TO	O	O
amevive	NNP	B	O
.	.	.	.

no	DT	O	O
abortifacient	NN	O	O
or	CC	O	O
teratogenic	JJ	O	O
effects	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
cynomolgus	NN	O	O
monkeys	NNS	O	O
following	VBG	O	O
intravenous	JJ	O	O
bolus	NN	O	O
injections	NNS	O	O
of	IN	O	O
amevive	NNP	B	B
administered	VBN	O	O
weekly	RB	O	O
during	IN	O	O
the	DT	O	O
period	NN	O	O
of	IN	O	O
organogenesis	NN	O	O
to	TO	O	O
gestation	NN	O	O
.	.	.	.

amevive	NNP	B	D
underwent	VBD	O	O
trans-placental	JJ	O	O
passage	NN	O	O
and	CC	O	O
produced	VBN	O	O
in	IN	O	O
utero	NN	O	O
exposure	NN	O	O
in	IN	O	O
the	DT	O	O
developing	VBG	O	O
monkeys	NNS	O	O
.	.	.	.

in	IN	O	O
utero	NN	O	O
","	","	O	O
serum	NN	O	O
levels	NNS	O	O
of	IN	O	O
exposure	NN	O	O
in	IN	O	O
these	DT	O	O
monkeys	NNS	O	O
were	VBD	O	O
23	CD	O	O
%	NN	O	O
of	IN	O	O
maternal	JJ	O	O
serum	NN	O	O
levels	NNS	O	O
.	.	.	.

no	DT	O	O
evidence	NN	O	O
of	IN	O	O
fetal	JJ	O	O
toxicity	NN	O	O
including	VBG	O	O
adverse	JJ	O	O
effects	NNS	O	O
on	IN	O	O
immune	JJ	O	O
system	NN	O	O
development	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
any	DT	O	O
of	IN	O	O
these	DT	O	O
animals	NNS	O	O
.	.	.	.

animal	NN	O	O
reproduction	NN	O	O
studies	NNS	O	O
","	","	O	O
however	RB	O	O
","	","	O	O
are	VBP	O	O
not	RB	O	O
always	RB	O	O
predictive	JJ	O	O
of	IN	O	O
human	JJ	O	O
response	NN	O	O
and	CC	O	O
there	EX	O	O
are	VBP	O	O
no	DT	O	O
adequate	JJ	O	O
and	CC	O	O
well-controlled	JJ	O	O
studies	NNS	O	O
in	IN	O	O
pregnant	JJ	O	O
women	NNS	O	O
.	.	.	.

because	IN	O	O
the	DT	O	O
risk	NN	O	O
to	TO	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
the	DT	O	O
fetal	JJ	O	O
immune	JJ	O	O
system	NN	O	O
and	CC	O	O
postnatal	JJ	O	O
immune	JJ	O	O
function	NN	O	O
in	IN	O	O
humans	NNS	O	O
is	VBZ	O	O
unknown	JJ	O	O
","	","	O	O
amevive	NNP	B	B
should	MD	O	O
be	VB	O	O
used	VBN	O	O
during	IN	O	O
pregnancy	NN	O	O
only	RB	O	O
if	IN	O	O
clearly	RB	O	O
needed	VBN	O	O
.	.	.	.

if	IN	O	O
pregnancy	NN	O	O
occurs	VBZ	O	O
while	IN	O	O
taking	VBG	O	O
amevive	NNP	B	B
","	","	O	O
continued	VBD	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	D	O
should	MD	O	O
be	VB	O	O
assessed	VBN	O	O
.	.	.	.

nursing	NNP	O	O
mothers	NNP	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
whether	IN	O	O
amevive	NNP	B	B
is	VBZ	O	O
excreted	VBN	O	O
in	IN	O	O
human	JJ	O	O
milk	NN	O	O
.	.	.	.

because	IN	O	O
many	JJ	O	O
drugs	NNS	D	D
are	VBP	O	O
excreted	VBN	O	O
in	IN	O	O
human	JJ	O	O
milk	NN	O	O
","	","	O	O
and	CC	O	O
because	IN	O	O
there	EX	O	O
exists	VBZ	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
serious	JJ	O	O
adverse	JJ	O	O
reactions	NNS	O	O
in	IN	O	O
nursing	NN	O	O
infants	NNS	O	O
from	IN	O	O
amevive	NNP	B	B
","	","	O	O
a	DT	O	O
decision	NN	O	O
should	MD	O	O
be	VB	O	O
made	VBN	O	O
whether	IN	O	O
to	TO	O	O
discontinue	VB	O	O
nursing	NN	O	O
while	IN	O	O
taking	VBG	O	O
the	DT	O	O
drug	NN	D	O
or	CC	O	O
to	TO	O	O
discontinue	VB	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	D	O
","	","	O	O
taking	VBG	O	O
into	IN	O	O
account	NN	O	O
the	DT	O	O
importance	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	D	O
to	TO	O	O
the	DT	O	O
mother	NN	O	O
.	.	.	.

geriatric	NNP	O	O
use	NNP	O	O
.	.	.	.

of	IN	O	O
the	DT	O	O
1357	CD	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
amevive	NNP	B	B
in	IN	O	O
clinical	JJ	O	O
trials	NNS	O	O
","	","	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
100	CD	O	O
patients	NNS	O	O
wer	NN	O	O
.	.	.	.

65	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
and	CC	O	O
13	CD	O	O
patients	NNS	O	O
were	VBD	O	O
.	.	.	.

75	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
.	.	.	.

no	DT	O	O
differences	NNS	O	O
in	IN	O	O
safety	NN	O	O
or	CC	O	O
efficacy	NN	O	O
were	VBD	O	O
observed	VBN	O	O
between	IN	O	O
older	JJR	O	O
and	CC	O	O
younger	JJR	O	O
patients	NNS	O	O
","	","	O	O
but	CC	O	O
there	EX	O	O
were	VBD	O	O
not	RB	O	O
sufficient	JJ	O	O
data	NNS	O	O
to	TO	O	O
exclude	VB	O	O
important	JJ	O	O
differences	NNS	O	O
.	.	.	.

because	IN	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
infections	NNS	O	O
and	CC	O	O
certain	JJ	O	O
malignancies	NNS	O	O
is	VBZ	O	O
higher	JJR	O	O
in	IN	O	O
the	DT	O	O
elderly	JJ	O	O
population	NN	O	O
","	","	O	O
in	IN	O	O
general	JJ	O	O
","	","	O	O
caution	NN	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
in	IN	O	O
treating	VBG	O	O
the	DT	O	O
elderly	JJ	O	O
.	.	.	.

pediatric	NNP	O	O
use	NNP	O	O
.	.	.	.

the	DT	O	O
safety	NN	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
amevive	NNP	B	B
in	IN	O	O
pediatric	JJ	O	O
patients	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
.	.	.	.

amevive	NNP	B	D
is	VBZ	O	O
not	RB	O	O
indicated	VBN	O	O
for	IN	O	O
pediatric	JJ	O	O
patients	NNS	O	O
.	.	.	.

drug/laboratory	NNP	O	O
interactions	NNS	O	O
no	DT	O	O
formal	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
studies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
performed	VBN	O	O
with	IN	O	O
campath	NNP	B	B
.	.	.	.

an	DT	O	O
immune	JJ	O	O
response	NN	O	O
to	TO	O	O
campath	NNP	B	B
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
subsequent	JJ	O	O
diagnostic	JJ	O	O
serum	NN	O	O
tests	NNS	O	O
that	WDT	O	O
utilize	VBP	O	O
antibodie	NN	O	O
.	.	.	.

intravenous	JJ	O	O
ranitidine	NN	D	D
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
double	VB	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
oral	JJ	O	O
alendronate	NN	D	O
.	.	.	.

the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
this	DT	O	O
increased	VBN	O	O
bioavailability	NN	O	O
and	CC	O	O
whether	IN	O	O
similar	JJ	O	O
increases	NNS	O	O
will	MD	O	O
occur	VB	O	O
in	IN	O	O
patients	NNS	O	O
given	VBN	O	O
oral	JJ	O	O
h2-antagonists	NNS	G	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	.	.

no	DT	O	O
other	JJ	O	O
specific	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
studies	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
.	.	.	.

products	NNPS	O	O
containing	VBG	O	O
calcium	NN	D	D
and	CC	O	O
other	JJ	O	O
multivalent	JJ	O	O
cations	NNS	O	O
likely	RB	O	O
will	MD	O	O
interfere	VB	O	O
with	IN	O	O
absorption	NN	O	O
of	IN	O	O
alendronate	NN	D	D
.	.	.	.

both	CC	O	O
the	DT	O	O
magnitude	NN	O	O
and	CC	O	O
duration	NN	O	O
of	IN	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
and	CC	O	O
cardiovascular	JJ	O	O
effects	NNS	O	O
may	MD	O	O
be	VB	O	O
enhanced	VBN	O	O
when	WRB	O	O
alfenta	NNP	B	B
is	VBZ	O	O
administered	VBN	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
other	JJ	O	O
cns	NN	O	O
depressants	NNS	O	O
such	JJ	O	O
as	IN	O	O
barbiturates	NNS	G	G
","	","	O	O
tranquilizers	NNS	G	G
","	","	O	O
opioids	NNS	G	G
","	","	O	O
or	CC	O	O
inhalation	NN	O	O
general	JJ	O	O
anesthetics	NNS	G	G
.	.	.	.

postoperative	JJ	O	O
respiratory	JJ	O	O
depression	NN	O	O
may	MD	O	O
be	VB	O	O
enhanced	VBN	O	O
or	CC	O	O
prolonged	VBN	O	O
by	IN	O	O
these	DT	O	O
agents	NNS	O	O
.	.	.	.

in	IN	O	O
such	JJ	O	O
cases	NNS	O	O
of	IN	O	O
combined	JJ	O	O
treatment	NN	O	O
","	","	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
one	CD	O	O
or	CC	O	O
both	DT	O	O
agents	NNS	O	O
should	MD	O	O
be	VB	O	O
reduced	VBN	O	O
.	.	.	.

limited	JJ	O	O
clinical	JJ	O	O
experience	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
requirements	NNS	O	O
for	IN	O	O
volatile	JJ	O	O
inhalation	NN	O	O
anesthetics	NNS	G	O
are	VBP	O	O
reduced	VBN	O	O
by	IN	O	O
30	CD	O	O
to	TO	O	O
50	CD	O	O
%	NN	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
sixty	NN	O	O
-lrb-	-LRB-	O	O
60	CD	O	O
-rrb-	-RRB-	O	O
minutes	NNS	O	O
following	VBG	O	O
alfenta	NNP	B	O
induction	NN	O	O
the	DT	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
erythromycin	NN	D	D
with	IN	O	O
alfenta	NN	B	D
can	MD	O	O
significantly	RB	O	O
inhibit	VB	O	O
alfenta	NN	B	D
clearance	NN	O	O
and	CC	O	O
may	MD	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
prolonged	JJ	O	O
or	CC	O	O
delayed	VBN	O	O
respiratory	JJ	O	O
depression	NN	O	O
.	.	.	.

cimetidine	NNP	D	D
reduces	VBZ	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
alfenta	NNP	B	B
.	.	.	.

therefore	RB	O	O
smaller	JJR	O	O
alfenta	NN	B	O
doses	NNS	O	O
will	MD	O	O
be	VB	O	O
required	VBN	O	O
with	IN	O	O
prolonged	JJ	O	O
administration	NN	O	O
and	CC	O	O
the	DT	O	O
duration	NN	O	O
of	IN	O	O
action	NN	O	O
of	IN	O	O
alfenta	NNP	B	B
my	PRP$	O	O
be	VB	O	O
extended	VBN	O	O
.	.	.	.

perioperative	NNP	O	O
administration	NN	O	O
of	IN	O	O
drugs	NNS	D	D
affecting	VBG	O	O
hepatic	JJ	O	O
blood	NN	O	O
flow	NN	O	O
or	CC	O	O
enzyme	NN	O	O
function	NN	O	O
may	MD	O	O
reduce	VB	O	O
plasma	NN	O	O
clearance	NN	O	O
and	CC	O	O
prolong	VB	O	O
recovery	NN	O	O
.	.	.	.

drug-drug	NNP	O	O
interactions	NNS	O	O
:	:	O	O
the	DT	O	O
pharmacokinetic	JJ	O	O
and	CC	O	O
pharmacodynamic	JJ	O	O
interactions	NNS	O	O
between	IN	O	O
uroxatral	NNP	B	B
and	CC	O	O
other	JJ	O	O
alpha-blockers	NNS	G	G
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
determined	VBN	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
interactions	NNS	O	O
may	MD	O	O
be	VB	O	O
expected	VBN	O	O
","	","	O	O
and	CC	O	O
uroxatral	NNP	B	B
should	MD	O	O
not	RB	O	O
be	VB	O	O
used	VBN	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
other	JJ	O	O
alpha-blockers	NNS	G	G
.	.	.	.

no	DT	O	O
drug	NN	D	O
interaction	NN	O	O
studies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
performed	VBN	O	O
.	.	.	.

effects	NNS	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	O	D
on	IN	O	O
aliskiren	NNP	D	B
based	VBD	O	O
on	IN	O	O
in-vitro	FW	O	O
studies	NNS	O	O
","	","	O	O
aliskiren	NN	D	D
is	VBZ	O	O
metabolized	VBN	O	O
by	IN	O	O
cyp	NN	O	O
3a4	NN	O	O
.	.	.	.

co-administration	NN	O	O
of	IN	O	O
lovastatin	NN	D	D
","	","	O	O
atenolol	NN	D	D
","	","	O	O
warfarin	NN	D	D
","	","	O	O
furosemide	NN	D	D
","	","	O	O
digoxin	NN	D	D
","	","	O	O
celecoxib	NN	D	D
","	","	O	O
hydrochlorothiazide	NN	D	D
","	","	O	O
ramipril	NN	D	D
","	","	O	O
valsartan	NN	D	O
","	","	O	O
metformin	NN	D	D
and	CC	O	O
amlodipine	NN	D	D
did	VBD	O	O
not	RB	O	O
result	VB	O	O
in	IN	O	O
clinically	RB	O	O
significant	JJ	O	O
increases	NNS	O	O
in	IN	O	O
aliskiren	JJ	D	O
exposure	NN	O	O
.	.	.	.

co-administration	NN	O	O
of	IN	O	O
irbesartan	NN	D	D
reduced	VBD	O	O
aliskiren	JJ	D	O
cmax	NN	O	O
up	IN	O	O
to	TO	O	O
50	CD	O	O
%	NN	O	O
after	IN	O	O
multiple	JJ	O	O
dosing	NN	O	O
.	.	.	.

co-administration	NN	O	O
of	IN	O	O
atorvastatin	NN	D	D
resulted	VBD	O	O
in	IN	O	O
about	IN	O	O
a	DT	O	O
50	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
aliskiren	NN	D	O
cmax	NN	O	O
and	CC	O	O
auc	NN	O	O
after	IN	O	O
multiple	JJ	O	O
dosing	NN	O	O
.	.	.	.

ketoconazole	NN	D	D
:	:	O	O
co-administration	NN	O	O
of	IN	O	O
200	CD	O	O
mg	NN	O	O
twice-daily	JJ	O	O
ketoconazole	NN	D	D
with	IN	O	O
aliskiren	NN	D	D
resulted	VBD	O	O
in	IN	O	O
an	DT	O	O
approximate	JJ	O	O
80	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
aliskiren	NN	D	D
.	.	.	.

a	DT	O	O
400	CD	O	O
mg	NN	O	O
once-daily	JJ	O	O
dose	NN	O	O
was	VBD	O	O
not	RB	O	O
studied	VBN	O	O
but	CC	O	O
would	MD	O	O
be	VB	O	O
expected	VBN	O	O
to	TO	O	O
increase	VB	O	O
aliskiren	JJ	D	O
blood	NN	O	O
levels	NNS	O	O
further	RB	O	O
.	.	.	.

effects	NNS	O	O
of	IN	O	O
aliskiren	NN	D	B
on	IN	O	O
other	JJ	O	O
drugs	NNS	O	D
aliskiren	NN	D	D
does	VBZ	O	O
not	RB	O	O
inhibit	VB	O	O
the	DT	O	O
cyp450	NN	O	O
isoenzymes	NNS	O	O
-lrb-	-LRB-	O	O
cyp1a2	NN	D	O
","	","	O	O
2c8	NN	O	O
","	","	O	O
2c9	NN	O	O
","	","	O	O
2c19	NN	O	O
","	","	O	O
2d6	NN	O	O
","	","	O	O
2.00E+01	NN	O	O
","	","	O	O
and	CC	O	O
cyp	NN	O	O
3a	NN	O	O
-rrb-	-RRB-	O	O
or	CC	O	O
induce	VB	O	O
cyp	NN	O	O
3a4	NN	O	O
.	.	.	.

co-administration	NN	O	O
of	IN	O	O
aliskiren	NN	D	D
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
affect	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
lovastatin	NN	D	D
","	","	O	O
digoxin	NN	D	D
","	","	O	O
valsartan	NN	D	D
","	","	O	O
amlodipine	NN	D	O
","	","	O	O
metformin	NN	D	D
","	","	O	O
celecoxib	NN	D	D
","	","	O	O
atenolol	NN	D	D
","	","	O	O
atorvastatin	NN	D	D
","	","	O	O
ramipril	NN	D	D
or	CC	O	O
hydrochlorothiazide	NN	D	D
.	.	.	.

warfarin	NNP	D	D
:	:	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
aliskiren	NN	D	D
on	IN	O	O
warfarin	NN	D	D
pharmacokinetics	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
evaluated	VBN	O	O
in	IN	O	O
a	DT	O	O
well-controlled	JJ	O	O
clinical	JJ	O	O
trial	NN	O	O
.	.	.	.

furosemide	NNP	D	D
:	:	O	O
when	WRB	O	O
aliskiren	NN	D	D
was	VBD	O	O
co-administered	VBN	O	O
with	IN	O	O
furosemide	NN	D	D
","	","	O	O
the	DT	O	O
auc	NN	O	O
and	CC	O	O
cmax	NN	O	O
of	IN	O	O
furosemide	NN	D	D
were	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
about	IN	O	O
30	CD	O	O
%	NN	O	O
and	CC	O	O
50	CD	O	O
%	NN	O	O
","	","	O	O
respectively	RB	O	O
.	.	.	.

patients	NNS	O	O
who	WP	O	O
are	VBP	O	O
applying	VBG	O	O
panretin	NNP	B	B
gel	NN	O	O
should	MD	O	O
not	RB	O	O
concurrently	RB	O	O
use	VB	O	O
products	NNS	O	O
that	WDT	O	O
contain	VBP	O	O
deet	NN	D	O
-lrb-	-LRB-	O	O
n	NN	O	O
","	","	O	O
n-diethyl-m-toluamide	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
a	DT	O	O
common	JJ	O	O
component	NN	O	O
of	IN	O	O
insect	JJ	O	O
repellent	NN	O	O
products	NNS	O	O
.	.	.	.

animal	NN	O	O
toxicology	NN	O	O
studies	NNS	O	O
showed	VBD	O	O
increased	VBN	O	O
deet	NNP	D	O
toxicity	NN	O	O
when	WRB	O	O
deet	NNP	D	B
was	VBD	O	O
included	VBN	O	O
as	IN	O	O
proof	NN	O	O
of	IN	O	O
the	DT	O	O
formulation	NN	O	O
.	.	.	.

although	IN	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
clinical	JJ	O	O
evidence	NN	O	O
in	IN	O	O
the	DT	O	O
vehicle-controlled	JJ	O	O
studies	NNS	O	O
of	IN	O	O
drug	NN	D	O
interactions	NNS	O	O
with	IN	O	O
systemic	JJ	O	O
antiretroviral	JJ	O	G
agents	NNS	O	O
","	","	O	O
including	VBG	O	O
protease	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
macrolide	NN	O	O
antibiotics	NNS	G	G
","	","	O	O
and	CC	O	O
azole	NN	O	O
antifungals	NNS	O	G
","	","	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
panretin	NNP	B	B
gel	NN	O	O
on	IN	O	O
the	DT	O	O
steady-state	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
these	DT	O	O
drugs	NNS	D	D
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
.	.	.	.

no	DT	O	O
drug	NN	D	O
interaction	NN	O	O
data	NNS	O	O
are	VBP	O	O
available	JJ	O	O
on	IN	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
panretin	NNP	B	B
gel	NN	O	O
and	CC	O	O
systemic	JJ	O	O
anti-ks	JJ	O	O
agents	NNS	O	O
.	.	.	.

the	DT	O	O
following	VBG	O	O
drug	NN	D	O
interactions	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
undergoing	VBG	O	O
treatment	NN	O	O
with	IN	O	O
oral	JJ	O	O
allopurinol	NN	D	D
.	.	.	.

although	IN	O	O
the	DT	O	O
pattern	NN	O	O
of	IN	O	O
use	NN	O	O
for	IN	O	O
oral	JJ	O	O
allopurinol	NN	D	D
includes	VBZ	O	O
longer	JJR	O	O
term	NN	O	O
therapy	NN	O	O
","	","	O	O
particularly	RB	O	O
for	IN	O	O
gout	NN	O	O
and	CC	O	O
renal	JJ	O	O
calculi	NNS	O	O
","	","	O	O
the	DT	O	O
experience	NN	O	O
gained	VBD	O	O
may	MD	O	O
be	VB	O	O
relevant	JJ	O	O
.	.	.	.

mercaptopurine/azathioprine	NNP	O	D
:	:	O	O
allopurinol	NN	D	D
inhibits	VBZ	O	O
the	DT	O	O
enzymatic	JJ	O	O
oxidation	NN	O	O
of	IN	O	O
mercaptopurine	NN	D	O
and	CC	O	O
azathioprine	NN	D	O
to	TO	O	O
6-thiouric	JJ	O	O
acid	NN	O	O
.	.	.	.

this	DT	O	O
oxidation	NN	O	O
","	","	O	O
which	WDT	O	O
is	VBZ	O	O
catalyzed	VBN	O	O
by	IN	O	O
xanthine	NN	O	O
oxidase	NN	O	O
","	","	O	O
inactivates	VBZ	O	O
mercaptopurine	NN	D	O
.	.	.	.

in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
mercaptopurine	NN	D	D
-lrb-	-LRB-	O	O
purinethol	NN	B	O
-rrb-	-RRB-	O	O
or	CC	O	O
azathioprine	NN	D	D
-lrb-	-LRB-	O	O
imuran	NN	B	B
-rrb-	-RRB-	O	O
","	","	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
300-600	CD	O	O
mg	NN	O	O
of	IN	O	O
allopurinol	NN	D	D
per	IN	O	O
day	NN	O	O
will	MD	O	O
require	VB	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
dose	NN	O	O
to	TO	O	O
approximately	RB	O	O
one-third	JJ	O	O
to	TO	O	O
one-fourth	NN	O	O
of	IN	O	O
the	DT	O	O
usual	JJ	O	O
dose	NN	O	O
of	IN	O	O
mercaptopurine	NN	D	D
or	CC	O	O
azathioprine	NN	D	D
.	.	.	.

subsequent	JJ	O	O
adjustment	NN	O	O
of	IN	O	O
doses	NNS	O	O
of	IN	O	O
mercaptopurine	NN	D	D
or	CC	O	O
azathioprine	NN	D	D
should	MD	O	O
be	VB	O	O
made	VBN	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
therapeutic	JJ	O	O
response	NN	O	O
and	CC	O	O
the	DT	O	O
appearance	NN	O	O
of	IN	O	O
toxic	JJ	O	O
effects	NNS	O	O
.	.	.	.

dicumarol	NNP	D	D
:	:	O	O
it	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
that	IN	O	O
allopurinol	NN	D	D
prolongs	VBZ	O	O
the	DT	O	O
half-life	NN	O	O
of	IN	O	O
the	DT	O	O
anticoagulant	NN	G	G
","	","	O	O
dicumarol	NN	D	O
.	.	.	.

the	DT	O	O
clinical	JJ	O	O
basis	NN	O	O
of	IN	O	O
this	DT	O	O
drug	NN	D	O
interaction	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
established	VBN	O	O
but	CC	O	O
should	MD	O	O
be	VB	O	O
noted	VBN	O	O
when	WRB	O	O
allopurinol	NN	D	D
is	VBZ	O	O
given	VBN	O	O
to	TO	O	O
patients	NNS	O	O
already	RB	O	O
on	IN	O	O
dicumarol	NN	D	D
therapy	NN	O	O
.	.	.	.

consequently	RB	O	O
","	","	O	O
prothrombin	NN	O	O
time	NN	O	O
should	MD	O	O
be	VB	O	O
reassessed	VBN	O	O
periodically	RB	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
both	CC	O	O
drugs	NNS	D	D
.	.	.	.

uricosuric	NNP	O	O
agents	NNPS	O	O
:	:	O	O
since	IN	O	O
the	DT	O	O
excretion	NN	O	O
of	IN	O	O
oxipurinol	NN	D	D
is	VBZ	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
of	IN	O	O
urate	NN	O	O
","	","	O	O
uricosuric	JJ	O	O
agents	NNS	O	O
","	","	O	O
which	WDT	O	O
increase	VBP	O	O
the	DT	O	O
excretion	NN	O	O
of	IN	O	O
urate	NN	O	D
","	","	O	O
are	VBP	O	O
also	RB	O	O
likely	JJ	O	O
to	TO	O	O
increase	VB	O	O
the	DT	O	O
excretion	NN	O	O
of	IN	O	O
oxipurinol	NN	D	D
and	CC	O	O
thus	RB	O	O
lower	JJR	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
inhibition	NN	O	O
of	IN	O	O
xanthine	NN	O	O
oxidase	NN	O	O
.	.	.	.

the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
uricosuric	JJ	O	O
agents	NNS	O	O
and	CC	O	O
allopurinol	NN	D	D
has	VBZ	O	O
been	VBN	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
excretion	NN	O	O
of	IN	O	O
oxypurines	NNS	O	G
-lrb-	-LRB-	O	O
hypoxanthine	NN	O	O
and	CC	O	O
xanthine	NN	O	D
-rrb-	-RRB-	O	O
and	CC	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
urinary	JJ	O	O
uric	JJ	O	O
acid	NN	O	O
excretion	NN	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
observed	VBN	O	O
with	IN	O	O
allopurinol	NN	D	D
alone	RB	O	O
.	.	.	.

although	IN	O	O
clinical	JJ	O	O
evidence	NN	O	O
to	TO	O	O
date	NN	O	O
has	VBZ	O	O
not	RB	O	O
demonstrated	VBN	O	O
renal	JJ	O	O
precipitation	NN	O	O
of	IN	O	O
oxypurines	NNS	O	O
in	IN	O	O
patients	NNS	O	O
either	CC	O	O
on	IN	O	O
allopurinol	NN	D	D
alone	RB	O	O
or	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
uricosuric	JJ	O	O
agents	NNS	O	O
","	","	O	O
the	DT	O	O
possibility	NN	O	O
should	MD	O	O
be	VB	O	O
kept	VBN	O	O
in	IN	O	O
mind	NN	O	O
.	.	.	.

thiazide	NNP	O	G
diuretics	NNPS	O	G
:	:	O	O
the	DT	O	O
reports	NNS	O	O
that	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
allopurinol	NN	D	D
and	CC	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
the	DT	O	O
enhancement	NN	O	O
of	IN	O	O
allopurinol	NN	D	D
toxicity	NN	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reviewed	VBN	O	O
in	IN	O	O
an	DT	O	O
attempt	NN	O	O
to	TO	O	O
establish	VB	O	O
a	DT	O	O
cause-and-effect	JJ	O	O
relationship	NN	O	O
and	CC	O	O
a	DT	O	O
mechanism	NN	O	O
of	IN	O	O
causation	NN	O	O
.	.	.	.

review	NN	O	O
of	IN	O	O
these	DT	O	O
case	NN	O	O
reports	VBZ	O	O
indicates	VBZ	O	O
that	IN	O	O
the	DT	O	O
patients	NNS	O	O
were	VBD	O	O
mainly	RB	O	O
receiving	VBG	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
for	IN	O	O
hypertension	NN	O	O
and	CC	O	O
that	IN	O	O
tests	NNS	O	O
to	TO	O	O
rule	VB	O	O
out	RP	O	O
decreased	VBN	O	O
renal	JJ	O	O
function	NN	O	O
secondary	JJ	O	O
to	TO	O	O
hypertensive	JJ	O	O
nephropathy	NN	O	O
were	VBD	O	O
not	RB	O	O
often	RB	O	O
performed	VBN	O	O
.	.	.	.

in	IN	O	O
those	DT	O	O
patients	NNS	O	O
in	IN	O	O
whom	WP	O	O
renal	JJ	O	O
insufficiency	NN	O	O
was	VBD	O	O
documented	VBN	O	O
","	","	O	O
however	RB	O	O
","	","	O	O
the	DT	O	O
recommendation	NN	O	O
to	TO	O	O
lower	VB	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
allopurinol	NN	D	D
was	VBD	O	O
not	RB	O	O
followed	VBN	O	O
.	.	.	.

although	IN	O	O
a	DT	O	O
causal	JJ	O	O
mechanism	NN	O	O
and	CC	O	O
a	DT	O	O
cause-and-effect	JJ	O	O
relationship	NN	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
established	VBN	O	O
","	","	O	O
current	JJ	O	O
evidence	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
renal	JJ	O	O
function	NN	O	O
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
in	IN	O	O
patients	NNS	O	O
on	IN	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
and	CC	O	O
allopurinol	NN	D	D
even	RB	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
renal	JJ	O	O
failure	NN	O	O
","	","	O	O
and	CC	O	O
dosage	NN	O	O
levels	NNS	O	O
should	MD	O	O
be	VB	O	O
even	RB	O	O
more	RBR	O	O
conservatively	RB	O	O
adjusted	VBN	O	O
in	IN	O	O
those	DT	O	O
patients	NNS	O	O
on	IN	O	O
such	JJ	O	O
combined	JJ	O	O
therapy	NN	O	O
if	IN	O	O
diminished	VBN	O	O
renal	JJ	O	O
function	NN	O	O
is	VBZ	O	O
detected	VBN	O	O
.	.	.	.

ampicillin/amoxicillin	NNP	O	D
:	:	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
frequency	NN	O	O
of	IN	O	O
skin	NN	O	O
rash	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
among	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
ampicillin	NN	D	D
or	CC	O	O
amoxicillin	NNP	D	D
concurrently	RB	O	O
with	IN	O	O
allopurinol	NN	D	D
compared	VBN	O	O
to	TO	O	O
patients	NNS	O	O
who	WP	O	O
are	VBP	O	O
not	RB	O	O
receiving	VBG	O	O
both	CC	O	O
drugs	NNS	D	D
.	.	.	.

the	DT	O	O
cause	NN	O	O
of	IN	O	O
the	DT	O	O
reported	VBN	O	O
association	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
established	VBN	O	O
.	.	.	.

cytotoxic	JJ	O	O
agents	NNS	O	O
:	:	O	O
enhanced	VBN	O	O
bone	NN	O	O
marrow	NN	O	O
suppression	NN	O	O
by	IN	O	O
cyclophosphamide	NN	D	D
and	CC	O	O
other	JJ	O	O
cytotoxic	JJ	G	O
agents	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
among	IN	O	O
patients	NNS	O	O
with	IN	O	O
neoplastic	JJ	O	O
disease	NN	O	O
","	","	O	O
except	IN	O	O
leukemia	NN	O	O
","	","	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
allopurinol	NN	D	D
.	.	.	.

however	RB	O	O
","	","	O	O
in	IN	O	O
a	DT	O	O
well-controlled	JJ	O	O
study	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
lymphoma	NN	O	D
on	IN	O	O
combination	NN	O	O
therapy	NN	O	O
","	","	O	O
allopurinol	NN	D	D
did	VBD	O	O
not	RB	O	O
increase	VB	O	O
the	DT	O	O
marrow	NN	O	O
toxicity	NN	O	O
of	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
cyclophosphamide	NN	D	D
","	","	O	O
doxorubicin	NN	D	D
","	","	O	O
bleomycin	NN	D	D
","	","	O	O
procarbazine	NN	D	O
and/or	CC	O	O
mechlorethamine	NN	D	O
.	.	.	.

chlorpropamide	NNP	D	D
:	:	O	O
chlorpropamides	NNP	O	O
plasma	NN	O	O
half-life	NN	O	O
may	MD	O	O
be	VB	O	O
prolonged	VBN	O	O
by	IN	O	O
allopurinol	NN	D	D
","	","	O	O
since	IN	O	O
allopurinol	NN	D	D
and	CC	O	O
chlorpropamide	NN	D	D
may	MD	O	O
compete	VB	O	O
for	IN	O	O
excretion	NN	O	O
in	IN	O	O
the	DT	O	O
renal	JJ	O	O
tubule	NN	O	O
.	.	.	.

the	DT	O	O
risk	NN	O	O
of	IN	O	O
hypoglycemia	NN	O	O
secondary	JJ	O	O
to	TO	O	O
this	DT	O	O
mechanism	NN	O	O
may	MD	O	O
be	VB	O	O
increased	VBN	O	O
if	IN	O	O
allopurinol	NN	D	D
and	CC	O	O
chlorpropamide	NN	D	D
are	VBP	O	O
given	VBN	O	O
concomitantly	RB	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
renal	JJ	O	O
insufficiency	NN	O	O
.	.	.	.

cyclosporin	NN	D	D
:	:	O	O
reports	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
cyclosporine	NN	D	D
levels	NNS	O	O
may	MD	O	O
be	VB	O	O
increased	VBN	O	O
during	IN	O	O
concomitant	JJ	O	O
treatment	NN	O	O
with	IN	O	O
allopurinol	NN	D	D
sodium	NN	O	O
for	IN	O	O
injection	NN	O	O
.	.	.	.

monitoring	NN	O	O
of	IN	O	O
cyclosporine	NN	D	D
levels	NNS	O	O
and	CC	O	O
possible	JJ	O	O
adjustment	NN	O	O
of	IN	O	O
cyclosporine	NN	D	D
dosage	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
when	WRB	O	O
these	DT	O	O
drugs	NNS	D	D
are	VBP	O	O
co-administered	JJ	O	O
.	.	.	.

tolbutamides	NNS	O	O
conversion	NN	O	O
to	TO	O	O
inactive	JJ	O	O
metabolites	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
catalyzed	VBN	O	O
by	IN	O	O
xanthine	NN	O	O
oxidase	NN	O	O
from	IN	O	O
rat	NN	O	O
liver	NN	O	O
.	.	.	.

the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
","	","	O	O
if	IN	O	O
any	DT	O	O
","	","	O	O
of	IN	O	O
these	DT	O	O
observations	NNS	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	.	.

ergot-containing	JJ	O	O
drugs	NNS	O	O
:	:	O	O
these	DT	O	O
drugs	NNS	D	D
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
cause	VB	O	O
prolonged	JJ	O	O
vasospastic	JJ	O	O
reactions	NNS	O	O
.	.	.	.

because	IN	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
theoretical	JJ	O	O
basis	NN	O	O
that	IN	O	O
these	DT	O	O
effects	NNS	O	O
may	MD	O	O
be	VB	O	O
additive	JJ	O	O
","	","	O	O
use	NN	O	O
of	IN	O	O
ergotamine-containing	JJ	O	O
or	CC	O	O
ergot-type	JJ	O	O
medications	NNS	O	O
-lrb-	-LRB-	O	O
like	IN	O	O
dihydroergotamine	NN	D	D
or	CC	O	O
methysergide	NN	D	D
-rrb-	-RRB-	O	O
and	CC	O	O
axert	NN	B	D
within	IN	O	O
24	CD	O	O
hours	NNS	O	O
of	IN	O	O
each	DT	O	O
other	JJ	O	O
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
.	.	.	.

monoamine	NNP	O	O
oxidase	NNP	O	O
inhibitors	NNS	O	O
:	:	O	O
coadministration	NN	O	O
of	IN	O	O
moclobemide	NN	D	D
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
27	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
almotriptan	NN	D	O
clearance	NN	O	O
and	CC	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
cmax	NN	O	O
of	IN	O	O
approximately	RB	O	O
6	CD	O	O
%	NN	O	O
.	.	.	.

no	DT	O	O
dose	NN	O	O
adjustment	NN	O	O
is	VBZ	O	O
necessary	JJ	O	O
.	.	.	.

other	JJ	O	O
5-ht1b	NN	O	O
/	:	O	O
1d	NN	O	O
agonists	NNS	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
other	JJ	O	O
5-ht1b	NN	O	O
/	:	O	O
1d	NN	O	O
agonists	NNS	O	O
within	IN	O	O
24	CD	O	O
hours	NNS	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
axert	NN	B	D
is	VBZ	O	O
contraindicated	VBN	O	O
.	.	.	.

propanolol	NNP	D	D
:	:	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
almotriptan	NN	D	D
were	VBD	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
coadministration	NN	O	O
of	IN	O	O
propranolol	NN	D	D
.	.	.	.

selective	JJ	O	O
serotonin	NN	O	O
reuptake	NNP	O	O
inhibitors	NNS	O	O
-lrb-	-LRB-	O	O
ssris	NNS	G	G
-rrb-	-RRB-	O	O
:	:	O	O
ssris	NNS	G	G
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
fluoxetine	NN	D	D
","	","	O	O
fluvoxamine	NN	D	D
","	","	O	O
paroxetine	NN	D	D
","	","	O	O
sertraline	NN	D	D
-rrb-	-RRB-	O	O
have	VBP	O	O
been	VBN	O	O
rarely	RB	O	O
reported	VBN	O	O
to	TO	O	O
cause	VB	O	O
weakness	NN	O	O
","	","	O	O
hyperreflexia	NN	O	O
","	","	O	O
and	CC	O	O
incoordination	NN	O	O
when	WRB	O	O
coadministered	VBN	O	O
with	IN	O	O
5-ht1	NN	O	O
agonists	NNS	O	O
.	.	.	.

if	IN	O	O
concomitant	JJ	O	O
treatment	NN	O	O
with	IN	O	O
axert	NN	B	D
and	CC	O	O
an	DT	O	O
ssri	NNP	G	G
is	VBZ	O	O
clinically	RB	O	O
warranted	VBN	O	O
","	","	O	O
appropriate	JJ	O	O
observation	NN	O	O
of	IN	O	O
the	DT	O	O
patient	NN	O	O
is	VBZ	O	O
advised	VBN	O	O
.	.	.	.

verapamil	NNP	D	D
:	:	O	O
coadministration	NNP	O	O
of	IN	O	O
almotriptan	NN	D	D
and	CC	O	O
verapamil	NN	D	D
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
24	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
almotriptan	NN	D	D
.	.	.	.

no	DT	O	O
dose	NN	O	O
adjustment	NN	O	O
is	VBZ	O	O
necessary	JJ	O	O
.	.	.	.

coadministration	NN	O	O
of	IN	O	O
almotriptan	NN	D	D
and	CC	O	O
the	DT	O	O
potent	JJ	O	O
cyp3a4	NN	D	D
inhibitor	NN	O	O
ketoconazole	NN	D	D
-lrb-	-LRB-	O	O
400	CD	O	O
mg	NN	O	O
q.d.	NN	O	O
for	IN	O	O
3	CD	O	O
days	NNS	O	O
-rrb-	-RRB-	O	O
resulted	VBD	O	O
in	IN	O	O
an	DT	O	O
approximately	RB	O	O
60	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
area	NN	O	O
under	IN	O	O
the	DT	O	O
plasma	NN	O	O
concentration-time	NN	O	O
curve	NN	O	O
and	CC	O	O
maximal	JJ	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
almotriptan	NN	D	D
.	.	.	.

although	IN	O	O
the	DT	O	O
interaction	NN	O	O
between	IN	O	O
almotriptan	NN	D	D
and	CC	O	O
other	JJ	O	O
potent	JJ	O	O
cyp3a4	NN	D	D
inhibitors	NNS	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
itraconazole	NN	D	D
","	","	O	O
ritonavir	NN	D	D
","	","	O	O
and	CC	O	O
erythromycin	NN	D	D
-rrb-	-RRB-	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
","	","	O	O
increased	VBD	O	O
exposures	NNS	O	O
to	TO	O	O
almotriptan	NN	D	O
may	MD	O	O
be	VB	O	O
expected	VBN	O	O
when	WRB	O	O
almotriptan	NN	D	D
is	VBZ	O	O
used	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
these	DT	O	O
medications	NNS	O	O
.	.	.	.

axert	NNP	B	D
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
to	TO	O	O
interfere	VB	O	O
with	IN	O	O
commonly	RB	O	O
employed	VBN	O	O
clinical	JJ	O	O
laboratory	NN	O	O
tests	NNS	O	O
.	.	.	.

because	IN	O	O
alosetron	NN	D	D
is	VBZ	O	O
metabolized	VBN	O	O
by	IN	O	O
a	DT	O	O
variety	NN	O	O
of	IN	O	O
hepatic	JJ	O	O
cyp	NN	O	O
drug-metabolizing	JJ	O	O
enzymes	NNS	O	O
","	","	O	O
inducers	NNS	O	O
or	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
these	DT	O	O
enzymes	NNS	O	O
may	MD	O	O
change	VB	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
alosetron	NN	D	D
.	.	.	.

fluvoxamine	NN	D	D
is	VBZ	O	O
a	DT	O	O
known	JJ	O	O
strong	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
cyp1a2	NN	D	O
and	CC	O	O
also	RB	O	O
inhibits	VBZ	O	O
cyp3a4	NN	D	D
","	","	O	O
cyp2c9	NN	D	O
","	","	O	O
and	CC	O	O
cyp2c19	NN	O	O
.	.	.	.

in	IN	O	O
a	DT	O	O
pharmacokinetic	JJ	O	O
study	NN	O	O
","	","	O	O
40	CD	O	O
healthy	JJ	O	O
female	JJ	O	O
subjects	NNS	O	O
received	VBD	O	O
fluvoxamine	NN	D	D
in	IN	O	O
escalating	VBG	O	O
doses	NNS	O	O
from	IN	O	O
50	CD	O	O
to	TO	O	O
200	CD	O	O
mg	NN	O	O
per	IN	O	O
day	NN	O	O
for	IN	O	O
16	CD	O	O
days	NNS	O	O
","	","	O	O
with	IN	O	O
coadministration	NN	O	O
of	IN	O	O
alosetron	NN	D	D
1	CD	O	O
mg	NN	O	O
on	IN	O	O
the	DT	O	O
last	JJ	O	O
day	NN	O	O
.	.	.	.

fluvoxamine	NN	D	D
increased	VBD	O	O
mean	JJ	O	O
alosetron	NN	D	O
plasma	NN	O	O
concentrations	NNS	O	O
-lrb-	-LRB-	O	O
auc	NN	O	O
-rrb-	-RRB-	O	O
approximately	RB	O	O
6-fold	RB	O	O
and	CC	O	O
prolonged	VBD	O	O
the	DT	O	O
half-life	NN	O	O
by	IN	O	O
approximately	RB	O	O
3-fold	RB	O	O
.	.	.	.

concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
alosetron	NN	D	D
and	CC	O	O
fluvoxamine	NN	D	D
is	VBZ	O	O
contraindicated	VBN	O	O
.	.	.	.

concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
alosetron	NN	D	D
and	CC	O	O
moderate	JJ	O	O
cyp1a2	NN	D	O
inhibitors	NNS	O	O
","	","	O	O
including	VBG	O	O
quinolone	JJ	G	G
antibiotics	NNS	G	G
and	CC	O	O
cimetidine	NN	D	D
","	","	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
evaluated	VBN	O	O
","	","	O	O
but	CC	O	O
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
unless	IN	O	O
clinically	RB	O	O
necessary	JJ	O	O
because	IN	O	O
of	IN	O	O
similar	JJ	O	O
potential	JJ	O	O
drug	NN	D	O
interactions	NNS	O	O
.	.	.	.

ketoconazole	NN	D	D
is	VBZ	O	O
a	DT	O	O
known	JJ	O	O
strong	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
cyp3a4	NN	D	D
.	.	.	.

in	IN	O	O
a	DT	O	O
pharmacokinetic	JJ	O	O
study	NN	O	O
","	","	O	O
38	CD	O	O
healthy	JJ	O	O
female	JJ	O	O
subjects	NNS	O	O
received	VBD	O	O
ketoconazole	NN	D	D
200	CD	O	O
mg	NN	O	O
twice	RB	O	O
daily	RB	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
","	","	O	O
with	IN	O	O
coadministration	NN	O	O
of	IN	O	O
alosetron	NN	D	D
1	CD	O	O
mg	NN	O	O
on	IN	O	O
the	DT	O	O
last	JJ	O	O
day	NN	O	O
.	.	.	.

ketoconazole	NN	D	D
increased	VBD	O	O
mean	JJ	O	O
alosetron	NN	D	O
plasma	NN	O	O
concentrations	NNS	O	O
-lrb-	-LRB-	O	O
auc	NN	O	O
-rrb-	-RRB-	O	O
by	IN	O	O
29	CD	O	O
%	NN	O	O
.	.	.	.

caution	NN	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
when	WRB	O	O
alosetron	NN	D	D
and	CC	O	O
ketoconazole	NN	D	D
are	VBP	O	O
administered	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

coadministration	NN	O	O
of	IN	O	O
alosetron	NN	D	D
and	CC	O	O
strong	JJ	O	O
cyp3a4	NN	D	D
inhibitors	NNS	O	O
","	","	O	O
such	JJ	O	O
as	IN	O	O
clarithromycin	NN	D	D
","	","	O	O
telithromycin	NN	D	D
","	","	O	O
protease	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
voriconazole	NN	D	D
","	","	O	O
and	CC	O	O
itraconazole	NN	D	D
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
evaluated	VBN	O	O
but	CC	O	O
should	MD	O	O
be	VB	O	O
undertaken	VBN	O	O
with	IN	O	O
caution	NN	O	O
because	IN	O	O
of	IN	O	O
similar	JJ	O	O
potential	JJ	O	O
drug	NN	D	O
interactions	NNS	O	O
.	.	.	.

the	DT	O	O
effect	NN	O	O
of	IN	O	O
induction	NN	O	D
or	CC	O	O
inhibition	NN	O	O
of	IN	O	O
other	JJ	O	O
pathways	NNS	O	O
on	IN	O	O
exposure	NN	O	O
to	TO	O	O
alosetron	NN	D	D
and	CC	O	O
its	PRP$	O	O
metabolites	NNS	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
.	.	.	.

in	FW	O	O
vitro	FW	O	O
human	JJ	O	O
liver	NN	O	O
microsome	NN	O	O
studies	NNS	O	O
and	CC	O	O
an	DT	O	O
in	FW	O	O
vivo	FW	O	O
metabolic	JJ	O	O
probe	NN	O	O
study	NN	O	O
demonstrated	VBD	O	O
that	IN	O	O
alosetron	NN	D	D
did	VBD	O	O
not	RB	O	O
inhibit	VB	O	O
cyp	NN	O	O
enzymes	NNS	O	O
2d6	NN	O	O
","	","	O	O
3a4	NN	O	O
","	","	O	O
2c9	NN	O	O
","	","	O	O
or	CC	O	O
2c19	NN	O	O
.	.	.	.

in	FW	O	O
vitro	FW	O	O
","	","	O	O
at	IN	O	O
total	JJ	O	O
drug	NN	D	O
concentrations	NNS	O	O
27-fold	RB	O	O
higher	JJR	O	O
than	IN	O	O
peak	JJ	O	O
plasma	NN	O	O
concentrations	NNS	O	O
observed	VBN	O	O
with	IN	O	O
the	DT	O	O
1-mg	JJ	O	O
dosage	NN	O	O
","	","	O	O
alosetron	NN	D	O
inhibited	VBD	O	O
cyp	NN	O	O
enzymes	NNS	O	O
1a2	NN	O	O
-lrb-	-LRB-	O	O
60	CD	O	O
%	NN	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
2.00E+01	NN	O	O
-lrb-	-LRB-	O	O
50	CD	O	O
%	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

in	IN	O	O
an	DT	O	O
in	FW	O	O
vivo	FW	O	O
metabolic	JJ	O	O
probe	NN	O	O
study	NN	O	O
","	","	O	O
alosetron	NN	D	D
did	VBD	O	O
not	RB	O	O
inhibit	VB	O	O
cyp2e1	NN	O	O
but	CC	O	O
did	VBD	O	O
produce	VB	O	O
30	CD	O	O
%	NN	O	O
inhibition	NN	O	O
of	IN	O	O
both	CC	O	O
cyp1a2	NN	D	O
and	CC	O	O
n-acetyltransferase	NN	O	O
.	.	.	.

although	IN	O	O
not	RB	O	O
studied	VBN	O	O
with	IN	O	O
alosetron	NN	D	D
","	","	O	O
inhibition	NN	O	O
of	IN	O	O
n-acetyltransferase	NN	O	D
may	MD	O	O
have	VB	O	O
clinically	RB	O	O
relevant	JJ	O	O
consequences	NNS	O	O
for	IN	O	O
drugs	NNS	D	D
such	JJ	O	O
as	IN	O	O
isoniazid	NN	D	D
","	","	O	O
procainamide	NN	D	D
","	","	O	O
and	CC	O	O
hydralazine	NN	D	D
.	.	.	.

the	DT	O	O
effect	NN	O	O
on	IN	O	O
cyp1a2	NN	D	O
was	VBD	O	O
explored	VBN	O	O
further	RB	O	O
in	IN	O	O
a	DT	O	O
clinical	JJ	O	O
interaction	NN	O	O
study	NN	O	O
with	IN	O	O
theophylline	NN	D	D
and	CC	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
metabolism	NN	O	O
was	VBD	O	O
observed	VBN	O	O
.	.	.	.

another	DT	O	O
study	NN	O	O
showed	VBD	O	O
that	IN	O	O
alosetron	NN	D	D
had	VBD	O	O
no	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
the	DT	O	O
oral	JJ	O	O
contraceptive	JJ	O	G
agents	NNS	O	O
ethinyl	NN	O	O
estradiol	NN	O	O
and	CC	O	O
levonorgestrel	NN	D	O
-lrb-	-LRB-	O	O
cyp3a4	NN	D	D
substrates	NNS	O	O
-rrb-	-RRB-	O	O
.	.	.	.

a	DT	O	O
clinical	JJ	O	O
interaction	NN	O	O
study	NN	O	O
was	VBD	O	O
also	RB	O	O
conducted	VBN	O	O
with	IN	O	O
alosetron	NN	D	D
and	CC	O	O
the	DT	O	O
cyp3a4	NN	D	D
substrate	NN	O	O
cisapride	NN	D	D
.	.	.	.

no	DT	O	O
significant	JJ	O	O
effects	NNS	O	O
on	IN	O	O
cisapride	NN	D	D
metabolism	NN	O	O
or	CC	O	O
qt	NN	O	O
interval	NN	O	O
were	VBD	O	O
noted	VBN	O	O
.	.	.	.

the	DT	O	O
effect	NN	O	O
of	IN	O	O
alosetron	NN	D	D
on	IN	O	O
monoamine	NN	O	O
oxidases	NNS	O	O
and	CC	O	O
on	IN	O	O
intestinal	JJ	O	O
first	JJ	O	O
pass	NN	O	O
secondary	JJ	O	O
to	TO	O	O
high	JJ	O	O
intraluminal	JJ	O	O
concentrations	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
examined	VBN	O	O
.	.	.	.

based	VBN	O	O
on	IN	O	O
the	DT	O	O
above	JJ	O	O
data	NNS	O	O
from	IN	O	O
in	FW	O	O
vitro	FW	O	O
and	CC	O	O
in	FW	O	O
vivo	FW	O	O
studies	NNS	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
unlikely	JJ	O	O
that	IN	O	O
alosetron	NN	D	D
will	MD	O	O
inhibit	VB	O	O
the	DT	O	O
hepatic	JJ	O	O
metabolic	JJ	O	O
clearance	NN	O	O
of	IN	O	O
drugs	NNS	D	D
metabolized	VBN	O	O
by	IN	O	O
the	DT	O	O
major	JJ	O	O
cyp	NN	O	O
enzyme	NN	O	O
3a4	NN	O	O
","	","	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
cyp	NN	O	O
enzymes	NNS	O	O
2d6	NN	O	O
","	","	O	O
2c9	NN	O	O
","	","	O	O
2c19	NN	O	O
","	","	O	O
2.00E+01	NN	O	O
","	","	O	O
or	CC	O	O
1a2	NN	O	O
.	.	.	.

alosetron	NNP	D	D
does	VBZ	O	O
not	RB	O	O
appear	VB	O	O
to	TO	O	O
induce	VB	O	O
the	DT	O	O
major	JJ	O	O
cytochrome	NN	O	O
p450	NN	O	O
-lrb-	-LRB-	O	O
cyp	NN	O	O
-rrb-	-RRB-	O	O
drug	NN	D	O
metabolizing	VBG	O	O
enzyme	NN	O	O
3a	NN	O	O
.	.	.	.

alosetron	NNP	D	D
also	RB	O	O
does	VBZ	O	O
not	RB	O	O
appear	VB	O	O
to	TO	O	O
induce	VB	O	O
cyp	NN	O	O
enzymes	NNS	O	O
2.00E+01	NN	O	O
or	CC	O	O
2c19	NN	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
whether	IN	O	O
alosetron	NN	D	D
might	MD	O	O
induce	VB	O	O
other	JJ	O	O
enzymes	NNS	O	O
.	.	.	.

the	DT	O	O
benzodiazepines	NNS	G	G
","	","	O	O
including	VBG	O	O
alprazolam	NN	D	D
","	","	O	O
produce	VBP	O	O
additive	JJ	O	O
cns	NNS	O	O
depressant	NN	O	O
effects	NNS	O	O
when	WRB	O	O
co-administered	VBN	O	O
with	IN	O	O
other	JJ	O	O
psychotropic	JJ	O	O
medications	NNS	O	O
","	","	O	O
anticonvulsants	NNS	G	G
","	","	O	O
antihistaminics	NNS	G	G
","	","	O	O
ethanol	NN	D	D
","	","	O	O
and	CC	O	O
other	JJ	O	O
drugs	NNS	D	D
which	WDT	O	O
themselves	PRP	O	O
produce	VBP	O	O
cns	NN	O	O
depression	NN	O	O
.	.	.	.

the	DT	O	O
steady	JJ	O	O
state	NN	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
imipramine	NN	D	D
and	CC	O	O
desipramine	NN	D	D
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
be	VB	O	O
increased	VBN	O	O
an	DT	O	O
average	NN	O	O
of	IN	O	O
31	CD	O	O
%	NN	O	O
and	CC	O	O
20	CD	O	O
%	NN	O	O
","	","	O	O
respectively	RB	O	O
","	","	O	O
by	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
alprazolam	NN	D	D
tablets	NNS	O	O
in	IN	O	O
doses	NNS	O	O
up	RB	O	O
to	TO	O	O
4	CD	O	O
mg/day	NN	O	O
.	.	.	.

the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
these	DT	O	O
changes	NNS	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	.	.

drugs	NNS	O	O
that	WDT	O	O
inhibit	VBP	O	O
alprazolam	NNP	D	D
metabolism	NNP	O	O
via	NNP	O	O
cytochrome	NNP	O	O
p450	NN	O	O
3a	NN	O	O
:	:	O	O
the	DT	O	O
initial	JJ	O	O
step	NN	O	O
in	IN	O	O
alprazolam	NN	D	D
metabolism	NN	O	O
is	VBZ	O	O
hydroxylation	NN	O	O
catalyzed	VBN	O	O
by	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
3a	NN	O	O
-lrb-	-LRB-	O	O
cyp	NN	O	O
3a	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

drugs	NNS	O	O
which	WDT	O	O
inhibit	VBP	O	O
this	DT	O	O
metabolic	JJ	O	O
pathway	NN	O	O
may	MD	O	O
have	VB	O	O
a	DT	O	O
profound	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
alprazolam	NN	D	D
.	.	.	.

drugs	NNS	O	O
demonstrated	VBN	O	O
to	TO	O	O
be	VB	O	O
cyp	NN	O	O
3a	NN	O	O
inhibitors	NNS	O	O
of	IN	O	O
possible	JJ	O	O
clinical	JJ	O	O
significance	NN	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
involving	VBG	O	O
alprazolam	NN	D	D
-lrb-	-LRB-	O	O
caution	NN	O	O
is	VBZ	O	O
recommended	VBN	O	O
during	IN	O	O
coadministration	NN	O	O
with	IN	O	O
alprazolam	NN	D	D
-rrb-	-RRB-	O	O
:	:	O	O
coadministration	NN	O	O
of	IN	O	O
fluoxetine	NN	D	D
with	IN	O	O
alprazolam	NN	D	D
increased	VBD	O	O
the	DT	O	O
maximum	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
of	IN	O	O
alprazolam	NN	D	D
by	IN	O	O
46	CD	O	O
%	NN	O	O
","	","	O	O
decreased	VBD	O	O
clearance	NN	O	O
by	IN	O	O
21	CD	O	O
%	NN	O	O
","	","	O	O
increased	VBD	O	O
half-life	NN	O	O
by	IN	O	O
17	CD	O	O
%	NN	O	O
","	","	O	O
and	CC	O	O
decreased	VBD	O	O
measured	VBN	O	O
psychomotor	NN	O	O
performance	NN	O	O
.	.	.	.

coadministration	NN	O	O
of	IN	O	O
propoxyphene	NN	D	D
decreased	VBD	O	O
the	DT	O	O
maximum	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
of	IN	O	O
alprazolam	NN	D	D
by	IN	O	O
6	CD	O	O
%	NN	O	O
","	","	O	O
decreased	VBD	O	O
clearance	NN	O	O
by	IN	O	O
38	CD	O	O
%	NN	O	O
","	","	O	O
and	CC	O	O
increased	VBD	O	O
half-life	NN	O	O
by	IN	O	O
58	CD	O	O
%	NN	O	O
.	.	.	.

coadministration	NN	O	O
of	IN	O	O
oral	JJ	O	O
contraceptives	NNS	G	G
increased	VBD	O	O
the	DT	O	O
maximum	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
of	IN	O	O
alprazolam	NN	D	D
by	IN	O	O
18	CD	O	O
%	NN	O	O
","	","	O	O
decreased	VBD	O	O
clearance	NN	O	O
by	IN	O	O
22	CD	O	O
%	NN	O	O
","	","	O	O
and	CC	O	O
increased	VBD	O	O
half-life	NN	O	O
by	IN	O	O
29	CD	O	O
%	NN	O	O
.	.	.	.

drugs	NNS	O	D
and	CC	O	O
other	JJ	O	O
substances	NNS	O	O
demonstrated	VBD	O	O
to	TO	O	O
be	VB	O	O
cyp	NN	O	O
3a	NN	O	O
inhibitors	NNS	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
involving	VBG	O	O
benzodiazepines	NNS	G	G
metabolized	VBN	O	O
similarly	RB	O	O
to	TO	O	O
alprazolam	NN	D	D
or	CC	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
with	IN	O	O
alprazolam	NN	D	D
or	CC	O	O
other	JJ	O	O
benzodiazepines	NNS	G	G
-lrb-	-LRB-	O	O
caution	NN	O	O
is	VBZ	O	O
recommended	VBN	O	O
during	IN	O	O
coadministration	NN	O	O
with	IN	O	O
alprazolam	NN	D	D
-rrb-	-RRB-	O	O
:	:	O	O
available	JJ	O	O
data	NNS	O	O
from	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
of	IN	O	O
benzodiazepines	NNS	G	G
other	JJ	O	O
than	IN	O	O
alprazolam	NN	D	D
suggest	VBP	O	O
a	DT	O	O
possible	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
with	IN	O	O
alprazolam	NN	D	D
for	IN	O	O
the	DT	O	O
following	NN	O	O
:	:	O	O
diltiazem	NN	D	D
","	","	O	O
isoniazid	NN	D	D
","	","	O	O
macrolide	NN	O	O
antibiotics	NNS	G	G
such	JJ	O	O
as	IN	O	O
erythromycin	NN	D	D
and	CC	O	O
clarithromycin	NN	D	D
","	","	O	O
and	CC	O	O
grapefruit	NN	O	O
juice	NN	O	O
.	.	.	.

data	NNS	O	O
from	IN	O	O
in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
of	IN	O	O
alprazolam	NN	D	D
suggest	VBP	O	O
a	DT	O	O
possible	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
with	IN	O	O
alprazolam	NN	D	D
for	IN	O	O
the	DT	O	O
following	NN	O	O
:	:	O	O
sertraline	NN	D	D
and	CC	O	O
paroxetine	NN	D	D
.	.	.	.

data	NNS	O	O
from	IN	O	O
in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
of	IN	O	O
benzodiazepines	NNS	G	G
other	JJ	O	O
than	IN	O	O
alprazolam	NN	D	D
suggest	VBP	O	O
a	DT	O	O
possible	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
for	IN	O	O
the	DT	O	O
following	NN	O	O
:	:	O	O
ergotamine	NN	D	D
","	","	O	O
cyclosporine	NN	D	D
","	","	O	O
amiodarone	NN	D	D
","	","	O	O
nicardipine	NN	D	D
","	","	O	O
and	CC	O	O
nifedipine	NN	D	D
.	.	.	.

caution	NN	O	O
is	VBZ	O	O
recommended	VBN	O	O
during	IN	O	O
the	DT	O	O
coadministration	NN	O	O
of	IN	O	O
any	DT	O	O
of	IN	O	O
these	DT	O	O
with	IN	O	O
alprazolam	NN	D	D
.	.	.	.

no	DT	O	O
drug	NN	D	O
interactions	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
between	IN	O	O
prostin	NNP	O	B
vr	NN	O	O
pediatric	NNP	O	O
and	CC	O	O
the	DT	O	O
therapy	NN	O	O
standard	NN	O	O
in	IN	O	O
neonates	NNS	O	O
with	IN	O	O
restricted	JJ	O	O
pulmonary	JJ	O	O
or	CC	O	O
systemic	JJ	O	O
blood	NN	O	O
flow	NN	O	O
.	.	.	.

standard	JJ	O	O
therapy	NN	O	O
includes	VBZ	O	O
antibiotics	NNS	G	G
","	","	O	O
such	JJ	O	O
as	IN	O	O
penicillin	NN	D	D
and	CC	O	O
gentamicin	NN	D	D
.	.	.	.

vasopressors	NNS	G	G
","	","	O	O
such	JJ	O	O
as	IN	O	O
dopamine	NN	D	D
and	CC	O	O
isoproterenol	NN	D	D
.	.	.	.

cardiac	JJ	O	O
glycosides	NNS	O	G
.	.	.	.

and	CC	O	O
diuretics	NNS	G	G
","	","	O	O
such	JJ	O	O
as	IN	O	O
furosemide	NN	D	D
.	.	.	.

caverject	NNP	B	D
:	:	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
pharmacokinetic	JJ	O	O
drug-drug	NN	O	O
interactions	NNS	O	O
between	IN	O	O
alprostadil	NN	D	D
and	CC	O	O
other	JJ	O	O
agents	NNS	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
formally	RB	O	O
studied	VBN	O	O
.	.	.	.

the	DT	O	O
interaction	NN	O	O
of	IN	O	O
activase	NN	B	D
with	IN	O	O
other	JJ	O	O
cardioactive	JJ	O	O
or	CC	O	O
cerebroactive	JJ	O	O
drugs	NNS	D	D
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
.	.	.	.

in	IN	O	O
addition	NN	O	O
to	TO	O	O
bleeding	NN	O	O
associated	VBN	O	O
with	IN	O	O
heparin	NN	D	D
and	CC	O	O
vitamin	NN	O	G
k	NN	O	O
antagonists	NNS	O	O
","	","	O	O
drugs	NNS	D	D
that	WDT	O	O
alter	VBP	O	O
platelet	NN	O	O
function	NN	O	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
acetylsalicylic	JJ	O	O
acid	NN	O	O
","	","	O	O
dipyridamole	NN	D	D
and	CC	O	O
abciximab	NNP	D	D
-rrb-	-RRB-	O	O
may	MD	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
bleeding	VBG	O	O
if	IN	O	O
administered	VBN	O	O
prior	RB	O	O
to	TO	O	O
","	","	O	O
during	IN	O	O
","	","	O	O
or	CC	O	O
after	IN	O	O
activase	NN	B	G
therapy	NN	O	O
.	.	.	.

use	NN	O	O
of	IN	O	O
antithrombotics	NNP	G	O
aspirin	NNP	B	B
and	CC	O	O
heparin	NN	D	D
have	VBP	O	O
been	VBN	O	O
administered	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
and	CC	O	O
following	VBG	O	O
infusions	NNS	O	O
of	IN	O	O
activase	NNP	B	B
in	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
acute	JJ	O	O
myocardial	JJ	O	O
infarction	NN	O	O
or	CC	O	O
pulmonary	JJ	O	O
embolism	NN	O	O
.	.	.	.

because	IN	O	O
heparin	NN	D	D
","	","	O	O
aspirin	NN	B	B
","	","	O	O
or	CC	O	O
activase	NNP	B	D
may	MD	O	O
cause	VB	O	O
bleeding	JJ	O	O
complications	NNS	O	O
","	","	O	O
careful	JJ	O	O
monitoring	NN	O	O
for	IN	O	O
bleeding	NN	O	O
is	VBZ	O	O
advised	VBN	O	O
","	","	O	O
especially	RB	O	O
at	IN	O	O
arterial	JJ	O	O
puncture	NN	O	O
sites	NNS	O	O
.	.	.	.

the	DT	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
heparin	NN	D	D
or	CC	O	O
aspirin	NN	B	B
during	IN	O	O
the	DT	O	O
first	JJ	O	O
24	CD	O	O
hours	NNS	O	O
following	VBG	O	O
symptom	NN	O	O
onset	NN	O	O
were	VBD	O	O
prohibited	VBN	O	O
in	IN	O	O
the	DT	O	O
ninds	NN	O	O
t-pa	NN	O	O
stroke	NNP	O	O
trial	NNP	O	O
.	.	.	.

the	DT	O	O
safety	NN	O	O
of	IN	O	O
such	JJ	O	O
concomitant	JJ	O	O
use	NN	O	O
with	IN	O	O
activase	NN	B	D
for	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
acute	JJ	O	O
ischemic	JJ	O	O
stroke	NN	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	.	.

concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
hexalen	NN	B	D
and	CC	O	O
antidepressants	NNS	G	O
of	IN	O	O
the	DT	O	O
mao	NNP	O	O
inhibitor	NN	O	O
class	NN	O	D
may	MD	O	O
cause	VB	O	O
severe	JJ	O	O
orthostatic	JJ	O	O
hypotension.cimetidine	NN	O	O
","	","	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
microsomal	JJ	O	O
drug	NN	D	O
metabolism	NN	O	O
","	","	O	O
increased	VBD	O	O
altretamines	NNS	O	O
half-life	NN	O	O
and	CC	O	O
toxicity	NN	O	O
in	IN	O	O
a	DT	O	O
rat	NN	O	O
model	NN	O	O
.	.	.	.

data	NNS	O	O
from	IN	O	O
a	DT	O	O
randomized	JJ	O	O
trial	NN	O	O
of	IN	O	O
hexalen	NN	B	D
and	CC	O	O
cisplatin	NN	D	D
plus	CC	O	O
or	CC	O	O
minus	CC	O	O
pyridoxine	NN	D	O
in	IN	O	O
ovarian	JJ	O	O
cancer	NN	O	O
indicated	VBD	O	O
that	IN	O	O
pyridoxine	NN	D	D
significantly	RB	O	O
reduced	VBD	O	O
neurotoxicity	NN	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
it	PRP	O	O
adversely	RB	O	O
affected	VBD	O	O
response	NN	O	O
duration	NN	O	O
suggesting	VBG	O	O
that	IN	O	O
pyridoxine	NN	D	D
should	MD	O	O
not	RB	O	O
be	VB	O	O
administered	VBN	O	O
with	IN	O	O
hexalen	NN	B	B
and/or	CC	O	O
cisplatin	NN	D	D
.	.	.	.

careful	JJ	O	O
observation	NN	O	O
is	VBZ	O	O
required	VBN	O	O
when	WRB	O	O
amantadine	NN	D	D
is	VBZ	O	O
administered	VBN	O	O
concurrently	RB	O	O
with	IN	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
stimulants	NNS	O	O
.	.	.	.

coadministration	NN	O	O
of	IN	O	O
thioridazine	NN	D	D
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
worsen	VB	O	O
the	DT	O	O
tremor	NN	O	O
in	IN	O	O
elderly	JJ	O	O
patients	NNS	O	O
with	IN	O	O
parkinsons	NNPS	O	O
disease	NN	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
if	IN	O	O
other	JJ	O	O
phenothiazines	NNS	G	G
produce	VBP	O	O
a	DT	O	O
similar	JJ	O	O
response	NN	O	O
.	.	.	.

special	JJ	O	O
consideration	NN	O	O
should	MD	O	O
be	VB	O	O
given	VBN	O	O
to	TO	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
ethyol	NNP	B	B
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
antihypertensive	JJ	O	G
medications	NNS	O	O
or	CC	O	O
other	JJ	O	O
drugs	NNS	D	D
that	WDT	O	O
could	MD	O	O
cause	VB	O	O
or	CC	O	O
potentiate	VB	O	O
hypotension	NN	O	O
.	.	.	.

when	WRB	O	O
amiloride	NN	D	D
hcl	NN	O	O
is	VBZ	O	O
administered	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
an	DT	O	O
angiotensin-converting	JJ	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
","	","	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
hyperkalemia	NN	O	O
may	MD	O	O
be	VB	O	O
increased	VBN	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
if	IN	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
these	DT	O	O
agents	NNS	O	O
is	VBZ	O	O
indicated	VBN	O	O
because	IN	O	O
of	IN	O	O
demonstrated	VBN	O	O
hypokalemia	NN	O	O
","	","	O	O
they	PRP	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
caution	NN	O	O
and	CC	O	O
with	IN	O	O
frequent	JJ	O	O
monitoring	NN	O	O
of	IN	O	O
serum	NN	O	O
potassium	NN	D	D
.	.	.	.

lithium	NN	D	D
generally	RB	O	O
should	MD	O	O
not	RB	O	O
be	VB	O	O
given	VBN	O	O
with	IN	O	O
diuretics	NNS	G	G
because	IN	O	O
they	PRP	O	O
reduce	VBP	O	O
its	PRP$	O	O
renal	JJ	O	O
clearance	NN	O	O
and	CC	O	O
add	VB	O	O
a	DT	O	O
high	JJ	O	O
risk	NN	O	O
of	IN	O	O
lithium	NN	D	D
toxicity	NN	O	O
.	.	.	.

read	VB	O	O
circulars	NNS	O	O
for	IN	O	O
lithium	NN	D	D
preparations	NNS	O	O
before	IN	O	O
use	NN	O	O
of	IN	O	O
such	JJ	O	O
concomitant	JJ	O	O
therapy	NN	O	O
.	.	.	.

in	IN	O	O
some	DT	O	O
patients	NNS	O	O
","	","	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
a	DT	O	O
non-steroidal	JJ	O	O
anti-inflammatory	JJ	O	G
agent	NN	O	O
can	MD	O	O
reduce	VB	O	O
the	DT	O	O
diuretic	JJ	G	G
","	","	O	O
natriuretic	JJ	O	O
","	","	O	O
and	CC	O	O
antihypertensive	JJ	O	G
effects	NNS	O	O
of	IN	O	O
loop	NN	O	O
","	","	O	O
potassium-sparing	NN	O	O
and	CC	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
.	.	.	.

therefore	RB	O	O
","	","	O	O
when	WRB	O	O
midamor	NN	B	D
and	CC	O	O
non-steroidal	JJ	O	O
anti-inflammatory	JJ	O	G
agents	NNS	O	O
are	VBP	O	O
used	VBN	O	O
concomitantly	RB	O	O
","	","	O	O
the	DT	O	O
patient	NN	O	O
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
closely	RB	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
the	DT	O	O
desired	VBN	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
diuretic	JJ	G	G
is	VBZ	O	O
obtained	VBN	O	O
.	.	.	.

since	IN	O	O
indomethacin	NN	D	D
and	CC	O	O
potassium-sparing	JJ	O	O
diuretics	NNS	G	G
","	","	O	O
including	VBG	O	O
midamor	NNP	B	B
","	","	O	O
may	MD	O	O
each	DT	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
increased	VBN	O	O
serum	NN	O	O
potassium	NN	D	D
levels	NNS	O	O
","	","	O	O
the	DT	O	O
potential	JJ	O	O
effects	NNS	O	O
on	IN	O	O
potassium	NN	D	D
kinetics	NNS	O	O
and	CC	O	O
renal	JJ	O	O
function	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
when	WRB	O	O
these	DT	O	O
agents	NNS	O	O
are	VBP	O	O
administered	VBN	O	O
concurrently	RB	O	O
.	.	.	.

drug	NNP	O	O
laboratory	NNP	O	O
test	NNP	O	O
interactions	NNS	O	O
:	:	O	O
prolongation	NN	O	O
of	IN	O	O
the	DT	O	O
template	NN	O	O
bleeding	NN	O	O
time	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
during	IN	O	O
continuous	JJ	O	O
intravenous	JJ	O	O
infusion	NN	O	O
of	IN	O	O
amicar	NN	B	D
at	IN	O	O
dosages	NNS	O	O
exceeding	VBG	O	O
24	CD	O	O
g/day	NN	O	O
.	.	.	.

platelet	NN	O	O
function	NN	O	O
studies	NNS	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
have	VBP	O	O
not	RB	O	O
demonstrated	VBN	O	O
any	DT	O	O
significant	JJ	O	O
platelet	NN	O	O
dysfunction	NN	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
at	IN	O	O
high	JJ	O	O
concentrations	NNS	O	O
-lrb-	-LRB-	O	O
7.4	CD	O	O
mmol/l	NN	O	O
or	CC	O	O
0.97	CD	O	O
mg/ml	NN	O	O
and	CC	O	O
greater	JJR	O	O
-rrb-	-RRB-	O	O
eaca	NN	D	D
inhibits	VBZ	O	O
adp	NN	O	O
and	CC	O	O
collagen-induced	JJ	O	O
platelet	NN	O	O
aggregation	NN	O	O
","	","	O	O
the	DT	O	O
release	NN	O	O
of	IN	O	O
atp	NN	O	D
and	CC	O	O
serotonin	NN	O	O
","	","	O	O
and	CC	O	O
the	DT	O	O
binding	NN	O	O
of	IN	O	O
fibrinogen	NN	O	D
to	TO	O	O
the	DT	O	O
platelets	NNS	O	O
in	IN	O	O
a	DT	O	O
concentration-response	JJ	O	O
manner	NN	O	O
.	.	.	.

following	VBG	O	O
a	DT	O	O
10	CD	O	O
g	NN	O	O
bolus	NN	O	O
of	IN	O	O
amicar	NNP	B	B
","	","	O	O
transient	JJ	O	O
peak	NN	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
4.6	CD	O	O
mmol/l	NN	O	O
or	CC	O	O
0.6	CD	O	O
mg/ml	NN	O	O
have	VBP	O	O
been	VBN	O	O
obtained	VBN	O	O
.	.	.	.

the	DT	O	O
concentration	NN	O	O
of	IN	O	O
amicar	NNP	B	B
necessary	JJ	O	O
to	TO	O	O
maintain	VB	O	O
inhibition	NN	O	O
of	IN	O	O
fibrinolysis	NN	O	O
is	VBZ	O	O
0.99	CD	O	O
mmol/l	NN	O	O
or	CC	O	O
0.13	CD	O	O
mg/ml	NN	O	O
.	.	.	.

administration	NN	O	O
of	IN	O	O
a	DT	O	O
5	CD	O	O
g	NN	O	O
bolus	NN	O	O
followed	VBN	O	O
by	IN	O	O
1	CD	O	O
to	TO	O	O
1.25	CD	O	O
g/hr	NN	O	O
should	MD	O	O
achieve	VB	O	O
and	CC	O	O
sustain	VB	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
0.13	CD	O	O
mg/ml	NN	O	O
.	.	.	.

thus	RB	O	O
","	","	O	O
concentrations	NNS	O	O
which	WDT	O	O
have	VBP	O	O
been	VBN	O	O
obtained	VBN	O	O
in	FW	O	O
vivo	FW	O	O
clinically	RB	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
normal	JJ	O	O
renal	JJ	O	O
function	NN	O	O
are	VBP	O	O
considerably	RB	O	O
lower	JJR	O	O
than	IN	O	O
the	DT	O	O
in	FW	O	O
vitro	FW	O	O
concentrations	NNS	O	O
found	VBN	O	O
to	TO	O	O
induce	VB	O	O
abnormalities	NNS	O	O
in	IN	O	O
platelet	NN	O	O
function	NN	O	O
tests	NNS	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
higher	JJR	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
amicar	NN	B	D
may	MD	O	O
occur	VB	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
severe	JJ	O	O
renal	JJ	O	O
failure	NN	O	O
.	.	.	.

cytadren	NN	B	D
accelerates	VBZ	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
dexamethasone	NN	D	D
.	.	.	.

therefore	RB	O	O
","	","	O	O
if	IN	O	O
glucocorticoid	NN	G	O
replacement	NN	O	O
is	VBZ	O	O
needed	VBN	O	O
","	","	O	O
hydrocortisone	NN	D	D
should	MD	O	O
be	VB	O	O
prescribed	VBN	O	O
.	.	.	.

aminoglutethimide	NNP	D	D
diminishes	VBZ	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
coumarin	NN	G	G
and	CC	O	O
warfarin	NN	D	D
.	.	.	.

renal	JJ	O	O
clearance	NN	O	O
measurements	NNS	O	O
of	IN	O	O
pah	NN	D	D
can	MD	O	O
not	RB	O	O
be	VB	O	O
made	VBN	O	O
with	IN	O	O
any	DT	O	O
significant	JJ	O	O
accuracy	NN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
sulfonamides	NNS	G	G
","	","	O	O
procaine	NN	D	D
","	","	O	O
or	CC	O	O
thiazolesulfone	NN	D	D
.	.	.	.

these	DT	O	O
compounds	NNS	O	O
interfere	VBP	O	O
with	IN	O	O
chemical	NN	O	O
color	NN	O	O
development	NN	O	O
essential	JJ	O	O
to	TO	O	O
the	DT	O	O
analytical	JJ	O	O
procedures	NNS	O	O
.	.	.	.

probenecid	NNP	D	D
depresses	VBZ	O	O
tubular	JJ	O	O
secretion	NN	O	O
of	IN	O	O
certain	JJ	O	O
weak	JJ	O	O
acids	NNS	O	O
such	JJ	O	O
as	IN	O	O
pah	NN	D	D
.	.	.	.

therefore	RB	O	O
","	","	O	O
patients	NNS	O	O
receiving	VBG	O	O
probenecid	NN	D	D
will	MD	O	O
have	VB	O	O
erroneously	RB	O	O
low	JJ	O	O
erpf	NN	O	O
and	CC	O	O
tm	NN	O	O
pah	NN	D	O
values	NNS	O	O
.	.	.	.

there	EX	O	O
have	VBP	O	O
been	VBN	O	O
no	DT	O	O
formal	JJ	O	O
studies	NNS	O	O
of	IN	O	O
the	DT	O	O
interaction	NN	O	O
of	IN	O	O
levulan	NNP	O	O
kerastick	NNP	O	O
for	IN	O	O
topical	NNP	O	O
solution	NN	O	O
with	IN	O	O
any	DT	O	O
other	JJ	O	O
drugs	NNS	D	D
","	","	O	O
and	CC	O	O
no	DT	O	O
drug-specific	JJ	O	O
interactions	NNS	O	O
were	VBD	O	O
noted	VBN	O	O
during	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
controlled	JJ	O	O
clinical	JJ	O	O
trials	NNS	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
","	","	O	O
however	RB	O	O
","	","	O	O
possible	JJ	O	O
that	IN	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
other	JJ	O	O
known	JJ	O	O
photosensitizing	JJ	O	O
agents	NNS	O	O
such	JJ	O	O
as	IN	O	O
griseofulvin	NN	D	D
","	","	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
","	","	O	O
sulfonylureas	NNS	G	G
","	","	O	O
phenothiazines	NNS	G	G
","	","	O	O
sulfonamides	NNS	G	G
and	CC	O	O
tetracyclines	NNS	G	G
might	MD	O	O
increase	VB	O	O
the	DT	O	O
photosensitivity	NN	O	O
reaction	NN	O	O
of	IN	O	O
actinic	JJ	O	O
keratoses	NNS	O	O
treated	VBN	O	O
with	IN	O	O
the	DT	O	O
levulan	NNP	O	O
kerastick	NNP	O	O
for	IN	O	O
topical	NNP	O	O
solution	NN	O	O
.	.	.	.

aminosalicylic	JJ	O	O
acid	NN	O	O
may	MD	O	O
decrease	VB	O	O
the	DT	O	O
amount	NN	O	O
of	IN	O	O
digoxin	NN	D	D
-lrb-	-LRB-	O	O
lanoxin	NN	B	D
","	","	O	O
lanoxicaps	NN	D	D
-rrb-	-RRB-	O	O
that	WDT	O	O
gets	VBZ	O	O
absorbed	VBN	O	O
into	IN	O	O
your	PRP$	O	O
body	NN	O	O
.	.	.	.

in	IN	O	O
the	DT	O	O
case	NN	O	O
that	IN	O	O
you	PRP	O	O
are	VBP	O	O
taking	VBG	O	O
digoxin	NN	D	D
while	IN	O	O
taking	VBG	O	O
aminosalicylic	JJ	O	O
acid	NN	O	O
","	","	O	O
higher	JJR	O	O
doses	NNS	O	O
of	IN	O	O
digoxin	NN	D	D
may	MD	O	O
be	VB	O	O
needed	VBN	O	O
.	.	.	.

aminosalicylic	JJ	O	O
acid	NN	O	O
may	MD	O	O
also	RB	O	O
decrease	VB	O	O
the	DT	O	O
absorption	NN	O	O
of	IN	O	O
vitamin	NN	O	G
b12	NN	O	O
","	","	O	O
which	WDT	O	O
can	MD	O	O
lead	VB	O	O
to	TO	O	O
a	DT	O	O
deficiency	NN	O	O
.	.	.	.

therefore	RB	O	O
you	PRP	O	O
may	MD	O	O
need	VB	O	O
to	TO	O	O
take	VB	O	O
a	DT	O	O
vitamin	NN	O	G
b12	NN	O	O
supplement	NN	O	O
while	IN	O	O
taking	VBG	O	O
aminosalicylic	JJ	O	O
acid	NN	O	O
.	.	.	.

amiodarone	NNP	D	D
is	VBZ	O	O
metabolized	VBN	O	O
to	TO	O	O
desethylamiodarone	VBN	D	O
by	IN	O	O
the	DT	O	O
cytochrome	NN	O	O
p450	NN	O	O
-lrb-	-LRB-	O	O
cyp450	NN	O	O
-rrb-	-RRB-	O	O
enzyme	NN	O	O
group	NN	O	O
","	","	O	O
specifically	RB	O	O
cytochromes	VBZ	O	O
p450	NN	O	O
3a4	NN	O	O
-lrb-	-LRB-	O	O
cyp3a4	NN	D	D
-rrb-	-RRB-	O	O
and	CC	O	O
cyp2c8	NN	O	O
.	.	.	.

the	DT	O	O
cyp3a4	NN	D	D
isoenzyme	NN	O	O
is	VBZ	O	O
present	JJ	O	O
in	IN	O	O
both	CC	O	O
the	DT	O	O
liver	NN	O	O
and	CC	O	O
intestines	NNS	O	O
.	.	.	.

amiodarone	NNP	D	D
is	VBZ	O	O
also	RB	O	O
known	VBN	O	O
to	TO	O	O
be	VB	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
cyp3a4	NN	D	D
.	.	.	.

therefore	RB	O	O
","	","	O	O
amiodarone	NN	D	D
has	VBZ	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
interactions	NNS	O	O
with	IN	O	O
drugs	NNS	D	D
or	CC	O	O
substances	NNS	O	O
that	WDT	O	O
may	MD	O	O
be	VB	O	O
substrates	NNS	O	O
","	","	O	O
inhibitors	NNS	O	O
or	CC	O	O
inducers	NNS	O	O
of	IN	O	O
cyp3a4	NN	D	D
.	.	.	.

while	IN	O	O
only	RB	O	O
a	DT	O	O
limited	JJ	O	O
number	NN	O	O
of	IN	O	O
in	FW	O	O
vivo	FW	O	O
drug-drug	JJ	O	O
interactions	NNS	O	O
with	IN	O	O
amiodarone	NN	D	D
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
","	","	O	O
chiefly	RB	O	O
with	IN	O	O
the	DT	O	O
oral	JJ	O	O
formulation	NN	O	O
","	","	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
other	JJ	O	O
interactions	NNS	O	O
should	MD	O	O
be	VB	O	O
anticipated	VBN	O	O
.	.	.	.

this	DT	O	O
is	VBZ	O	O
especially	RB	O	O
important	JJ	O	O
for	IN	O	O
drugs	NNS	D	D
associated	VBN	O	O
with	IN	O	O
serious	JJ	O	O
toxicity	NN	O	O
","	","	O	O
such	JJ	O	O
as	IN	O	O
other	JJ	O	O
antiarrhythmics	NNS	G	G
.	.	.	.

if	IN	O	O
such	JJ	O	O
drugs	NNS	D	D
are	VBP	O	O
needed	VBN	O	O
","	","	O	O
their	PRP$	O	O
dose	NN	O	O
should	MD	O	O
be	VB	O	O
reassessed	VBN	O	O
and	CC	O	O
","	","	O	O
where	WRB	O	O
appropriate	JJ	O	O
","	","	O	O
plasma	NN	O	O
concentration	NN	O	O
measured	VBN	O	O
.	.	.	.

in	IN	O	O
view	NN	O	O
of	IN	O	O
the	DT	O	O
long	JJ	O	O
and	CC	O	O
variable	JJ	O	O
half-life	NN	O	O
of	IN	O	O
amiodarone	NN	D	D
","	","	O	O
potential	NN	O	O
for	IN	O	O
drug	NN	D	O
interactions	NNS	O	O
exists	VBZ	O	O
not	RB	O	O
only	RB	O	O
with	IN	O	O
concomitant	JJ	O	O
medication	NN	O	O
but	CC	O	O
also	RB	O	O
with	IN	O	O
drugs	NNS	D	D
administered	VBN	O	O
after	IN	O	O
discontinuation	NN	O	O
of	IN	O	O
amiodarone	NN	D	D
.	.	.	.

since	IN	O	O
amiodarone	NN	D	D
is	VBZ	O	O
a	DT	O	O
substrate	NN	O	O
for	IN	O	O
cyp3a4	NN	D	D
and	CC	O	O
cyp2c8	NN	O	O
","	","	O	O
drugs/substances	NNS	O	O
that	WDT	O	O
inhibit	VBP	O	O
these	DT	O	O
isoenzymes	NNS	O	O
may	MD	O	O
decrease	VB	O	O
the	DT	O	O
metabolism	NN	O	O
and	CC	O	O
increase	NN	O	O
serum	NN	O	O
concentration	NN	O	O
of	IN	O	O
amiodarone	NN	D	D
.	.	.	.

reported	VBN	O	O
examples	NNS	O	O
include	VBP	O	O
the	DT	O	O
following	NN	O	O
:	:	O	O
protease	NN	O	O
inhibitors	NNS	O	O
:	:	O	O
protease	NN	O	O
inhibitors	NNS	O	O
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
inhibit	VB	O	O
cyp3a4	NN	D	D
to	TO	O	O
varying	VBG	O	O
degrees	NNS	O	O
.	.	.	.

a	DT	O	O
case	NN	O	O
report	NN	O	O
of	IN	O	O
one	CD	O	O
patient	NN	O	O
taking	VBG	O	O
amiodarone	NN	D	D
200	CD	O	O
mg	NN	O	O
and	CC	O	O
indinavir	NN	D	D
800	CD	O	O
mg	NN	O	O
three	CD	O	O
times	NNS	O	O
a	DT	O	O
day	NN	O	O
resulted	VBD	O	O
in	IN	O	O
increases	NNS	O	O
in	IN	O	O
amiodarone	NN	D	D
concentrations	NNS	O	O
from	IN	O	O
0.9	CD	O	O
mg/l	NN	O	O
to	TO	O	O
1.3	CD	O	O
mg/l	NN	O	O
.	.	.	.

dea	NNP	O	D
concentrations	NNS	O	O
were	VBD	O	O
not	RB	O	O
affected	VBN	O	O
.	.	.	.

there	EX	O	O
was	VBD	O	O
no	DT	O	O
evidence	NN	O	O
of	IN	O	O
toxicity	NN	O	O
.	.	.	.

monitoring	VBG	O	O
for	IN	O	O
amiodarone	NN	D	O
toxicity	NN	O	O
and	CC	O	O
serial	NN	O	O
measurement	NN	O	O
of	IN	O	O
amiodarone	NN	D	D
serum	NN	O	O
concentration	NN	O	O
during	IN	O	O
concomitant	JJ	O	O
protease	NN	O	O
inhibitor	NN	O	O
therapy	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
.	.	.	.

histamine	NN	O	O
h2	NN	O	O
antagonists	NNS	O	O
:	:	O	O
cimetidine	NN	D	D
inhibits	VBZ	O	O
cyp3a4	NN	D	D
and	CC	O	O
can	MD	O	O
increase	VB	O	O
serum	NN	O	O
amiodarone	NN	D	D
levels	NNS	O	O
.	.	.	.

other	JJ	O	O
substances	NNS	O	O
:	:	O	O
grapefruit	NN	O	O
juice	NN	O	O
given	VBN	O	O
to	TO	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
increased	VBD	O	O
amiodarone	NN	D	D
auc	NN	O	O
by	IN	O	O
50	CD	O	O
%	NN	O	O
and	CC	O	O
cmax	NN	O	O
by	IN	O	O
84	CD	O	O
%	NN	O	O
","	","	O	O
resulting	VBG	O	O
in	IN	O	O
increased	VBN	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
amiodarone	NN	D	D
.	.	.	.

grapefruit	NN	O	O
juice	NN	O	O
should	MD	O	O
not	RB	O	O
be	VB	O	O
taken	VBN	O	O
during	IN	O	O
treatment	NN	O	O
with	IN	O	O
oral	JJ	O	O
amiodarone	NN	D	D
.	.	.	.

this	DT	O	O
information	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
when	WRB	O	O
changing	VBG	O	O
from	IN	O	O
intravenous	JJ	O	O
amiodarone	NN	D	D
to	TO	O	O
oral	JJ	O	O
amiodarone	NN	D	D
.	.	.	.

amiodarone	NNP	D	D
may	MD	O	O
suppress	VB	O	O
certain	JJ	O	O
cyp450	NN	O	O
enzymes	NNS	O	O
","	","	O	O
including	VBG	O	O
cyp1a2	NN	D	O
","	","	O	O
cyp2c9	NN	D	O
","	","	O	O
cyp2d6	NN	D	O
","	","	O	O
and	CC	O	O
cyp3a4	NN	D	D
.	.	.	.

this	DT	O	O
inhibition	NN	O	O
can	MD	O	O
result	VB	O	O
in	IN	O	O
unexpectedly	RB	O	O
high	JJ	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
which	WDT	O	O
are	VBP	O	O
metabolized	VBN	O	O
by	IN	O	O
those	DT	O	O
cyp450	NN	O	O
enzymes	NNS	O	O
.	.	.	.

reported	VBN	O	O
examples	NNS	O	O
of	IN	O	O
this	DT	O	O
interaction	NN	O	O
include	VBP	O	O
the	DT	O	O
following	NN	O	O
:	:	O	O
immunosuppressives	NNS	O	O
:	:	O	O
cyclosporine	NN	D	D
-lrb-	-LRB-	O	O
cyp3a4	NN	D	D
substrate	NN	O	O
-rrb-	-RRB-	O	O
administered	VBN	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
oral	JJ	O	O
amiodarone	NN	D	D
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
produce	VB	O	O
persistently	RB	O	O
elevated	JJ	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
cyclosporine	NN	D	D
resulting	VBG	O	O
in	IN	O	O
elevated	JJ	O	O
creatinine	NN	O	O
","	","	O	O
despite	IN	O	O
reduction	NN	O	O
in	IN	O	O
dose	NN	O	O
of	IN	O	O
cyclosporine	NN	D	D
.	.	.	.

hmg-coa	NN	O	O
reductase	NN	O	O
inhibitors	NNS	O	O
:	:	O	O
simvastatin	NN	D	D
-lrb-	-LRB-	O	O
cyp3a4	NN	D	D
substrate	NN	O	O
-rrb-	-RRB-	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
amiodarone	NN	D	D
has	VBZ	O	O
been	VBN	O	O
associated	VBN	O	O
with	IN	O	O
reports	NNS	O	O
of	IN	O	O
myopathy/rhabdomyolysis	NN	O	O
.	.	.	.

cardiovasculars	NNP	O	O
:	:	O	O
cardiac	JJ	O	O
glycosides	NNS	O	O
:	:	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
digoxin	NN	D	D
therapy	NN	O	O
","	","	O	O
administration	NN	O	O
of	IN	O	O
oral	JJ	O	O
amiodarone	NN	D	D
regularly	RB	O	O
results	VBZ	O	O
in	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
serum	NN	O	O
digoxin	NN	D	D
concentration	NN	O	O
that	WDT	O	O
may	MD	O	O
reach	VB	O	O
toxic	JJ	O	O
levels	NNS	O	O
with	IN	O	O
resultant	JJ	O	O
clinical	JJ	O	O
toxicity	NN	O	O
.	.	.	.

amiodarone	NNP	D	D
taken	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
digoxin	NN	D	D
increases	VBZ	O	O
the	DT	O	O
serum	NN	O	O
digoxin	NN	D	D
concentration	NN	O	O
by	IN	O	O
70	CD	O	O
%	NN	O	O
after	IN	O	O
one	CD	O	O
day	NN	O	O
.	.	.	.

on	IN	O	O
administration	NN	O	O
of	IN	O	O
oral	JJ	O	O
amiodarone	NN	D	D
","	","	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
digitalis	NN	G	G
therapy	NN	O	O
should	MD	O	O
be	VB	O	O
reviewed	VBN	O	O
and	CC	O	O
the	DT	O	O
dose	NN	O	O
reduced	VBN	O	O
by	IN	O	O
approximately	RB	O	O
50	CD	O	O
%	NN	O	O
or	CC	O	O
discontinued	VBN	O	O
.	.	.	.

if	IN	O	O
digitalis	NN	G	G
treatment	NN	O	O
is	VBZ	O	O
continued	VBN	O	O
","	","	O	O
serum	NN	O	O
levels	NNS	O	O
should	MD	O	O
be	VB	O	O
closely	RB	O	O
monitored	VBN	O	O
and	CC	O	O
patients	NNS	O	O
observed	VBN	O	O
for	IN	O	O
clinical	JJ	O	O
evidence	NN	O	O
of	IN	O	O
toxicity	NN	O	O
.	.	.	.

these	DT	O	O
precautions	NNS	O	O
probably	RB	O	O
should	MD	O	O
apply	VB	O	O
to	TO	O	O
digitoxin	NN	D	O
administration	NN	O	O
as	RB	O	O
well	RB	O	O
.	.	.	.

antiarrhythmics	NNS	D	G
:	:	O	O
other	JJ	O	O
antiarrhythmic	JJ	D	O
drugs	NNS	D	D
","	","	O	O
such	JJ	O	O
as	IN	O	O
quinidine	NN	D	D
","	","	O	O
procainamide	NN	D	D
","	","	O	O
disopyramide	NN	D	D
","	","	O	O
and	CC	O	O
phenytoin	NN	D	D
","	","	O	O
have	VBP	O	O
been	VBN	O	O
used	VBN	O	O
concurrently	RB	O	O
with	IN	O	O
amiodarone	NN	D	D
.	.	.	.

there	EX	O	O
have	VBP	O	O
been	VBN	O	O
case	NN	O	O
reports	NNS	O	O
of	IN	O	O
increased	VBN	O	O
steady-state	JJ	O	O
levels	NNS	O	O
of	IN	O	O
quinidine	NN	D	D
","	","	O	O
procainamide	NN	D	D
","	","	O	O
and	CC	O	O
phenytoin	NN	D	D
during	IN	O	O
concomitant	JJ	O	O
therapy	NN	O	O
with	IN	O	O
amiodarone	NN	D	D
.	.	.	.

phenytoin	NN	D	D
decreases	VBZ	O	O
serum	NN	O	O
amiodarone	NN	D	D
levels	NNS	O	O
.	.	.	.

amiodarone	NNP	D	D
taken	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
quinidine	NN	D	D
increases	VBZ	O	O
quinidine	NN	D	D
serum	NN	O	O
concentration	NN	O	O
by	IN	O	O
33	CD	O	O
%	NN	O	O
after	IN	O	O
two	CD	O	O
days	NNS	O	O
.	.	.	.

amiodarone	NNP	D	D
taken	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
procainamide	NN	D	D
for	IN	O	O
less	JJR	O	O
than	IN	O	O
seven	CD	O	O
days	NNS	O	O
increases	VBZ	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
procainamide	NN	D	D
and	CC	O	O
n-acetyl	NN	O	O
procainamide	NN	D	O
by	IN	O	O
55	CD	O	O
%	NN	O	O
and	CC	O	O
33	CD	O	O
%	NN	O	O
","	","	O	O
respectively	RB	O	O
.	.	.	.

quinidine	NN	D	D
and	CC	O	O
procainamide	NN	D	D
doses	NNS	O	O
should	MD	O	O
be	VB	O	O
reduced	VBN	O	O
by	IN	O	O
one-third	NN	O	O
when	WRB	O	O
either	CC	O	O
is	VBZ	O	O
administered	VBN	O	O
with	IN	O	O
amiodarone	NN	D	D
.	.	.	.

plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
flecainide	NN	D	D
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
increase	VB	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
oral	JJ	O	O
amiodarone	NN	D	D
.	.	.	.

because	IN	O	O
of	IN	O	O
this	DT	O	O
","	","	O	O
the	DT	O	O
dosage	NN	O	O
of	IN	O	O
flecainide	NN	D	D
should	MD	O	O
be	VB	O	O
adjusted	VBN	O	O
when	WRB	O	O
these	DT	O	O
drugs	NNS	D	D
are	VBP	O	O
administered	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

in	IN	O	O
general	JJ	O	O
","	","	O	O
any	DT	O	O
added	VBD	O	O
antiarrhythmic	JJ	D	O
drug	NN	D	O
should	MD	O	O
be	VB	O	O
initiated	VBN	O	O
at	IN	O	O
a	DT	O	O
lower	JJR	O	O
than	IN	O	O
usual	JJ	O	O
dose	NN	O	O
with	IN	O	O
careful	JJ	O	O
monitoring	NN	O	O
.	.	.	.

combination	NN	O	O
of	IN	O	O
amiodarone	NN	D	D
with	IN	O	O
other	JJ	O	O
antiarrhythmic	JJ	D	O
therapy	NN	O	O
should	MD	O	O
be	VB	O	O
reserved	VBN	O	O
for	IN	O	O
patients	NNS	O	O
with	IN	O	O
life-threatening	JJ	O	O
ventricular	JJ	O	O
arrhythmias	NNS	O	O
who	WP	O	O
are	VBP	O	O
incompletely	RB	O	O
responsive	JJ	O	O
to	TO	O	O
a	DT	O	O
single	JJ	O	O
agent	NN	O	O
or	CC	O	O
incompletely	RB	O	O
responsive	JJ	O	O
to	TO	O	O
amiodarone	NN	D	D
.	.	.	.

during	IN	O	O
transfer	NN	O	O
to	TO	O	O
oral	JJ	O	O
amiodarone	NN	D	D
","	","	O	O
the	DT	O	O
dose	NN	O	O
levels	NNS	O	O
of	IN	O	O
previously	RB	O	O
administered	VBN	O	O
agents	NNS	O	O
should	MD	O	O
be	VB	O	O
reduced	VBN	O	O
by	IN	O	O
30	CD	O	O
to	TO	O	O
50	CD	O	O
%	NN	O	O
several	JJ	O	O
days	NNS	O	O
after	IN	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
oral	JJ	O	O
amiodarone	NN	D	D
.	.	.	.

the	DT	O	O
continued	JJ	O	O
need	NN	O	O
for	IN	O	O
the	DT	O	O
other	JJ	O	O
antiarrhythmic	JJ	D	O
agent	NN	O	O
should	MD	O	O
be	VB	O	O
reviewed	VBN	O	O
after	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
amiodarone	NN	D	D
have	VBP	O	O
been	VBN	O	O
established	VBN	O	O
","	","	O	O
and	CC	O	O
discontinuation	NN	O	D
ordinarily	RB	O	O
should	MD	O	O
be	VB	O	O
attempted	VBN	O	O
.	.	.	.

if	IN	O	O
the	DT	O	O
treatment	NN	O	O
is	VBZ	O	O
continued	VBN	O	O
","	","	O	O
these	DT	O	O
patients	NNS	O	O
should	MD	O	O
be	VB	O	O
particularly	RB	O	O
carefully	RB	O	O
monitored	VBN	O	O
for	IN	O	O
adverse	JJ	O	O
effects	NNS	O	O
","	","	O	O
especially	RB	O	O
conduction	NN	O	O
disturbances	NNS	O	O
and	CC	O	O
exacerbation	NN	O	O
of	IN	O	O
tachyarrhythmias	NNS	O	G
","	","	O	O
as	IN	O	O
amiodarone	NN	D	D
is	VBZ	O	O
continued	VBN	O	O
.	.	.	.

in	IN	O	O
amiodarone-treated	JJ	O	O
patients	NNS	O	O
who	WP	O	O
require	VBP	O	O
additional	JJ	O	O
antiarrhythmic	JJ	D	O
therapy	NN	O	O
","	","	O	O
the	DT	O	O
initial	JJ	O	O
dose	NN	O	O
of	IN	O	O
such	JJ	O	O
agents	NNS	O	O
should	MD	O	O
be	VB	O	O
approximately	RB	O	O
half	NN	O	O
of	IN	O	O
the	DT	O	O
usual	JJ	O	O
recommended	VBN	O	O
dose	NN	O	O
.	.	.	.

antihypertensives	NNS	D	G
:	:	O	O
amiodarone	NN	D	D
should	MD	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
caution	NN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
-	:	O	O
receptor	NN	D	O
blocking	VBG	O	O
agents	NNS	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
propranolol	NN	D	D
","	","	O	O
a	DT	O	O
cyp3a4	NN	D	D
inhibitor	NN	O	O
-rrb-	-RRB-	O	O
or	CC	O	O
calcium	NN	D	D
channel	NN	O	O
antagonists	NNS	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
verapamil	NN	D	D
","	","	O	O
a	DT	O	O
cyp3a4	NN	D	D
substrate	NN	O	O
","	","	O	O
and	CC	O	O
diltiazem	NN	D	D
","	","	O	O
a	DT	O	O
cyp3a4	NN	D	D
inhibitor	NN	O	O
-rrb-	-RRB-	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
possible	JJ	O	O
potentiation	NN	O	O
of	IN	O	O
bradycardia	NN	O	O
","	","	O	O
sinus	NN	O	O
arrest	NN	O	O
","	","	O	O
and	CC	O	O
av	NN	O	O
block	NN	O	O
.	.	.	.

if	IN	O	O
necessary	JJ	O	O
","	","	O	O
amiodarone	NN	D	D
can	MD	O	O
continue	VB	O	O
to	TO	O	O
be	VB	O	O
used	VBN	O	O
after	IN	O	O
insertion	NN	O	O
of	IN	O	O
a	DT	O	O
pacemaker	NN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
severe	JJ	O	O
bradycardia	NN	O	O
or	CC	O	O
sinus	NN	O	O
arrest	NN	O	O
.	.	.	.

anticoagulants	NNPS	G	G
:	:	O	O
potentiation	NN	O	O
of	IN	O	O
warfarin-type	JJ	O	O
-lrb-	-LRB-	O	O
cyp2c9	NN	D	O
and	CC	O	O
cyp3a4	NN	D	D
substrate	NN	O	O
-rrb-	-RRB-	O	O
anticoagulant	JJ	G	O
response	NN	O	O
is	VBZ	O	O
almost	RB	O	O
always	RB	O	O
seen	VBN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
amiodarone	NN	D	D
and	CC	O	O
can	MD	O	O
result	VB	O	O
in	IN	O	O
serious	JJ	O	O
or	CC	O	O
fatal	JJ	O	O
bleeding	NN	O	O
.	.	.	.

since	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
warfarin	NN	D	D
with	IN	O	O
amiodarone	NN	D	D
increases	VBZ	O	O
the	DT	O	O
prothrombin	NN	O	O
time	NN	O	O
by	IN	O	O
100	CD	O	O
%	NN	O	O
after	IN	O	O
3	CD	O	O
to	TO	O	O
4	CD	O	O
days	NNS	O	O
","	","	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
the	DT	O	O
anticoagulant	NN	G	G
should	MD	O	O
be	VB	O	O
reduced	VBN	O	O
by	IN	O	O
one-third	NN	O	O
to	TO	O	O
one-half	NN	O	O
","	","	O	O
and	CC	O	O
prothrombin	NN	O	O
times	NNS	O	O
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
closely	RB	O	O
.	.	.	.

some	DT	O	O
drugs/substances	NNS	O	G
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
accelerate	VB	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
amiodarone	NN	D	D
by	IN	O	O
stimulating	VBG	O	O
the	DT	O	O
synthesis	NN	O	O
of	IN	O	O
cyp3a4	NN	D	D
-lrb-	-LRB-	O	O
enzyme	NN	O	O
induction	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

this	DT	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
low	JJ	O	O
amiodarone	NN	D	D
serum	NN	O	O
levels	NNS	O	O
and	CC	O	O
potential	JJ	O	O
decrease	NN	O	O
in	IN	O	O
efficacy	NN	O	O
.	.	.	.

reported	VBN	O	O
examples	NNS	O	O
of	IN	O	O
this	DT	O	O
interaction	NN	O	O
include	VBP	O	O
the	DT	O	O
following	NN	O	O
:	:	O	O
antibiotics	NNS	G	G
:	:	O	O
rifampin	NNP	D	D
is	VBZ	O	O
a	DT	O	O
potent	JJ	O	O
inducer	NN	O	O
of	IN	O	O
cyp3a4	NN	D	D
.	.	.	.

administration	NN	O	O
of	IN	O	O
rifampin	NN	D	D
concomitantly	RB	O	O
with	IN	O	O
oral	JJ	O	O
amiodarone	NN	D	D
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
result	VB	O	O
in	IN	O	O
decreases	NNS	O	O
in	IN	O	O
serum	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
amiodarone	NN	D	D
and	CC	O	O
desethylamiodarone	NN	D	D
.	.	.	.

other	JJ	O	O
substances	NNS	O	O
","	","	O	O
including	VBG	O	O
herbal	JJ	O	O
preparations	NNS	O	O
:	:	O	O
st.	NNP	O	O
john	NNP	O	O
s	VBZ	O	O
wort	NNP	O	O
-lrb-	-LRB-	O	O
hypericum	NNP	O	O
perforatum	NN	O	O
-rrb-	-RRB-	O	O
induces	VBZ	O	O
cyp3a4	NN	D	D
.	.	.	.

since	IN	O	O
amiodarone	NN	D	D
is	VBZ	O	O
a	DT	O	O
substrate	NN	O	O
for	IN	O	O
cyp3a4	NN	D	D
","	","	O	O
there	EX	O	O
is	VBZ	O	O
the	DT	O	O
potential	NN	O	O
that	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
st.	NNP	O	O
john	NNP	O	O
s	VBZ	O	O
wort	NNP	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
amiodarone	NN	D	D
could	MD	O	O
result	VB	O	O
in	IN	O	O
reduced	VBN	O	O
amiodarone	NN	D	D
levels	NNS	O	O
.	.	.	.

other	JJ	O	O
reported	VBN	O	O
interactions	NNS	O	O
with	IN	O	O
amiodarone	NN	D	D
:	:	O	O
fentanyl	NN	D	D
-lrb-	-LRB-	O	O
cyp3a4	NN	D	D
substrate	NN	O	O
-rrb-	-RRB-	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
amiodarone	NN	D	D
may	MD	O	O
cause	VB	O	O
hypotension	NN	O	O
","	","	O	O
bradycardia	NN	O	O
","	","	O	O
and	CC	O	O
decreased	VBD	O	O
cardiac	JJ	O	O
output	NN	O	O
.	.	.	.

sinus	NN	O	O
bradycardia	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
with	IN	O	O
oral	JJ	O	O
amiodarone	NN	D	D
in	IN	O	O
combination	NN	O	O
with	IN	O	O
lidocaine	NN	D	D
-lrb-	-LRB-	O	O
cyp3a4	NN	D	D
substrate	NN	O	O
-rrb-	-RRB-	O	O
given	VBN	O	O
for	IN	O	O
local	JJ	O	O
anesthesia	NN	D	O
.	.	.	.

seizure	NN	O	O
","	","	O	O
associated	VBN	O	O
with	IN	O	O
increased	VBN	O	O
lidocaine	NN	D	D
concentrations	NNS	O	O
","	","	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
with	IN	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
intravenous	JJ	O	O
amiodarone	NN	D	D
.	.	.	.

dextromethorphan	NNP	D	D
is	VBZ	O	O
a	DT	O	O
substrate	NN	O	O
for	IN	O	O
both	DT	O	O
cyp2d6	NN	D	O
and	CC	O	O
cyp3a4	NN	D	D
.	.	.	.

amiodarone	NN	D	D
inhibits	VBZ	O	O
cyp2d6	NN	D	O
.	.	.	.

cholestyramine	NNP	D	D
increases	VBZ	O	O
enterohepatic	JJ	O	O
elimination	NN	O	O
of	IN	O	O
amiodarone	NN	D	D
and	CC	O	O
may	MD	O	O
reduce	VB	O	O
its	PRP$	O	O
serum	NN	O	O
levels	NNS	O	O
and	CC	O	O
t1/2	NN	O	O
.	.	.	.

disopyramide	NNP	D	D
increases	VBZ	O	O
qt	NNP	O	O
prolongation	NN	O	O
which	WDT	O	O
could	MD	O	O
cause	VB	O	O
arrhythmia	NN	O	O
.	.	.	.

fluoroquinolones	NNP	D	D
","	","	O	O
macrolide	NN	O	O
antibiotics	NNS	G	G
","	","	O	O
and	CC	O	O
azoles	NNS	O	G
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
cause	VB	O	O
qtc	NN	O	O
prolongation	NN	O	O
.	.	.	.

there	EX	O	O
have	VBP	O	O
been	VBN	O	O
reports	NNS	O	O
of	IN	O	O
qtc	NN	O	O
prolongation	NN	O	O
","	","	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
tdp	NN	O	O
","	","	O	O
in	IN	O	O
patients	NNS	O	O
taking	VBG	O	O
amiodarone	NN	D	D
when	WRB	O	O
fluoroquinolones	NNS	D	O
","	","	O	O
macrolide	NN	O	O
antibiotics	NNS	G	G
","	","	O	O
or	CC	O	O
azoles	NNS	O	O
were	VBD	O	O
administered	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

hemodynamic	JJ	O	O
and	CC	O	O
electrophysiologic	JJ	O	O
interactions	NNS	O	O
have	VBP	O	O
also	RB	O	O
been	VBN	O	O
observed	VBN	O	O
after	IN	O	O
concomitant	JJ	O	O
administration	NN	O	O
with	IN	O	O
propranolol	NN	D	D
","	","	O	O
diltiazem	NN	D	D
","	","	O	O
and	CC	O	O
verapamil	NN	D	D
.	.	.	.

volatile	JJ	O	O
anesthetic	NNP	D	O
agents	NNPS	O	O
:	:	O	O
.	.	.	.

in	IN	O	O
addition	NN	O	O
to	TO	O	O
the	DT	O	O
interactions	NNS	O	O
noted	VBD	O	O
above	RB	O	O
","	","	O	O
chronic	JJ	O	O
-lrb-	-LRB-	O	O
2	CD	O	O
weeks	NNS	O	O
-rrb-	-RRB-	O	O
oral	JJ	O	O
cordarone	NNP	D	B
administration	NN	O	O
impairs	VBZ	O	O
metabolism	NN	O	O
of	IN	O	O
phenytoin	NN	D	D
","	","	O	O
dextromethorphan	NN	D	D
","	","	O	O
and	CC	O	O
methotrexate	NN	D	D
.	.	.	.

electrolyte	NNP	O	O
disturbances	NNPS	O	O
patients	NNPS	O	O
with	IN	O	O
hypokalemia	NN	O	O
or	CC	O	O
hypomagnesemia	NN	O	D
should	MD	O	O
have	VB	O	O
the	DT	O	O
condition	NN	O	O
corrected	VBN	O	O
whenever	WRB	O	O
possible	JJ	O	O
before	IN	O	O
being	VBG	O	O
treated	VBN	O	O
with	IN	O	O
cordarone	JJ	D	O
i.v.	NNP	O	B
","	","	O	O
as	IN	O	O
these	DT	O	O
disorders	NNS	O	O
can	MD	O	O
exaggerate	VB	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
qtc	NN	O	O
prolongation	NN	O	O
and	CC	O	O
increase	VB	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
tdp	NN	O	O
.	.	.	.

special	JJ	O	O
attention	NN	O	O
should	MD	O	O
be	VB	O	O
given	VBN	O	O
to	TO	O	O
electrolyte	NN	O	O
and	CC	O	O
acid-base	NN	O	O
balance	NN	O	O
in	IN	O	O
patients	NNS	O	O
experiencing	VBG	O	O
severe	JJ	O	O
or	CC	O	O
prolonged	JJ	O	O
diarrhea	NN	O	O
or	CC	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
concomitant	JJ	O	O
diuretics	NNS	G	G
.	.	.	.

drugs	NNS	O	O
metabolized	VBN	O	O
by	IN	O	O
p450	NN	O	O
2d6	NN	O	O
-	:	O	O
the	DT	O	O
biochemical	JJ	O	O
activity	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	D	O
metabolizing	VBG	O	O
isozyme	NN	O	O
cytochrome	NN	O	O
p450	NN	O	O
2d6	NN	O	O
-lrb-	-LRB-	O	O
debrisoquin	NN	D	D
hydroxylase	NN	O	O
-rrb-	-RRB-	O	O
is	VBZ	O	O
reduced	VBN	O	O
in	IN	O	O
a	DT	O	O
subset	NN	O	O
of	IN	O	O
the	DT	O	O
caucasian	JJ	O	O
population	NN	O	O
-lrb-	-LRB-	O	O
about	IN	O	O
10-Jul	CD	O	O
%	NN	O	O
of	IN	O	O
caucasians	NNS	O	O
are	VBP	O	O
so	RB	O	O
called	VBN	O	O
poor	JJ	O	O
metabolizers	NNS	O	O
-rrb-	-RRB-	O	O
;	:	O	O
.	.	.	.

reliable	JJ	O	O
estimates	NNS	O	O
of	IN	O	O
the	DT	O	O
prevalence	NN	O	O
of	IN	O	O
reduced	VBN	O	O
p450	NN	O	O
2d6	NN	O	O
isozyme	NN	O	O
activity	NN	O	O
among	IN	O	O
asian	JJ	O	O
","	","	O	O
african	JJ	O	O
and	CC	O	O
other	JJ	O	O
populations	NNS	O	O
are	VBP	O	O
not	RB	O	O
yet	RB	O	O
available	JJ	O	O
.	.	.	.

poor	NNP	O	O
metabolizers	NNS	O	O
have	VBP	O	O
higher	JJR	O	O
than	IN	O	O
expected	VBN	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
-lrb-	-LRB-	O	O
tcas	NNS	G	G
-rrb-	-RRB-	O	O
when	WRB	O	O
given	VBN	O	O
usual	JJ	O	O
doses	NNS	O	O
depending	VBG	O	O
on	IN	O	O
the	DT	O	O
fraction	NN	O	O
of	IN	O	O
drug	NN	D	O
metabolized	VBN	O	O
by	IN	O	O
p450	NN	O	O
2d6	NN	O	O
","	","	O	O
the	DT	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
concentration	NN	O	O
may	MD	O	O
be	VB	O	O
small	JJ	O	O
","	","	O	O
or	CC	O	O
quite	RB	O	O
large	JJ	O	O
-lrb-	-LRB-	O	O
8-fold	JJ	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
auc	NN	O	O
of	IN	O	O
the	DT	O	O
tca	NNP	G	G
-rrb-	-RRB-	O	O
.	.	.	.

in	IN	O	O
addition	NN	O	O
","	","	O	O
certain	JJ	O	O
drugs	NNS	D	D
inhibit	VBP	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
this	DT	O	O
isozyme	NN	O	O
and	CC	O	O
make	VB	O	O
normal	JJ	O	O
metabolizers	NNS	O	O
resemble	VBP	O	O
poor	JJ	O	O
metabolizers	NNS	O	O
.	.	.	.

an	DT	O	O
individual	NN	O	O
who	WP	O	O
is	VBZ	O	O
stable	JJ	O	O
on	IN	O	O
a	DT	O	O
given	VBN	O	O
dose	NN	O	O
of	IN	O	O
tca	NNP	G	G
may	MD	O	O
become	VB	O	O
abruptly	RB	O	O
toxic	JJ	O	O
when	WRB	O	O
given	VBN	O	O
one	CD	O	O
of	IN	O	O
these	DT	O	O
inhibiting	VBG	O	O
drugs	NNS	D	D
as	IN	O	O
concomitant	JJ	O	O
therapy	NN	O	O
.	.	.	.

the	DT	O	O
drugs	NNS	D	D
that	WDT	O	O
inhibit	VBP	O	O
cytochrome	NN	O	O
p450	NN	O	O
2d6	NN	O	O
include	VBP	O	O
some	DT	O	O
that	WDT	O	O
are	VBP	O	O
not	RB	O	O
metabolized	VBN	O	O
by	IN	O	O
the	DT	O	O
enzyme	NN	O	O
-lrb-	-LRB-	O	O
quinidine	NN	D	D
.	.	.	.

cimetidine	NN	D	D
-rrb-	-RRB-	O	O
and	CC	O	O
many	JJ	O	O
that	WDT	O	O
are	VBP	O	O
substrates	NNS	O	O
for	IN	O	O
p450	NN	O	O
2d6	NN	O	O
-lrb-	-LRB-	O	O
many	JJ	O	O
other	JJ	O	O
antidepressants	NNS	G	G
","	","	O	O
phenothiazines	NNS	G	G
","	","	O	O
and	CC	O	O
the	DT	O	O
type	NN	O	O
1c	NN	O	O
antiarrhythmics	NNS	G	G
propafenone	NN	D	D
and	CC	O	O
flecainide	NN	D	D
-rrb-	-RRB-	O	O
.	.	.	.

while	IN	O	O
all	PDT	O	O
the	DT	O	O
selective	JJ	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NNS	O	O
-lrb-	-LRB-	O	O
ssris	NNS	G	G
-rrb-	-RRB-	O	O
","	","	O	O
e.g.	FW	O	O
","	","	O	O
fluoxetine	NN	D	D
","	","	O	O
sertraline	NN	D	D
","	","	O	O
and	CC	O	O
paroxetine	NN	D	D
","	","	O	O
inhibit	VBP	O	O
p450	NN	O	O
2d6	NN	O	O
","	","	O	O
they	PRP	O	O
may	MD	O	O
vary	VB	O	O
in	IN	O	O
the	DT	O	O
extent	NN	O	O
of	IN	O	O
inhibition	NN	O	O
.	.	.	.

the	DT	O	O
extent	NN	O	O
to	TO	O	O
which	WDT	O	O
ssri-tca	NNP	O	O
interactions	NNS	O	O
may	MD	O	O
pose	VB	O	O
clinical	JJ	O	O
problems	NNS	O	O
will	MD	O	O
depend	VB	O	O
on	IN	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
inhibition	NN	O	O
and	CC	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
the	DT	O	O
ssri	NNP	G	G
involved	VBN	O	O
.	.	.	.

nevertheless	RB	O	O
","	","	O	O
caution	NN	O	O
is	VBZ	O	O
indicated	VBN	O	O
in	IN	O	O
the	DT	O	O
coadministration	NN	O	O
of	IN	O	O
tcas	NNS	G	G
with	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
ssris	NNS	G	G
and	CC	O	O
also	RB	O	O
in	IN	O	O
switching	NN	O	O
from	IN	O	O
one	CD	O	O
class	NN	O	O
to	TO	O	O
the	DT	O	O
other	JJ	O	O
.	.	.	.

of	IN	O	O
particular	JJ	O	O
importance	NN	O	O
","	","	O	O
sufficient	JJ	O	O
time	NN	O	O
must	MD	O	O
elapse	VB	O	O
before	IN	O	O
initiating	VBG	O	O
tca	NNP	G	G
treatment	NN	O	O
in	IN	O	O
a	DT	O	O
patient	NN	O	O
being	VBG	O	O
withdrawn	VBN	O	O
from	IN	O	O
fluoxetine	NN	D	D
","	","	O	O
given	VBN	O	O
the	DT	O	O
long	JJ	O	O
half-life	NN	O	O
of	IN	O	O
the	DT	O	O
parent	NN	O	O
and	CC	O	O
active	JJ	O	O
metabolite	NN	O	O
-lrb-	-LRB-	O	O
at	IN	O	O
least	JJS	O	O
5	CD	O	O
weeks	NNS	O	O
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
-rrb-	-RRB-	O	O
.	.	.	.

concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
with	IN	O	O
drugs	NNS	D	D
that	WDT	O	O
can	MD	O	O
inhibit	VB	O	O
cytochrome	NN	O	O
p450	NN	O	O
2d6	NN	O	O
may	MD	O	O
require	VB	O	O
lower	JJR	O	O
doses	NNS	O	O
than	IN	O	O
usually	RB	O	O
prescribed	VBN	O	O
for	IN	O	O
either	CC	O	O
the	DT	O	O
tricyclic	JJ	O	G
antidepressant	JJ	O	G
or	CC	O	O
the	DT	O	O
other	JJ	O	O
drug	NN	D	O
.	.	.	.

furthermore	RB	O	O
","	","	O	O
whenever	WRB	O	O
one	CD	O	O
of	IN	O	O
these	DT	O	O
other	JJ	O	O
drugs	NNS	D	D
is	VBZ	O	O
withdrawn	VBN	O	O
from	IN	O	O
co-therapy	JJ	O	O
","	","	O	O
an	DT	O	O
increased	VBN	O	O
dose	NN	O	O
of	IN	O	O
tricyclic	JJ	O	G
antidepressant	JJ	O	G
may	MD	O	O
be	VB	O	O
required	VBN	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
desirable	JJ	O	O
to	TO	O	O
monitor	VB	O	O
tca	NNP	G	G
plasma	NN	O	O
levels	NNS	O	O
whenever	WRB	O	O
a	DT	O	O
tca	NNP	G	G
is	VBZ	O	O
going	VBG	O	O
to	TO	O	O
be	VB	O	O
coadministered	VBN	O	O
with	IN	O	O
another	DT	O	O
drug	NN	D	O
known	VBN	O	O
to	TO	O	O
be	VB	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
p450	NN	O	O
2d6	NN	O	O
.	.	.	.

monoamine	NNP	O	O
oxidase	NNP	O	O
inhibitors	NNS	O	O
:	:	O	O
guanethidine	NN	D	D
or	CC	O	O
similarly	RB	O	O
acting	VBG	O	O
compounds	NNS	O	O
.	.	.	.

thyroid	NN	D	G
medication	NN	O	O
.	.	.	.

alcohol	NN	D	D
","	","	O	O
barbiturates	NNS	G	G
and	CC	O	O
other	JJ	O	O
cns	NN	O	O
depressants	NNS	O	O
.	.	.	.

and	CC	O	O
disulfiram	NN	D	D
when	WRB	O	O
amitriptyline	NNP	D	O
hcl	NN	O	O
is	VBZ	O	O
given	VBN	O	O
with	IN	O	O
anticholinergic	JJ	G	G
agents	NNS	O	O
or	CC	O	O
sympathomimetic	JJ	D	G
drugs	NNS	D	D
","	","	O	O
including	VBG	O	O
epinephrine	NN	D	D
combined	VBN	O	O
with	IN	O	O
local	JJ	O	O
anesthetics	NNS	G	G
","	","	O	O
close	JJ	O	O
supervision	NN	O	O
and	CC	O	O
careful	JJ	O	O
adjustment	NN	O	O
of	IN	O	O
dosages	NNS	O	O
are	VBP	O	O
required	VBN	O	O
.	.	.	.

hyperpyrexia	NNP	O	D
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
when	WRB	O	O
amitriptyline	NNP	D	B
hcl	NN	O	O
is	VBZ	O	O
administered	VBN	O	O
with	IN	O	O
anticholinergic	JJ	G	G
agents	NNS	O	O
or	CC	O	O
with	IN	O	O
neuroleptic	JJ	D	G
drugs	NNS	D	D
","	","	O	O
particularly	RB	O	O
during	IN	O	O
hot	JJ	O	O
weather	NN	O	O
.	.	.	.

paralytic	JJ	O	O
ileus	NN	O	O
may	MD	O	O
occur	VB	O	O
in	IN	O	O
patients	NNS	O	O
taking	VBG	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
in	IN	O	O
combination	NN	O	O
with	IN	O	O
anticholinergic-type	JJ	O	O
drugs	NNS	D	D
.	.	.	.

cimetidine	NNP	D	D
is	VBZ	O	O
reported	VBN	O	O
to	TO	O	O
reduce	VB	O	O
hepatic	JJ	O	O
metabolism	NN	O	O
of	IN	O	O
certain	JJ	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
","	","	O	O
thereby	RB	O	O
delaying	VBG	O	O
elimination	NN	O	O
and	CC	O	O
increasing	VBG	O	O
steady-state	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
these	DT	O	O
drugs	NNS	D	D
.	.	.	.

clinically	RB	O	O
significant	JJ	O	O
effects	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
with	IN	O	O
the	DT	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
when	WRB	O	O
used	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
cimetidine	NN	D	D
.	.	.	.

increases	NNS	O	O
in	IN	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
","	","	O	O
and	CC	O	O
in	IN	O	O
the	DT	O	O
frequency	NN	O	O
and	CC	O	O
severity	NN	O	O
of	IN	O	O
side	JJ	O	O
effects	NNS	O	O
","	","	O	O
particularly	RB	O	O
anticholinergic	JJ	G	O
","	","	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
when	WRB	O	O
cimetidine	NN	D	D
was	VBD	O	O
added	VBN	O	O
to	TO	O	O
the	DT	O	O
drug	NN	D	O
regimen	NN	O	O
.	.	.	.

discontinuation	NN	O	O
of	IN	O	O
cimetidine	NN	D	D
in	IN	O	O
well-controlled	JJ	O	O
patients	NNS	O	O
receiving	VBG	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
and	CC	O	O
cimetidine	NN	D	D
may	MD	O	O
decrease	VB	O	O
the	DT	O	O
plasma	NN	O	O
levels	NNS	O	O
and	CC	O	O
efficacy	NN	O	O
of	IN	O	O
the	DT	O	O
antidepressants	NNS	G	G
.	.	.	.

caution	NN	O	O
is	VBZ	O	O
advised	VBN	O	O
if	IN	O	O
patients	NNS	O	O
receive	VBP	O	O
large	JJ	O	O
doses	NNS	O	O
of	IN	O	O
ethchlorvynol	NN	D	D
concurrently	RB	O	O
.	.	.	.

transient	JJ	O	O
delirium	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
one	CD	O	O
gram	NN	O	O
of	IN	O	O
ethchlorvynol	NN	D	D
and	CC	O	O
75	CD	O	O
-	:	O	O
150	CD	O	O
mg	NN	O	O
of	IN	O	O
amitriptyline	NNP	D	D
hcl	NN	O	O
.	.	.	.

when	WRB	O	O
administered	VBN	O	O
concurrently	RB	O	O
","	","	O	O
the	DT	O	O
following	VBG	O	O
drugs	NNS	D	D
may	MD	O	O
interact	VB	O	O
with	IN	O	O
amphotericin	NN	O	D
b	NN	O	O
:	:	O	O
antineoplastic	JJ	O	O
agents	NNS	O	O
:	:	O	O
may	MD	O	O
enhance	VB	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
renal	JJ	O	O
toxicity	NN	O	O
","	","	O	O
bronchospasm	NN	O	O
and	CC	O	O
hypotension	NN	O	O
.	.	.	.

antineoplastic	JJ	O	O
agents	NNS	O	O
-lrb-	-LRB-	O	O
e.	FW	O	O
g.	FW	O	O
","	","	O	O
nitrogen	NN	O	O
mustard	NN	O	O
","	","	O	O
etc.	FW	O	O
-rrb-	-RRB-	O	O
should	MD	O	O
be	VB	O	O
given	VBN	O	O
concomitantly	RB	O	O
only	RB	O	O
with	IN	O	O
great	JJ	O	O
caution	NN	O	O
.	.	.	.

corticosteroids	NNS	G	G
and	CC	O	O
corticotropin	NN	D	D
-lrb-	-LRB-	O	O
acth	NN	D	D
-rrb-	-RRB-	O	O
:	:	O	O
may	MD	O	O
potentiate	VB	O	O
amphotericin	NN	O	D
b	NN	O	O
-	:	O	O
induced	VBN	O	O
hypokalemia	NN	O	O
which	WDT	O	O
may	MD	O	O
predispose	VB	O	O
the	DT	O	O
patient	NN	O	O
to	TO	O	O
cardiac	JJ	O	O
dysfunction	NN	O	O
.	.	.	.

avoid	VB	O	O
concomitant	JJ	O	O
use	NN	O	O
unless	IN	O	O
necessary	JJ	O	O
to	TO	O	O
control	VB	O	O
side	JJ	O	O
effects	NNS	O	O
of	IN	O	O
amphotericin	NN	O	D
b	NN	O	O
.	.	.	.

if	IN	O	O
used	VBN	O	O
concomitantly	RB	O	O
","	","	O	O
closely	RB	O	O
monitor	VB	O	O
serum	NN	O	O
electrolytes	NNS	O	O
and	CC	O	O
cardiac	JJ	O	O
function	NN	O	O
.	.	.	.

digitalis	NN	G	G
glycosides	NNS	O	G
:	:	O	O
amphotericin	NN	O	D
b-induced	JJ	O	O
hypokalemia	NN	O	O
may	MD	O	O
potentiate	VB	O	O
digitalis	NN	G	G
toxicity	NN	O	O
.	.	.	.

serum	NN	O	O
potassium	NN	D	D
levels	NNS	O	O
and	CC	O	O
cardiac	JJ	O	O
function	NN	O	O
should	MD	O	O
be	VB	O	O
closely	RB	O	O
monitored	VBN	O	O
and	CC	O	O
any	DT	O	O
deficit	NN	O	O
promptly	RB	O	O
corrected	VBN	O	O
.	.	.	.

flucytosine	NNP	D	D
:	:	O	O
while	IN	O	O
a	DT	O	O
synergistic	JJ	O	O
relationship	NN	O	O
with	IN	O	O
amphotericin	NN	O	D
b	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
","	","	O	O
concomitant	JJ	O	O
use	NN	O	O
may	MD	O	O
increase	VB	O	O
the	DT	O	O
toxicity	NN	O	O
of	IN	O	O
flucytosine	NN	D	D
by	IN	O	O
possibly	RB	O	O
increasing	VBG	O	O
its	PRP$	O	O
cellular	JJ	O	O
uptake	NN	O	O
and/or	CC	O	O
impairing	VBG	O	O
its	PRP$	O	O
renal	JJ	O	O
excretion	NN	O	O
.	.	.	.

imidazoles	NNS	G	G
-lrb-	-LRB-	O	O
e.	FW	O	O
g.	FW	O	O
","	","	O	O
ketoconazole	NN	D	D
","	","	O	O
miconazole	NN	D	D
","	","	O	O
clotrimazole	NN	D	D
","	","	O	O
fluconazole	NN	D	D
","	","	O	O
etc.	FW	O	O
-rrb-	-RRB-	O	O
:	:	O	O
in	FW	O	O
vitro	FW	O	O
and	CC	O	O
animal	JJ	O	O
studies	NNS	O	O
with	IN	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
amphotericin	NN	O	D
b	NN	O	O
and	CC	O	O
imidazoles	NNS	G	O
suggest	VBP	O	O
that	IN	O	O
imidazoles	NNS	G	G
may	MD	O	O
induce	VB	O	O
fungal	JJ	O	O
resistance	NN	O	O
to	TO	O	O
amphotericin	NN	O	D
b.	NNP	O	O
combination	NNP	O	O
therapy	NN	O	O
should	MD	O	O
be	VB	O	O
administered	VBN	O	O
with	IN	O	O
caution	NN	O	O
","	","	O	O
especially	RB	O	O
in	IN	O	O
immunocompromised	JJ	O	O
patients	NNS	O	O
.	.	.	.

other	JJ	O	O
nephrotoxic	JJ	O	O
medications	NNS	O	O
:	:	O	O
agents	NNS	O	O
such	JJ	O	O
as	IN	O	O
aminoglycosides	NNS	G	G
","	","	O	O
cyclosporine	NN	D	D
","	","	O	O
and	CC	O	O
pentamidine	NN	D	D
may	MD	O	O
enhance	VB	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
drug-induced	JJ	O	O
renal	JJ	O	O
toxicity	NN	O	O
","	","	O	O
and	CC	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
concomitantly	RB	O	O
only	RB	O	O
with	IN	O	O
great	JJ	O	O
caution	NN	O	O
.	.	.	.

intensive	JJ	O	O
monitoring	NN	O	O
of	IN	O	O
renal	JJ	O	O
function	NN	O	O
is	VBZ	O	O
recommended	VBN	O	O
in	IN	O	O
patients	NNS	O	O
requiring	VBG	O	O
any	DT	O	O
combination	NN	O	O
of	IN	O	O
nephrotoxic	JJ	O	O
medications	NNS	O	O
.	.	.	.

skeletal	JJ	O	O
muscle	NN	O	O
relaxants	NNS	O	O
:	:	O	O
amphotericin	NN	O	O
b-induced	JJ	O	O
hypokalemia	NN	O	O
may	MD	O	O
enhance	VB	O	O
the	DT	O	O
curariform	NN	O	O
effect	NN	O	O
of	IN	O	O
skeletal	JJ	O	O
muscle	NN	O	O
relaxants	NNS	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
tubocurarine	NN	D	D
-rrb-	-RRB-	O	O
.	.	.	.

serum	NN	O	O
potassium	NN	D	D
levels	NNS	O	O
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
and	CC	O	O
deficiencies	NNS	O	O
corrected	VBN	O	O
.	.	.	.

leukocyte	NN	O	O
transfusions	NNS	O	O
:	:	O	O
acute	JJ	O	O
pulmonary	JJ	O	O
toxicity	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
intravenous	JJ	O	O
amphotericin	NN	O	D
b	NN	O	O
and	CC	O	O
leukocyte	NN	O	O
transfusions	NNS	O	O
.	.	.	.

when	WRB	O	O
administered	VBN	O	O
concurrently	RB	O	O
","	","	O	O
the	DT	O	O
following	VBG	O	O
drugs	NNS	D	D
may	MD	O	O
interact	VB	O	O
with	IN	O	O
ampicillin	NN	D	D
.	.	.	.

allopurinol	NNP	D	D
:	:	O	O
increased	VBN	O	O
possibility	NN	O	O
of	IN	O	O
skin	NN	O	O
rash	NN	O	O
","	","	O	O
particularly	RB	O	O
in	IN	O	O
hyperuricemic	JJ	O	O
patients	NNS	O	O
may	MD	O	O
occur	VB	O	O
.	.	.	.

bacteriostatic	JJ	O	O
antibiotics	NNS	G	G
:	:	O	O
chloramphenicol	NN	D	D
","	","	O	O
erythromycins	NNS	D	G
","	","	O	O
sulfonamides	NNS	G	G
","	","	O	O
or	CC	O	O
tetracyclines	NNS	G	G
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
the	DT	O	O
bactericidal	JJ	O	O
effect	NN	O	O
of	IN	O	O
penicillins	NNS	G	O
.	.	.	.

this	DT	O	O
has	VBZ	O	O
been	VBN	O	O
demonstrated	VBN	O	O
in	IN	O	O
view	NN	O	O
","	","	O	O
however	RB	O	O
","	","	O	O
the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
this	DT	O	O
interaction	NN	O	O
is	VBZ	O	O
not	RB	O	O
well	RB	O	O
documented	VBN	O	O
.	.	.	.

oral	JJ	O	O
contraceptives	NNS	G	G
:	:	O	O
may	MD	O	O
be	VB	O	O
less	RBR	O	O
effective	JJ	O	O
and	CC	O	O
increased	VBD	O	O
breakthrough	NN	O	O
bleeding	NN	O	O
may	MD	O	O
occur	VB	O	O
.	.	.	.

probenecid	NNP	D	D
:	:	O	O
may	NNP	O	O
decrease	VB	O	O
renal	JJ	O	O
tubular	JJ	O	O
secretion	NN	O	O
of	IN	O	O
ampicillin	NN	D	D
resulting	VBG	O	O
in	IN	O	O
increased	VBN	O	O
blood	NN	O	O
levels	NNS	O	O
and/or	CC	O	O
ampicillin	NN	D	D
toxicity	NN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interaction	NN	O	O
after	IN	O	O
treatment	NN	O	O
with	IN	O	O
ampicillin	NN	D	D
","	","	O	O
a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
may	MD	O	O
occur	VB	O	O
with	IN	O	O
copper	NN	O	D
sulfate	NN	O	O
tests	NNS	O	O
-lrb-	-LRB-	O	O
benedicts	NNS	O	O
solution	NN	O	O
","	","	O	O
fehlings	NNP	O	O
solution	NN	O	O
","	","	O	O
or	CC	O	O
clinitest	NNP	O	O
tablets	NNS	O	O
-rrb-	-RRB-	O	O
but	CC	O	O
not	RB	O	O
with	IN	O	O
enzyme	NN	O	O
based	VBN	O	O
tests	NNS	O	O
such	JJ	O	O
as	IN	O	O
clinistix	NNP	O	B
and	CC	O	O
glucose	NNP	O	O
enzymatic	JJ	O	O
test	NN	O	O
strip	NNP	O	O
usp	NNP	O	O
.	.	.	.

amprenavir	NNP	D	D
is	VBZ	O	O
metabolized	VBN	O	O
in	IN	O	O
the	DT	O	O
liver	NN	O	O
by	IN	O	O
the	DT	O	O
cytochrome	NN	O	O
p450	NN	O	O
enzyme	NN	O	O
system	NN	O	O
.	.	.	.

amprenavir	NN	D	D
inhibits	VBZ	O	O
cyp3a4	NN	D	D
.	.	.	.

caution	NN	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
when	WRB	O	O
coadministering	VBG	O	O
medications	NNS	O	O
that	WDT	O	O
are	VBP	O	O
substrates	NNS	O	O
","	","	O	O
inhibitors	NNS	O	O
","	","	O	O
or	CC	O	O
inducers	NNS	O	O
of	IN	O	O
cyp3a4	NN	D	D
","	","	O	O
or	CC	O	O
potentially	RB	O	O
toxic	JJ	O	O
medications	NNS	O	O
that	WDT	O	O
are	VBP	O	O
metabolized	VBN	O	O
by	IN	O	O
cyp3a4	NN	D	D
.	.	.	.

amprenavir	NNP	D	D
does	VBZ	O	O
not	RB	O	O
inhibit	VB	O	O
cyp2d6	NN	D	O
","	","	O	O
cyp1a2	NN	D	O
","	","	O	O
cyp2c9	NN	D	O
","	","	O	O
cyp2c19	NN	O	O
","	","	O	O
cyp2e1	NN	O	O
","	","	O	O
or	CC	O	O
uridine	NN	O	O
glucuronosyltransferase	NN	O	O
-lrb-	-LRB-	O	O
udpgt	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

hiv	NN	O	O
protease	NN	O	O
inhibitors	NNS	O	O
:	:	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
amprenavir	NN	D	D
on	IN	O	O
total	JJ	O	O
drug	NN	D	O
concentrations	NNS	O	O
of	IN	O	O
other	JJ	O	O
hiv	NN	O	O
protease	NN	O	O
inhibitors	NNS	O	O
in	IN	O	O
subjects	NNS	O	O
receiving	VBG	O	O
both	CC	O	O
agents	NNS	O	O
was	VBD	O	O
evaluated	VBN	O	O
using	VBG	O	O
comparisons	NNS	O	O
to	TO	O	O
historical	JJ	O	O
data	NNS	O	O
.	.	.	.

indinavir	NNP	D	D
steady-state	JJ	O	O
cmax	NNP	O	O
","	","	O	O
a.c.	NNP	O	O
and	CC	O	O
cmin	NNP	O	O
were	VBD	O	O
decreased	VBN	O	O
by	IN	O	O
22	CD	O	O
%	NN	O	O
","	","	O	O
38	CD	O	O
%	NN	O	O
","	","	O	O
and	CC	O	O
27	CD	O	O
%	NN	O	O
","	","	O	O
respectively	RB	O	O
","	","	O	O
by	IN	O	O
concomitant	JJ	O	O
amprenavir	NN	D	O
.	.	.	.

similar	JJ	O	O
decreases	NNS	O	O
in	IN	O	O
cmax	NN	O	O
and	CC	O	O
auc	NN	O	O
were	VBD	O	O
seen	VBN	O	O
after	IN	O	O
the	DT	O	O
first	JJ	O	O
dose	NN	O	O
.	.	.	.

saquinavir	NNP	D	D
steady-state	JJ	O	O
cmax	NNP	O	O
","	","	O	O
a.c.	NNP	O	O
and	CC	O	O
cmin	NNP	O	B
were	VBD	O	O
increased	VBN	O	O
21	CD	O	O
%	NN	O	O
","	","	O	O
decreased	VBD	O	O
19	CD	O	O
%	NN	O	O
","	","	O	O
and	CC	O	O
decreased	VBD	O	O
48	CD	O	O
%	NN	O	O
","	","	O	O
respectively	RB	O	O
","	","	O	O
by	IN	O	O
concomitant	JJ	O	O
amprenavir	NN	D	O
.	.	.	.

nelfinavir	NNP	D	D
steady-state	JJ	O	O
cmax	NNP	O	O
","	","	O	O
a.c.	NNP	O	O
and	CC	O	O
cmin	NNP	O	B
were	VBD	O	O
increased	VBN	O	O
by	IN	O	O
12	CD	O	O
%	NN	O	O
","	","	O	O
15	CD	O	O
%	NN	O	O
","	","	O	O
and	CC	O	O
14	CD	O	O
%	NN	O	O
","	","	O	O
respectively	RB	O	O
","	","	O	O
by	IN	O	O
concomitant	JJ	O	O
amprenavir	NN	D	O
.	.	.	.

methadone	NNP	D	D
:	:	O	O
coadministration	NNP	O	O
of	IN	O	O
amprenavir	NN	D	O
and	CC	O	O
methadone	NN	D	D
can	MD	O	O
decrease	VB	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
methadone	NN	D	D
.	.	.	.

coadministration	NN	O	O
of	IN	O	O
amprenavir	NN	D	D
and	CC	O	O
methadone	NN	D	D
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
a	DT	O	O
non-matched	JJ	O	O
historicalcontrol	NN	O	O
group	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
30	CD	O	O
%	NN	O	O
","	","	O	O
27	CD	O	O
%	NN	O	O
","	","	O	O
and	CC	O	O
25	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
serum	NN	O	O
amprenavir	NN	D	D
auc	NN	O	O
","	","	O	O
cmax	NN	O	O
","	","	O	O
andcmin	NN	O	O
","	","	O	O
respectively	RB	O	O
.	.	.	.

amprenavir	NNP	D	D
is	VBZ	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
c.p.a.	NN	O	O
metabolism	NN	O	O
and	CC	O	O
therefore	RB	O	O
should	MD	O	O
not	RB	O	O
be	VB	O	O
administered	VBN	O	O
concurrently	RB	O	O
with	IN	O	O
medications	NNS	O	O
with	IN	O	O
narrow	JJ	O	O
therapeutic	JJ	O	O
windows	NNS	O	O
that	WDT	O	O
are	VBP	O	O
substrates	NNS	O	O
of	IN	O	O
cyp3a4	NN	D	D
.	.	.	.

there	EX	O	O
are	VBP	O	O
other	JJ	O	O
agents	NNS	O	O
that	WDT	O	O
may	MD	O	O
result	VB	O	O
in	IN	O	O
serious	JJ	O	O
and/or	CC	O	O
life-threatening	JJ	O	O
drug	NN	D	O
interactions	NNS	O	O
.	.	.	.

laboratory	NN	O	O
tests	NNS	O	O
:	:	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
amprenavir	NNP	D	B
and	CC	O	O
low-dose	JJ	O	O
ritonavir	NN	D	D
has	VBZ	O	O
been	VBN	O	O
associated	VBN	O	O
with	IN	O	O
elevations	NNS	O	O
of	IN	O	O
cholesterol	NN	O	O
and	CC	O	O
triglycerides	NNS	O	O
","	","	O	O
sgot	NN	O	D
-lrb-	-LRB-	O	O
ast	NNP	O	O
-rrb-	-RRB-	O	O
","	","	O	O
and	CC	O	O
sgpt	NN	O	O
-lrb-	-LRB-	O	O
alt	NN	O	O
-rrb-	-RRB-	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
.	.	.	.

appropriate	JJ	O	O
laboratory	NN	O	O
testing	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
prior	RB	O	O
to	TO	O	O
initiating	VBG	O	O
combination	NN	O	O
therapy	NN	O	O
with	IN	O	O
amprenavir	NN	D	D
and	CC	O	O
ritonavir	NN	D	D
and	CC	O	O
at	IN	O	O
periodic	JJ	O	O
intervals	NNS	O	O
or	CC	O	O
if	IN	O	O
any	DT	O	O
clinical	JJ	O	O
signs	NNS	O	O
or	CC	O	O
symptoms	NNS	O	O
of	IN	O	O
hyperlipidemia	NN	O	O
or	CC	O	O
elevated	JJ	O	O
liver	NN	O	O
function	NN	O	O
tests	NNS	O	O
occur	VBP	O	O
during	IN	O	O
therapy	NN	O	O
.	.	.	.

for	IN	O	O
comprehensive	JJ	O	O
information	NN	O	O
concerning	VBG	O	O
laboratory	NN	O	O
test	NN	O	O
alterations	NNS	O	O
associated	VBN	O	O
with	IN	O	O
ritonavir	NN	D	D
","	","	O	O
physicians	NNS	O	O
should	MD	O	O
refer	VB	O	O
to	TO	O	O
the	DT	O	O
complete	JJ	O	O
prescribing	VBG	O	O
information	NN	O	O
for	IN	O	O
norvir	NN	B	D
-lrb-	-LRB-	O	O
ritonavir	NN	D	D
-rrb-	-RRB-	O	O
.	.	.	.

taking	VBG	O	O
amyl	NN	O	D
nitrite	NN	D	O
after	IN	O	O
drinking	VBG	O	O
alcohol	NN	D	D
may	MD	O	O
worsen	VB	O	O
side	JJ	O	O
effects	NNS	O	O
and	CC	O	O
may	MD	O	O
cause	VB	O	O
severe	JJ	O	O
hypotension	NN	O	O
and	CC	O	O
cardiovascular	JJ	O	O
collapse	NN	O	O
.	.	.	.

limited	JJ	O	O
pk	NN	O	O
and/or	CC	O	O
pd	NN	O	O
studies	NNS	O	O
investigating	VBG	O	O
possible	JJ	O	O
interactions	NNS	O	O
between	IN	O	O
anagrelide	NN	D	D
and	CC	O	O
other	JJ	O	O
medicinal	JJ	O	O
products	NNS	O	O
have	VBP	O	O
been	VBN	O	O
conducted	VBN	O	O
.	.	.	.

in	FW	O	O
vivo	FW	O	O
interaction	NN	O	O
studies	NNS	O	O
in	IN	O	O
humans	NNS	O	O
have	VBP	O	O
demonstrated	VBN	O	O
that	IN	O	O
digoxin	NN	D	D
and	CC	O	O
warfarin	NN	D	D
do	VBP	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
pk	NN	O	O
properties	NNS	O	O
of	IN	O	O
anagrelide	NN	D	D
","	","	O	O
nor	CC	O	O
does	VBZ	O	O
anagrelide	NN	D	O
affect	VB	O	O
the	DT	O	O
pk	NN	O	O
properties	NNS	O	O
of	IN	O	O
digoxin	NN	D	D
or	CC	O	O
warfarin	NN	D	D
.	.	.	.

although	IN	O	O
additional	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
studies	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
conducted	VBN	O	O
","	","	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
medications	NNS	O	O
used	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
anagrelide	NN	D	D
in	IN	O	O
clinical	JJ	O	O
trials	NNS	O	O
were	VBD	O	O
aspirin	NN	B	B
","	","	O	O
acetaminophen	NN	D	D
","	","	O	O
furosemide	NN	D	D
","	","	O	O
iron	NN	D	D
","	","	O	O
ranitidine	NN	D	D
","	","	O	O
hydroxyurea	NN	D	D
","	","	O	O
and	CC	O	O
allopurinol	NN	D	D
.	.	.	.

there	EX	O	O
is	VBZ	O	O
no	DT	O	O
clinical	JJ	O	O
evidence	NN	O	O
to	TO	O	O
suggest	VB	O	O
that	IN	O	O
anagrelide	NN	D	D
interacts	VBZ	O	O
with	IN	O	O
any	DT	O	O
of	IN	O	O
these	DT	O	O
compounds	NNS	O	O
.	.	.	.

an	DT	O	O
in	FW	O	O
vivo	FW	O	O
interaction	NN	O	O
study	NN	O	O
in	IN	O	O
humans	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
a	DT	O	O
single	JJ	O	O
1mg	JJ	O	O
dose	NN	O	O
of	IN	O	O
anagrelide	NN	D	D
administered	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
a	DT	O	O
single	JJ	O	O
900	CD	O	O
mg	NN	O	O
dose	NN	O	O
of	IN	O	O
aspirin	NN	B	B
was	VBD	O	O
generally	RB	O	O
well	RB	O	O
tolerated	VBN	O	O
.	.	.	.

there	EX	O	O
was	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
bleeding	JJ	O	O
time	NN	O	O
","	","	O	O
pt	NN	O	O
or	CC	O	O
aptt	NN	O	O
.	.	.	.

no	DT	O	O
clinically	RB	O	O
relevant	JJ	O	O
pharmacokinetic	JJ	O	O
interactions	NNS	O	O
between	IN	O	O
anagrelide	NN	D	D
and	CC	O	O
acetylsalicylic	JJ	O	O
acid	NN	O	O
were	VBD	O	O
observed	VBN	O	O
.	.	.	.

in	IN	O	O
that	DT	O	O
same	JJ	O	O
study	NN	O	O
","	","	O	O
aspirin	NN	B	B
alone	RB	O	O
produced	VBD	O	O
a	DT	O	O
marked	JJ	O	O
inhibition	NN	O	O
in	IN	O	O
platelet	NN	O	O
aggregation	NN	O	O
ex	FW	O	O
vivo	FW	O	O
.	.	.	.

anagrelide	NN	D	D
alone	RB	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
platelet	NN	O	O
aggregation	NN	O	O
","	","	O	O
but	CC	O	O
did	VBD	O	O
slightly	RB	O	O
enhance	VB	O	O
the	DT	O	O
inhibition	NN	O	O
of	IN	O	O
platelet	NN	O	O
aggregation	NN	O	O
by	IN	O	O
aspirin	NN	B	B
.	.	.	.

anagrelide	NNP	D	D
is	VBZ	O	O
metabolized	VBN	O	O
at	IN	O	O
least	JJS	O	O
in	IN	O	O
part	NN	O	O
by	IN	O	O
cyp1a2	NN	D	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
known	VBN	O	O
that	IN	O	O
cyp1a2	NN	D	O
is	VBZ	O	O
inhibited	VBN	O	O
by	IN	O	O
several	JJ	O	O
medicinal	JJ	O	O
products	NNS	O	O
","	","	O	O
including	VBG	O	O
fluvoxamine	NN	D	D
","	","	O	O
and	CC	O	O
such	JJ	O	O
medicinal	JJ	O	O
products	NNS	O	O
could	MD	O	O
theoretically	RB	O	O
adversely	RB	O	O
influence	VB	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
anagrelide	NN	D	D
.	.	.	.

anagrelide	NNP	D	D
demonstrates	VBZ	O	O
some	DT	O	O
limited	JJ	O	O
inhibitory	JJ	O	O
activity	NN	O	O
towards	IN	O	O
cyp1a2	NN	D	O
which	WDT	O	O
may	MD	O	O
present	VB	O	O
a	DT	O	O
theoretical	JJ	O	O
potential	NN	O	O
for	IN	O	O
interaction	NN	O	O
with	IN	O	O
other	JJ	O	O
coadministered	JJ	O	O
medicinal	JJ	O	O
products	NNS	O	O
sharing	VBG	O	O
that	IN	O	O
clearance	NN	O	O
mechanism	NN	O	O
e.g.	FW	O	O
anagrelide	FW	D	O
demonstrates	VBZ	O	O
some	DT	O	O
limited	JJ	O	O
inhibitory	JJ	O	O
activity	NN	O	O
towards	IN	O	O
cyp1a2	NN	D	O
which	WDT	O	O
may	MD	O	O
present	VB	O	O
a	DT	O	O
theoretical	JJ	O	O
potential	NN	O	O
for	IN	O	O
interaction	NN	O	O
with	IN	O	O
other	JJ	O	O
coadministered	JJ	O	O
medicinal	JJ	O	O
products	NNS	O	O
sharing	VBG	O	O
that	IN	O	O
clearance	NN	O	O
mechanism	NN	O	O
e.g.	FW	O	O
theophylline	FW	D	D
.	.	.	.

anagrelide	NNP	D	D
is	VBZ	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
cyclic	JJ	O	O
amp	NN	O	O
pde	NN	O	O
iii	CD	O	O
.	.	.	.

the	DT	O	O
effects	NNS	O	O
of	IN	O	O
medicinal	JJ	O	O
products	NNS	O	O
with	IN	O	O
similar	JJ	O	O
properties	NNS	O	O
such	JJ	O	O
as	IN	O	O
inotropes	NNS	O	O
milrinone	NN	D	O
","	","	O	O
enoximone	NN	D	D
","	","	O	O
amrinone	NN	D	D
","	","	O	O
olprinone	NN	D_n	O
and	CC	O	O
cilostazol	NN	D	D
may	MD	O	O
be	VB	O	O
exacerbated	VBN	O	O
by	IN	O	O
anagrelide	NN	D	O
.	.	.	.

there	EX	O	O
is	VBZ	O	O
a	DT	O	O
single	JJ	O	O
case	NN	O	O
report	NN	O	O
","	","	O	O
which	WDT	O	O
suggests	VBZ	O	O
that	IN	O	O
sucralfate	NN	D	D
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
anagrelide	NN	D	O
absorption	NN	O	O
.	.	.	.

food	NNP	O	O
has	VBZ	O	O
no	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
anagrelide	NN	D	O
.	.	.	.

no	DT	O	O
drug-drug	NN	O	O
interaction	NN	O	O
studies	NNS	O	O
in	IN	O	O
human	JJ	O	O
subjects	NNS	O	O
have	VBP	O	O
been	VBN	O	O
conducted	VBN	O	O
.	.	.	.

toxicologic	JJ	O	O
and	CC	O	O
toxicokinetic	JJ	O	O
studies	NNS	O	O
in	IN	O	O
rats	NNS	O	O
did	VBD	O	O
not	RB	O	O
demonstrate	VB	O	O
any	DT	O	O
alterations	NNS	O	O
in	IN	O	O
the	DT	O	O
clearance	NN	O	O
or	CC	O	O
toxicologic	JJ	O	O
profile	NN	O	O
of	IN	O	O
either	CC	O	O
methotrexate	NN	D	D
or	CC	O	O
kineret	NN	B	O
when	WRB	O	O
the	DT	O	O
two	CD	O	O
agents	NNS	O	O
were	VBD	O	O
administered	VBN	O	O
together	RB	O	O
.	.	.	.

in	IN	O	O
a	DT	O	O
study	NN	O	O
in	IN	O	O
which	WDT	O	O
patients	NNS	O	O
with	IN	O	O
active	JJ	O	O
ra	NN	O	O
were	VBD	O	O
treated	VBN	O	O
for	IN	O	O
up	RB	O	O
to	TO	O	O
24	CD	O	O
weeks	NNS	O	O
with	IN	O	O
concurrent	JJ	O	O
kineret	NN	B	O
and	CC	O	O
etanercept	NN	D	O
therapy	NN	O	O
","	","	O	O
a	DT	O	O
7	CD	O	O
%	NN	O	O
rate	NN	O	O
of	IN	O	O
serious	JJ	O	O
infections	NNS	O	O
was	VBD	O	O
observed	VBN	O	O
","	","	O	O
which	WDT	O	O
was	VBD	O	O
higher	JJR	O	O
than	IN	O	O
that	DT	O	O
observed	VBN	O	O
with	IN	O	O
etanercept	NN	D	B
alone	RB	O	O
-lrb-	-LRB-	O	O
0	CD	O	O
%	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

two	CD	O	O
percent	NN	O	O
of	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
concurrently	RB	O	O
with	IN	O	O
kineret	NN	B	D
and	CC	O	O
etanercept	NN	D	D
developed	VBD	O	O
neutropenia	NN	O	O
-lrb-	-LRB-	O	O
anc	NNP	O	O
1	CD	O	O
x	CC	O	O
109/l	CD	O	O
-rrb-	-RRB-	O	O
.	.	.	.

anastrozole	NNP	D	D
inhibited	VBD	O	O
in	FW	O	O
vitro	FW	O	O
metabolic	JJ	O	O
reactions	NNS	O	O
catalyzed	VBN	O	O
by	IN	O	O
cytochromes	NNS	O	O
p450	NN	O	O
1a2	NN	O	O
","	","	O	O
2c8/9	NN	O	O
","	","	O	O
and	CC	O	O
3a4	NN	O	O
but	CC	O	O
only	RB	O	O
at	IN	O	O
relatively	RB	O	O
high	JJ	O	O
concentrations	NNS	O	O
.	.	.	.

anastrozole	NNP	D	D
did	VBD	O	O
not	RB	O	O
inhibit	VB	O	O
p450	NN	O	O
2a6	NN	O	O
or	CC	O	O
the	DT	O	O
polymorphic	JJ	O	O
p450	NN	O	O
2d6	NN	O	O
in	IN	O	O
human	JJ	O	O
liver	NN	O	O
microsomes	NNS	O	O
.	.	.	.

anastrozole	NNP	D	D
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
antipyrine	NN	D	D
.	.	.	.

although	IN	O	O
there	EX	O	O
have	VBP	O	O
been	VBN	O	O
no	DT	O	O
formal	JJ	O	O
interaction	NN	O	O
studies	NNS	O	O
other	JJ	O	O
than	IN	O	O
with	IN	O	O
antipyrine	NN	D	D
","	","	O	O
based	VBN	O	O
on	IN	O	O
these	DT	O	O
in	FW	O	O
vivo	FW	O	O
and	CC	O	O
in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
unlikely	JJ	O	O
that	IN	O	O
co-administration	NN	O	O
of	IN	O	O
a	DT	O	O
1	CD	O	O
mg	NN	O	O
dose	NN	O	O
of	IN	O	O
arimidex	NN	B	D
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
will	MD	O	O
result	VB	O	O
in	IN	O	O
clinically	RB	O	O
significant	JJ	O	O
drug	NN	D	O
inhibition	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p450-mediated	JJ	O	O
metabolism	NN	O	O
of	IN	O	O
the	DT	O	O
other	JJ	O	O
drugs	NNS	D	D
.	.	.	.

an	DT	O	O
interaction	NN	O	O
study	NN	O	O
with	IN	O	O
warfarin	NN	D	D
showed	VBD	O	O
no	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
effect	NN	O	O
of	IN	O	O
anastrozole	NN	D	D
on	IN	O	O
warfarin	NN	D	D
pharmacokinetics	NNS	O	O
or	CC	O	O
anticoagulant	JJ	G	G
activity	NN	O	O
.	.	.	.

at	IN	O	O
a	DT	O	O
median	JJ	O	O
follow-up	NN	O	O
of	IN	O	O
33	CD	O	O
months	NNS	O	O
","	","	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
arimidex	NNP	B	B
and	CC	O	O
tamoxifen	NN	D	D
did	VBD	O	O
not	RB	O	O
demonstrate	VB	O	O
any	DT	O	O
efficacy	NN	O	O
benefit	NN	O	O
when	WRB	O	O
compared	VBN	O	O
with	IN	O	O
tamoxifen	NN	D	D
in	IN	O	O
all	DT	O	O
patients	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
in	IN	O	O
the	DT	O	O
hormone	NN	O	O
receptor-positive	JJ	O	O
subpopulation	NN	O	O
.	.	.	.

this	DT	O	O
treatment	NN	O	O
arm	NN	O	O
was	VBD	O	O
discontinued	VBN	O	O
from	IN	O	O
the	DT	O	O
trial	NN	O	O
.	.	.	.

based	VBN	O	O
on	IN	O	O
clinical	JJ	O	O
and	CC	O	O
pharmacokinetic	JJ	O	O
results	NNS	O	O
from	IN	O	O
the	DT	O	O
atac	NN	O	O
trial	NN	O	O
","	","	O	O
tamoxifen	NN	D	D
should	MD	O	O
not	RB	O	O
be	VB	O	O
administered	VBN	O	O
with	IN	O	O
anastrozole	NN	D	D
-lrb-	-LRB-	O	O
see	VB	O	O
clinical	NNP	O	O
pharmacology	NNP	O	O
drug	NNP	O	O
interactions	NNS	O	O
and	CC	O	O
clinical	JJ	O	O
pharmacology	NN	O	O
-	:	O	O
clinical	JJ	O	O
studies	NNS	O	O
-	:	O	O
adjuvant	JJ	O	O
treatment	NN	O	O
of	IN	O	O
breast	NN	O	O
cancer	NN	O	O
in	IN	O	O
postmenopausal	NNP	O	O
women	NNP	O	O
subsections	NNS	O	O
-rrb-	-RRB-	O	O
.	.	.	.

co-administration	NN	O	O
of	IN	O	O
anastrozole	NN	D	D
and	CC	O	O
tamoxifen	NN	D	D
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
reduction	NN	O	O
of	IN	O	O
anastrozole	NN	D	D
plasma	NN	O	O
levels	NNS	O	O
by	IN	O	O
27	CD	O	O
%	NN	O	O
compared	VBN	O	O
with	IN	O	O
those	DT	O	O
achieved	VBN	O	O
with	IN	O	O
anastrozole	NN	D	D
alone	RB	O	O
.	.	.	.

estrogen-containing	JJ	O	O
therapies	NNS	O	O
should	MD	O	O
not	RB	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
arimidex	NN	B	O
as	IN	O	O
they	PRP	O	O
may	MD	O	O
diminish	VB	O	O
its	PRP$	O	O
pharmacologic	JJ	O	O
action	NN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
no	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
clinical	JJ	O	O
laboratory	NN	O	O
tests	NNS	O	O
have	VBP	O	O
been	VBN	O	O
observed	VBN	O	O
.	.	.	.

no	DT	O	O
clinically	RB	O	O
relevant	JJ	O	O
drug-drug	JJ	O	O
interactions	NNS	O	O
have	VBP	O	O
been	VBN	O	O
observed	VBN	O	O
with	IN	O	O
drugs	NNS	D	D
likely	JJ	O	O
to	TO	O	O
be	VB	O	O
co-administered	VBN	O	O
with	IN	O	O
anidulafungin	NN	D	D
.	.	.	.

caution	NN	O	O
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
when	WRB	O	O
anileridine	NN	D	D
is	VBZ	O	O
coadministered	VBN	O	O
with	IN	O	O
other	JJ	O	O
opioids	NNS	G	G
","	","	O	O
sedatives	NNS	G	G
","	","	O	O
phenothiazines	NNS	G	G
","	","	O	O
or	CC	O	O
anesthetics	NNS	G	G
","	","	O	O
as	IN	O	O
these	DT	O	O
agents	NNS	O	O
may	MD	O	O
increase	VB	O	O
respiratory	JJ	O	O
and	CC	O	O
circulatory	JJ	O	O
depression	NN	O	O
.	.	.	.

addition	NN	O	O
or	CC	O	O
deletion	NN	O	O
of	IN	O	O
any	DT	O	O
drug	NN	D	O
from	IN	O	O
the	DT	O	O
therapeutic	JJ	O	O
regimen	NN	O	O
of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
oral	JJ	O	O
anticoagulants	NNS	G	G
may	MD	O	O
affect	VB	O	O
patient	NN	O	O
response	NN	O	O
to	TO	O	O
the	DT	O	O
anticoagulant	NN	G	G
.	.	.	.

frequent	JJ	O	O
determination	NN	O	O
of	IN	O	O
prothrombin	NN	O	O
time	NN	O	O
and	CC	O	O
close	JJ	O	O
monitoring	NN	O	O
of	IN	O	O
the	DT	O	O
patient	NN	O	O
is	VBZ	O	O
essential	JJ	O	O
to	TO	O	O
ascertain	VB	O	O
when	WRB	O	O
adjustment	NN	O	O
of	IN	O	O
dosage	NN	O	O
of	IN	O	O
anticoagulant	NN	G	D
may	MD	O	O
be	VB	O	O
needed	VBN	O	O
.	.	.	.

because	IN	O	O
of	IN	O	O
the	DT	O	O
variability	NN	O	O
of	IN	O	O
individual	JJ	O	O
patient	NN	O	O
response	NN	O	O
","	","	O	O
multiple	JJ	O	O
interacting	VBG	O	O
mechanisms	NNS	O	O
with	IN	O	O
some	DT	O	O
drugs	NNS	D	D
","	","	O	O
the	DT	O	O
dependency	NN	O	O
of	IN	O	O
the	DT	O	O
extent	NN	O	O
of	IN	O	O
the	DT	O	O
interaction	NN	O	O
on	IN	O	O
the	DT	O	O
dosage	NN	O	O
and	CC	O	O
duration	NN	O	O
of	IN	O	O
therapy	NN	O	O
","	","	O	O
and	CC	O	O
the	DT	O	O
possible	JJ	O	O
administration	NN	O	O
of	IN	O	O
several	JJ	O	O
interacting	VBG	O	O
drugs	NNS	D	D
simultaneously	RB	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
difficult	JJ	O	O
to	TO	O	O
predict	VB	O	O
the	DT	O	O
direction	NN	O	O
and	CC	O	O
degree	NN	O	O
of	IN	O	O
the	DT	O	O
ultimate	JJ	O	O
effect	NN	O	O
of	IN	O	O
concomitant	JJ	O	O
medications	NNS	O	O
on	IN	O	O
anticoagulant	JJ	G	G
response	NN	O	O
.	.	.	.

for	IN	O	O
example	NN	O	O
","	","	O	O
since	IN	O	O
cholestyramine	NN	D	D
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
gastrointestinal	JJ	O	O
absorption	NN	O	O
of	IN	O	O
both	CC	O	O
the	DT	O	O
oral	JJ	O	O
anticoagulants	NNS	G	G
and	CC	O	O
vitamin	NN	O	G
k	NN	O	O
","	","	O	O
the	DT	O	O
net	JJ	O	O
effects	NNS	O	O
are	VBP	O	O
unpredictable	JJ	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
the	DT	O	O
potential	JJ	O	O
exists	VBZ	O	O
for	IN	O	O
interaction	NN	O	O
between	IN	O	O
carbamazepine	NN	D	D
and	CC	O	O
any	DT	O	O
agent	NN	O	O
metabolized	VBN	O	O
by	IN	O	O
one	CD	O	O
-lrb-	-LRB-	O	O
or	CC	O	O
more	JJR	O	O
-rrb-	-RRB-	O	O
of	IN	O	O
these	DT	O	O
enzymes	NNS	O	O
.	.	.	.

agents	NNS	O	O
that	WDT	O	O
have	VBP	O	O
been	VBN	O	O
found	VBN	O	O
","	","	O	O
or	CC	O	O
are	VBP	O	O
expected	VBN	O	O
to	TO	O	O
have	VB	O	O
decreased	VBN	O	O
plasma	NN	O	O
levels	NNS	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
equetrotm	NNP	B	B
due	JJ	O	O
to	TO	O	O
induction	NN	O	O
of	IN	O	O
cyp	NN	O	O
enzymes	NNS	O	O
are	VBP	O	O
the	DT	O	O
following	NN	O	O
:	:	O	O
acetaminophen	NNP	D	D
","	","	O	O
alprazolam	NN	D	D
","	","	O	O
amitriptyline	NNP	D	D
","	","	O	O
bupropion	NN	D	D
","	","	O	O
buspirone	NN	D	D
","	","	O	O
citalopram	NN	D	D
","	","	O	O
clobazam	NN	D	D
","	","	O	O
clonazepam	NN	D	D
","	","	O	O
clozapine	NN	D	D
","	","	O	O
cyclosporin	NN	D	D
","	","	O	O
delavirdine	NN	D	D
","	","	O	O
desipramine	NN	D	D
","	","	O	O
diazepam	NN	D	D
","	","	O	O
dicumarol	NN	D	D
","	","	O	O
doxycycline	NN	D	D
","	","	O	O
ethosuximide	NN	D	D
","	","	O	O
felbamate	NN	D	D
","	","	O	O
felodipine	NN	D	D
","	","	O	O
glucocorticoids	NNS	G	G
","	","	O	O
haloperidol	NN	D	D
","	","	O	O
itraconazole	NN	D	D
","	","	O	O
lamotrigine	NN	D	D
","	","	O	O
levothyroxine	NN	D	D
","	","	O	O
lorazepam	NN	D	D
","	","	O	O
methadone	NN	D	D
","	","	O	O
midazolam	NN	D	D
","	","	O	O
mirtazapine	NN	D	D
","	","	O	O
nortriptyline	NN	D_n	D
","	","	O	O
olanzapine	NN	D	O
","	","	O	O
oral	JJ	O	O
contraceptives	NNS	G	G
-lrb-	-LRB-	O	O
3	CD	O	O
-rrb-	-RRB-	O	O
","	","	O	O
oxcarbazepine	NN	D	D
","	","	O	O
phenytoin	NN	D	D
-lrb-	-LRB-	O	O
4	CD	O	O
-rrb-	-RRB-	O	O
","	","	O	O
praziquantel	NN	D	D
","	","	O	O
protease	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
quetiapine	NN	D	O
","	","	O	O
risperidone	NN	D	D
","	","	O	O
theophylline	NN	D	D
","	","	O	O
topiramate	NN	D	D
","	","	O	O
tiagabine	NN	D	D
","	","	O	O
tramadol	NN	D	D
","	","	O	O
triazolam	NN	D	D
","	","	O	O
valproate	NN	D	D
","	","	O	O
warfarin	NN	D	D
-lrb-	-LRB-	O	O
5	CD	O	O
-rrb-	-RRB-	O	O
","	","	O	O
ziprasidone	NN	D	D
","	","	O	O
and	CC	O	O
zonisamide	NN	D	D
.	.	.	.

thus	RB	O	O
","	","	O	O
if	IN	O	O
a	DT	O	O
patient	NN	O	O
has	VBZ	O	O
been	VBN	O	O
titrated	VBN	O	O
to	TO	O	O
a	DT	O	O
stable	JJ	O	O
dosage	NN	O	O
on	IN	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
agents	NNS	O	O
in	IN	O	O
this	DT	O	O
category	NN	O	O
","	","	O	O
and	CC	O	O
then	RB	O	O
begins	VBZ	O	O
a	DT	O	O
course	NN	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
equetrotm	NN	B	D
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
reasonable	JJ	O	O
to	TO	O	O
expect	VB	O	O
that	IN	O	O
a	DT	O	O
dose	NN	O	O
increase	NN	O	O
for	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
agent	NN	O	O
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
.	.	.	.

agents	NNS	O	O
with	IN	O	O
increased	VBN	O	O
levels	NNS	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
carbamazepine	NNP	D	D
:	:	O	O
equetrotm	NNP	B	D
increases	VBZ	O	O
the	DT	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
the	DT	O	O
following	VBG	O	O
agents	NNS	O	O
:	:	O	O
clomipramine	NNP	O	D
hcl	NN	O	O
","	","	O	O
phenytoin	NNP	D	D
-lrb-	-LRB-	O	O
6	CD	O	O
-rrb-	-RRB-	O	O
","	","	O	O
and	CC	O	O
primidone	NN	D	D
thus	RB	O	O
","	","	O	O
if	IN	O	O
a	DT	O	O
patient	NN	O	O
has	VBZ	O	O
been	VBN	O	O
titrated	VBN	O	O
to	TO	O	O
a	DT	O	O
stable	JJ	O	O
dosage	NN	O	O
on	IN	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
agents	NNS	O	O
in	IN	O	O
this	DT	O	O
category	NN	O	O
","	","	O	O
and	CC	O	O
then	RB	O	O
begins	VBZ	O	O
a	DT	O	O
course	NN	O	O
of	IN	O	O
the	DT	O	O
treatment	NN	O	O
with	IN	O	O
equetrotm	NN	B	D
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
reasonable	JJ	O	O
to	TO	O	O
expect	VB	O	O
that	IN	O	O
a	DT	O	O
dose	NN	O	O
decrease	NN	O	O
for	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
agent	NN	O	O
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
.	.	.	.

pharmacological/pharmacodynamic	JJ	O	O
interactions	NNS	O	O
with	IN	O	O
carbamazepine	NNP	D	B
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
carbamazepine	NN	D	D
and	CC	O	O
lithium	NN	D	D
may	MD	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
neurotoxic	JJ	O	O
side	JJ	O	O
effects	NNS	O	O
.	.	.	.

given	VBN	O	O
the	DT	O	O
anticonvulsant	JJ	O	O
properties	NNS	O	O
of	IN	O	O
carbamazepine	NN	D	D
","	","	O	O
equetrotm	NN	B	D
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
thyroid	NN	D	G
function	NN	O	O
as	IN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
with	IN	O	O
other	JJ	O	O
anticonvulsants	NNS	G	G
.	.	.	.

additionally	RB	O	O
","	","	O	O
anti-malarial	JJ	O	O
drugs	NNS	D	D
","	","	O	O
such	JJ	O	O
as	IN	O	O
chloroquine	NN	D	D
and	CC	O	O
mefloquine	NN	D	D
","	","	O	O
may	MD	O	O
antagonize	VB	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
carbamazepine	NN	D	D
.	.	.	.

thus	RB	O	O
if	IN	O	O
a	DT	O	O
patient	NN	O	O
has	VBZ	O	O
been	VBN	O	O
titrated	VBN	O	O
to	TO	O	O
a	DT	O	O
stable	JJ	O	O
dosage	NN	O	O
on	IN	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
agents	NNS	O	O
in	IN	O	O
this	DT	O	O
category	NN	O	O
","	","	O	O
and	CC	O	O
then	RB	O	O
begins	VBZ	O	O
a	DT	O	O
course	NN	O	O
of	IN	O	O
treatment	NN	O	O
with	IN	O	O
equetrotm	NN	B	D
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
reasonable	JJ	O	O
to	TO	O	O
expect	VB	O	O
that	IN	O	O
a	DT	O	O
dose	NN	O	O
adjustment	NN	O	O
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
.	.	.	.

because	IN	O	O
of	IN	O	O
its	PRP$	O	O
primary	JJ	O	O
cns	NN	O	O
effect	NN	O	O
","	","	O	O
caution	NN	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
when	WRB	O	O
equetrotm	NNP	B	B
is	VBZ	O	O
taken	VBN	O	O
with	IN	O	O
other	JJ	O	O
centrally	RB	O	O
acting	VBG	O	O
drugs	NNS	D	D
and	CC	O	O
alcohol	NN	D	D
.	.	.	.

geocillin	NN	B	O
-lrb-	-LRB-	O	O
carbenicillin	NN	O	O
indanyl	NN	O	O
sodium	NN	O	O
-rrb-	-RRB-	O	O
blood	NN	O	O
levels	NNS	O	O
may	MD	O	O
be	VB	O	O
increased	VBN	O	O
and	CC	O	O
prolonged	VBN	O	O
by	IN	O	O
concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
probenecid	NN	D	D
.	.	.	.

caution	NN	O	O
should	MD	O	O
be	VB	O	O
exercised	VBN	O	O
when	WRB	O	O
the	DT	O	O
following	VBG	O	O
drugs	NNS	D	D
are	VBP	O	O
administered	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
lodosyn	NN	B	D
-lrb-	-LRB-	O	O
carbidopa	NN	D	O
-rrb-	-RRB-	O	O
given	VBN	O	O
with	IN	O	O
levodopa	NN	D	D
or	CC	O	O
carbidopa-levodopa	NN	O	O
combination	NN	O	O
products	NNS	O	O
.	.	.	.

for	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
monoamine	NN	O	O
oxidase	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
see	VBP	O	O
contraindications	NNS	O	O
.	.	.	.

dopamine	NN	O	D
d2	NN	O	O
receptor	NN	D	O
antagonists	NNS	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
phenothiazines	NNS	G	G
","	","	O	O
butyrophenones	NNS	G	G
","	","	O	O
risperidone	NN	D	D
-rrb-	-RRB-	O	O
and	CC	O	O
isoniazid	NN	D	D
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
therapeutic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
levodopa	NN	D	D
.	.	.	.

in	IN	O	O
addition	NN	O	O
","	","	O	O
the	DT	O	O
beneficial	JJ	O	O
effects	NNS	O	O
of	IN	O	O
levodopa	NN	D	D
in	IN	O	O
parkinsons	NNPS	O	O
disease	NN	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
be	VB	O	O
reversed	VBN	O	O
by	IN	O	O
phenytoin	NN	D	D
and	CC	O	O
papaverine	NN	D	D
.	.	.	.

patients	NNS	O	O
taking	VBG	O	O
these	DT	O	O
drugs	NNS	D	D
with	IN	O	O
lodosyn	NN	B	O
and	CC	O	O
levodopa	NN	D	D
or	CC	O	O
carbidopa-levodopa	NN	O	O
combination	NN	O	O
products	NNS	O	O
should	MD	O	O
be	VB	O	O
carefully	RB	O	O
observed	VBN	O	O
for	IN	O	O
loss	NN	O	O
of	IN	O	O
therapeutic	JJ	O	O
response	NN	O	O
.	.	.	.

iron	NNP	D	D
salts	NNS	O	O
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
carbidopa	NN	D	D
and	CC	O	O
levodopa	NN	D	D
.	.	.	.

the	DT	O	O
clinical	JJ	O	O
relevance	NN	O	O
is	VBZ	O	O
unclear	JJ	O	O
.	.	.	.

although	IN	O	O
metoclopramide	NN	D	D
may	MD	O	O
increase	VB	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
levodopa	NN	D	D
by	IN	O	O
increasing	VBG	O	O
gastric	JJ	O	O
emptying	NN	O	O
","	","	O	O
metoclopramide	NN	D	D
may	MD	O	O
also	RB	O	O
adversely	RB	O	O
affect	VB	O	O
disease	NN	O	O
control	NN	O	O
by	IN	O	O
its	PRP$	O	O
dopamine	NN	D	O
receptor	NN	D	O
antagonistic	JJ	O	O
properties	NNS	O	O
.	.	.	.

iodine	NN	D	D
or	CC	O	O
iodine	NN	D	O
excess	NN	O	O
may	MD	O	O
decrease	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
carbimazole	NNP	D	B
","	","	O	O
and	CC	O	O
an	DT	O	O
iodine	NN	D	G
deficiency	NN	O	O
can	MD	O	O
increase	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
carbimazole	NN	D	D
.	.	.	.

serum	NN	O	O
concentration	NN	O	O
of	IN	O	O
digoxin	NN	D	D
and	CC	O	O
digitoxin	NN	D	D
may	MD	O	O
increase	VB	O	O
when	WRB	O	O
patients	NNS	O	O
take	VBP	O	O
antithyroid	JJ	O	O
agents	NNS	O	O
.	.	.	.

a	DT	O	O
decrease	NN	O	O
of	IN	O	O
the	DT	O	O
dosage	NN	O	O
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
when	WRB	O	O
patient	NN	O	O
becomes	VBZ	O	O
euthyroid	JJ	O	O
.	.	.	.

antithyroid	JJ	O	O
agents	NNS	O	O
may	MD	O	O
decrease	VB	O	O
thyroidal	JJ	O	O
uptake	NN	O	O
of	IN	O	O
sodium	NN	O	O
iodide	NN	O	O
i131	NN	O	O
","	","	O	O
a	DT	O	O
rebound	NN	O	O
in	IN	O	O
uptake	NN	O	O
may	MD	O	O
occur	VB	O	O
up	RP	O	O
to	TO	O	O
5	CD	O	O
days	NNS	O	O
after	IN	O	O
sudden	JJ	O	O
withdrawal	NN	O	O
of	IN	O	O
carbimazole	NN	D	D
.	.	.	.

patients	NNS	O	O
response	NN	O	O
to	TO	O	O
oral	JJ	O	O
anticoagulants	NNS	G	G
may	MD	O	O
be	VB	O	O
affected	VBN	O	O
by	IN	O	O
his/her	NN	O	O
thyroid	NN	D	O
and	CC	O	O
metabolic	JJ	O	O
status	NN	O	O
.	.	.	.

an	DT	O	O
evaluation	NN	O	O
of	IN	O	O
prothrombin	NN	O	O
time	NN	O	O
and	CC	O	O
an	DT	O	O
adjustment	NN	O	O
of	IN	O	O
anticoagulant	JJ	G	G
dosage	NN	O	O
are	VBP	O	O
recommende	NN	O	O
.	.	.	.

antihistamines	NNS	G	D
may	MD	O	O
enhance	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
","	","	O	O
barbiturates	NNS	G	G
","	","	O	O
alcohol	NN	D	D
","	","	O	O
and	CC	O	O
other	JJ	O	O
cns	NN	O	O
depressants	NNS	O	O
.	.	.	.

mao	NN	O	O
inhibitors	NNS	O	O
prolong	VB	O	O
and	CC	O	O
intensify	VB	O	O
the	DT	O	O
anticholinergic	JJ	G	G
effects	NNS	O	O
of	IN	O	O
antihistamines	NNS	G	G
.	.	.	.

sympathomimetic	JJ	O	O
amines	NNS	O	O
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
antihypertensive	JJ	O	G
effects	NNS	O	O
of	IN	O	O
reserpine	NN	D	D
","	","	O	O
veratrum	NN	O	O
alkaloids	NNS	O	O
","	","	O	O
methyldopa	NN	D	D
and	CC	O	O
mecamylamine	NN	D	D
.	.	.	.

effects	NNS	O	O
of	IN	O	O
sympathomimetics	NNS	G	G
are	VBP	O	O
increased	VBN	O	O
with	IN	O	O
mao	NN	O	O
inhibitors	NNS	O	O
and	CC	O	O
beta	NN	O	O
adrenergic	JJ	O	G
blockers	NNS	O	O
.	.	.	.

the	DT	O	O
renal	JJ	O	O
effects	NNS	O	O
of	IN	O	O
nephrotoxic	JJ	O	O
compounds	NNS	O	O
may	MD	O	O
be	VB	O	O
potentiated	VBN	O	O
by	IN	O	O
carboplatin	NNP	D	B
.	.	.	.

hemabate	NN	B	D
may	MD	O	O
augment	VB	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
other	JJ	O	O
oxytocic	JJ	O	O
agents	NNS	O	O
.	.	.	.

concomitant	JJ	O	O
use	NN	O	O
with	IN	O	O
other	JJ	O	O
oxytocic	JJ	O	O
agents	NNS	O	O
is	VBZ	O	O
not	RB	O	O
recommende	NN	O	O
.	.	.	.

ocupress	NN	B	D
should	MD	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
caution	NN	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
are	VBP	O	O
receiving	VBG	O	O
a	DT	O	O
beta-adrenergic	JJ	O	O
blocking	VBG	O	O
agent	NN	O	O
orally	RB	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
additive	JJ	O	O
effects	NNS	O	O
on	IN	O	O
systemic	JJ	O	O
beta-blockade	NN	O	O
.	.	.	.

close	JJ	O	O
observation	NN	O	O
of	IN	O	O
the	DT	O	O
patient	NN	O	O
is	VBZ	O	O
recommended	VBN	O	O
when	WRB	O	O
a	DT	O	O
beta-blocker	NN	G	G
is	VBZ	O	O
administered	VBN	O	O
to	TO	O	O
patients	NNS	O	O
receiving	VBG	O	O
catecholamine-depleting	JJ	O	O
drugs	NNS	D	D
such	JJ	O	O
as	IN	O	O
reserpine	NN	D	D
","	","	O	O
because	IN	O	O
of	IN	O	O
possible	JJ	O	O
additive	JJ	O	O
effects	NNS	O	O
and	CC	O	O
the	DT	O	O
production	NN	O	O
of	IN	O	O
hypotension	NN	O	O
and/or	CC	O	O
marked	JJ	O	O
bradycardia	NN	O	O
","	","	O	O
which	WDT	O	O
may	MD	O	O
produce	VB	O	O
vertigo	NN	O	O
","	","	O	O
syncope	NN	O	O
","	","	O	O
or	CC	O	O
postural	JJ	O	O
hypotension	NN	O	O
.	.	.	.

inhibitors	NNS	O	O
of	IN	O	O
cyp2d6	NN	D	O
;	:	O	O
.	.	.	.

poor	JJ	O	O
metabolizers	NNS	O	O
of	IN	O	O
debrisoquin	NN	D	O
:	:	O	O
interactions	NNS	O	O
of	IN	O	O
carvedilol	NN	D	B
with	IN	O	O
strong	JJ	O	O
inhibitors	NNS	O	O
of	IN	O	O
cyp2d6	NN	D	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
quinidine	NN	D	D
","	","	O	O
fluoxetine	NN	D	D
","	","	O	O
paroxetine	NN	D	D
","	","	O	O
and	CC	O	O
propafenone	NN	D	D
-rrb-	-RRB-	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
","	","	O	O
but	CC	O	O
these	DT	O	O
drugs	NNS	D	D
would	MD	O	O
be	VB	O	O
expected	VBN	O	O
to	TO	O	O
increase	VB	O	O
blood	NN	O	O
levels	NNS	O	O
of	IN	O	O
the	DT	O	O
r	NN	O	O
-lrb-	-LRB-	O	O
+	CC	O	O
-rrb-	-RRB-	O	O
enantiomer	NN	O	O
of	IN	O	O
carvedilol	NN	D	D
.	.	.	.

retrospective	JJ	O	O
analysis	NN	O	O
of	IN	O	O
side	JJ	O	O
effects	NNS	O	O
in	IN	O	O
clinical	JJ	O	O
trials	NNS	O	O
showed	VBD	O	O
that	IN	O	O
poor	JJ	O	O
2d6	NN	O	O
metabolizers	NNS	O	O
had	VBD	O	O
a	DT	O	O
higher	JJR	O	O
rate	NN	O	O
of	IN	O	O
dizziness	NN	O	O
during	IN	O	O
up-titration	NN	O	O
","	","	O	O
presumably	RB	O	O
resulting	VBG	O	O
from	IN	O	O
vasodilating	VBG	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
higher	JJR	O	O
concentrations	NNS	O	O
of	IN	O	O
the	DT	O	O
a-blocking	NN	O	O
r	NN	O	O
-lrb-	-LRB-	O	O
+	CC	O	O
-rrb-	-RRB-	O	O
enantiomer	NN	O	O
.	.	.	.

catecholamine-depleting	JJ	O	O
agents	NNS	O	O
:	:	O	O
patients	NNS	O	O
taking	VBG	O	O
both	CC	O	O
agents	NNS	O	O
with	IN	O	O
b-blocking	NN	O	O
properties	NNS	O	O
and	CC	O	O
a	DT	O	O
drug	NN	D	O
that	WDT	O	O
can	MD	O	O
deplete	VB	O	O
catecholamines	NNS	O	G
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
reserpine	NN	D	D
and	CC	O	O
monoamine	NN	O	O
oxidase	NN	O	O
inhibitors	NNS	O	O
-rrb-	-RRB-	O	O
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
closely	RB	O	O
for	IN	O	O
signs	NNS	O	O
of	IN	O	O
hypotension	NN	O	O
and/or	CC	O	O
severe	JJ	O	O
bradycardia	NN	O	O
.	.	.	.

clonidine	NNP	D	D
:	:	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
clonidine	NN	D	D
with	IN	O	O
agents	NNS	O	O
with	IN	O	O
b-blocking	NN	O	O
properties	NNS	O	O
may	MD	O	O
potentiate	VB	O	O
blood-pressure	NN	O	O
-	:	O	O
and	CC	O	O
heart-rate-lowering	JJ	O	O
effects	NNS	O	O
.	.	.	.

when	WRB	O	O
concomitant	JJ	O	O
treatment	NN	O	O
with	IN	O	O
agents	NNS	O	O
with	IN	O	O
b-blocking	NN	O	O
properties	NNS	O	O
and	CC	O	O
clonidine	NN	D	D
is	VBZ	O	O
to	TO	O	O
be	VB	O	O
terminated	VBN	O	O
","	","	O	O
the	DT	O	O
b-blocking	JJ	O	O
agent	NN	O	O
should	MD	O	O
be	VB	O	O
discontinued	VBN	O	O
first	RB	O	O
.	.	.	.

clonidine	NN	D	D
therapy	NN	O	O
can	MD	O	O
then	RB	O	O
be	VB	O	O
discontinued	VBN	O	O
several	JJ	O	O
days	NNS	O	O
later	RB	O	O
by	IN	O	O
gradually	RB	O	O
decreasing	VBG	O	O
the	DT	O	O
dosage	NN	O	O
.	.	.	.

cyclosporine	NN	D	D
:	:	O	O
modest	JJ	O	O
increases	NNS	O	O
in	IN	O	O
mean	JJ	O	O
trough	NN	O	O
cyclosporine	NN	D	D
concentrations	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
following	VBG	O	O
initiation	NN	O	O
of	IN	O	O
carvedilol	NN	D	D
treatment	NN	O	O
in	IN	O	O
21	CD	O	O
renal	JJ	O	O
transplant	NN	O	O
patients	NNS	O	O
suffering	VBG	O	O
from	IN	O	O
chronic	JJ	O	O
vascular	JJ	O	O
rejection	NN	O	O
.	.	.	.

in	IN	O	O
about	RB	O	O
30	CD	O	O
%	NN	O	O
of	IN	O	O
patients	NNS	O	O
","	","	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
cyclosporine	NN	D	D
had	VBD	O	O
to	TO	O	O
be	VB	O	O
reduced	VBN	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
maintain	VB	O	O
cyclosporine	NN	D	D
concentrations	NNS	O	O
within	IN	O	O
the	DT	O	O
therapeutic	JJ	O	O
range	NN	O	O
","	","	O	O
while	IN	O	O
in	IN	O	O
the	DT	O	O
remainder	NN	O	O
no	DT	O	O
adjustment	NN	O	O
was	VBD	O	O
needed	VBN	O	O
.	.	.	.

on	IN	O	O
the	DT	O	O
average	NN	O	O
for	IN	O	O
the	DT	O	O
group	NN	O	O
","	","	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
cyclosporine	NN	D	D
was	VBD	O	O
reduced	VBN	O	O
about	IN	O	O
20	CD	O	O
%	NN	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	.	.

due	JJ	O	O
to	TO	O	O
wide	JJ	O	O
interindividual	JJ	O	O
variability	NN	O	O
in	IN	O	O
the	DT	O	O
dose	NN	O	O
adjustment	NN	O	O
required	VBN	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
cyclosporine	NN	D	D
concentrations	NNS	O	O
be	VB	O	O
monitored	VBN	O	O
closely	RB	O	O
after	IN	O	O
initiation	NN	O	O
of	IN	O	O
carvedilol	NN	D	D
therapy	NN	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
dose	NN	O	O
of	IN	O	O
cyclosporine	NN	D	D
be	VB	O	O
adjusted	VBN	O	O
as	IN	O	O
appropriate	JJ	O	O
.	.	.	.

digoxin	NNP	D	D
:	:	O	O
digoxin	NN	D	D
concentrations	NNS	O	O
are	VBP	O	O
increased	VBN	O	O
by	IN	O	O
about	RB	O	O
15	CD	O	O
%	NN	O	O
when	WRB	O	O
digoxin	NN	D	D
and	CC	O	O
carvedilol	NN	D	D
are	VBP	O	O
administered	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

both	DT	O	O
digoxin	NN	D	D
and	CC	O	O
coreg	NNP	B	B
slow	JJ	O	O
av	NN	O	O
conduction	NN	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
increased	VBD	O	O
monitoring	NN	O	O
of	IN	O	O
digoxin	NN	D	D
is	VBZ	O	O
recommended	VBN	O	O
when	WRB	O	O
initiating	VBG	O	O
","	","	O	O
adjusting	VBG	O	O
","	","	O	O
or	CC	O	O
discontinuing	VBG	O	O
coreg	NNP	B	O
.	.	.	.

inducers	NNS	O	O
and	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
hepatic	JJ	O	O
metabolism	NN	O	O
:	:	O	O
rifampin	NNP	D	D
reduced	VBD	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
carvedilol	NN	D	D
by	IN	O	O
about	RB	O	O
70	CD	O	O
%	NN	O	O
.	.	.	.

cimetidine	NN	D	D
increased	VBD	O	O
auc	NN	O	O
by	IN	O	O
about	IN	O	O
30	CD	O	O
%	NN	O	O
but	CC	O	O
caused	VBD	O	O
no	DT	O	O
change	NN	O	O
in	IN	O	O
cmax	NNP	O	O
.	.	.	.

calcium	NN	D	D
channel	NNP	O	O
blockers	NNPS	O	O
:	:	O	O
isolated	VBN	O	O
cases	NNS	O	O
of	IN	O	O
conduction	NN	O	O
disturbance	NN	O	O
-lrb-	-LRB-	O	O
rarely	RB	O	O
with	IN	O	O
hemodynamic	JJ	O	O
compromise	NN	O	O
-rrb-	-RRB-	O	O
have	VBP	O	O
been	VBN	O	O
observed	VBN	O	O
when	WRB	O	O
coreg	NNP	B	B
is	VBZ	O	O
co-administered	VBN	O	O
with	IN	O	O
diltiazem	NN	D	D
.	.	.	.

as	IN	O	O
with	IN	O	O
other	JJ	O	O
agents	NNS	O	O
with	IN	O	O
b-blocking	NN	O	O
properties	NNS	O	O
","	","	O	O
if	IN	O	O
coreg	NNP	B	B
is	VBZ	O	O
to	TO	O	O
be	VB	O	O
administered	VBN	O	O
orally	RB	O	O
with	IN	O	O
calcium	NN	D	D
channel	NN	O	O
blockers	NNS	O	O
of	IN	O	O
the	DT	O	O
verapamil	NN	D	D
or	CC	O	O
diltiazem	NN	D	D
type	NN	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
ecg	NN	O	O
and	CC	O	O
blood	NN	O	O
pressure	NN	O	O
be	VB	O	O
monitored	VBN	O	O
.	.	.	.

insulin	NN	D	D
or	CC	O	O
oral	JJ	O	O
hypoglycemics	NNS	G	G
:	:	O	O
agents	NNS	O	O
with	IN	O	O
b-blocking	NN	O	O
properties	NNS	O	O
may	MD	O	O
enhance	VB	O	O
the	DT	O	O
blood-sugar-reducing	JJ	O	O
effect	NN	O	O
of	IN	O	O
insulin	NN	D	D
and	CC	O	O
oral	JJ	O	O
hypoglycemics	NNS	G	G
.	.	.	.

therefore	RB	O	O
","	","	O	O
in	IN	O	O
patients	NNS	O	O
taking	VBG	O	O
insulin	NN	D	D
or	CC	O	O
oral	JJ	O	O
hypoglycemics	NNS	G	G
","	","	O	O
regular	JJ	O	O
monitoring	NN	O	O
of	IN	O	O
blood	NN	O	O
glucose	NN	O	O
is	VBZ	O	O
recommended	VBN	O	O
.	.	.	.

studies	NNS	O	O
in	FW	O	O
vitro	FW	O	O
show	VBP	O	O
that	IN	O	O
caspofungin	NN	D	O
acetate	NN	O	O
is	VBZ	O	O
not	RB	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
any	DT	O	O
enzyme	NN	O	O
in	IN	O	O
the	DT	O	O
cytochrome	NN	O	O
p450	NN	O	O
-lrb-	-LRB-	O	O
cyp	NN	O	O
-rrb-	-RRB-	O	O
system	NN	O	O
.	.	.	.

in	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
","	","	O	O
caspofungin	NN	D	D
did	VBD	O	O
not	RB	O	O
induce	VB	O	O
the	DT	O	O
cyp3a4	NN	D	D
metabolism	NN	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
.	.	.	.

caspofungin	NNP	D	D
is	VBZ	O	O
not	RB	O	O
a	DT	O	O
substrate	NN	O	O
for	IN	O	O
p-glycoprotein	NN	O	O
and	CC	O	O
is	VBZ	O	O
a	DT	O	O
poor	JJ	O	O
substrate	NN	O	O
for	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
enzymes	NNS	O	O
.	.	.	.

clinical	JJ	O	O
studies	NNS	O	O
in	IN	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
show	VBP	O	O
that	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
cancidas	NNP	B	B
are	VBP	O	O
not	RB	O	O
altered	VBN	O	O
by	IN	O	O
itraconazole	NN	D	D
","	","	O	O
amphotericin	NN	O	D
b	NN	O	O
","	","	O	O
mycophenolate	NN	D	D
","	","	O	O
nelfinavir	NN	D	D
","	","	O	O
or	CC	O	O
tacrolimus	NN	D	D
.	.	.	.

cancidas	NNP	B	D
has	VBZ	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
itraconazole	NN	D	D
","	","	O	O
amphotericin	NN	O	D
b	NN	O	O
","	","	O	O
or	CC	O	O
the	DT	O	O
active	JJ	O	O
metabolite	NN	O	O
of	IN	O	O
mycophenolate	NN	D	D
.	.	.	.

cancidas	NNP	B	D
reduced	VBD	O	O
the	DT	O	O
blood	NN	O	O
auc0-12	NN	O	O
of	IN	O	O
tacrolimus	NN	D	D
by	IN	O	O
approximately	RB	O	O
20	CD	O	O
%	NN	O	O
","	","	O	O
peak	JJ	O	O
blood	NN	O	O
concentration	NN	O	O
-lrb-	-LRB-	O	O
cmax	NN	O	O
-rrb-	-RRB-	O	O
by	IN	O	O
16	CD	O	O
%	NN	O	O
","	","	O	O
and	CC	O	O
12-hour	JJ	O	O
blood	NN	O	O
concentration	NN	O	O
-lrb-	-LRB-	O	O
c12hr	NN	O	D
-rrb-	-RRB-	O	O
by	IN	O	O
26	CD	O	O
%	NN	O	O
in	IN	O	O
healthy	JJ	O	O
subjects	NNS	O	O
when	WRB	O	O
tacrolimus	NN	D	D
-lrb-	-LRB-	O	O
2	CD	O	O
doses	NNS	O	O
of	IN	O	O
0.1	CD	O	O
mg/kg	NN	O	O
12	CD	O	O
hours	NNS	O	O
apart	RB	O	O
-rrb-	-RRB-	O	O
was	VBD	O	O
administered	VBN	O	O
on	IN	O	O
the	DT	O	O
10th	JJ	O	O
day	NN	O	O
of	IN	O	O
cancidas	NNP	B	B
70	CD	O	O
mg	NN	O	O
daily	RB	O	O
","	","	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
results	NNS	O	O
from	IN	O	O
a	DT	O	O
control	NN	O	O
period	NN	O	O
in	IN	O	O
which	WDT	O	O
tacrolimus	NN	D	D
was	VBD	O	O
administered	VBN	O	O
alone	RB	O	O
.	.	.	.

for	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
both	CC	O	O
therapies	NNS	O	O
","	","	O	O
standard	JJ	O	O
monitoring	NN	O	O
of	IN	O	O
tacrolimus	NN	D	D
blood	NN	O	O
concentrations	NNS	O	O
and	CC	O	O
appropriate	JJ	O	O
tacrolimus	NN	D	D
dosage	NN	O	O
adjustments	NNS	O	O
are	VBP	O	O
recommended	VBN	O	O
.	.	.	.

in	IN	O	O
two	CD	O	O
clinical	JJ	O	O
studies	NNS	O	O
","	","	O	O
cyclosporine	NN	D	D
-lrb-	-LRB-	O	O
one	CD	O	O
4	CD	O	O
mg/kg	NN	O	O
dose	NN	O	O
or	CC	O	O
two	CD	O	O
3	CD	O	O
mg/kg	NN	O	O
doses	NNS	O	O
-rrb-	-RRB-	O	O
increased	VBD	O	O
the	DT	O	O
auc	NN	O	O
of	IN	O	O
caspofungin	NN	D	D
by	IN	O	O
approximately	RB	O	O
35	CD	O	O
%	NN	O	O
.	.	.	.

cancidas	NNP	B	D
did	VBD	O	O
not	RB	O	O
increase	VB	O	O
the	DT	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
cyclosporine	NN	D	D
.	.	.	.

there	EX	O	O
were	VBD	O	O
transient	JJ	O	O
increases	NNS	O	O
in	IN	O	O
liver	NN	O	O
alt	NN	O	O
and	CC	O	O
ast	NNP	O	O
when	WRB	O	O
cancidas	NNP	B	B
and	CC	O	O
cyclosporine	NN	D	D
were	VBD	O	O
co-administered	VBN	O	O
.	.	.	.

a	DT	O	O
drug-drug	JJ	O	O
interaction	NN	O	O
study	NN	O	O
with	IN	O	O
rifampin	NN	D	D
in	IN	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
has	VBZ	O	O
shown	VBN	O	O
a	DT	O	O
30	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
caspofungin	NN	D	O
trough	NN	O	O
concentrations	NNS	O	O
.	.	.	.

patients	NNS	O	O
on	IN	O	O
rifampin	NN	D	D
should	MD	O	O
receive	VB	O	O
70	CD	O	O
mg	NN	O	O
of	IN	O	O
cancidas	NNP	B	D
daily	RB	O	O
.	.	.	.

in	IN	O	O
addition	NN	O	O
","	","	O	O
results	VBZ	O	O
from	IN	O	O
regression	NN	O	O
analyses	NNS	O	O
of	IN	O	O
patient	NN	O	O
pharmacokinetic	JJ	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
co-administration	NN	O	O
of	IN	O	O
other	JJ	O	O
inducers	NNS	O	O
of	IN	O	O
drug	NN	D	O
clearance	NN	O	O
-lrb-	-LRB-	O	O
efavirenz	NN	D	D
","	","	O	O
nevirapine	NN	D	D
","	","	O	O
phenytoin	NN	D	D
","	","	O	O
dexamethasone	NN	D	D
","	","	O	O
or	CC	O	O
carbamazepine	NN	D	D
-rrb-	-RRB-	O	O
with	IN	O	O
cancidas	NNS	B	O
may	MD	O	O
result	VB	O	O
in	IN	O	O
clinically	RB	O	O
meaningful	JJ	O	O
reductions	NNS	O	O
in	IN	O	O
caspofungin	NN	D	O
concentrations	NNS	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
which	WDT	O	O
drug	NN	D	O
clearance	NN	O	O
mechanism	NN	O	O
involved	VBN	O	O
in	IN	O	O
caspofungin	NN	D	O
disposition	NN	O	O
may	MD	O	O
be	VB	O	O
inducible	JJ	O	O
.	.	.	.

when	WRB	O	O
cancidas	NNP	B	B
is	VBZ	O	O
co-administered	VBN	O	O
with	IN	O	O
inducers	NNS	O	O
of	IN	O	O
drug	NN	D	O
clearance	NN	O	O
","	","	O	O
such	JJ	O	O
as	IN	O	O
efavirenz	NN	D	D
","	","	O	O
nevirapine	NN	D	D
","	","	O	O
phenytoin	NN	D	D
","	","	O	O
dexamethasone	NN	D	D
","	","	O	O
or	CC	O	O
carbamazepine	NN	D	D
","	","	O	O
use	NN	O	O
of	IN	O	O
a	DT	O	O
daily	JJ	O	O
dose	NN	O	O
of	IN	O	O
70	CD	O	O
mg	NN	O	O
of	IN	O	O
cancidas	NNP	B	B
should	MD	O	O
be	VB	O	O
considere	NN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
positive	JJ	O	O
direct	JJ	O	O
coombs	NNP	O	O
tests	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
during	IN	O	O
treatment	NN	O	O
with	IN	O	O
the	DT	O	O
cephalosporin	NN	G	O
antibiotics	NNS	G	G
.	.	.	.

in	IN	O	O
hematologic	JJ	O	O
studies	NNS	O	O
or	CC	O	O
in	IN	O	O
transfusion	NN	O	O
cross-matching	NN	O	O
procedures	NNS	O	O
when	WRB	O	O
anti-globulin	JJ	O	O
tests	NNS	O	O
are	VBP	O	O
performed	VBN	O	O
on	IN	O	O
the	DT	O	O
minor	JJ	O	O
side	NN	O	O
or	CC	O	O
in	IN	O	O
coombs	NNP	O	O
testing	NN	O	O
of	IN	O	O
newborns	NNS	O	O
whose	WP$	O	O
mothers	NNS	O	O
have	VBP	O	O
received	VBN	O	O
cephalosporin	NN	G	O
antibiotics	NNS	G	G
before	IN	O	O
parturition	NN	O	D
","	","	O	O
it	PRP	O	O
should	MD	O	O
be	VB	O	O
recognized	VBN	O	O
that	IN	O	O
a	DT	O	O
positive	JJ	O	O
coombs	NNP	O	O
test	NN	O	O
may	MD	O	O
be	VB	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
drug	NN	D	O
.	.	.	.

probenecid	NNP	D	D
may	MD	O	O
decrease	VB	O	O
renal	JJ	O	O
tubular	JJ	O	O
secretion	NN	O	O
of	IN	O	O
cephalosporins	NNS	G	G
when	WRB	O	O
used	VBN	O	O
concurrently	RB	O	O
","	","	O	O
resulting	VBG	O	O
in	IN	O	O
increased	VBN	O	O
and	CC	O	O
more	RBR	O	O
prolonged	JJ	O	O
cephalosporin	NN	G	O
blood	NN	O	O
levels	NNS	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
a	DT	O	O
FALSE	JJ	O	O
positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
may	MD	O	O
occur	VB	O	O
with	IN	O	O
benedicts	NNS	O	O
solution	NN	O	O
","	","	O	O
fehlings	NNP	O	O
solution	NN	O	O
or	CC	O	O
with	IN	O	O
clinitest	NN	O	D
tablets	NNS	O	O
","	","	O	O
but	CC	O	O
not	RB	O	O
with	IN	O	O
enzyme-based	JJ	O	O
tests	NNS	O	O
such	JJ	O	O
as	IN	O	O
clinistix	NN	O	D
.	.	.	.

positive	JJ	O	O
direct	JJ	O	O
and	CC	O	O
indirect	JJ	O	O
antiglobulin	NN	O	O
-lrb-	-LRB-	O	O
coombs	NNS	O	O
-rrb-	-RRB-	O	O
tests	NNS	O	O
have	VBP	O	O
occurred	VBN	O	O
;	:	O	O
.	.	.	.

these	DT	O	O
may	MD	O	O
also	RB	O	O
occur	VB	O	O
in	IN	O	O
neonates	NNS	O	O
whose	WP$	O	O
mothers	NNS	O	O
received	VBD	O	O
cephalosporins	NNS	G	O
before	IN	O	O
delivery	NN	O	O
.	.	.	.

antacids	NNS	G	G
-lrb-	-LRB-	O	O
aluminum	NN	D	D
-	:	O	O
or	CC	O	O
magnesium-containing	JJ	O	O
-rrb-	-RRB-	O	O
:	:	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
300-mg	JJ	O	O
cefdinir	NN	D	O
capsules	NNS	O	O
with	IN	O	O
30	CD	O	O
ml	NN	O	O
maalox	NNP	B	O
tc	NNP	O	O
suspension	NN	O	O
reduces	VBZ	O	O
the	DT	O	O
rate	NN	O	O
-lrb-	-LRB-	O	O
cmax	NN	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
extent	NN	O	O
-lrb-	-LRB-	O	O
auc	NN	O	O
-rrb-	-RRB-	O	O
of	IN	O	O
absorption	NN	O	O
by	IN	O	O
approximately	RB	O	O
40	CD	O	O
%	NN	O	O
.	.	.	.

time	NNP	O	O
to	TO	O	O
reach	VB	O	O
cmax	NNP	O	O
is	VBZ	O	O
also	RB	O	O
prolonged	VBN	O	O
by	IN	O	O
1	CD	O	O
hour	NN	O	O
.	.	.	.

there	EX	O	O
are	VBP	O	O
no	DT	O	O
significant	JJ	O	O
effects	NNS	O	O
on	IN	O	O
cefdinir	NN	D	D
pharmacokinetics	NNS	O	O
if	IN	O	O
the	DT	O	O
antacid	NN	G	G
is	VBZ	O	O
administered	VBN	O	O
2	CD	O	O
hours	NNS	O	O
before	IN	O	O
or	CC	O	O
2	CD	O	O
hours	NNS	O	O
after	IN	O	O
cefdinir	NN	D	O
.	.	.	.

if	IN	O	O
antacids	NNS	G	G
are	VBP	O	O
required	VBN	O	O
during	IN	O	O
omnicef	NN	B	O
therapy	NN	O	O
","	","	O	O
omnicef	NN	B	D
should	MD	O	O
be	VB	O	O
taken	VBN	O	O
at	IN	O	O
least	JJS	O	O
2	CD	O	O
hours	NNS	O	O
before	IN	O	O
or	CC	O	O
after	IN	O	O
the	DT	O	O
antacid	NN	G	G
.	.	.	.

probenecid	NNP	D	D
:	:	O	O
as	IN	O	O
with	IN	O	O
other	JJ	O	O
b-lactam	NN	O	O
antibiotics	NNS	G	G
","	","	O	O
probenecid	NN	D	D
inhibits	VBZ	O	O
the	DT	O	O
renal	JJ	O	O
excretion	NN	O	O
of	IN	O	O
cefdinir	NN	D	D
","	","	O	O
resulting	VBG	O	O
in	IN	O	O
an	DT	O	O
approximate	JJ	O	O
doubling	NN	O	O
in	IN	O	O
a.c.	NNP	O	O
a	DT	O	O
54	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
peak	JJ	O	O
cefdinir	NN	D	D
plasma	NN	O	O
levels	NNS	O	O
","	","	O	O
and	CC	O	O
a	DT	O	O
50	CD	O	O
%	NN	O	O
prolongation	NN	O	O
in	IN	O	O
the	DT	O	O
apparent	JJ	O	O
elimination	NN	O	O
half-life	NN	O	O
.	.	.	.

iron	NNP	D	D
supplements	NNP	O	O
and	CC	O	O
foods	NNP	O	B
fortified	VBD	O	O
with	IN	O	O
iron	NNP	D	D
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
cefdinir	NN	D	D
with	IN	O	O
a	DT	O	O
therapeutic	JJ	O	O
iron	NN	D	O
supplement	NN	O	O
containing	VBG	O	O
60	CD	O	O
mg	NN	O	O
of	IN	O	O
elemental	JJ	O	O
iron	NN	D	O
-lrb-	-LRB-	O	O
as	IN	O	O
feso4	NN	O	O
-rrb-	-RRB-	O	O
or	CC	O	O
vitamins	NNS	G	O
supplemented	VBN	O	O
with	IN	O	O
10	CD	O	O
mg	NN	O	O
of	IN	O	O
elemental	JJ	O	O
iron	NN	D	D
reduced	VBD	O	O
extent	NN	O	O
of	IN	O	O
absorption	NN	O	O
by	IN	O	O
80	CD	O	O
%	NN	O	O
and	CC	O	O
31	CD	O	O
%	NN	O	O
","	","	O	O
respectively	RB	O	O
.	.	.	.

if	IN	O	O
iron	NN	D	D
supplements	NNS	O	O
are	VBP	O	O
required	VBN	O	O
during	IN	O	O
omnicef	NN	B	O
therapy	NN	O	O
","	","	O	O
omnicef	NN	B	D
should	MD	O	O
be	VB	O	O
taken	VBN	O	O
at	IN	O	O
least	JJS	O	O
2	CD	O	O
hours	NNS	O	O
before	IN	O	O
or	CC	O	O
after	IN	O	O
the	DT	O	O
supplement	NN	O	O
.	.	.	.

the	DT	O	O
effect	NN	O	O
of	IN	O	O
foods	NNS	O	O
highly	RB	O	O
fortified	VBD	O	O
with	IN	O	O
elemental	JJ	O	O
iron	NN	D	D
-lrb-	-LRB-	O	O
primarily	RB	O	O
iron-fortified	JJ	O	O
breakfast	NN	O	O
cereals	NNS	O	O
-rrb-	-RRB-	O	O
on	IN	O	O
cefdinir	NN	D	D
absorption	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
.	.	.	.

concomitantly	RB	O	O
administered	VBN	O	O
iron-fortified	JJ	O	O
infant	NN	O	O
formula	NN	O	O
-lrb-	-LRB-	O	O
2.2	CD	O	O
mg	NN	O	O
elemental	JJ	O	O
iron/6	NN	O	O
oz	NN	O	O
-rrb-	-RRB-	O	O
has	VBZ	O	O
no	DT	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
cefdinir	NN	D	D
pharmacokinetics	NNS	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
omnicef	NN	B	O
for	IN	O	O
oral	NNP	O	O
suspension	NNP	O	O
can	MD	O	O
be	VB	O	O
administered	VBN	O	O
with	IN	O	O
iron-fortified	JJ	O	O
infant	NN	O	O
formula	NN	O	O
.	.	.	.

there	EX	O	O
have	VBP	O	O
been	VBN	O	O
rare	JJ	O	O
reports	NNS	O	O
of	IN	O	O
reddish	JJ	O	O
stools	NNS	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
have	VBP	O	O
received	VBN	O	O
cefdinir	NN	D	D
in	IN	O	O
japan	NNP	O	O
.	.	.	.

the	DT	O	O
reddish	JJ	O	O
color	NN	O	O
is	VBZ	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
a	DT	O	O
nonabsorbable	JJ	O	O
complex	NN	O	O
between	IN	O	O
cefdinir	NN	D	D
or	CC	O	O
its	PRP$	O	O
breakdown	NN	O	O
products	NNS	O	O
and	CC	O	O
iron	NN	D	D
in	IN	O	O
the	DT	O	O
gastrointestinal	JJ	O	O
tract	NN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
ketones	NNS	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
may	MD	O	O
occur	VB	O	O
with	IN	O	O
tests	NNS	O	O
using	VBG	O	O
nitroprusside	NN	D	D
","	","	O	O
but	CC	O	O
not	RB	O	O
with	IN	O	O
those	DT	O	O
using	VBG	O	O
nitroferricyanide	NN	D	O
.	.	.	.

the	DT	O	O
administration	NN	O	O
of	IN	O	O
cefdinir	NN	D	D
may	MD	O	O
result	VB	O	O
in	IN	O	O
a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
urine	NN	O	O
using	VBG	O	O
clinitest	NNP	O	B
","	","	O	O
benedict	NNP	O	B
s	VBZ	O	O
solution	NN	O	O
","	","	O	O
or	CC	O	O
fehlings	NNP	O	O
solution	NN	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
glucose	NN	O	O
tests	NNS	O	O
based	VBN	O	O
on	IN	O	O
enzymatic	JJ	O	O
glucose	NN	O	O
oxidase	NN	O	O
reactions	NNS	O	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
clinistix	NNP	O	B
or	CC	O	O
tes-tape	NNP	O	B
-rrb-	-RRB-	O	O
be	VB	O	O
used	VBN	O	O
.	.	.	.

cephalosporins	NNS	G	G
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
occasionally	RB	O	O
induce	VB	O	O
a	DT	O	O
positive	JJ	O	O
direct	JJ	O	O
coombs	NNS	O	O
test	NN	O	O
.	.	.	.

oral	JJ	O	O
contraceptives	NNS	G	G
multiple	JJ	O	O
doses	NNS	O	O
of	IN	O	O
cefditoren	NN	D	D
pivoxil	NN	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
ethinyl	NN	O	O
estradiol	NN	O	O
","	","	O	O
the	DT	O	O
estrogenic	JJ	O	O
component	NN	O	O
in	IN	O	O
most	JJS	O	O
oral	JJ	O	O
contraceptives	NNS	G	G
.	.	.	.

although	IN	O	O
the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
recommended	VBN	O	O
that	IN	O	O
cefditoren	NN	D	O
pivoxil	NN	O	O
be	VB	O	O
taken	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
antacids	NNS	G	G
.	.	.	.

h2-receptor	NN	O	O
antagonists	NNS	O	O
:	:	O	O
co-administration	NN	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
intravenously	RB	O	O
administered	VBN	O	O
famotidine	NN	D	D
-lrb-	-LRB-	O	O
20	CD	O	O
mg	NN	O	O
-rrb-	-RRB-	O	O
reduced	VBD	O	O
the	DT	O	O
oral	JJ	O	O
absorption	NN	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
400	CD	O	O
mg	NN	O	O
dose	NN	O	O
of	IN	O	O
cefditoren	NN	D	D
pivoxil	NN	O	O
administered	VBN	O	O
following	VBG	O	O
a	DT	O	O
meal	NN	O	O
","	","	O	O
as	IN	O	O
evidenced	VBN	O	O
by	IN	O	O
a	DT	O	O
27	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
mean	JJ	O	O
cmax	NN	O	O
and	CC	O	O
a	DT	O	O
22	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
mean	JJ	O	O
auc	NN	O	O
.	.	.	.

although	IN	O	O
the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
recommended	VBN	O	O
that	IN	O	O
cefditoren	NN	D	O
pivoxil	NN	O	O
be	VB	O	O
taken	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
h2	NN	O	O
receptor	NN	D	O
antagonists	NNS	O	O
.	.	.	.

probenecid	NNP	D	D
:	:	O	O
as	IN	O	O
with	IN	O	O
other	JJ	O	O
b-lactam	NN	O	O
antibiotics	NNS	G	G
","	","	O	O
co-administration	NN	O	O
of	IN	O	O
probenecid	NN	D	D
with	IN	O	O
cefditoren	NN	D	D
pivoxil	NN	O	O
resulted	VBD	O	O
in	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
plasma	NN	O	O
exposure	NN	O	O
of	IN	O	O
cefditoren	NNS	D	O
","	","	O	O
with	IN	O	O
a	DT	O	O
49	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
mean	NN	O	O
cmax	NN	O	O
","	","	O	O
a	DT	O	O
122	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
mean	JJ	O	O
auc	NN	O	O
","	","	O	O
and	CC	O	O
a	DT	O	O
53	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
half-life	NN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
cephalosporins	NNS	G	O
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
occasionally	RB	O	O
induce	VB	O	O
a	DT	O	O
positive	JJ	O	O
direct	JJ	O	O
coombs	NNS	O	O
test	NN	O	O
.	.	.	.

a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
may	MD	O	O
occur	VB	O	O
with	IN	O	O
copper	NN	O	O
reduction	NN	O	O
tests	NNS	O	O
-lrb-	-LRB-	O	O
benedicts	NNS	O	O
or	CC	O	O
fehlings	NNS	O	O
solution	NN	O	O
or	CC	O	O
with	IN	O	O
clinitest	NN	O	O
tablets	NNS	O	O
-rrb-	-RRB-	O	O
","	","	O	O
but	CC	O	O
not	RB	O	O
with	IN	O	O
enzyme-based	JJ	O	O
tests	NNS	O	O
for	IN	O	O
glycosuria	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
clinistix	NN	O	D
","	","	O	O
tes-tape	NN	O	D
-rrb-	-RRB-	O	O
.	.	.	.

as	IN	O	O
a	DT	O	O
false-negative	JJ	O	O
result	NN	O	O
may	MD	O	O
occur	VB	O	O
in	IN	O	O
the	DT	O	O
ferricyanide	JJ	O	O
test	NN	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
either	CC	O	O
the	DT	O	O
glucose	NN	O	O
oxidase	NN	O	O
or	CC	O	O
hexokinase	NN	O	O
method	NN	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
determine	VB	O	O
blood/plasma	NN	O	O
glucose	NN	O	O
levels	NNS	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
cefditoren	NN	D	O
pivoxil	NN	O	O
.	.	.	.

renal	JJ	O	O
function	NN	O	O
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
carefully	RB	O	O
if	IN	O	O
high	JJ	O	O
doses	NNS	O	O
of	IN	O	O
aminoglycosides	NNS	G	G
are	VBP	O	O
to	TO	O	O
be	VB	O	O
administered	VBN	O	O
with	IN	O	O
maxipime	NN	B	D
because	IN	O	O
of	IN	O	O
the	DT	O	O
increased	VBN	O	O
potential	NN	O	O
of	IN	O	O
nephrotoxicity	NN	O	O
and	CC	O	O
ototoxicity	NN	O	O
of	IN	O	O
aminoglycoside	NN	G	G
antibiotics	NNS	G	G
.	.	.	.

nephrotoxicity	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
following	VBG	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
other	JJ	O	O
cephalosporins	NNS	G	O
with	IN	O	O
potent	JJ	O	O
diuretics	NNS	G	G
such	JJ	O	O
as	IN	O	O
furosemide	NN	D	D
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
cefepime	NN	D	D
may	MD	O	O
result	VB	O	O
in	IN	O	O
a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
when	WRB	O	O
using	VBG	O	O
clinitest	NNP	O	B
tablets	NNS	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
glucose	NN	O	O
tests	NNS	O	O
based	VBN	O	O
on	IN	O	O
enzymatic	JJ	O	O
glucose	NN	O	O
oxidase	NN	O	O
reactions	NNS	O	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
clinistix	NNP	O	B
or	CC	O	O
tes-tape	NNP	O	B
-rrb-	-RRB-	O	O
be	VB	O	O
used	VBN	O	O
.	.	.	.

carbamazepine	NNP	D	D
:	:	O	O
elevated	JJ	O	O
carbamazepine	NN	D	D
levels	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
postmarketing	VBG	O	O
experience	NN	O	O
when	WRB	O	O
suprax	NNP	B	B
is	VBZ	O	O
administered	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

drug	NN	O	O
monitoring	NN	O	O
may	MD	O	O
be	VB	O	O
of	IN	O	O
assistance	NN	O	O
in	IN	O	O
detecting	VBG	O	O
alterations	NNS	O	O
in	IN	O	O
carbamazepine	NN	D	D
plasma	NN	O	O
concentrations	NNS	O	O
.	.	.	.

warfarin	NNP	D	D
and	CC	O	O
anticoagulants	NNPS	G	G
:	:	O	O
increased	VBN	O	O
prothrombin	NN	O	O
time	NN	O	O
","	","	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
clinical	JJ	O	O
bleeding	NN	O	O
","	","	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
when	WRB	O	O
cefixime	NN	D	D
is	VBZ	O	O
administered	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
ketones	NNS	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
may	MD	O	O
occur	VB	O	O
with	IN	O	O
tests	NNS	O	O
using	VBG	O	O
nitroprusside	NN	D	D
but	CC	O	O
not	RB	O	O
with	IN	O	O
those	DT	O	O
using	VBG	O	O
nitroferricyanide	NN	D	O
.	.	.	.

the	DT	O	O
administration	NN	O	O
of	IN	O	O
suprax	NNP	B	B
may	MD	O	O
result	VB	O	O
in	IN	O	O
a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
using	VBG	O	O
clinitest	NNP	O	B
**	SYM	O	O
","	","	O	O
benedict	NNP	O	B
s	VBZ	O	O
solution	NN	O	O
","	","	O	O
or	CC	O	O
fehling	NN	O	O
s	NNS	O	O
solution	NN	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
glucose	NN	O	O
tests	NNS	O	O
based	VBN	O	O
on	IN	O	O
enzymatic	JJ	O	O
glucose	NN	O	O
oxidase	NN	O	O
reactions	NNS	O	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
clinistix	NNP	O	B
**	SYM	O	O
or	CC	O	O
tes-tape	JJ	O	O
**	SYM	O	O
-rrb-	-RRB-	O	O
be	VB	O	O
used	VBN	O	O
.	.	.	.

a	DT	O	O
false-positive	JJ	O	O
direct	JJ	O	O
coombs	NNS	O	O
test	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
during	IN	O	O
treatment	NN	O	O
with	IN	O	O
other	JJ	O	O
cephalosporin	NN	G	O
antibiotics	NNS	G	G
.	.	.	.

therefore	RB	O	O
","	","	O	O
it	PRP	O	O
should	MD	O	O
be	VB	O	O
recognized	VBN	O	O
that	IN	O	O
a	DT	O	O
positive	JJ	O	O
coombs	NNP	O	O
test	NN	O	O
may	MD	O	O
be	VB	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
drug	NN	D	O
.	.	.	.

increased	VBN	O	O
nephrotoxicity	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
following	VBG	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
cephalosporins	NNS	G	G
and	CC	O	O
aminoglycoside	NN	G	G
antibiotics	NNS	G	G
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
cephalosporins	NNS	G	O
","	","	O	O
including	VBG	O	O
cefotaxime	NN	O	D
sodium	NN	O	O
","	","	O	O
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
occasionally	RB	O	O
induce	VB	O	O
a	DT	O	O
positive	JJ	O	O
direct	JJ	O	O
coombs	NNS	O	O
test	NN	O	O
.	.	.	.

increases	NNS	O	O
in	IN	O	O
serum	NN	O	O
creatinine	NN	O	O
have	VBP	O	O
occurred	VBN	O	O
when	WRB	O	O
cefotan	NNP	B	B
was	VBD	O	O
given	VBN	O	O
alone	RB	O	O
.	.	.	.

if	IN	O	O
cefotan	NNP	B	B
and	CC	O	O
an	DT	O	O
aminoglycoside	NN	G	G
are	VBP	O	O
used	VBN	O	O
concomitantly	RB	O	O
","	","	O	O
renal	JJ	O	O
function	NN	O	O
should	MD	O	O
be	VB	O	O
carefully	RB	O	O
monitored	VBN	O	O
","	","	O	O
because	IN	O	O
nephrotoxicity	NN	O	O
may	MD	O	O
be	VB	O	O
potentiated	VBN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
:	:	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
cefotan	NNP	B	B
may	MD	O	O
result	VB	O	O
in	IN	O	O
a	DT	O	O
FALSE	JJ	O	O
positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
using	VBG	O	O
clinitest	NNP	O	B
","	","	O	O
benedicts	NNP	O	B
solution	NN	O	O
","	","	O	O
or	CC	O	O
fehlings	NNP	O	O
solution	NN	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
glucose	NN	O	O
tests	NNS	O	O
based	VBN	O	O
on	IN	O	O
enzymatic	JJ	O	O
glucose	NN	O	O
oxidase	NN	O	O
be	VB	O	O
used	VBN	O	O
.	.	.	.

as	IN	O	O
with	IN	O	O
other	JJ	O	O
cephalosporins	NNS	G	O
","	","	O	O
high	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
cefotetan	NN	D	D
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
measurement	NN	O	O
of	IN	O	O
serum	NN	O	O
and	CC	O	O
urine	NN	O	O
creatinine	NN	O	O
levels	NNS	O	O
by	IN	O	O
jaffe	NNP	O	O
reaction	NN	O	O
and	CC	O	O
produce	VBP	O	O
FALSE	JJ	O	O
increases	NNS	O	O
in	IN	O	O
the	DT	O	O
levels	NNS	O	O
of	IN	O	O
creatinine	NN	O	O
reported	VBD	O	O
.	.	.	.

increased	VBN	O	O
nephrotoxicity	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
following	VBG	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
cephalosporins	NNS	G	G
and	CC	O	O
aminoglycoside	NN	G	G
antibiotics	NNS	G	G
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
as	IN	O	O
with	IN	O	O
cephalothin	NN	D	D
","	","	O	O
high	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
cefoxitin	NN	D	D
-lrb-	-LRB-	O	O
100	CD	O	O
micrograms/ml	NNS	O	O
-rrb-	-RRB-	O	O
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
measurement	NN	O	O
of	IN	O	O
serum	NN	O	O
and	CC	O	O
urine	NN	O	O
creatinine	NN	O	O
levels	NNS	O	O
by	IN	O	O
the	DT	O	O
jaff	NNP	O	O
reaction	NN	O	O
","	","	O	O
and	CC	O	O
produce	VBP	O	O
FALSE	JJ	O	O
increases	NNS	O	O
of	IN	O	O
modest	JJ	O	O
degree	NN	O	O
in	IN	O	O
the	DT	O	O
levels	NNS	O	O
of	IN	O	O
creatinine	NN	O	O
reported	VBD	O	O
.	.	.	.

serum	NN	O	O
samples	NNS	O	O
from	IN	O	O
patients	NNS	O	O
treated	VBN	O	O
with	IN	O	O
cefoxitin	NN	D	B
should	MD	O	O
not	RB	O	O
be	VB	O	O
analyzed	VBN	O	O
for	IN	O	O
creatinine	NN	O	O
if	IN	O	O
withdrawn	VBN	O	O
within	IN	O	O
2	CD	O	O
hours	NNS	O	O
of	IN	O	O
drug	NN	D	O
administration	NN	O	O
.	.	.	.

high	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
cefoxitin	NN	D	D
in	IN	O	O
the	DT	O	O
urine	NN	O	O
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
measurement	NN	O	O
of	IN	O	O
urinary	JJ	O	O
17-hydroxy-corticosteroids	NNS	O	O
by	IN	O	O
the	DT	O	O
porter-silber	NNP	O	O
reaction	NN	O	O
","	","	O	O
and	CC	O	O
produce	VBP	O	O
FALSE	JJ	O	O
increases	NNS	O	O
of	IN	O	O
modest	JJ	O	O
degree	NN	O	O
in	IN	O	O
the	DT	O	O
levels	NNS	O	O
reported	VBD	O	O
.	.	.	.

a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
may	MD	O	O
occur	VB	O	O
.	.	.	.

this	DT	O	O
has	VBZ	O	O
been	VBN	O	O
observed	VBN	O	O
with	IN	O	O
clinitest	NN	O	O
reagent	NN	O	O
tablets	NNS	O	O
.	.	.	.

registered	NNP	O	O
trademark	NN	O	O
of	IN	O	O
ames	NNP	O	O
company	NNP	O	O
","	","	O	O
division	NNP	O	O
of	IN	O	O
miles	NNP	O	O
laboratories	NNPS	O	O
","	","	O	O
inc.	NNP	O	O
.	.	.	.

nephrotoxicity	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
following	VBG	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
aminoglycoside	NN	G	G
antibiotics	NNS	G	G
and	CC	O	O
cephalosporin	NN	G	O
antibiotics	NNS	G	G
.	.	.	.

concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
probenecid	NN	D	D
doubled	VBD	O	O
the	DT	O	O
auc	NN	O	O
for	IN	O	O
cefprozil	NN	D	D
.	.	.	.

the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
the	DT	O	O
capsule	NN	O	O
formulation	NN	O	O
of	IN	O	O
cefprozil	NN	D	D
was	VBD	O	O
not	RB	O	O
affected	VBN	O	O
when	WRB	O	O
administered	VBN	O	O
5	CD	O	O
minutes	NNS	O	O
following	VBG	O	O
an	DT	O	O
antacid	NN	G	G
.	.	.	.

nephrotoxicity	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
following	VBG	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
cephalosporins	NNS	G	G
with	IN	O	O
aminoglycoside	NN	G	G
antibiotics	NNS	G	G
or	CC	O	O
potent	JJ	O	O
diuretics	NNS	G	G
such	JJ	O	O
as	IN	O	O
furosemide	NN	D	D
.	.	.	.

renal	JJ	O	O
function	NN	O	O
should	MD	O	O
be	VB	O	O
carefully	RB	O	O
monitored	VBN	O	O
","	","	O	O
especially	RB	O	O
if	IN	O	O
higher	JJR	O	O
dosages	NNS	O	O
of	IN	O	O
the	DT	O	O
aminoglycosides	NNS	G	G
are	VBP	O	O
to	TO	O	O
be	VB	O	O
administered	VBN	O	O
or	CC	O	O
if	IN	O	O
therapy	NN	O	O
is	VBZ	O	O
prolonged	VBN	O	O
","	","	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
potential	JJ	O	O
nephrotoxicity	NN	O	O
and	CC	O	O
ototoxicity	NN	O	O
of	IN	O	O
aminoglycosidic	JJ	O	O
antibiotics	NNS	G	G
.	.	.	.

nephrotoxicity	NN	O	O
and	CC	O	O
ototoxicity	NN	O	O
were	VBD	O	O
not	RB	O	O
noted	VBN	O	O
when	WRB	O	O
ceftazidime	NN	D	D
was	VBD	O	O
given	VBN	O	O
alone	RB	O	O
in	IN	O	O
clinical	JJ	O	O
trials	NNS	O	O
.	.	.	.

chloramphenicol	NN	D	D
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
antagonistic	JJ	O	O
to	TO	O	O
beta-lactam	JJ	O	O
antibiotics	NNS	G	G
","	","	O	O
including	VBG	O	O
ceftazidime	NN	D	D
","	","	O	O
based	VBN	O	O
on	IN	O	O
in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
and	CC	O	O
time	NN	O	O
kill	VBP	O	O
curves	NNS	O	O
with	IN	O	O
enteric	JJ	O	O
gram-negative	JJ	O	O
bacilli	NNS	O	O
.	.	.	.

due	JJ	O	O
to	TO	O	O
the	DT	O	O
possibility	NN	O	O
of	IN	O	O
antagonism	NN	O	O
in	FW	O	O
vivo	FW	O	O
","	","	O	O
particularly	RB	O	O
when	WRB	O	O
bactericidal	JJ	O	O
activity	NN	O	O
is	VBZ	O	O
desired	VBN	O	O
","	","	O	O
this	DT	O	O
drug	NN	D	O
combination	NN	O	O
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
ceftazidime	NN	D	D
may	MD	O	O
result	VB	O	O
in	IN	O	O
a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
when	WRB	O	O
using	VBG	O	O
clinitest	NN	O	D
tablets	NNS	O	O
","	","	O	O
benedicts	NNP	O	O
solution	NN	O	O
","	","	O	O
or	CC	O	O
fehlings	NNP	O	O
solution	NN	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
glucose	NN	O	O
tests	NNS	O	O
based	VBN	O	O
on	IN	O	O
enzymatic	JJ	O	O
glucose	NN	O	O
oxidase	NN	O	O
reactions	NNS	O	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
clinistix	NN	O	D
or	CC	O	O
tes-tape	NN	O	O
-rrb-	-RRB-	O	O
be	VB	O	O
used	VBN	O	O
.	.	.	.

theophylline	NNP	D	D
:	:	O	O
twelve	CD	O	O
healthy	JJ	O	O
male	JJ	O	O
volunteers	NNS	O	O
were	VBD	O	O
administered	VBN	O	O
one	CD	O	O
200-mg	JJ	O	O
ceftibuten	NN	D	O
capsule	NN	O	O
twice	RB	O	O
daily	RB	O	O
for	IN	O	O
6	CD	O	O
days	NNS	O	O
.	.	.	.

with	IN	O	O
the	DT	O	O
morning	NN	O	O
dose	NN	O	O
of	IN	O	O
ceftibuten	NN	D	D
on	IN	O	O
day	NN	O	O
6	CD	O	O
","	","	O	O
each	DT	O	O
volunteer	NN	O	O
received	VBD	O	O
a	DT	O	O
single	JJ	O	O
intravenous	JJ	O	O
infusion	NN	O	O
of	IN	O	O
theophylline	NN	D	D
-lrb-	-LRB-	O	O
4	CD	O	O
mg/kg	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
theophylline	NN	D	D
were	VBD	O	O
not	RB	O	O
altered	VBN	O	O
.	.	.	.

the	DT	O	O
effect	NN	O	O
of	IN	O	O
ceftibuten	NN	D	D
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
theophylline	NN	D	D
administered	VBN	O	O
orally	RB	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
investigated	VBN	O	O
.	.	.	.

antacids	NNS	G	G
or	CC	O	O
h	NN	O	O
2	CD	O	O
-	:	O	O
receptor	NN	D	O
antagonists	NNS	O	O
:	:	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
increased	VBN	O	O
gastric	JJ	O	O
ph	NN	O	O
on	IN	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
ceftibuten	NN	D	D
was	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
18	CD	O	O
healthy	JJ	O	O
adult	JJ	O	O
volunteers	NNS	O	O
.	.	.	.

each	DT	O	O
volunteer	NN	O	O
was	VBD	O	O
administered	VBN	O	O
one	CD	O	O
400-mg	JJ	O	O
ceftibuten	NN	D	O
capsule	NN	O	O
.	.	.	.

a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
liquid	JJ	O	O
antacid	NN	G	G
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
c	NN	O	O
max	NN	O	O
or	CC	O	O
auc	NN	O	O
of	IN	O	O
ceftibuten	NN	D	D
.	.	.	.

however	RB	O	O
","	","	O	O
150	CD	O	O
mg	NN	O	O
of	IN	O	O
ranitidine	NN	D	D
q12h	NN	O	O
for	IN	O	O
3	CD	O	O
days	NNS	O	O
increased	VBD	O	O
the	DT	O	O
ceftibuten	NN	D	O
c	NN	O	O
max	NN	O	O
by	IN	O	O
23	CD	O	O
%	NN	O	O
and	CC	O	O
ceftibuten	NN	D	D
auc	NN	O	O
by	IN	O	O
16	CD	O	O
%	NN	O	O
.	.	.	.

the	DT	O	O
clinical	JJ	O	O
relevance	NN	O	O
of	IN	O	O
these	DT	O	O
increases	NNS	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
:	:	O	O
there	EX	O	O
have	VBP	O	O
been	VBN	O	O
no	DT	O	O
chemical	NN	O	O
or	CC	O	O
laboratory	NN	O	O
test	NN	O	O
interactions	NNS	O	O
with	IN	O	O
ceftibuten	NN	D	B
noted	VBD	O	O
to	TO	O	O
date	NN	O	O
.	.	.	.

false-positive	JJ	O	O
direct	JJ	O	O
coombs	NNP	O	O
tests	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
during	IN	O	O
treatment	NN	O	O
with	IN	O	O
other	JJ	O	O
cephalosporins	NNS	G	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
it	PRP	O	O
should	MD	O	O
be	VB	O	O
recognized	VBN	O	O
that	IN	O	O
a	DT	O	O
positive	JJ	O	O
coombs	NNP	O	O
test	NN	O	O
could	MD	O	O
be	VB	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
drug	NN	D	O
.	.	.	.

the	DT	O	O
results	NNS	O	O
of	IN	O	O
assays	NNS	O	O
using	VBG	O	O
red	JJ	O	O
cells	NNS	O	O
from	IN	O	O
healthy	JJ	O	O
subjects	NNS	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
ceftibuten	NN	D	D
would	MD	O	O
cause	VB	O	O
direct	JJ	O	O
coombs	NNP	O	O
reactions	NNS	O	O
in	FW	O	O
vitro	FW	O	O
showed	VBD	O	O
no	DT	O	O
positive	JJ	O	O
reaction	NN	O	O
at	IN	O	O
ceftibuten	NN	D	O
concentrations	NNS	O	O
as	IN	O	O
high	JJ	O	O
as	IN	O	O
40	CD	O	O
g/ml	NN	O	O
.	.	.	.

although	IN	O	O
the	DT	O	O
occurrence	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
reported	VBN	O	O
with	IN	O	O
cefizox	NN	B	D
","	","	O	O
nephrotoxicity	NN	O	D
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
following	VBG	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
other	JJ	O	O
cephalosporins	NNS	G	O
and	CC	O	O
aminoglycosides	NNS	G	G
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
:	:	O	O
a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
may	MD	O	O
occur	VB	O	O
with	IN	O	O
copper	NN	O	O
reduction	NN	O	O
tests	NNS	O	O
-lrb-	-LRB-	O	O
benedict	NNP	O	O
s	NNS	O	O
or	CC	O	O
fehling	NN	O	O
s	NNS	O	O
solution	NN	O	O
or	CC	O	O
with	IN	O	O
clinitest	NNP	O	B
tablets	NNS	O	O
-rrb-	-RRB-	O	O
but	CC	O	O
not	RB	O	O
with	IN	O	O
enzyme-based	JJ	O	O
tests	NNS	O	O
for	IN	O	O
glycosuria	NN	O	O
.	.	.	.

as	IN	O	O
a	DT	O	O
false-negative	JJ	O	O
result	NN	O	O
may	MD	O	O
occur	VB	O	O
in	IN	O	O
the	DT	O	O
ferricyanide	JJ	O	O
test	NN	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
either	CC	O	O
the	DT	O	O
glucose	NN	O	O
oxidase	NN	O	O
or	CC	O	O
hexokinase	NN	O	O
method	NN	O	O
be	VB	O	O
used	VBN	O	O
to	TO	O	O
determine	VB	O	O
blood	NN	O	O
plasma	NN	O	O
glucose	NN	O	O
levels	NNS	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
cefuroxime	NN	D	D
.	.	.	.

cefuroxime	RB	D	O
does	VBZ	O	O
not	RB	O	O
interfere	VB	O	O
with	IN	O	O
the	DT	O	O
assay	NN	O	O
of	IN	O	O
serum	NN	O	O
and	CC	O	O
urine	NN	O	O
creatinine	NN	O	O
by	IN	O	O
the	DT	O	O
alkaline	NN	O	O
picrate	NN	O	O
method	NN	O	O
.	.	.	.

general	NNP	O	O
:	:	O	O
significant	JJ	O	O
interactions	NNS	O	O
may	MD	O	O
occur	VB	O	O
when	WRB	O	O
celecoxib	NN	D	D
is	VBZ	O	O
administered	VBN	O	O
together	RB	O	O
with	IN	O	O
drugs	NNS	D	D
that	WDT	O	O
inhibit	VBP	O	O
p450	NN	O	O
2c9	NN	O	O
.	.	.	.

celecoxib	NNP	D	O
metabolism	NN	O	O
is	VBZ	O	O
predominantly	RB	O	O
mediated	VBN	O	O
via	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
2c9	NN	O	O
in	IN	O	O
the	DT	O	O
liver	NN	O	O
.	.	.	.

co-administration	NN	O	O
of	IN	O	O
celecoxib	NN	D	D
with	IN	O	O
drugs	NNS	D	D
that	WDT	O	O
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
inhibit	VB	O	O
2c9	NN	O	O
should	MD	O	O
be	VB	O	O
done	VBN	O	O
with	IN	O	O
caution	NN	O	O
.	.	.	.

in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
celecoxib	NN	D	D
is	VBZ	O	O
not	RB	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
2c9	NN	O	O
","	","	O	O
2c19	NN	O	O
or	CC	O	O
3a4	NN	O	O
.	.	.	.

in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
also	RB	O	O
indicate	VBP	O	O
that	IN	O	O
celecoxib	NN	D	D
","	","	O	O
although	IN	O	O
not	RB	O	O
a	DT	O	O
substrate	NN	O	O
","	","	O	O
is	VBZ	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
2d6	NN	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
potential	NN	O	O
for	IN	O	O
an	DT	O	O
in	FW	O	O
vivo	FW	O	O
drug	NN	D	O
interaction	NN	O	O
with	IN	O	O
drugs	NNS	D	D
that	WDT	O	O
are	VBP	O	O
metabolized	VBN	O	O
by	IN	O	O
p450	NN	O	O
2d6	NN	O	O
.	.	.	.

clinical	JJ	O	O
studies	NNS	O	O
with	IN	O	O
celecoxib	NNS	D	O
have	VBP	O	O
identified	VBN	O	O
potentially	RB	O	O
significant	JJ	O	O
interactions	NNS	O	O
with	IN	O	O
fluconazole	NN	D	D
and	CC	O	O
lithium	NN	D	D
.	.	.	.

experience	NN	O	O
with	IN	O	O
nonsteroidal	JJ	O	O
anti-inflammatory	JJ	O	G
drugs	NNS	D	O
-lrb-	-LRB-	O	O
nsaids	NNS	G	G
-rrb-	-RRB-	O	O
suggests	VBZ	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
interactions	NNS	O	O
with	IN	O	O
furosemide	NN	D	D
and	CC	O	O
ace	NN	O	O
inhibitors	NNS	O	O
.	.	.	.

the	DT	O	O
effects	NNS	O	O
celecoxib	VBP	D	O
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
and/or	CC	O	O
pharmacodynamics	NNS	O	O
of	IN	O	O
glyburide	NN	D	D
","	","	O	O
ketoconazole	NN	D	D
","	","	O	O
methotrexate	NN	D	D
","	","	O	O
phenytoin	NN	D	D
","	","	O	O
tolbutamide	NN	D	D
","	","	O	O
and	CC	O	O
warfarin	NN	D	D
have	VBP	O	O
been	VBN	O	O
studied	VBN	O	O
in	FW	O	O
vivo	FW	O	O
and	CC	O	O
clinically	RB	O	O
important	JJ	O	O
interactions	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
found	VBN	O	O
.	.	.	.

ace	NN	O	O
inhibitors	NNS	O	O
:	:	O	O
reports	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
nsaids	NNS	G	G
may	MD	O	O
diminish	VB	O	O
the	DT	O	O
antihypertensive	JJ	O	G
effect	NN	O	O
of	IN	O	O
angiotensin	NN	O	O
converting	VBG	O	O
enzyme	NN	O	O
-lrb-	-LRB-	O	O
ace	NN	O	O
-rrb-	-RRB-	O	O
inhibitors	NNS	O	O
.	.	.	.

this	DT	O	O
interaction	NN	O	O
should	MD	O	O
be	VB	O	O
given	VBN	O	O
consideration	NN	O	O
in	IN	O	O
patients	NNS	O	O
taking	VBG	O	O
celebrex	NNP	B	B
concomitantly	RB	O	O
with	IN	O	O
ace-inhibitors	NNS	G	G
.	.	.	.

furosemide	NNP	D	D
:	:	O	O
clinical	JJ	O	O
studies	NNS	O	O
","	","	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
post	NN	O	O
marketing	NN	O	O
observations	NNS	O	O
","	","	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
nsaids	NNS	G	G
can	MD	O	O
reduce	VB	O	O
the	DT	O	O
natriuretic	JJ	O	O
effect	NN	O	O
of	IN	O	O
furosemide	NN	D	D
and	CC	O	O
thiazides	NNS	G	G
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
.	.	.	.

this	DT	O	O
response	NN	O	O
has	VBZ	O	O
been	VBN	O	O
attributed	VBN	O	O
to	TO	O	O
inhibition	NN	O	O
of	IN	O	O
renal	JJ	O	O
prostaglandin	NN	O	O
synthesis	NN	O	O
.	.	.	.

aspirin	NN	B	B
:	:	O	O
celebrex	NNP	B	D
can	MD	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
low	JJ	O	O
dose	NN	O	O
aspirin	NN	B	B
.	.	.	.

however	RB	O	O
","	","	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
aspirin	NN	B	B
with	IN	O	O
celebrex	NNP	B	B
may	MD	O	O
result	VB	O	O
in	IN	O	O
an	DT	O	O
increased	VBN	O	O
rate	NN	O	O
of	IN	O	O
gi	NN	O	O
ulceration	NN	O	O
or	CC	O	O
other	JJ	O	O
complications	NNS	O	O
","	","	O	O
compared	VBN	O	O
to	TO	O	O
use	VB	O	O
of	IN	O	O
celebrex	NNP	B	B
alone	RB	O	O
.	.	.	.

because	IN	O	O
of	IN	O	O
its	PRP$	O	O
lack	NN	O	O
of	IN	O	O
platelet	NN	O	O
effects	NNS	O	O
","	","	O	O
celebrex	NNP	B	B
is	VBZ	O	O
not	RB	O	O
a	DT	O	O
substitute	NN	O	O
for	IN	O	O
aspirin	NN	B	B
for	IN	O	O
cardiovascular	JJ	O	O
prophylaxis	NN	O	O
.	.	.	.

fluconazole	NNP	D	D
:	:	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
fluconazole	NN	D	D
at	IN	O	O
200	CD	O	O
mg	NN	O	O
qd	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
two-fold	JJ	O	O
increase	NN	O	O
in	IN	O	O
celecoxib	NN	D	D
plasma	NN	O	O
concentration	NN	O	O
.	.	.	.

this	DT	O	O
increase	NN	O	O
is	VBZ	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
inhibition	NN	O	O
of	IN	O	O
celecoxib	NN	D	D
metabolism	NN	O	O
via	IN	O	O
p450	NN	O	O
2c9	NN	O	O
by	IN	O	O
fluconazole	NN	D	D
-lrb-	-LRB-	O	O
see	VB	O	O
clinical	NNP	O	O
pharmacology	NNP	O	O
-	:	O	O
pharmacokinetics	NNS	O	O
:	:	O	O
metabolism	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

celebrex	NNP	B	B
should	MD	O	O
be	VB	O	O
introduced	VBN	O	O
at	IN	O	O
the	DT	O	O
lowest	JJS	O	O
recommended	VBN	O	O
dose	NN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
fluconazole	NN	D	D
.	.	.	.

lithium	NN	D	D
:	:	O	O
in	IN	O	O
a	DT	O	O
study	NN	O	O
conducted	VBN	O	O
in	IN	O	O
healthy	JJ	O	O
subjects	NNS	O	O
","	","	O	O
mean	VB	O	O
steady-state	JJ	O	O
lithium	NN	D	D
plasma	NN	O	O
levels	NNS	O	O
increased	VBD	O	O
approximately	RB	O	O
17	CD	O	O
%	NN	O	O
in	IN	O	O
subjects	NNS	O	O
receiving	VBG	O	O
lithium	NN	D	D
450	CD	O	O
mg	NN	O	O
bid	NNP	O	O
with	IN	O	O
celebrex	NNP	B	B
200	CD	O	O
mg	NN	O	O
bid	NNP	O	O
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
subjects	NNS	O	O
receiving	VBG	O	O
lithium	NN	D	D
alone	RB	O	O
.	.	.	.

patients	NNS	O	O
on	IN	O	O
lithium	NN	D	D
treatment	NN	O	O
should	MD	O	O
be	VB	O	O
closely	RB	O	O
monitored	VBN	O	O
when	WRB	O	O
celebrex	NNP	B	B
is	VBZ	O	O
introduced	VBN	O	O
or	CC	O	O
withdrawn	VBN	O	O
.	.	.	.

methotrexate	NNP	D	D
:	:	O	O
in	IN	O	O
an	DT	O	O
interaction	NN	O	O
study	NN	O	O
of	IN	O	O
rheumatoid	JJ	O	O
arthritis	NN	O	O
patients	NNS	O	O
taking	VBG	O	O
methotrexate	NN	D	D
","	","	O	O
celebrex	NNP	B	B
did	VBD	O	O
not	RB	O	O
have	VB	O	O
a	DT	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
methotrexate	NN	D	D
.	.	.	.

warfarin	NNP	D	D
:	:	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
celecoxib	NN	D	D
on	IN	O	O
the	DT	O	O
anti-coagulant	JJ	O	O
effect	NN	O	O
of	IN	O	O
warfarin	NN	D	D
was	VBD	O	O
studied	VBN	O	O
in	IN	O	O
a	DT	O	O
group	NN	O	O
of	IN	O	O
healthy	JJ	O	O
subjects	NNS	O	O
receiving	VBG	O	O
daily	JJ	O	O
doses	NNS	O	O
of	IN	O	O
5-Feb	CD	O	O
mg	NN	O	O
of	IN	O	O
warfarin	NN	D	D
.	.	.	.

in	IN	O	O
these	DT	O	O
subjects	NNS	O	O
","	","	O	O
celecoxib	NN	D	D
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
the	DT	O	O
anticoagulant	JJ	G	G
effect	NN	O	O
of	IN	O	O
warfarin	NN	D	D
as	IN	O	O
determined	VBN	O	O
by	IN	O	O
prothrombin	NN	O	O
time	NN	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
caution	NN	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
when	WRB	O	O
administering	VBG	O	O
celebrex	NN	B	D
with	IN	O	O
warfarin	NN	D	D
since	IN	O	O
these	DT	O	O
patients	NNS	O	O
are	VBP	O	O
at	IN	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
bleeding	VBG	O	O
complications	NNS	O	O
.	.	.	.

metformin	NNP	D	D
:	:	O	O
in	IN	O	O
healthy	JJ	O	O
subjects	NNS	O	O
given	VBN	O	O
single	JJ	O	O
500	CD	O	O
mg	NN	O	O
doses	NNS	O	O
of	IN	O	O
cephalexin	NN	D	D
and	CC	O	O
metformin	NN	D	D
","	","	O	O
plasma	NN	O	O
metformin	NN	D	O
mean	VB	O	O
cmax	NN	O	O
and	CC	O	O
auc	NN	O	O
increased	VBN	O	O
by	IN	O	O
an	DT	O	O
average	NN	O	O
of	IN	O	O
34	CD	O	O
%	NN	O	O
and	CC	O	O
24	CD	O	O
%	NN	O	O
","	","	O	O
respectively	RB	O	O
","	","	O	O
and	CC	O	O
metformin	NN	D	D
mean	VBP	O	O
renal	JJ	O	O
clearance	NN	O	O
decreased	VBN	O	O
by	IN	O	O
14	CD	O	O
%	NN	O	O
.	.	.	.

no	DT	O	O
information	NN	O	O
is	VBZ	O	O
available	JJ	O	O
about	IN	O	O
the	DT	O	O
interaction	NN	O	O
of	IN	O	O
cephalexin	NN	D	O
and	CC	O	O
metformin	NN	D	D
following	VBG	O	O
multiple	JJ	O	O
doses	NNS	O	O
of	IN	O	O
either	CC	O	O
drug	NN	D	O
.	.	.	.

although	IN	O	O
not	RB	O	O
observed	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
","	","	O	O
adverse	JJ	O	O
effects	NNS	O	O
could	MD	O	O
potentially	RB	O	O
arise	VB	O	O
from	IN	O	O
co-administration	NN	O	O
of	IN	O	O
cephalexin	NN	D	D
and	CC	O	O
metformin	NN	D	D
by	IN	O	O
inhibition	NN	O	O
of	IN	O	O
tubular	JJ	O	O
secretion	NN	O	O
via	IN	O	O
organic	JJ	O	O
cationic	JJ	O	O
transporter	NN	O	O
systems	NNS	O	O
.	.	.	.

accordingly	RB	O	O
","	","	O	O
careful	JJ	O	O
patient	NN	O	O
monitoring	NN	O	O
and	CC	O	O
dose	NN	O	O
adjustment	NN	O	O
of	IN	O	O
metformin	NN	D	D
is	VBZ	O	O
recommended	VBN	O	O
in	IN	O	O
patients	NNS	O	O
concomitantly	RB	O	O
taking	VBG	O	O
cephalexin	NN	D	D
and	CC	O	O
metformin	NN	D	D
.	.	.	.

probenecid	NNP	D	D
:	:	O	O
as	IN	O	O
with	IN	O	O
other	JJ	O	O
b-lactams	NNS	G	O
","	","	O	O
the	DT	O	O
renal	JJ	O	O
excretion	NN	O	O
of	IN	O	O
cephalexin	NN	D	D
is	VBZ	O	O
inhibited	VBN	O	O
by	IN	O	O
probenecid	NN	D	D
.	.	.	.

drug	NN	O	O
/	:	O	O
laboratory	NNP	O	O
test	NNP	O	O
interactions	NNS	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
administration	NN	O	O
of	IN	O	O
keflex	NNP	B	B
","	","	O	O
a	DT	O	O
false-positive	JJ	O	O
reaction	NN	O	O
for	IN	O	O
glucose	NN	O	O
in	IN	O	O
the	DT	O	O
urine	NN	O	O
may	MD	O	O
occur	VB	O	O
.	.	.	.

this	DT	O	O
has	VBZ	O	O
been	VBN	O	O
observed	VBN	O	O
with	IN	O	O
benedict	NNP	O	O
s	NNS	O	O
and	CC	O	O
fehling	NN	O	O
s	NNS	O	O
solutions	NNS	O	O
and	CC	O	O
also	RB	O	O
with	IN	O	O
clinitest	NNP	O	B
tablets	NNS	O	O
.	.	.	.

immunosuppressive	JJ	D	O
drugs	NNS	O	D
","	","	O	O
fibric	JJ	O	O
acid	NN	O	O
derivatives	NNS	O	O
","	","	O	O
niacin	NN	D	D
-lrb-	-LRB-	O	O
nicotinic	JJ	O	O
acid	NN	O	O
","	","	O	O
erythromycin	NNP	D	D
","	","	O	O
azole	NNP	O	O
antifungals	NNPS	G	G
:	:	O	O
skeletal	JJ	O	O
muscle	NN	O	O
.	.	.	.

antacid	NN	G	G
-lrb-	-LRB-	O	O
magnesium-aluminum	NNP	O	O
hydroxide	NNP	O	O
-rrb-	-RRB-	O	O
:	:	O	O
cerivastatin	NNP	D	D
plasma	NN	O	O
concentrations	NNS	O	O
were	VBD	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
co-administration	NN	O	O
of	IN	O	O
antacid	NN	G	G
.	.	.	.

cimetldine	NNP	D	D
:	:	O	O
cerivastatin	NNP	D	O
plasma	NN	O	O
concentrations	NNS	O	O
were	VBD	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
co-administration	NN	O	O
of	IN	O	O
cimetidine	NN	D	D
.	.	.	.

cholestyramine	NNP	D	D
:	:	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
the	DT	O	O
bile-acidsequestering	JJ	O	O
agent	NN	O	O
cholestyramine	NN	D	O
on	IN	O	O
the	DT	O	O
pharmacokinetits	NNS	O	O
of	IN	O	O
cerivastatin	NN	D	O
sodium	NN	O	O
was	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
12	CD	O	O
healthy	JJ	O	O
males	NNS	O	O
in	IN	O	O
2	CD	O	O
separate	JJ	O	O
randomized	JJ	O	O
crossover	NN	O	O
studies	NNS	O	O
.	.	.	.

in	IN	O	O
the	DT	O	O
first	JJ	O	O
study	NN	O	O
","	","	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
0.2	CD	O	O
mg	NN	O	O
cerivastatin	NN	D	O
sodium	NN	O	O
and	CC	O	O
12	CD	O	O
g	NN	O	O
cholestyramine	NN	D	D
resulted	VBD	O	O
in	IN	O	O
decreases	NNS	O	O
of	IN	O	O
more	JJR	O	O
than	IN	O	O
22	CD	O	O
%	NN	O	O
for	IN	O	O
auc	NN	O	O
and	CC	O	O
40	CD	O	O
%	NN	O	O
for	IN	O	O
cmax	NNP	O	O
when	WRB	O	O
compared	VBN	O	O
to	TO	O	O
dosing	NN	O	O
cerivastatin	NN	D	O
sodium	NN	O	O
alone	RB	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
in	IN	O	O
the	DT	O	O
second	JJ	O	O
study	NN	O	O
","	","	O	O
administration	NN	O	O
of	IN	O	O
12	CD	O	O
g	NN	O	O
cholestyramine	NN	D	O
1	CD	O	O
hour	NN	O	O
before	IN	O	O
the	DT	O	O
evening	NN	O	O
meal	NN	O	O
and	CC	O	O
0.3	CD	O	O
mg	NN	O	O
cerivastatin	NN	D	O
sodium	NN	O	O
approximately	RB	O	O
4	CD	O	O
hours	NNS	O	O
after	IN	O	O
the	DT	O	O
same	JJ	O	O
evening	NN	O	O
meal	NN	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
cerivastatin	NN	D	O
auc	NN	O	O
of	IN	O	O
less	JJR	O	O
than	IN	O	O
8	CD	O	O
%	NN	O	O
","	","	O	O
and	CC	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
cmax	NN	O	O
of	IN	O	O
about	IN	O	O
30	CD	O	O
%	NN	O	O
when	WRB	O	O
compared	VBN	O	O
to	TO	O	O
dosing	NN	O	O
cerivastatin	NN	D	O
sodium	NN	O	O
alone	RB	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
it	PRP	O	O
would	MD	O	O
be	VB	O	O
expected	VBN	O	O
that	IN	O	O
a	DT	O	O
dosing	NN	O	O
schedule	NN	O	O
of	IN	O	O
cerivastatin	NN	D	D
sodium	NN	O	O
given	VBN	O	O
at	IN	O	O
bedtime	NN	O	O
and	CC	O	O
cholestyramine	NN	D	D
given	VBN	O	O
before	IN	O	O
the	DT	O	O
evening	NN	O	O
meal	NN	O	O
would	MD	O	O
not	RB	O	O
result	VB	O	O
in	IN	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
clinical	JJ	O	O
effect	NN	O	O
of	IN	O	O
cerivastatin	NN	D	D
sodium	NN	O	O
.	.	.	.

digoxin	NNP	D	D
:	:	O	O
plasma	NN	O	O
digoxin	NN	D	D
levels	NNS	O	O
and	CC	O	O
digoxin	NN	D	D
clearance	NN	O	O
at	IN	O	O
steady-state	JJ	O	O
were	VBD	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
co-administration	NN	O	O
of	IN	O	O
0.2	CD	O	O
mg	NN	O	O
cerivastatin	NN	D	O
sodium	NN	O	O
.	.	.	.

cerivastatin	NNP	D	D
plasma	NN	O	O
concentrations	NNS	O	O
were	VBD	O	O
also	RB	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
co-administration	NN	O	O
of	IN	O	O
digoxin	NN	D	D
.	.	.	.

warfarin	NNP	D	D
:	:	O	O
co	NNP	O	O
-	:	O	O
administration	NN	O	O
of	IN	O	O
warfarin	NN	D	D
and	CC	O	O
cerivastatin	NN	D	O
to	TO	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
did	VBD	O	O
not	RB	O	O
result	VB	O	O
in	IN	O	O
any	DT	O	O
changes	NNS	O	O
in	IN	O	O
prothrombin	NN	O	O
time	NN	O	O
or	CC	O	O
clotting	NN	O	O
factor	NN	O	O
vii	NN	O	O
when	WRB	O	O
compared	VBN	O	O
to	TO	O	O
co-administration	NN	O	O
of	IN	O	O
warfarin	NN	D	D
and	CC	O	O
placebo	NN	O	O
.	.	.	.

the	DT	O	O
auc	NN	O	O
and	CC	O	O
cmax	NN	O	O
of	IN	O	O
both	CC	O	O
the	DT	O	O
-lrb-	-LRB-	O	O
r	NN	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
-lrb-	-LRB-	O	O
s	NN	O	O
-rrb-	-RRB-	O	O
isomers	NNS	O	O
of	IN	O	O
warfarin	NN	D	D
were	VBD	O	O
unaffected	JJ	O	O
by	IN	O	O
concurrent	JJ	O	O
dosing	NN	O	O
of	IN	O	O
0.3	CD	O	O
mg	NN	O	O
cerivastatin	NN	D	O
sodium	NN	O	O
.	.	.	.

co-administration	NN	O	O
of	IN	O	O
warfarin	NN	D	D
and	CC	O	O
cerivastatin	NN	D	D
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
cerivastatin	NN	D	D
sodium	NN	O	O
.	.	.	.

erythromycin	NNP	D	D
:	:	O	O
in	IN	O	O
hypercholesterolemic	JJ	O	O
patients	NNS	O	O
","	","	O	O
steady-state	JJ	O	O
cerivastatin	NN	D	O
auc	NN	O	O
and	CC	O	O
cmax	NN	O	O
increased	VBD	O	O
approximately	RB	O	O
50	CD	O	O
%	NN	O	O
and	CC	O	O
24	CD	O	O
%	NN	O	O
respectively	RB	O	O
after	IN	O	O
10	CD	O	O
days	NNS	O	O
with	IN	O	O
co-administration	NN	O	O
of	IN	O	O
erythromycin	NN	D	D
","	","	O	O
a	DT	O	O
known	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
3a4	NN	O	O
.	.	.	.

other	JJ	O	O
concomitant	JJ	O	O
therapy	NN	O	O
:	:	O	O
although	IN	O	O
specific	JJ	O	O
interaction	NN	O	O
studies	NNS	O	O
were	VBD	O	O
not	RB	O	O
performed	VBN	O	O
","	","	O	O
in	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
","	","	O	O
cerivastatin	NN	D	D
sodium	NN	O	O
was	VBD	O	O
used	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
angiotensin	NN	O	O
-	:	O	O
converting	VBG	O	O
enzyme	NN	O	O
-lrb-	-LRB-	O	O
ace	NN	O	O
-rrb-	-RRB-	O	O
inhibitors	NNS	O	O
","	","	O	O
betablockers	NNS	G	G
","	","	O	O
calcium-channel	JJ	O	O
blockers	NNS	O	O
","	","	O	O
diuretics	NNS	G	G
","	","	O	O
and	CC	O	O
nonsteroidal	JJ	O	O
anti-inflammatory	JJ	O	G
drugs	NNS	D	O
-lrb-	-LRB-	O	O
nsaids	NNS	G	G
-rrb-	-RRB-	O	O
without	IN	O	O
evidence	NN	O	O
of	IN	O	O
clinically	RB	O	O
significant	JJ	O	O
adverse	JJ	O	O
interactions	NNS	O	O
.	.	.	.

pharmacokinetic	JJ	O	O
interaction	NN	O	O
studies	NNS	O	O
with	IN	O	O
cetirizine	NN	D	D
in	IN	O	O
adults	NNS	O	O
were	VBD	O	O
conducted	VBN	O	O
with	IN	O	O
pseudoephedrine	NN	D	D
","	","	O	O
antipyrine	NN	D	D
","	","	O	O
ketoconazole	NN	D	D
","	","	O	O
erythromycin	NN	D	D
and	CC	O	O
azithromycin	NN	D	D
.	.	.	.

no	DT	O	O
interactions	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
a	DT	O	O
multiple	JJ	O	O
dose	NN	O	O
study	NN	O	O
of	IN	O	O
theophylline	NN	D	D
-lrb-	-LRB-	O	O
400	CD	O	O
mg	NN	O	O
once	RB	O	O
daily	RB	O	O
for	IN	O	O
3	CD	O	O
days	NNS	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
cetirizine	NN	D	O
-lrb-	-LRB-	O	O
20	CD	O	O
mg	NN	O	O
once	RB	O	O
daily	RB	O	O
for	IN	O	O
3	CD	O	O
days	NNS	O	O
-rrb-	-RRB-	O	O
","	","	O	O
a	DT	O	O
16	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
cetirizine	NN	D	D
was	VBD	O	O
observed	VBN	O	O
.	.	.	.

the	DT	O	O
disposition	NN	O	O
of	IN	O	O
theophylline	NN	D	D
was	VBD	O	O
not	RB	O	O
altered	VBN	O	O
by	IN	O	O
concomitant	JJ	O	O
cetirizine	NN	D	D
administration	NN	O	O
.	.	.	.

drug-drug	NNP	O	O
interactions	NNS	O	O
:	:	O	O
no	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
drug	NN	D	O
interactions	NNS	O	O
have	VBP	O	O
been	VBN	O	O
found	VBN	O	O
with	IN	O	O
theophylline	NN	D	D
at	IN	O	O
a	DT	O	O
low	JJ	O	O
dose	NN	O	O
","	","	O	O
azithromycin	NN	D	D
","	","	O	O
pseudoephedrine	NN	D	D
","	","	O	O
ketoconazole	NN	D	D
","	","	O	O
or	CC	O	O
erythromycin	NN	D	D
.	.	.	.

there	EX	O	O
was	VBD	O	O
a	DT	O	O
small	JJ	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
cetirizine	NN	D	D
caused	VBN	O	O
by	IN	O	O
a	DT	O	O
400-mg	JJ	O	O
dose	NN	O	O
of	IN	O	O
theophylline	NN	D	D
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
possible	JJ	O	O
that	IN	O	O
larger	JJR	O	O
theophylline	NN	D	D
doses	NNS	O	O
could	MD	O	O
have	VB	O	O
a	DT	O	O
greater	JJR	O	O
effect	NN	O	O
.	.	.	.

no	DT	O	O
formal	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
studies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
performed	VBN	O	O
with	IN	O	O
cetrotide	NN	B	B
.	.	.	.

a	DT	O	O
drug	NN	D	O
interaction	NN	O	O
study	NN	O	O
was	VBD	O	O
performed	VBN	O	O
in	IN	O	O
which	WDT	O	O
erbitux	NNP	B	B
was	VBD	O	O
administered	VBN	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
irinotecan	NN	D	D
.	.	.	.

there	EX	O	O
was	VBD	O	O
no	DT	O	O
evidence	NN	O	O
of	IN	O	O
any	DT	O	O
pharmacokinetic	JJ	O	O
interactions	NNS	O	O
between	IN	O	O
erbitux	NNP	B	B
and	CC	O	O
irinotecan	NN	D	D
.	.	.	.

cevimeline	NNP	D	B
should	MD	O	O
be	VB	O	O
administered	VBN	O	O
with	IN	O	O
caution	NN	O	O
to	TO	O	O
patients	NNS	O	O
taking	VBG	O	O
beta	NN	O	O
adrenergic	JJ	O	O
antagonists	NNS	O	O
","	","	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
possibility	NN	O	O
of	IN	O	O
conduction	NN	O	O
disturbances	NNS	O	O
.	.	.	.

drugs	NNS	O	O
with	IN	O	O
parasympathomimetic	JJ	O	O
effects	NNS	O	O
administered	VBN	O	O
concurrently	RB	O	O
with	IN	O	O
cevimeline	NN	D	D
can	MD	O	O
be	VB	O	O
expected	VBN	O	O
to	TO	O	O
have	VB	O	O
additive	JJ	O	O
effects	NNS	O	O
.	.	.	.

cevimeline	NNP	D	D
might	MD	O	O
interfere	VB	O	O
with	IN	O	O
desirable	JJ	O	O
antimuscarinic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
drugs	NNS	D	D
used	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

drugs	NNS	O	O
which	WDT	O	O
inhibit	VBP	O	O
cyp2d6	NN	D	O
and	CC	O	O
cyp3a3/4	NN	O	D
also	RB	O	O
inhibit	VBP	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
cevimeline	NN	D	D
.	.	.	.

cevimeline	NNP	D	B
should	MD	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
caution	NN	O	O
in	IN	O	O
individuals	NNS	O	O
known	VBN	O	O
or	CC	O	O
suspected	VBN	O	O
to	TO	O	O
be	VB	O	O
deficient	JJ	O	O
in	IN	O	O
cyp2d6	NN	D	O
activity	NN	O	O
","	","	O	O
based	VBN	O	O
on	IN	O	O
previous	JJ	O	O
experience	NN	O	O
","	","	O	O
as	IN	O	O
they	PRP	O	O
may	MD	O	O
be	VB	O	O
at	IN	O	O
a	DT	O	O
higher	JJR	O	O
risk	NN	O	O
of	IN	O	O
adverse	JJ	O	O
events	NNS	O	O
.	.	.	.

in	IN	O	O
an	DT	O	O
in	FW	O	O
vitro	FW	O	O
study	NN	O	O
","	","	O	O
cytochrome	NN	O	O
p450	NN	O	O
isozymes	NNS	O	O
1a2	NN	O	O
","	","	O	O
2a6	NN	O	O
","	","	O	O
2c9	NN	O	O
","	","	O	O
2c19	NN	O	O
","	","	O	O
2d6	NN	O	O
","	","	O	O
2.00E+01	NN	O	O
","	","	O	O
and	CC	O	O
3a4	NN	O	O
were	VBD	O	O
not	RB	O	O
inhibited	VBN	O	O
by	IN	O	O
exposure	NN	O	O
to	TO	O	O
cevimeline	NN	D	D
.	.	.	.

there	EX	O	O
are	VBP	O	O
no	DT	O	O
known	JJ	O	O
drug/drug	NN	O	O
interactions	NNS	O	O
with	IN	O	O
chlorambucil	NN	D	O
.	.	.	.

although	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
not	RB	O	O
established	VBN	O	O
a	DT	O	O
cause	NN	O	O
and	CC	O	O
effect	NN	O	O
relationship	NN	O	O
","	","	O	O
physicians	NNS	O	O
should	MD	O	O
be	VB	O	O
aware	JJ	O	O
that	IN	O	O
variable	JJ	O	O
effects	NNS	O	O
an	DT	O	O
blood	NN	O	O
coagulation	NN	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
very	RB	O	O
rarely	RB	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
oral	JJ	O	O
anticoagulants	NNS	G	G
and	CC	O	O
chlordiazepoxide	NN	D	D
.	.	.	.

the	DT	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
alcohol	NN	D	D
or	CC	O	O
other	JJ	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
depressants	NNS	O	O
may	MD	O	O
have	VB	O	O
an	DT	O	O
additive	JJ	O	O
effect	NN	O	O
.	.	.	.

the	DT	O	O
administration	NN	O	O
of	IN	O	O
local	JJ	O	O
anesthetic	JJ	O	G
solutions	NNS	O	O
containing	VBG	O	O
epinephrine	NN	D	D
or	CC	O	O
norepinephrine	NN	D	D
to	TO	O	O
patients	NNS	O	O
receiving	VBG	O	O
monoamine	NN	O	O
oxidase	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
or	CC	O	O
phenothiazines	NNS	G	G
may	MD	O	O
produce	VB	O	O
severe	JJ	O	O
","	","	O	O
prolonged	JJ	O	O
hypotension	NN	O	O
or	CC	O	O
hypertension	NN	O	O
.	.	.	.

concurrent	JJ	O	O
use	NN	O	O
of	IN	O	O
these	DT	O	O
agents	NNS	O	O
should	MD	O	O
generally	RB	O	O
be	VB	O	O
avoided	VBN	O	O
.	.	.	.

in	IN	O	O
situations	NNS	O	O
when	WRB	O	O
concurrent	JJ	O	O
therapy	NN	O	O
is	VBZ	O	O
necessary	JJ	O	O
","	","	O	O
careful	JJ	O	O
patient	NN	O	O
monitoring	NN	O	O
is	VBZ	O	O
essential	JJ	O	O
.	.	.	.

concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
vasopressor	NN	O	G
drugs	NNS	D	D
-lrb-	-LRB-	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
hypotension	NN	O	O
related	JJ	O	O
to	TO	O	O
obstetric	JJ	O	O
blocks	NNS	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
ergot-type	JJ	O	O
oxytocic	JJ	O	O
drugs	NNS	D	D
may	MD	O	O
cause	VB	O	O
severe	JJ	O	O
","	","	O	O
persistent	JJ	O	O
hypertension	NN	O	O
or	CC	O	O
cerebrovascular	JJ	O	O
accidents	NNS	O	O
.	.	.	.

the	DT	O	O
para-aminobenzoic	JJ	O	O
acid	NN	O	O
metabolite	NN	O	O
of	IN	O	O
chloroprocaine	NN	D	D
inhibits	VBZ	O	O
the	DT	O	O
action	NN	O	O
of	IN	O	O
sulfonamides	NNS	G	G
.	.	.	.

therefore	RB	O	O
","	","	O	O
chloroprocaine	NN	D	D
should	MD	O	O
not	RB	O	O
be	VB	O	O
used	VBN	O	O
in	IN	O	O
any	DT	O	O
condition	NN	O	O
in	IN	O	O
which	WDT	O	O
a	DT	O	O
sulfonamide	NN	O	O
drug	NN	D	O
is	VBZ	O	O
being	VBG	O	O
employed	VBN	O	O
.	.	.	.

antacids	NNS	G	G
and	CC	O	O
kaolin	NN	D	O
:	:	O	O
antacids	NNS	G	G
and	CC	O	O
kaolin	NN	D	D
can	MD	O	O
reduce	VB	O	O
absorption	NN	O	O
of	IN	O	O
chloroquine	NN	D	D
.	.	.	.

an	DT	O	O
interval	NN	O	O
of	IN	O	O
at	IN	O	O
least	JJS	O	O
4	CD	O	O
hours	NNS	O	O
between	IN	O	O
intake	NN	O	O
of	IN	O	O
these	DT	O	O
agents	NNS	O	O
and	CC	O	O
chloroquine	NN	D	O
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
.	.	.	.

cimetidine	NNP	D	D
:	:	O	O
cimetidine	NNP	D	D
can	MD	O	O
inhibit	VB	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
chloroquine	NN	D	D
","	","	O	O
increasing	VBG	O	O
its	PRP$	O	O
plasma	NN	O	O
level	NN	O	O
.	.	.	.

concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
cimetidine	NN	D	D
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
.	.	.	.

ampicillin	NNP	D	D
:	:	O	O
in	IN	O	O
a	DT	O	O
study	NN	O	O
of	IN	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
","	","	O	O
chloroquine	NN	D	D
significantly	RB	O	O
reduced	VBD	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
ampicillin	NN	D	D
.	.	.	.

an	DT	O	O
interval	NN	O	O
of	IN	O	O
at	IN	O	O
least	JJS	O	O
two	CD	O	O
hours	NNS	O	O
between	IN	O	O
intake	NN	O	O
of	IN	O	O
this	DT	O	O
agent	NN	O	O
and	CC	O	O
chloroquine	NN	D	D
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
.	.	.	.

cyclosporin	NN	D	D
:	:	O	O
after	IN	O	O
introduction	NN	O	O
of	IN	O	O
chloroquine	NN	D	D
-lrb-	-LRB-	O	O
oral	JJ	O	O
form	NN	O	O
-rrb-	-RRB-	O	O
","	","	O	O
a	DT	O	O
sudden	JJ	O	O
increase	NN	O	O
in	IN	O	O
serum	NN	O	O
cyclosporin	NN	D	O
level	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
close	JJ	O	O
monitoring	NN	O	O
of	IN	O	O
serum	NN	O	O
cyclosporin	NN	D	O
level	NN	O	O
is	VBZ	O	O
recommended	VBN	O	O
and	CC	O	O
","	","	O	O
if	IN	O	O
necessary	JJ	O	O
","	","	O	O
chloroquine	NN	D	O
should	MD	O	O
be	VB	O	O
discontinued	VBN	O	O
.	.	.	.

when	WRB	O	O
given	VBN	O	O
concurrently	RB	O	O
the	DT	O	O
following	VBG	O	O
drugs	NNS	D	D
may	MD	O	O
interact	VB	O	O
with	IN	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
.	.	.	.

-	:	O	O
alcohol	NN	D	D
","	","	O	O
barbiturates	NNS	G	G
","	","	O	O
or	CC	O	O
narcotics	NNS	G	G
:	:	O	O
potentiation	NN	O	O
of	IN	O	O
otthostatic	JJ	O	O
hypotension	NN	O	O
may	MD	O	O
occu	VB	O	O
.	.	.	.

-	:	O	O
antidiabetic	JJ	O	O
drugs	NNS	D	D
:	:	O	O
-lrb-	-LRB-	O	O
oral	JJ	O	O
agents	NNS	O	O
and	CC	O	O
insulin	NN	D	D
-rrb-	-RRB-	O	O
dosage	NN	O	O
adjustment	NN	O	O
of	IN	O	O
the	DT	O	O
antidiabetic	JJ	O	D
drug	NN	D	O
may	MD	O	O
be	VB	O	O
require	VB	O	O
.	.	.	.

-	:	O	O
other	JJ	O	O
antihypertensive	JJ	O	G
drugs	NNS	D	D
:	:	O	O
additive	JJ	O	O
effect	NN	O	O
or	CC	O	O
potentiatio	NN	O	D
.	.	.	.

-	:	O	O
cholestyramine	NN	D	D
and	CC	O	O
colestipol	NN	D	D
resins	NNS	G	G
:	:	O	O
cholestytamine	NN	D	D
and	CC	O	O
colestipol	NN	D	O
resins	NNS	G	G
have	VBP	O	O
the	DT	O	O
potential	NN	O	O
of	IN	O	O
binding	VBG	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
and	CC	O	O
reducing	VBG	O	O
diuretic	JJ	G	G
absorption	NN	O	O
from	IN	O	O
the	DT	O	O
gastrointestinal	JJ	O	O
trac	NN	O	O
.	.	.	.

-	:	O	O
corticosteroids	NNS	G	G
","	","	O	O
acth	NN	D	D
:	:	O	O
intensified	VBN	O	O
electrolyte	NN	O	O
depletion	NN	O	O
","	","	O	O
particularly	RB	O	O
hypokalemi	NN	O	O
.	.	.	.

-	:	O	O
pressor	NN	O	O
amines	NNS	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
norepinephrine	NN	D	D
-rrb-	-RRB-	O	O
:	:	O	O
possible	JJ	O	O
decreased	VBN	O	O
response	NN	O	O
to	TO	O	O
pressor	NN	O	O
amines	NNS	O	O
but	CC	O	O
not	RB	O	O
sufficient	JJ	O	O
to	TO	O	O
preclude	VB	O	O
their	PRP$	O	O
us	PRP	O	O
.	.	.	.

-	:	O	O
skeletal	JJ	O	O
muscle	NN	O	O
relaxants	NNS	O	O
","	","	O	O
nondepolarizing	JJ	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
tubocurarine	NN	D	D
-rrb-	-RRB-	O	O
:	:	O	O
possible	JJ	O	O
increased	VBN	O	O
responsiveness	NN	O	O
to	TO	O	O
the	DT	O	O
muscle	NN	O	O
relaxan	NN	O	O
.	.	.	.

-	:	O	O
lithium	NN	D	D
:	:	O	O
generally	RB	O	O
should	MD	O	O
not	RB	O	O
be	VB	O	O
given	VBN	O	O
with	IN	O	O
diuretics	NNS	G	G
.	.	.	.

diuretic	JJ	O	G
agents	NNS	O	O
reduce	VB	O	O
the	DT	O	O
renal	JJ	O	O
clearance	NN	O	O
of	IN	O	O
lithium	NN	D	D
and	CC	O	O
add	VB	O	O
a	DT	O	O
high	JJ	O	O
risk	NN	O	O
of	IN	O	O
lithium	NN	D	D
toxicity	NN	O	O
.	.	.	.

refer	VB	O	O
to	TO	O	O
the	DT	O	O
package	NN	O	O
insert	NN	O	O
for	IN	O	O
lithium	NN	D	D
preparations	NNS	O	O
before	IN	O	O
use	NN	O	O
of	IN	O	O
such	JJ	O	O
preparations	NNS	O	O
with	IN	O	O
chlorothiazid	NN	O	D
.	.	.	.

-	:	O	O
non-steroidal	JJ	O	O
anti-inflammatory	JJ	O	O
drugs	NNS	O	O
:	:	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
","	","	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
a	DT	O	O
non-steroidal	JJ	O	O
anti-inflammatory	JJ	O	G
agent	NN	O	O
can	MD	O	O
reduce	VB	O	O
the	DT	O	O
diuretic	JJ	G	G
","	","	O	O
natriuretic	JJ	O	O
","	","	O	O
and	CC	O	O
antihypertensive	JJ	O	G
effects	NNS	O	O
of	IN	O	O
loop	NN	O	O
","	","	O	O
potassium-sparing	NN	O	O
and	CC	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
.	.	.	.

therefore	RB	O	O
","	","	O	O
when	WRB	O	O
chlorothiazide	NN	D	D
and	CC	O	O
non-steroidal	JJ	O	O
anti-inflammatory	JJ	O	G
agents	NNS	O	O
are	VBP	O	O
used	VBN	O	O
concomitantly	RB	O	O
","	","	O	O
the	DT	O	O
patient	NN	O	O
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
closely	RB	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
the	DT	O	O
desired	VBN	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
diuretic	JJ	G	G
is	VBZ	O	O
obtaine	NN	O	O
.	.	.	.

-	:	O	O
drug/laboratory	NN	O	O
test	NN	O	O
interactions	NNS	O	O
:	:	O	O
thiazides	NNS	G	G
should	MD	O	O
be	VB	O	O
discontinued	VBN	O	O
before	IN	O	O
carrying	VBG	O	O
out	RP	O	O
tests	NNS	O	O
for	IN	O	O
parathyroid	JJ	O	O
function	NN	O	O
.	.	.	.

chlorotrianisene	NN	D	D
may	MD	O	O
interact	VB	O	O
with	IN	O	O
antidepressants	NNS	G	G
","	","	O	O
aspirin	NN	B	B
","	","	O	O
barbiturates	NNS	G	G
","	","	O	O
bromocriptine	NN	D	O
","	","	O	O
calcium	NN	D	D
supplements	NNS	O	O
","	","	O	O
corticosteroids	NNS	G	G
","	","	O	O
corticotropin	NN	D	D
","	","	O	O
cyclosporine	NN	D	D
","	","	O	O
dantrolene	NN	D	D
","	","	O	O
nicotine	NN	D	D
","	","	O	O
somatropin	NN	D	D
","	","	O	O
tamoxifen	NN	D	D
","	","	O	O
and	CC	O	O
warfarin	NN	D	D
.	.	.	.

may	NNP	O	O
interact	VBP	O	O
with	IN	O	O
skin	NN	O	O
products	NNS	O	O
or	CC	O	O
shampoos	NNS	O	O
for	IN	O	O
dandruff	NN	O	O
or	CC	O	O
psoriasis	NN	O	D
.	.	.	.

substrate	NN	O	O
of	IN	O	O
cyp2d6	NN	D	O
-lrb-	-LRB-	O	O
minor	JJ	O	O
-rrb-	-RRB-	O	O
","	","	O	O
3a4	NN	O	O
-lrb-	-LRB-	O	O
major	JJ	O	O
-rrb-	-RRB-	O	O
;	:	O	O
.	.	.	.

inhibits	VBZ	O	O
cyp2d6	NN	D	O
-lrb-	-LRB-	O	O
weak	JJ	O	O
-rrb-	-RRB-	O	O
.	.	.	.

increased	VBN	O	O
toxicity	NN	O	O
-lrb-	-LRB-	O	O
cns	NN	O	O
depression	NN	O	O
-rrb-	-RRB-	O	O
:	:	O	O
cns	NN	O	O
depressants	NNS	O	O
","	","	O	O
mao	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
","	","	O	O
phenothiazines	NNS	G	G
.	.	.	.

cyp3a4	NN	D	D
inhibitors	NNS	O	O
:	:	O	O
may	NNP	O	O
increase	VB	O	O
the	DT	O	O
levels/effects	NNS	O	O
of	IN	O	O
chlorpheniramine	NN	D	O
.	.	.	.

example	NN	O	O
inhibitors	NNS	O	O
include	VBP	O	O
azole	NN	O	O
antifungals	NNS	O	G
","	","	O	O
ciprofloxacin	NN	D	D
","	","	O	O
clarithromycin	NN	D	D
","	","	O	O
diclofenac	NN	D	D
","	","	O	O
doxycycline	NN	D	D
","	","	O	O
erythromycin	NN	D	D
","	","	O	O
imatinib	NN	D	D
","	","	O	O
isoniazid	NN	D	D
","	","	O	O
nefazodone	NN	D	D
","	","	O	O
nicardipine	NN	D	D
","	","	O	O
propofol	NN	D	D
","	","	O	O
protease	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
quinidine	NN	D	D
","	","	O	O
and	CC	O	O
verapamil	NN	D	D
.	.	.	.

the	DT	O	O
concurrent	JJ	O	O
use	NN	O	O
of	IN	O	O
two	CD	O	O
or	CC	O	O
more	JJR	O	O
drugs	NNS	D	D
with	IN	O	O
anticholinergic	JJ	G	G
activity	NN	O	O
--	:	O	O
such	JJ	O	O
as	IN	O	O
an	DT	O	O
antipsychotic	JJ	O	O
drug	NN	D	O
-lrb-	-LRB-	O	O
eg	FW	O	O
","	","	O	O
chlorpromazine	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
an	DT	O	O
antiparkinsonian	JJ	O	O
drug	NN	D	O
-lrb-	-LRB-	O	O
eg	FW	O	O
","	","	O	O
trihexyphenidyl	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
and/or	CC	O	O
a	DT	O	O
tricyclic	JJ	O	G
antidepressant	JJ	O	G
-lrb-	-LRB-	O	O
eg	FW	O	O
","	","	O	O
amitriptyline	NNP	D	D
-rrb-	-RRB-	O	O
--	:	O	O
commonly	RB	O	O
results	VBZ	O	O
in	IN	O	O
excessive	JJ	O	O
anticholinergic	JJ	G	G
effects	NNS	O	O
","	","	O	O
including	VBG	O	O
dry	JJ	O	O
mouth	NN	O	O
and	CC	O	O
associated	VBN	O	O
dental	JJ	O	O
complications	NNS	O	O
","	","	O	O
blurred	VBD	O	O
vision	NN	O	O
","	","	O	O
and	CC	O	O
","	","	O	O
in	IN	O	O
patients	NNS	O	O
exposed	VBN	O	O
to	TO	O	O
high	JJ	O	O
temperature	NN	O	O
and	CC	O	O
humidity	NN	O	D
","	","	O	O
hyperpyrexia	NN	O	O
.	.	.	.

interactions	NNS	O	O
may	MD	O	O
also	RB	O	O
occur	VB	O	O
with	IN	O	O
the	DT	O	O
following	NN	O	O
:	:	O	O
anti-depressants/anti-anxiety	JJ	O	O
drugs	NNS	D	D
","	","	O	O
drugs	NNS	D	D
used	VBN	O	O
to	TO	O	O
treat	VB	O	O
an	DT	O	O
overactive	JJ	O	O
thyroid	NN	D	G
","	","	O	O
beta-blockers	NNS	G	G
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
propranolol	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
sparfloxacin	NN	D	D
","	","	O	O
grepafloxacin	NN	D	D
","	","	O	O
guanethidine	NN	D	D
","	","	O	O
guanadrel	NN	D	D
","	","	O	O
metrizamide	NN	D	D
","	","	O	O
cabergoline	NN	D	D
","	","	O	O
lithium	NN	D	D
","	","	O	O
narcotic	JJ	G	O
pain	NN	O	O
medication	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
codeine	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
drugs	NNS	D	D
used	VBN	O	O
to	TO	O	O
aid	VB	O	O
sleep	NN	O	O
","	","	O	O
drowsiness-causing	JJ	O	O
antihistamines	NNS	G	G
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
diphenhydramine	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
any	DT	O	O
other	JJ	O	O
drugs	NNS	D	D
that	WDT	O	O
may	MD	O	O
make	VB	O	O
you	PRP	O	O
drowsy	JJ	O	O
.	.	.	.

the	DT	O	O
hypoglycemic	JJ	O	G
action	NN	O	O
of	IN	O	O
sulfonylurea	NN	G	D
may	MD	O	O
be	VB	O	O
potentiated	VBN	O	O
by	IN	O	O
certain	JJ	O	O
drugs	NNS	D	D
including	VBG	O	O
nonsteroidal	JJ	O	O
anti-inflammatory	JJ	O	G
agents	NNS	O	O
and	CC	O	O
other	JJ	O	O
drugs	NNS	D	D
that	WDT	O	O
are	VBP	O	O
highly	RB	O	O
protein	NN	O	O
bound	VBD	O	O
","	","	O	O
salicylates	NNS	G	G
","	","	O	O
sulfonamides	NNS	G	G
","	","	O	O
chloramphenicol	NN	D	D
","	","	O	O
probenecid	NN	D	D
","	","	O	O
coumarins	NNS	G	G
","	","	O	O
monoamine	NN	O	O
oxidase	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
and	CC	O	O
beta	NN	O	O
adrenergic	JJ	O	G
blocking	VBG	O	O
agents	NNS	O	O
.	.	.	.

when	WRB	O	O
such	JJ	O	O
drugs	NNS	D	D
are	VBP	O	O
administered	VBN	O	O
to	TO	O	O
a	DT	O	O
patient	NN	O	O
receiving	VBG	O	O
diabinese	NNP	B	B
","	","	O	O
the	DT	O	O
patient	NN	O	O
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
closely	RB	O	O
for	IN	O	O
hypoglycemia	NN	O	O
.	.	.	.

when	WRB	O	O
such	JJ	O	O
drugs	NNS	D	D
are	VBP	O	O
withdrawn	VBN	O	O
from	IN	O	O
a	DT	O	O
patient	NN	O	O
receiving	VBG	O	O
diabinese	NNP	B	B
","	","	O	O
the	DT	O	O
patient	NN	O	O
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
closely	RB	O	O
for	IN	O	O
loss	NN	O	O
of	IN	O	O
control	NN	O	O
.	.	.	.

certain	JJ	O	O
drugs	NNS	D	D
tend	VBP	O	O
to	TO	O	O
produce	VB	O	O
hyperglycemia	NN	O	O
and	CC	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
loss	NN	O	O
of	IN	O	O
control	NN	O	O
.	.	.	.

these	DT	O	O
drugs	NNS	D	D
include	VBP	O	O
the	DT	O	O
thiazides	NNS	G	G
and	CC	O	O
other	JJ	O	O
diuretics	NNS	G	G
","	","	O	O
corticosteroids	NNS	G	G
","	","	O	O
phenothiazines	NNS	G	G
","	","	O	O
thyroid	NN	D	G
products	NNS	O	O
","	","	O	O
estrogens	NNS	G	G
","	","	O	O
oral	JJ	O	O
contraceptives	NNS	G	G
","	","	O	O
phenytoin	NN	D	D
","	","	O	O
nicotinic	JJ	O	O
acid	NN	O	O
","	","	O	O
sympathomimetics	NNS	G	G
","	","	O	O
calcium	NN	D	D
channel	NN	O	O
blocking	VBG	O	O
drugs	NNS	D	D
","	","	O	O
and	CC	O	O
isoniazid	NN	D	D
.	.	.	.

when	WRB	O	O
such	JJ	O	O
drugs	NNS	D	D
are	VBP	O	O
administered	VBN	O	O
to	TO	O	O
a	DT	O	O
patient	NN	O	O
receiving	VBG	O	O
diabinese	NNP	B	B
","	","	O	O
the	DT	O	O
patient	NN	O	O
should	MD	O	O
be	VB	O	O
closely	RB	O	O
observed	VBN	O	O
for	IN	O	O
loss	NN	O	O
of	IN	O	O
control	NN	O	O
.	.	.	.

when	WRB	O	O
such	JJ	O	O
drugs	NNS	D	D
are	VBP	O	O
withdrawn	VBN	O	O
from	IN	O	O
a	DT	O	O
patient	NN	O	O
receiving	VBG	O	O
diabinese	NNP	B	B
","	","	O	O
the	DT	O	O
patient	NN	O	O
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
closely	RB	O	O
for	IN	O	O
hypoglycemia	NN	O	O
.	.	.	.

since	IN	O	O
animal	NN	O	O
studies	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
action	NN	O	O
of	IN	O	O
barbiturates	NNS	G	G
may	MD	O	O
be	VB	O	O
prolonged	VBN	O	O
by	IN	O	O
therapy	NN	O	O
with	IN	O	O
chlorpropamide	NN	D	D
","	","	O	O
barbiturates	NNS	G	G
should	MD	O	O
be	VB	O	O
employed	VBN	O	O
with	IN	O	O
caution	NN	O	O
.	.	.	.

in	IN	O	O
some	DT	O	O
patients	NNS	O	O
","	","	O	O
a	DT	O	O
disulfiram-like	JJ	O	O
reaction	NN	O	O
may	MD	O	O
be	VB	O	O
produced	VBN	O	O
by	IN	O	O
the	DT	O	O
ingestion	NN	O	O
of	IN	O	O
alcohol	NN	D	D
.	.	.	.

a	DT	O	O
potential	JJ	O	O
interaction	NN	O	O
between	IN	O	O
oral	JJ	O	O
miconazole	NN	D	D
and	CC	O	O
oral	JJ	O	O
hypoglycemic	JJ	O	G
agents	NNS	O	O
leading	VBG	O	O
to	TO	O	O
severe	JJ	O	O
hypoglycemia	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
.	.	.	.

whether	IN	O	O
this	DT	O	O
interaction	NN	O	O
also	RB	O	O
occurs	VBZ	O	O
with	IN	O	O
the	DT	O	O
intravenous	JJ	O	O
","	","	O	O
topical	JJ	O	O
","	","	O	O
or	CC	O	O
vaginal	JJ	O	O
preparations	NNS	O	O
of	IN	O	O
miconazole	NN	D	D
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
.	.	.	.

chlorprothixene	NN	D	D
may	MD	O	O
increase	VB	O	O
the	DT	O	O
plasma-level	NN	O	O
of	IN	O	O
concomitantly	RB	O	O
given	VBN	O	O
lithium	NN	D	D
.	.	.	.

in	IN	O	O
order	NN	O	O
to	TO	O	O
avoid	VB	O	O
lithium	NN	D	D
intoxication	NN	O	O
","	","	O	O
lithium	NN	D	D
plasma	NN	O	O
levels	NNS	O	O
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
closely	RB	O	O
.	.	.	.

if	IN	O	O
chlorprothixene	NN	D	D
is	VBZ	O	O
given	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
opioids	NNS	G	G
","	","	O	O
the	DT	O	O
opioid	JJ	G	O
dose	NN	O	O
should	MD	O	O
be	VB	O	O
reduced	VBN	O	O
-lrb-	-LRB-	O	O
by	IN	O	O
approx	RB	O	O
.	.	.	.

50	CD	O	O
%	NN	O	O
-rrb-	-RRB-	O	O
","	","	O	O
because	IN	O	O
chlorprothixene	NN	D	D
amplifies	VBZ	O	O
the	DT	O	O
therapeutic	JJ	O	O
actions	NNS	O	O
and	CC	O	O
side-effects	NNS	O	O
of	IN	O	O
opioids	NNS	G	G
massively	RB	O	O
.	.	.	.

avoid	VB	O	O
the	DT	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
chlorprothixene	NN	D	D
and	CC	O	O
tramadol	NN	D	D
-lrb-	-LRB-	O	O
ultram	NN	B	O
-rrb-	-RRB-	O	O
.	.	.	.

massive	JJ	O	O
seizures	NNS	O	O
may	MD	O	O
be	VB	O	O
encountered	VBN	O	O
with	IN	O	O
this	DT	O	O
combination	NN	O	O
.	.	.	.

consider	VB	O	O
additive	JJ	O	O
sedative	JJ	G	O
effects	NNS	O	O
and	CC	O	O
confusional	JJ	O	O
states	NNS	O	O
to	TO	O	O
emerge	VB	O	O
","	","	O	O
if	IN	O	O
chlorprothixene	NN	D	D
is	VBZ	O	O
given	VBN	O	O
with	IN	O	O
benzodiazepines	NNS	G	G
or	CC	O	O
barbituates	NNS	G	O
.	.	.	.

choose	VB	O	O
particular	JJ	O	O
low	JJ	O	O
doses	NNS	O	O
of	IN	O	O
these	DT	O	O
drugs	NNS	D	D
.	.	.	.

exert	VB	O	O
particular	JJ	O	O
caution	NN	O	O
in	IN	O	O
combining	VBG	O	O
chlorprothixene	NN	D	O
with	IN	O	O
other	JJ	O	O
anticholinergic	JJ	G	G
drugs	NNS	D	D
-lrb-	-LRB-	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
and	CC	O	O
antiparkinsonian	JJ	O	O
agents	NNS	O	O
-rrb-	-RRB-	O	O
:	:	O	O
particularly	RB	O	O
the	DT	O	O
elderly	JJ	O	O
may	MD	O	O
develop	VB	O	O
delirium	NN	O	O
","	","	O	O
high	JJ	O	O
fever	NN	O	O
","	","	O	O
severe	JJ	O	O
obstipation	NN	O	O
","	","	O	O
even	RB	O	O
ileus	NN	O	O
and	CC	O	O
glaucoma	NN	O	O
.	.	.	.

chlorthalidone	NNP	D	D
may	MD	O	O
add	VB	O	O
to	TO	O	O
or	CC	O	O
potentiate	VB	O	O
the	DT	O	O
action	NN	O	O
of	IN	O	O
other	JJ	O	O
antihypertensive	JJ	O	G
drugs	NNS	D	D
.	.	.	.

potentiation	NN	O	O
occurs	VBZ	O	O
with	IN	O	O
ganglionic	JJ	O	O
peripheral	JJ	O	O
adrenergic	JJ	O	G
blocking	NN	O	O
drugs	NNS	D	D
.	.	.	.

medication	NN	O	O
such	JJ	O	O
as	IN	O	O
digitalis	NN	G	G
may	MD	O	O
also	RB	O	O
influence	VB	O	O
serum	NN	O	O
electrolytes	NNS	O	O
.	.	.	.

warning	NN	O	O
signs	NNS	O	O
","	","	O	O
irrespective	RB	O	O
of	IN	O	O
cause	NN	O	D
","	","	O	O
are	VBP	O	O
:	:	O	O
dryness	NN	O	O
of	IN	O	O
mouth	NN	O	O
","	","	O	O
thirst	NN	O	O
","	","	O	O
weakness	NN	O	O
","	","	O	O
lethargy	NN	O	O
","	","	O	O
drowsiness	NN	O	O
","	","	O	O
restlessness	NN	O	O
","	","	O	O
muscle	NN	O	O
pains	NNS	O	O
or	CC	O	O
cramps	NNS	O	O
","	","	O	O
muscular	JJ	O	O
fatigue	NN	O	O
","	","	O	O
hypotension	NN	O	O
","	","	O	O
oliguria	NN	O	O
","	","	O	O
tachycardia	NN	O	O
","	","	O	O
and	CC	O	O
gastrointestinal	JJ	O	O
disturbances	NNS	O	O
such	JJ	O	O
as	IN	O	O
nausea	NN	O	O
and	CC	O	O
vomiting	NN	O	O
.	.	.	.

insulin	NN	D	D
requirements	NNS	O	O
in	IN	O	O
diabetic	JJ	O	O
patients	NNS	O	O
may	MD	O	O
be	VB	O	O
increased	VBN	O	O
","	","	O	O
decreased	VBN	O	O
","	","	O	O
or	CC	O	O
unchanged	JJ	O	O
.	.	.	.

higher	JJR	O	O
dosage	NN	O	O
of	IN	O	O
oral	JJ	O	O
hypoglycemic	JJ	O	G
agents	NNS	O	O
may	MD	O	O
be	VB	O	O
required	VBN	O	O
.	.	.	.

latent	JJ	O	O
diabetes	NN	O	O
mellitus	NN	O	O
may	MD	O	O
become	VB	O	O
manifest	JJ	O	O
during	IN	O	O
chlorthalidone	NN	D	D
administration	NN	O	O
.	.	.	.

chlorthalidone	NNP	D	D
and	CC	O	O
related	JJ	O	O
drugs	NNS	D	D
may	MD	O	O
increase	VB	O	O
the	DT	O	O
responsiveness	NN	O	O
to	TO	O	O
tubocurarine	NN	D	D
.	.	.	.

chlorthalidone	NNP	D	D
and	CC	O	O
related	JJ	O	O
drugs	NNS	D	D
may	MD	O	O
decrease	VB	O	O
arterial	JJ	O	O
responsiveness	NN	O	O
to	TO	O	O
norepinephrine	NN	D	D
.	.	.	.

this	DT	O	O
diminution	NN	O	O
is	VBZ	O	O
not	RB	O	O
sufficient	JJ	O	O
to	TO	O	O
preclude	VB	O	O
effectiveness	NN	O	O
of	IN	O	O
the	DT	O	O
pressor	NN	O	O
agent	NN	O	O
for	IN	O	O
therapeutic	JJ	O	O
use	NN	O	O
.	.	.	.

the	DT	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
alcohol	NN	D	D
or	CC	O	O
other	JJ	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
depressants	NNS	O	O
may	MD	O	O
have	VB	O	O
an	DT	O	O
additive	JJ	O	O
effect	NN	O	O
.	.	.	.

interactions	NNS	O	O
for	IN	O	O
vitamin	NN	O	G
d	NN	O	O
analogues	NNS	O	O
-lrb-	-LRB-	O	O
vitamin	NN	O	O
d2	NN	O	O
","	","	O	O
vitamin	NN	O	O
d3	NN	O	O
","	","	O	O
calcitriol	NN	D	D
","	","	O	O
and	CC	O	O
calcidiol	NN	D	D
-rrb-	-RRB-	O	O
:	:	O	O
cholestyramine	NNP	D	D
:	:	O	O
cholestyramine	NNP	D	D
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
reduce	VB	O	O
intestinal	JJ	O	O
absorption	NN	O	O
of	IN	O	O
fat	JJ	O	O
soluble	JJ	O	O
vitamins	NNS	G	G
.	.	.	.

as	IN	O	O
such	JJ	O	O
it	PRP	O	O
may	MD	O	O
impair	VB	O	O
intestinal	JJ	O	O
absorption	NN	O	O
of	IN	O	O
any	DT	O	O
of	IN	O	O
vitamin	NN	O	G
d.	NNP	O	O
phenytoin/phenobarbital	NNP	O	O
:	:	O	O
the	DT	O	O
coadministration	NN	O	O
of	IN	O	O
phenytoin	NN	D	D
or	CC	O	O
phenobarbital	NN	D	D
will	MD	O	O
not	RB	O	O
affect	VB	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
vitamin	NN	O	G
d	NN	O	O
","	","	O	O
but	CC	O	O
may	MD	O	O
reduce	VB	O	O
endogenous	JJ	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
calcitriol/ergocalcitriol	NN	O	O
by	IN	O	O
accelerating	VBG	O	O
metabolism	NN	O	O
.	.	.	.

since	IN	O	O
blood	NN	O	O
level	NN	O	O
of	IN	O	O
calcitriol/ergocalcitriol	NN	O	O
will	MD	O	O
be	VB	O	O
reduced	VBN	O	O
","	","	O	O
higher	JJR	O	O
doses	NNS	O	O
of	IN	O	O
rocaltrol	NNP	B	B
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
if	IN	O	O
these	DT	O	O
drugs	NNS	D	D
are	VBP	O	O
administered	VBN	O	O
simultaneously	RB	O	O
.	.	.	.

thiazides	NNP	G	G
:	:	O	O
thiazides	NNS	G	G
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
induce	VB	O	O
hypercalcemia	NN	O	O
by	IN	O	O
the	DT	O	O
reduction	NN	O	O
of	IN	O	O
calcium	NN	D	D
excretion	NN	O	O
in	IN	O	O
urine	NN	O	O
.	.	.	.

some	DT	O	O
reports	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
thiazides	NNS	G	G
with	IN	O	O
vitamin	NN	O	G
d	NN	O	O
causes	VBZ	O	O
hypercalcemia	NN	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
precaution	NN	O	O
should	MD	O	O
be	VB	O	O
taken	VBN	O	O
when	WRB	O	O
coadministration	NN	O	O
is	VBZ	O	O
necessary	JJ	O	O
.	.	.	.

digitalis	NNP	G	G
:	:	O	O
vitamin	NN	O	O
d	NN	O	O
dosage	NN	O	O
must	MD	O	O
be	VB	O	O
determined	VBN	O	O
with	IN	O	O
care	NN	O	O
in	IN	O	O
patients	NNS	O	O
undergoing	VBG	O	O
treatment	NN	O	O
with	IN	O	O
digitalis	NN	G	G
","	","	O	O
as	IN	O	O
hypercalcemia	NN	O	O
in	IN	O	O
such	JJ	O	O
patients	NNS	O	O
may	MD	O	O
precipitate	VB	O	O
cardiac	JJ	O	O
arrhythmias	NNS	O	O
.	.	.	.

ketoconazole	NN	D	D
:	:	O	O
ketoconazole	NN	D	D
may	MD	O	O
inhibit	VB	O	O
both	DT	O	O
synthetic	JJ	O	O
and	CC	O	O
catabolic	JJ	O	O
enzymes	NNS	O	O
of	IN	O	O
vitamin	NN	O	G
d.	NNP	O	O
reductions	NNPS	O	O
in	IN	O	O
serum	NN	O	O
endogenous	JJ	O	O
vitamin	NN	O	G
d	NN	O	O
concentrations	NNS	O	O
have	VBP	O	O
been	VBN	O	O
observed	VBN	O	O
following	VBG	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
300	CD	O	O
mg/day	NN	O	O
to	TO	O	O
1200	CD	O	O
mg/day	NN	O	O
ketoconazole	NN	D	D
for	IN	O	O
a	DT	O	O
week	NN	O	O
to	TO	O	O
healthy	JJ	O	O
men	NNS	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
in	FW	O	O
vivo	FW	O	O
drug	NN	D	O
interaction	NN	O	O
studies	NNS	O	O
of	IN	O	O
ketoconazole	NN	D	D
with	IN	O	O
vitamin	NN	O	G
d	NN	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
investigated	VBN	O	O
.	.	.	.

corticosteroids	NNS	G	G
:	:	O	O
a	DT	O	O
relationship	NN	O	O
of	IN	O	O
functional	JJ	O	O
antagonism	NN	O	O
exists	VBZ	O	O
between	IN	O	O
vitamin	NN	O	G
d	NN	O	O
analogues	NNS	O	O
","	","	O	O
which	WDT	O	O
promote	VBP	O	O
calcium	NN	D	D
absorption	NN	O	O
","	","	O	O
and	CC	O	O
corticosteroids	NNS	G	G
","	","	O	O
which	WDT	O	O
inhibit	VBP	O	O
calcium	NN	D	D
absorption	NN	O	O
.	.	.	.

phosphate-binding	JJ	O	O
agents	NNS	O	O
:	:	O	O
since	IN	O	O
vitamin	NN	O	G
d	NN	O	O
also	RB	O	O
has	VBZ	O	O
an	DT	O	O
effect	NN	O	O
on	IN	O	O
phosphate	NN	D_n	D
transport	NN	O	O
in	IN	O	O
the	DT	O	O
intestine	NN	O	O
","	","	O	O
kidneys	NNS	O	O
and	CC	O	O
bones	NNS	O	O
","	","	O	O
the	DT	O	O
dosage	NN	O	O
of	IN	O	O
phosphate-binding	JJ	O	O
agents	NNS	O	O
must	MD	O	O
be	VB	O	O
adjusted	VBN	O	O
in	IN	O	O
accordance	NN	O	O
with	IN	O	O
the	DT	O	O
serum	NN	O	O
phosphate	NN	D_n	D
concentration	NN	O	O
.	.	.	.

vitamin	NN	O	O
d	NN	O	O
:	:	O	O
the	DT	O	O
coadministration	NN	O	O
of	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
vitamin	NN	O	G
d	NN	O	O
analogues	NNS	O	O
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
as	IN	O	O
this	DT	O	O
could	MD	O	O
create	VB	O	O
possible	JJ	O	O
additive	JJ	O	O
effects	NNS	O	O
and	CC	O	O
hypercalcemia	NN	O	O
.	.	.	.

calcium	NN	D	D
supplements	NNS	O	O
:	:	O	O
uncontrolled	JJ	O	O
intake	NN	O	O
of	IN	O	O
additional	JJ	O	O
calcium-containing	JJ	O	O
preparations	NNS	O	O
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
.	.	.	.

magnesium	NN	D	D
:	:	O	O
magnesium-containing	JJ	O	O
preparations	NNS	O	O
-lrb-	-LRB-	O	O
eg	FW	O	O
","	","	O	O
antacids	NNS	G	G
-rrb-	-RRB-	O	O
may	MD	O	O
cause	VB	O	O
hypermagnesemia	NN	O	O
and	CC	O	O
should	MD	O	O
therefore	RB	O	O
not	RB	O	O
be	VB	O	O
taken	VBN	O	O
during	IN	O	O
therapy	NN	O	O
with	IN	O	O
vitamin	NN	O	G
d	NN	O	O
by	IN	O	O
patients	NNS	O	O
on	IN	O	O
chronic	JJ	O	O
renal	JJ	O	O
dialysis	NN	O	O
.	.	.	.

cholestyramine	NNP	D	D
resin	NN	G	O
may	MD	O	O
delay	VB	O	O
or	CC	O	O
reduce	VB	O	O
the	DT	O	O
absorption	NN	O	O
of	IN	O	O
concomitant	JJ	O	O
oral	JJ	O	O
medication	NN	O	O
such	JJ	O	O
as	IN	O	O
phenylbutazone	NN	G	D
","	","	O	O
warfarin	NN	D	D
","	","	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
-lrb-	-LRB-	O	O
acidic	JJ	O	O
-rrb-	-RRB-	O	O
or	CC	O	O
propranolol	NN	D	D
-lrb-	-LRB-	O	O
basic	JJ	O	O
-rrb-	-RRB-	O	O
","	","	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
tetracycline	NN	D	O
penicillin	NN	D	O
g	NN	O	O
","	","	O	O
phenobarbital	NN	D	D
","	","	O	O
thyroid	NN	D	G
and	CC	O	O
thyroxine	NN	D	O
preparations	NNS	O	O
","	","	O	O
estrogens	NNS	G	G
and	CC	O	O
progestins	NNS	G	G
","	","	O	O
and	CC	O	O
digitalis	NN	G	G
.	.	.	.

interference	NN	O	O
with	IN	O	O
the	DT	O	O
absorption	NN	O	O
of	IN	O	O
oral	JJ	O	O
phosphate	NN	D_n	D
supplements	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
observed	VBN	O	O
with	IN	O	O
another	DT	O	O
positively-charged	JJ	O	O
bile	NN	O	O
acid	NN	O	O
sequestrant	NN	O	O
.	.	.	.

cholestyramine	NNP	D	D
resin	NN	G	O
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
drugs	NNS	D	D
that	WDT	O	O
undergo	VBP	O	O
enterohepatic	JJ	O	O
circulation	NN	O	O
","	","	O	O
the	DT	O	O
discontinuance	NN	O	O
of	IN	O	O
cholestyramine	NN	D	D
resin	NN	G	O
could	MD	O	O
pose	VB	O	O
a	DT	O	O
hazard	NN	O	O
to	TO	O	O
health	NN	O	O
if	IN	O	O
a	DT	O	O
potentially	RB	O	O
toxic	JJ	O	O
drug	NN	D	O
such	JJ	O	O
as	IN	O	O
digitalis	NN	G	G
has	VBZ	O	O
been	VBN	O	O
filtrated	VBN	O	O
to	TO	O	O
a	DT	O	O
maintenance	NN	O	O
level	NN	O	O
while	IN	O	O
the	DT	O	O
patient	NN	O	O
was	VBD	O	O
taking	VBG	O	O
cholestyramine	NN	D	D
resin	NN	G	O
.	.	.	.

because	IN	O	O
cholestyramine	NN	D	D
binds	VBZ	O	O
bile	NN	O	O
acids	NNS	O	O
","	","	O	O
cholestyramine	NN	D	D
resin	NN	G	G
may	MD	O	O
interfere	VB	O	O
with	IN	O	O
normal	JJ	O	O
fat	JJ	O	O
digestion	NN	O	O
and	CC	O	O
absorption	NN	O	O
and	CC	O	O
thus	RB	O	O
may	MD	O	O
prevent	VB	O	O
absorption	NN	O	O
of	IN	O	O
fat	JJ	O	O
soluble	JJ	O	O
vitamins	NNS	G	G
such	JJ	O	O
as	IN	O	O
a	DT	O	O
","	","	O	O
d	NN	O	O
","	","	O	O
e	NN	O	D
","	","	O	O
and	CC	O	O
k	NN	O	O
.	.	.	.

when	WRB	O	O
cholestyramine	NN	D	D
resin	NN	G	O
is	VBZ	O	O
given	VBN	O	O
for	IN	O	O
long	JJ	O	O
periods	NNS	O	O
of	IN	O	O
time	NN	O	O
","	","	O	O
concomitant	JJ	O	O
supplementation	NN	O	O
with	IN	O	O
water-miscible	JJ	O	O
-lrb-	-LRB-	O	O
or	CC	O	O
parenteral	JJ	O	O
-rrb-	-RRB-	O	O
forms	NNS	O	O
of	IN	O	O
fat-soluble	JJ	O	O
vitamins	NNS	G	G
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
.	.	.	.

since	IN	O	O
cholestyramine	NNP	D	B
resin	NNP	G	G
may	NNP	O	O
bind	VBP	O	O
other	JJ	O	O
drugs	NNS	O	D
given	VBP	O	O
concurrently	RB	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
recommended	NNP	O	O
that	WDT	O	O
patients	NNS	O	O
take	VBP	O	O
other	JJ	O	O
drugs	NNS	O	D
at	IN	O	O
least	NN	O	O
1	CD	O	O
hour	NN	O	O
before	IN	O	O
or	NN	O	O
4	CD	O	O
to	TO	O	O
6	CD	O	O
hours	NNS	O	O
after	IN	O	O
cholestyramine	NNP	D	D
resin	NNP	G	B
-lrb-	-LRB-	O	O
or	NN	O	O
at	IN	O	O
as	JJ	O	O
great	JJ	O	O
an	DT	O	O
interval	NNP	O	O
as	NNP	O	O
possible	NN	O	O
-rrb-	-RRB-	O	O
to	TO	O	O
avoid	VB	O	O
impeding	NNP	O	O
their	NNP	O	O
absorption	NNP	O	O
.	.	.	.

based	VBN	O	O
on	IN	O	O
in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
in	IN	O	O
human	JJ	O	O
liver	NN	O	O
microsomes	NNS	O	O
","	","	O	O
des-ciclesonide	NN	D	D
appears	VBZ	O	O
to	TO	O	O
have	VB	O	O
no	DT	O	O
inhibitory	JJ	O	O
or	CC	O	O
induction	NN	O	O
potential	NN	O	O
on	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
metabolized	VBN	O	O
by	IN	O	O
cyp	NN	O	O
450	CD	O	O
enzymes	NNS	O	O
.	.	.	.

the	DT	O	O
inhibitory	JJ	O	O
potential	NN	O	O
of	IN	O	O
ciclesonide	NN	D	D
on	IN	O	O
cyp450	NN	O	O
isoenzymes	NNS	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
.	.	.	.

in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
the	DT	O	O
plasma	NN	O	O
protein	NN	O	O
binding	NN	O	O
of	IN	O	O
des-ciclesonide	NN	D	D
was	VBD	O	O
not	RB	O	O
affected	VBN	O	O
by	IN	O	O
warfarin	NN	D	D
or	CC	O	O
salicylic	JJ	O	O
acid	NN	O	O
","	","	O	O
indicating	VBG	O	O
no	DT	O	O
potential	NN	O	O
for	IN	O	O
protein	NN	O	O
binding-based	JJ	O	O
drug	NN	D	O
interactions	NNS	O	O
.	.	.	.

in	IN	O	O
a	DT	O	O
drug	NN	D	O
interaction	NN	O	O
study	NN	O	O
","	","	O	O
co-administration	NN	O	O
of	IN	O	O
orally	RB	O	O
inhaled	VBN	O	O
ciclesonide	NN	D	D
and	CC	O	O
oral	JJ	O	O
erythromycin	NN	D	D
","	","	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
3a4	NN	O	O
","	","	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
either	CC	O	O
des-ciclesonide	NN	D	D
or	CC	O	O
erythromycin	NN	D	D
.	.	.	.

in	IN	O	O
another	DT	O	O
drug	NN	D	O
interaction	NN	O	O
study	NN	O	O
","	","	O	O
co-administration	NN	O	O
of	IN	O	O
orally	RB	O	O
inhaled	VBN	O	O
ciclesonide	NN	D	D
and	CC	O	O
oral	JJ	O	O
ketoconazole	NN	D	D
","	","	O	O
a	DT	O	O
potent	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
3a4	NN	O	O
","	","	O	O
increased	VBD	O	O
the	DT	O	O
exposure	NN	O	O
-lrb-	-LRB-	O	O
auc	NN	O	O
-rrb-	-RRB-	O	O
of	IN	O	O
des-ciclesonide	NN	D	D
by	IN	O	O
approximately	RB	O	O
3.6-fold	RB	O	O
at	IN	O	O
steady	JJ	O	O
state	NN	O	O
","	","	O	O
while	IN	O	O
levels	NNS	O	O
of	IN	O	O
ciclesonide	NN	D	D
remained	VBD	O	O
unchanged	JJ	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
ketoconazole	NN	D	D
should	MD	O	O
be	VB	O	O
administered	VBN	O	O
with	IN	O	O
caution	NN	O	O
with	IN	O	O
intranasal	JJ	O	O
ciclesonide	NN	D	O
.	.	.	.

probenecid	NNP	D	D
:	:	O	O
probenecid	NNP	D	D
is	VBZ	O	O
known	VBN	O	O
to	TO	O	O
interact	VB	O	O
with	IN	O	O
the	DT	O	O
metabolism	NN	O	O
or	CC	O	O
renal	JJ	O	O
tubular	JJ	O	O
excretion	NN	O	O
of	IN	O	O
many	JJ	O	O
drugs	NNS	D	D
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
acetaminophen	NN	D	D
","	","	O	O
acyclovir	NN	D	O
","	","	O	O
angiotensin-converting	JJ	O	O
enzyme	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
aminosalicylic	JJ	O	O
acid	NN	O	O
","	","	O	O
barbiturates	NNS	G	G
","	","	O	O
benzodiazepines	NNS	G	G
","	","	O	O
bumetanide	NN	D	D
","	","	O	O
clofibrate	NN	D	D
","	","	O	O
methotrexate	NN	D	D
","	","	O	O
famotidine	NN	D	D
","	","	O	O
furosemide	NN	D	D
","	","	O	O
nonsteroidal	JJ	O	O
anti-inflammatory	JJ	O	G
agents	NNS	O	O
","	","	O	O
theophylline	NN	D	D
","	","	O	O
and	CC	O	O
zidovudine	NN	D	D
-rrb-	-RRB-	O	O
.	.	.	.

concomitant	JJ	O	O
medications	NNS	O	O
should	MD	O	O
be	VB	O	O
carefully	RB	O	O
assessed	VBN	O	O
.	.	.	.

zidovudine	NN	D	D
should	MD	O	O
either	RB	O	O
be	VB	O	O
temporarily	RB	O	O
discontinued	VBN	O	O
or	CC	O	O
decreased	VBN	O	O
by	IN	O	O
50	CD	O	O
%	NN	O	O
when	WRB	O	O
coadministered	VBN	O	O
with	IN	O	O
probenecid	NN	D	D
on	IN	O	O
the	DT	O	O
day	NN	O	O
of	IN	O	O
vistide	NNP	B	B
infusion	NN	O	O
.	.	.	.

nephrotoxic	JJ	O	O
agents	NNS	O	O
:	:	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
vistide	NNP	B	B
and	CC	O	O
agents	NNS	O	O
with	IN	O	O
nephrotoxic	JJ	O	O
potential	JJ	O	O
-lsb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
intravenous	JJ	O	O
aminoglycosides	NNS	G	G
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
tobramycin	NN	D	D
","	","	O	O
gentamicin	NN	D	D
","	","	O	O
and	CC	O	O
amikacin	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
amphotericin	NN	O	D
b	NN	O	O
","	","	O	O
foscarnet	NN	D	D
","	","	O	O
intravenous	JJ	O	O
pentamidine	NN	D	D
","	","	O	O
vancomycin	NN	D	D
","	","	O	O
and	CC	O	O
non-steroidal	JJ	O	O
anti-inflammatory	JJ	O	G
agents	NNS	O	O
-rsb-	-RRB-	O	O
is	VBZ	O	O
contraindicated	VBN	O	O
.	.	.	.

such	JJ	O	O
agents	NNS	O	O
must	MD	O	O
be	VB	O	O
discontinued	VBN	O	O
at	IN	O	O
least	JJS	O	O
seven	CD	O	O
days	NNS	O	O
prior	RB	O	O
to	TO	O	O
starting	VBG	O	O
therapy	NN	O	O
with	IN	O	O
vistide	NN	B	D
.	.	.	.

since	IN	O	O
pletal	NN	B	D
is	VBZ	O	O
extensively	RB	O	O
metabolized	VBN	O	O
by	IN	O	O
cytochrome	NN	O	O
p-450	NN	O	O
isoenzymes	NNS	O	O
","	","	O	O
caution	NN	O	O
should	MD	O	O
be	VB	O	O
exercised	VBN	O	O
when	WRB	O	O
pletal	NNP	B	B
is	VBZ	O	O
coadministered	VBN	O	O
with	IN	O	O
inhibitors	NNS	O	O
of	IN	O	O
c.p.a.	NNP	O	O
such	JJ	O	O
as	IN	O	O
ketoconazole	NN	D	D
and	CC	O	O
erythromycin	NN	D	D
or	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
cyp2c19	NN	O	O
such	JJ	O	O
as	IN	O	O
omeprazole	NN	D	D
.	.	.	.

pharmacokinetic	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
demonstrated	VBN	O	O
that	IN	O	O
omeprazole	NN	D	D
and	CC	O	O
erythromycin	NN	D	D
significantly	RB	O	O
increased	VBD	O	O
the	DT	O	O
systemic	JJ	O	O
exposure	NN	O	O
of	IN	O	O
cilostazol	NN	D	D
and/or	CC	O	O
its	PRP$	O	O
major	JJ	O	O
metabolites	NNS	O	O
.	.	.	.

population	NNP	O	O
pharmacokinetic	JJ	O	O
studies	NNS	O	O
showed	VBD	O	O
higher	JJR	O	O
concentrations	NNS	O	O
of	IN	O	O
cilostazol	NN	D	D
among	IN	O	O
patients	NNS	O	O
concurrently	RB	O	O
treated	VBN	O	O
with	IN	O	O
diltiazem	NN	D	D
","	","	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
c.p.a.	NNP	O	O
pletal	NNP	B	D
does	VBZ	O	O
not	RB	O	O
","	","	O	O
however	RB	O	O
","	","	O	O
appear	VBP	O	O
to	TO	O	O
cause	VB	O	O
increased	VBN	O	O
blood	NN	O	O
levels	NNS	O	O
of	IN	O	O
drugs	NNS	D	D
metabolized	VBN	O	O
by	IN	O	O
cyp3a4	NN	D	D
","	","	O	O
as	IN	O	O
it	PRP	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
lovastatin	NN	D	D
","	","	O	O
a	DT	O	O
drug	NN	D	O
with	IN	O	O
metabolism	NN	O	O
very	RB	O	O
sensitive	JJ	O	O
to	TO	O	O
c.p.a.	NNP	O	O
inhibition	NN	O	O
.	.	.	.

tagamet	NNP	B	D
","	","	O	O
apparently	RB	O	O
through	IN	O	O
an	DT	O	O
effect	NN	O	O
on	IN	O	O
certain	JJ	O	O
microsomal	JJ	O	O
enzyme	NN	O	O
systems	NNS	O	O
","	","	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
reduce	VB	O	O
the	DT	O	O
hepatic	JJ	O	O
metabolism	NN	O	O
of	IN	O	O
warfarin-type	JJ	O	O
anticoagulants	NNS	G	G
","	","	O	O
phenytoin	NN	D	D
","	","	O	O
propranolol	NN	D	D
","	","	O	O
nifedipine	NN	D	D
","	","	O	O
chlordiazepoxide	NN	D	D
","	","	O	O
diazepam	NN	D	D
","	","	O	O
certain	JJ	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
","	","	O	O
lidocaine	NN	D	D
","	","	O	O
theophylline	NN	D	D
and	CC	O	O
metronidazole	NN	D	D
","	","	O	O
thereby	RB	O	O
delaying	VBG	O	O
elimination	NN	O	O
and	CC	O	O
increasing	VBG	O	O
blood	NN	O	O
levels	NNS	O	O
of	IN	O	O
these	DT	O	O
drugs	NNS	D	D
.	.	.	.

clinically	RB	O	O
significant	JJ	O	O
effects	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
with	IN	O	O
the	DT	O	O
warfarin	NN	D	D
anticoagulants	NNS	G	G
.	.	.	.

therefore	RB	O	O
","	","	O	O
close	JJ	O	O
monitoring	NN	O	O
of	IN	O	O
prothrombin	NN	O	O
time	NN	O	O
is	VBZ	O	O
recommended	VBN	O	O
","	","	O	O
and	CC	O	O
adjustment	NN	O	O
of	IN	O	O
the	DT	O	O
anticoagulant	JJ	G	G
dose	NN	O	O
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
when	WRB	O	O
tagamet	NNP	B	B
is	VBZ	O	O
administered	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

interaction	NN	O	O
with	IN	O	O
phenytoin	NN	D	D
","	","	O	O
lidocaine	NN	D	D
and	CC	O	O
theophylline	NN	D	D
has	VBZ	O	O
also	RB	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
produce	VB	O	O
adverse	JJ	O	O
clinical	JJ	O	O
effects	NNS	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
a	DT	O	O
crossover	NN	O	O
study	NN	O	O
in	IN	O	O
healthy	JJ	O	O
subjects	NNS	O	O
receiving	VBG	O	O
either	CC	O	O
tagamet	NNP	B	B
300	CD	O	O
mg	NN	O	O
q.i.d.	NN	O	O
or	CC	O	O
800	CD	O	O
mg	NN	O	O
h.s.	NN	O	O
concomitantly	RB	O	O
with	IN	O	O
a	DT	O	O
300	CD	O	O
mg	NN	O	O
b.i.d.	NN	O	O
dosage	NN	O	O
of	IN	O	O
theophylline	NN	D	D
-lrb-	-LRB-	O	O
theo-dur	NNP	B	B
","	","	O	O
key	NNP	O	O
pharmaceuticals	NNP	O	O
","	","	O	O
inc.	NNP	O	B
-rrb-	-RRB-	O	O
demonstrated	VBD	O	O
less	JJR	O	O
alteration	NN	O	O
in	IN	O	O
steady-state	JJ	O	O
theophylline	NN	D	D
peak	NN	O	O
serum	NN	O	O
levels	NNS	O	O
with	IN	O	O
the	DT	O	O
800	CD	O	O
mg	NN	O	O
h.s.	NN	O	O
regimen	NN	O	O
","	","	O	O
particularly	RB	O	O
in	IN	O	O
subjects	NNS	O	O
aged	JJ	O	O
54	CD	O	O
years	NNS	O	O
and	CC	O	O
older	JJR	O	O
.	.	.	.

data	NNS	O	O
beyond	IN	O	O
10	CD	O	O
days	NNS	O	O
are	VBP	O	O
not	RB	O	O
available	JJ	O	O
.	.	.	.

-lrb-	-LRB-	O	O
note	NN	O	O
:	:	O	O
all	DT	O	O
patients	NNS	O	O
receiving	VBG	O	O
theophylline	NN	D	D
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
appropriately	RB	O	O
","	","	O	O
regardless	RB	O	O
of	IN	O	O
concomitant	JJ	O	O
drug	NN	D	O
therapy	NN	O	O
.	.	.	.

dosage	NN	O	O
of	IN	O	O
the	DT	O	O
drugs	NNS	D	D
mentioned	VBN	O	O
above	IN	O	O
and	CC	O	O
other	JJ	O	O
similarly	RB	O	O
metabolized	VBN	O	O
drugs	NNS	D	D
","	","	O	O
particularly	RB	O	O
those	DT	O	O
of	IN	O	O
low	JJ	O	O
therapeutic	JJ	O	O
ratio	NN	O	O
or	CC	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
renal	JJ	O	O
and/or	CC	O	O
hepatic	JJ	O	O
impairment	NN	O	O
","	","	O	O
may	MD	O	O
require	VB	O	O
adjustment	NN	O	O
when	WRB	O	O
starting	VBG	O	O
or	CC	O	O
stopping	VBG	O	O
concomitantly	RB	O	O
administered	VBN	O	O
tagamet	NNP	B	B
to	TO	O	O
maintain	VB	O	O
optimum	JJ	O	O
therapeutic	JJ	O	O
blood	NN	O	O
levels	NNS	O	O
.	.	.	.

alteration	NN	O	O
of	IN	O	O
ph	NN	O	D
may	MD	O	O
affect	VB	O	O
absorption	NN	O	O
of	IN	O	O
certain	JJ	O	O
drugs	NNS	D	D
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
ketoconazole	NN	D	D
-rrb-	-RRB-	O	O
.	.	.	.

if	IN	O	O
these	DT	O	O
products	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
","	","	O	O
they	PRP	O	O
should	MD	O	O
be	VB	O	O
given	VBN	O	O
at	IN	O	O
least	JJS	O	O
2	CD	O	O
hours	NNS	O	O
before	IN	O	O
cimetidine	NN	D	D
administration	NN	O	O
.	.	.	.

additional	JJ	O	O
clinical	JJ	O	O
experience	NN	O	O
may	MD	O	O
reveal	VB	O	O
other	JJ	O	O
drugs	NNS	D	D
affected	VBN	O	O
by	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
tagamet	NNP	B	B
.	.	.	.

and/or	CC	O	O
drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
see	VB	O	O
clinical	NNP	O	O
pharmacology	NNP	O	O
","	","	O	O
pharmacokinetics	NNP	O	O
and	CC	O	O
drug	NNP	O	O
interactions	NNS	O	O
.	.	.	.

effect	NN	O	O
of	IN	O	O
sensipar	NN	B	D
on	IN	O	O
other	JJ	O	O
drugs	NNS	D	O
:	:	O	O
drugs	NNS	O	O
metabolized	VBN	O	O
by	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
2d6	NN	O	O
-lrb-	-LRB-	O	O
cyp2d6	NN	D	O
-rrb-	-RRB-	O	O
:	:	O	O
sensipar	NN	B	D
is	VBZ	O	O
a	DT	O	O
strong	JJ	O	O
in	FW	O	O
vitro	FW	O	O
inhibitor	NN	O	O
of	IN	O	O
cyp2d6	NN	D	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
dose	NN	O	O
adjustments	NNS	O	O
of	IN	O	O
concomitant	JJ	O	O
medications	NNS	O	O
that	WDT	O	O
are	VBP	O	O
predominantly	RB	O	O
metabolized	VBN	O	O
by	IN	O	O
cyp2d6	NN	D	O
and	CC	O	O
have	VBP	O	O
a	DT	O	O
narrow	JJ	O	O
therapeutic	JJ	O	O
index	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
flecainide	NN	D	D
","	","	O	O
vinblastine	NN	D	D
","	","	O	O
thioridazine	NN	D	D
and	CC	O	O
most	RBS	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
-rrb-	-RRB-	O	O
may	MD	O	O
be	VB	O	O
required	VBN	O	O
.	.	.	.

amitriptyline	NNP	D	D
:	:	O	O
concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
25	CD	O	O
mg	NN	O	O
or	CC	O	O
100	CD	O	O
mg	NN	O	O
cinacalcet	NN	D	O
with	IN	O	O
50	CD	O	O
mg	NN	O	O
amitriptyline	NNP	D	O
increased	VBD	O	O
amitriptyline	NNP	D	O
exposure	NN	O	O
and	CC	O	O
nortriptyline	NN	D_n	D
-lrb-	-LRB-	O	O
active	JJ	O	O
metabolite	NN	O	O
-rrb-	-RRB-	O	O
exposure	NN	O	O
by	IN	O	O
approximately	RB	O	O
20	CD	O	O
%	NN	O	O
in	IN	O	O
cyp2d6	NN	D	O
extensive	JJ	O	O
metabolizers	NNS	O	O
.	.	.	.

effect	NN	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
on	IN	O	O
sensipar	NNP	B	O
:	:	O	O
sensipar	NNP	B	D
is	VBZ	O	O
metabolized	VBN	O	O
by	IN	O	O
multiple	JJ	O	O
cytochrome	NN	O	O
p450	NN	O	O
enzymes	NNS	O	O
","	","	O	O
primarily	RB	O	O
cyp3a4	NN	D	D
","	","	O	O
cyp2d6	NN	D	O
","	","	O	O
and	CC	O	O
cyp1a2	NN	D	O
.	.	.	.

ketoconazole	NN	D	D
:	:	O	O
sensipar	NN	B	D
is	VBZ	O	O
metabolized	VBN	O	O
in	IN	O	O
part	NN	O	O
by	IN	O	O
cyp3a4	NN	D	D
.	.	.	.

co-administration	NN	O	O
of	IN	O	O
ketoconazole	NN	D	D
","	","	O	O
a	DT	O	O
strong	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
cyp3a4	NN	D	D
","	","	O	O
increased	VBD	O	O
cinacalcet	NN	D	D
exposure	NN	O	O
following	VBG	O	O
a	DT	O	O
single	JJ	O	O
90	CD	O	O
mg	NN	O	O
dose	NN	O	O
of	IN	O	O
sensipar	NN	B	D
by	IN	O	O
2.3	CD	O	O
fold	NN	O	O
.	.	.	.

dose	NN	O	O
adjustment	NN	O	O
of	IN	O	O
sensipar	NN	B	D
may	MD	O	O
be	VB	O	O
required	VBN	O	O
and	CC	O	O
pth	NN	O	O
and	CC	O	O
serum	NN	O	O
calcium	NN	D	D
concentrations	NNS	O	O
should	MD	O	O
be	VB	O	O
closely	RB	O	O
monitored	VBN	O	O
if	IN	O	O
a	DT	O	O
patient	NN	O	O
initiates	VBZ	O	O
or	CC	O	O
discontinues	VBZ	O	O
therapy	NN	O	O
with	IN	O	O
a	DT	O	O
strong	JJ	O	O
cyp3a4	NN	D	D
inhibitor	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
ketoconazole	NN	D	D
","	","	O	O
erythromycin	NN	D	D
","	","	O	O
itraconazole	NN	D	D
.	.	.	.

see	VB	O	O
dosage	NNP	O	O
and	CC	O	O
administration	NNP	O	O
-rrb-	-RRB-	O	O
.	.	.	.

elevated	JJ	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
theophylline	NN	D	D
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
with	IN	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
some	DT	O	O
quinolones	NNS	G	G
.	.	.	.

there	EX	O	O
have	VBP	O	O
been	VBN	O	O
reports	NNS	O	O
of	IN	O	O
theophylline-related	JJ	O	O
side-effects	NNS	O	O
in	IN	O	O
patients	NNS	O	O
on	IN	O	O
concomitant	JJ	O	O
theophylline-quinolone	JJ	O	O
therapy	NN	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
monitoring	NN	O	O
of	IN	O	O
theophylline	NN	D	D
plasma	NN	O	O
levels	NNS	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
and	CC	O	O
dosage	NN	O	O
of	IN	O	O
theophylline	NN	D	D
adjusted	VBN	O	O
as	IN	O	O
required	VBN	O	O
.	.	.	.

quinolones	NNS	G	G
have	VBP	O	O
also	RB	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
interfere	VB	O	O
with	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
caffeine	NN	D	D
.	.	.	.

this	DT	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
reduced	VBN	O	O
clearance	NN	O	O
of	IN	O	O
caffeine	NN	D	D
and	CC	O	O
a	DT	O	O
prolongation	NN	O	O
of	IN	O	O
its	PRP$	O	O
plasma	NN	O	O
half-life	NN	O	O
.	.	.	.

although	IN	O	O
this	DT	O	O
interaction	NN	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
reported	VBN	O	O
with	IN	O	O
cinoxacin	NN	D	D
","	","	O	O
caution	NN	O	O
should	MD	O	O
be	VB	O	O
exercised	VBN	O	O
when	WRB	O	O
cinoxacin	NN	D	D
is	VBZ	O	O
given	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
caffeine-containing	JJ	O	O
products	NNS	O	O
.	.	.	.

antacids	NNS	G	G
or	CC	O	O
sucralfate	NN	D	D
substantially	RB	O	O
interfere	VBP	O	O
with	IN	O	O
the	DT	O	O
absorption	NN	O	O
of	IN	O	O
some	DT	O	O
quinolones	NNS	G	G
","	","	O	O
resulting	VBG	O	O
in	IN	O	O
low	JJ	O	O
urine	NN	O	O
levels	NNS	O	O
.	.	.	.

also	RB	O	O
","	","	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
quinolones	NNS	G	G
with	IN	O	O
products	NNS	O	O
containing	VBG	O	O
iron	NN	D	D
","	","	O	O
multivitamins	NNS	G	G
containing	VBG	O	O
zinc	NN	D	D
","	","	O	O
or	CC	O	O
videx	NNP	B	B
-lrb-	-LRB-	O	O
didanosine	NN	D	D
-rrb-	-RRB-	O	O
chewable/buffered	VBD	O	O
tablets	NNS	O	O
or	CC	O	O
the	DT	O	O
pediatric	JJ	O	O
powder	NN	O	O
for	IN	O	O
oral	JJ	O	O
solution	NN	O	O
may	MD	O	O
result	VB	O	O
in	IN	O	O
low	JJ	O	O
urine	NN	O	O
levels	NNS	O	O
.	.	.	.

quinolones	NNP	G	G
","	","	O	O
including	VBG	O	O
cinoxacin	NN	D	D
","	","	O	O
may	MD	O	O
enhance	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
oral	JJ	O	O
anticoagulants	NNS	G	G
","	","	O	O
such	JJ	O	O
as	IN	O	O
warfarin	NN	D	D
or	CC	O	O
its	PRP$	O	O
derivatives	NNS	O	O
.	.	.	.

when	WRB	O	O
these	DT	O	O
products	NNS	O	O
are	VBP	O	O
administered	VBN	O	O
concomitantly	RB	O	O
","	","	O	O
prothrombin	NN	O	O
time	NN	O	O
or	CC	O	O
other	JJ	O	O
suitable	JJ	O	O
coagulation	NN	O	O
tests	NNS	O	O
should	MD	O	O
be	VB	O	O
closely	RB	O	O
monitored	VBN	O	O
.	.	.	.

seizures	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
patients	NNS	O	O
taking	VBG	O	O
another	DT	O	O
quinolone	NN	G	G
class	NN	O	O
antimicrobial	JJ	O	O
and	CC	O	O
the	DT	O	O
nonsteroidal	JJ	O	O
anti-inflammatory	JJ	O	G
drug	NN	D	O
fenbufen	NN	D	D
concurrently	RB	O	O
.	.	.	.

animal	NN	O	O
studies	NNS	O	O
also	RB	O	O
suggest	VBP	O	O
an	DT	O	O
increased	VBN	O	O
potential	NN	O	O
for	IN	O	O
seizures	NNS	O	O
when	WRB	O	O
these	DT	O	O
2	CD	O	O
drugs	NNS	D	D
are	VBP	O	O
given	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

fenbufen	NNP	D	D
is	VBZ	O	O
not	RB	O	O
approved	VBN	O	O
in	IN	O	O
the	DT	O	O
united	NNP	O	O
states	NNPS	O	O
at	IN	O	O
this	DT	O	O
time	NN	O	O
.	.	.	.

physicians	NNP	O	O
are	VBP	O	O
provided	VBN	O	O
this	DT	O	O
information	NN	O	O
to	TO	O	O
increase	VB	O	O
awareness	NN	O	O
of	IN	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
serious	JJ	O	O
interactions	NNS	O	O
when	WRB	O	O
cinoxacin	NN	D	D
and	CC	O	O
certain	JJ	O	O
nonsteroidal	JJ	O	O
anti-inflammatory	JJ	O	G
agents	NNS	O	O
are	VBP	O	O
administered	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

elevated	JJ	O	O
cyclosporine	NN	D	D
serum	NN	O	O
levels	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
with	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
quinolones	NNS	G	G
and	CC	O	O
cyclosporine	NN	D	D
.	.	.	.

some	DT	O	O
quinolones	NNS	G	G
","	","	O	O
including	VBG	O	O
ciprofloxacin	NN	D	D
","	","	O	O
have	VBP	O	O
also	RB	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
interfere	VB	O	O
with	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
caffeine	NN	D	D
.	.	.	.

this	DT	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
reduced	VBN	O	O
clearance	NN	O	O
of	IN	O	O
caffeine	NN	D	D
and	CC	O	O
a	DT	O	O
prolongation	NN	O	O
of	IN	O	O
its	PRP$	O	O
serum	NN	O	O
half-life	NN	O	O
.	.	.	.

some	DT	O	O
quinolones	NNS	G	G
","	","	O	O
including	VBG	O	O
ciprofloxacin	NN	D	D
","	","	O	O
have	VBP	O	O
been	VBN	O	O
associated	VBN	O	O
with	IN	O	O
transient	JJ	O	O
elevations	NNS	O	O
in	IN	O	O
serum	NN	O	O
creatinine	NN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
cyclosporine	NN	D	D
concomitantly	RB	O	O
.	.	.	.

glyburide	NNP	D	D
:	:	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
ciprofloxacin	NN	D	D
with	IN	O	O
the	DT	O	O
sulfonylurea	NN	G	G
glyburide	NN	D	D
has	VBZ	O	O
","	","	O	O
on	IN	O	O
rare	JJ	O	O
occasions	NNS	O	O
","	","	O	O
resulted	VBD	O	O
in	IN	O	O
severe	JJ	O	O
hypoglycemia	NN	O	O
.	.	.	.

histamine	NN	O	O
h2-receptor	NN	O	O
antagonists	NNS	O	O
:	:	O	O
histamine	NN	O	O
h2-receptor	NN	O	O
antagonists	NNS	O	O
appear	VBP	O	O
to	TO	O	O
have	VB	O	O
no	DT	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
ciprofloxacin	NN	D	D
.	.	.	.

methotrexate	NNP	D	D
renal	JJ	O	O
tubular	JJ	O	O
transport	NN	O	O
of	IN	O	O
methotrexate	NN	D	D
may	MD	O	O
be	VB	O	O
inhibited	VBN	O	O
by	IN	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
ciprofloxacin	NN	D	D
","	","	O	O
potentially	RB	O	O
leading	VBG	O	O
to	TO	O	O
increased	VBN	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
methotrexate	NN	D	D
.	.	.	.

this	DT	O	O
might	MD	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
methotrexate	NN	D	D
toxic	JJ	O	O
reactions	NNS	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
patients	NNS	O	O
under	IN	O	O
methotrexate	NN	D	D
therapy	NN	O	O
should	MD	O	O
be	VB	O	O
carefully	RB	O	O
monitored	VBN	O	O
when	WRB	O	O
concomitant	JJ	O	O
ciprofloxacin	NN	D	D
therapy	NN	O	O
is	VBZ	O	O
indicated	VBN	O	O
.	.	.	.

multivalent	JJ	O	O
cation-containing	NNP	O	O
products	NNPS	O	O
:	:	O	O
concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
a	DT	O	O
quinolone	NN	G	G
","	","	O	O
including	VBG	O	O
ciprofloxacin	NN	D	D
","	","	O	O
with	IN	O	O
multivalent	JJ	O	O
cation-containing	JJ	O	O
products	NNS	O	O
such	JJ	O	O
as	IN	O	O
magnesium	NN	D	D
or	CC	O	O
aluminum	NN	D	D
antacids	NNS	G	G
","	","	O	O
sucralfate	NN	D	D
","	","	O	O
videx	NNP	B	B
chewable/buffered	VBD	O	O
tablets	NNS	O	O
or	CC	O	O
pediatric	JJ	O	O
powder	NN	O	O
","	","	O	O
or	CC	O	O
products	NNS	O	O
containing	VBG	O	O
calcium	NN	D	D
","	","	O	O
iron	NN	D	D
","	","	O	O
or	CC	O	O
zinc	NN	D	D
may	MD	O	O
substantially	RB	O	O
decrease	VB	O	O
the	DT	O	O
absorption	NN	O	O
of	IN	O	O
ciprofloxacin	NN	D	D
","	","	O	O
resulting	VBG	O	O
in	IN	O	O
serum	NN	O	O
and	CC	O	O
urine	NN	O	O
levels	NNS	O	O
considerably	RB	O	O
lower	JJR	O	O
than	IN	O	O
desired	VBN	O	O
.	.	.	.

proquin	NNP	O	O
xr	NNP	O	O
should	MD	O	O
be	VB	O	O
administered	VBN	O	O
at	IN	O	O
least	JJS	O	O
4	CD	O	O
hours	NNS	O	O
before	IN	O	O
or	CC	O	O
2	CD	O	O
hours	NNS	O	O
after	IN	O	O
these	DT	O	O
products	NNS	O	O
.	.	.	.

this	DT	O	O
time	NN	O	O
window	NN	O	O
is	VBZ	O	O
different	JJ	O	O
than	IN	O	O
for	IN	O	O
other	JJ	O	O
oral	JJ	O	O
formulations	NNS	O	O
of	IN	O	O
ciprofloxacin	NN	D	D
","	","	O	O
which	WDT	O	O
are	VBP	O	O
usually	RB	O	O
administered	VBN	O	O
2	CD	O	O
hours	NNS	O	O
before	IN	O	O
or	CC	O	O
6	CD	O	O
hours	NNS	O	O
after	IN	O	O
antacids	NNS	G	G
.	.	.	.

non-steroidal	JJ	O	O
anti-inflammatory	JJ	O	O
drugs	NNS	D	D
-lrb-	-LRB-	O	O
but	CC	O	O
not	RB	O	O
aspirin	NN	B	B
-rrb-	-RRB-	O	O
:	:	O	O
these	DT	O	O
drugs	NNS	D	D
in	IN	O	O
combination	NN	O	O
with	IN	O	O
very	RB	O	O
high	JJ	O	O
doses	NNS	O	O
of	IN	O	O
quinolones	NNS	G	G
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
provoke	VB	O	O
convulsions	NNS	O	O
in	IN	O	O
pre-clinical	JJ	O	O
studies	NNS	O	O
.	.	.	.

omeprazole	NNP	D	D
:	:	O	O
the	DT	O	O
rate	NN	O	O
and	CC	O	O
extent	NN	O	O
of	IN	O	O
absorption	NN	O	O
of	IN	O	O
ciprofloxacin	NN	D	D
was	VBD	O	O
bioequivalent	JJ	O	O
when	WRB	O	O
proquin	NNP	O	O
xr	NNP	O	O
was	VBD	O	O
given	VBN	O	O
alone	RB	O	O
or	CC	O	O
when	WRB	O	O
proquin	NNP	O	O
xr	NNP	O	O
was	VBD	O	O
given	VBN	O	O
2	CD	O	O
hours	NNS	O	O
after	IN	O	O
omeprazole	NN	D	D
at	IN	O	O
the	DT	O	O
dose	NN	O	O
that	WDT	O	O
maximally	RB	O	O
suppresses	VBZ	O	O
gastric	JJ	O	O
acid	NN	O	O
secretion	NN	O	O
.	.	.	.

omeprazole	NNP	D	D
should	MD	O	O
be	VB	O	O
taken	VBN	O	O
as	IN	O	O
directed	VBN	O	O
and	CC	O	O
proquin	NNP	O	O
xr	NN	O	O
should	MD	O	O
be	VB	O	O
taken	VBN	O	O
with	IN	O	O
a	DT	O	O
main	JJ	O	O
meal	NN	O	O
of	IN	O	O
the	DT	O	O
day	NN	O	O
","	","	O	O
preferably	RB	O	O
the	DT	O	O
evening	NN	O	O
meal	NN	O	O
.	.	.	.

phenytoin	NNP	D	D
:	:	O	O
altered	JJ	O	O
serum	NN	O	O
levels	NNS	O	O
of	IN	O	O
phenytoin	NN	D	D
-lrb-	-LRB-	O	O
increased	VBN	O	O
and	CC	O	O
decreased	VBN	O	O
-rrb-	-RRB-	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
concomitant	JJ	O	O
ciprofloxacin	NN	D	D
.	.	.	.

probenecid	NNP	D	D
:	:	O	O
probenecid	NNP	D	D
interferes	VBZ	O	O
with	IN	O	O
renal	JJ	O	O
tubular	JJ	O	O
secretion	NN	O	O
of	IN	O	O
ciprofloxacin	NN	D	D
and	CC	O	O
produces	VBZ	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
level	NN	O	O
of	IN	O	O
ciprofloxacin	NN	D	D
in	IN	O	O
serum	NN	O	O
.	.	.	.

theophylline	NNP	D	D
:	:	O	O
as	IN	O	O
with	IN	O	O
some	DT	O	O
other	JJ	O	O
quinolones	NNS	G	G
","	","	O	O
concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
ciprofloxacin	NN	D	D
with	IN	O	O
theophylline	NN	D	D
may	MD	O	O
lead	VB	O	O
to	TO	O	O
elevated	JJ	O	O
serum	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
theophylline	NN	D	D
and	CC	O	O
prolongation	NN	O	O
of	IN	O	O
its	PRP$	O	O
elimination	NN	O	O
half-life	NN	O	O
.	.	.	.

this	DT	O	O
may	MD	O	O
result	VB	O	O
in	IN	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
theophylline-related	JJ	O	O
adverse	JJ	O	O
reactions	NNS	O	O
.	.	.	.

if	IN	O	O
concomitant	JJ	O	O
use	NN	O	O
can	MD	O	O
not	RB	O	O
be	VB	O	O
avoided	VBN	O	O
","	","	O	O
serum	NN	O	O
levels	NNS	O	O
of	IN	O	O
theophylline	NN	D	D
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
and	CC	O	O
dosage	NN	O	O
adjustments	NNS	O	O
made	VBN	O	O
as	IN	O	O
appropriate	JJ	O	O
.	.	.	.

warfarin	NNP	D	D
:	:	O	O
quinolones	NNS	G	G
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
enhance	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
oral	JJ	O	O
anticoagulant	JJ	G	G
warfarin	NN	D	D
or	CC	O	O
its	PRP$	O	O
derivatives	NNS	O	O
.	.	.	.

when	WRB	O	O
these	DT	O	O
products	NNS	O	O
are	VBP	O	O
administered	VBN	O	O
concomitantly	RB	O	O
","	","	O	O
prothrombin	NN	O	O
time	NN	O	O
or	CC	O	O
other	JJ	O	O
suitable	JJ	O	O
coagulation	NN	O	O
tests	NNS	O	O
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
.	.	.	.

cisapride	NNP	D	D
is	VBZ	O	O
metabolized	VBN	O	O
mainly	RB	O	O
via	IN	O	O
the	DT	O	O
cytochrome	NN	O	O
p450	NN	O	O
3a4	NN	O	O
enzyme	NN	O	O
.	.	.	.

in	IN	O	O
some	DT	O	O
cases	NNS	O	O
where	WRB	O	O
serious	JJ	O	O
ventricular	JJ	O	O
arrhythmias	NNS	O	O
","	","	O	O
qt	NN	O	O
prolongation	NN	O	O
","	","	O	O
and	CC	O	O
torsades	NNS	O	O
de	IN	O	O
pointes	NNS	O	O
have	VBP	O	O
occurred	VBN	O	O
when	WRB	O	O
cisapride	NN	D	D
was	VBD	O	O
taken	VBN	O	O
in	IN	O	O
conjunction	NN	O	O
with	IN	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
cytochrome	NN	O	O
p450	NN	O	O
3a4	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
elevated	JJ	O	O
blood	NN	O	O
cisapride	NN	D	D
levels	NNS	O	O
were	VBD	O	O
noted	VBN	O	O
at	IN	O	O
the	DT	O	O
time	NN	O	O
of	IN	O	O
the	DT	O	O
qt	NNP	O	O
prolongation	NN	O	O
.	.	.	.

antibiotics	NNS	G	G
:	:	O	O
in	FW	O	O
vitro	FW	O	O
and/or	CC	O	O
in	FW	O	O
vivo	FW	O	O
data	NNS	O	O
show	VBP	O	O
that	IN	O	O
clarithromycin	NN	D	D
","	","	O	O
erythromycin	NN	D	D
","	","	O	O
and	CC	O	O
troleandomycin	NN	D	D
markedly	RB	O	O
inhibit	VBP	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
cisapride	NN	D	D
","	","	O	O
which	WDT	O	O
can	MD	O	O
result	VB	O	O
in	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
cisapride	NN	D	D
levels	NNS	O	O
and	CC	O	O
prolongation	NN	O	O
of	IN	O	O
the	DT	O	O
qt	NNP	O	O
interval	NN	O	O
on	IN	O	O
the	DT	O	O
ecg	NN	O	O
.	.	.	.

anticholinergics	NNP	G	D
:	:	O	O
concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
certain	JJ	O	O
anticholinergic	JJ	G	G
compounds	NNS	O	O
","	","	O	O
such	JJ	O	O
as	IN	O	O
belladonna	NN	O	O
alkaloids	NNS	O	O
and	CC	O	O
dicyclomine	NN	D	O
","	","	O	O
would	MD	O	O
be	VB	O	O
expected	VBN	O	O
to	TO	O	O
compromise	VB	O	O
the	DT	O	O
beneficial	JJ	O	O
effects	NNS	O	O
of	IN	O	O
cisapride	NN	D	D
.	.	.	.

anticoagulants	NNS	G	G
-lrb-	-LRB-	O	O
oral	JJ	O	O
-rrb-	-RRB-	O	O
:	:	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
oral	JJ	O	O
anticoagulants	NNS	G	G
","	","	O	O
the	DT	O	O
coagulation	NN	O	O
times	NNS	O	O
were	VBD	O	O
increased	VBN	O	O
in	IN	O	O
some	DT	O	O
cases	NNS	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
advisable	JJ	O	O
to	TO	O	O
check	VB	O	O
coagulation	NN	O	O
time	NN	O	O
within	IN	O	O
the	DT	O	O
first	JJ	O	O
few	JJ	O	O
days	NNS	O	O
after	IN	O	O
the	DT	O	O
start	NN	O	O
and	CC	O	O
discontinuation	NN	O	O
of	IN	O	O
cisapride	NN	D	D
therapy	NN	O	O
","	","	O	O
with	IN	O	O
an	DT	O	O
appropriate	JJ	O	O
adjustment	NN	O	O
of	IN	O	O
the	DT	O	O
anticoagulant	JJ	G	G
dose	NN	O	O
","	","	O	O
if	IN	O	O
necessary	JJ	O	O
.	.	.	.

antidepressants	NNS	G	G
:	:	O	O
in	FW	O	O
vitro	FW	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
nefazodone	NN	D	D
inhibits	VBZ	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
cisapride	NN	D	D
","	","	O	O
which	WDT	O	O
can	MD	O	O
result	VB	O	O
in	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
cisapride	NN	D	D
levels	NNS	O	O
and	CC	O	O
prolongation	NN	O	O
of	IN	O	O
the	DT	O	O
qt	NNP	O	O
interval	NN	O	O
on	IN	O	O
the	DT	O	O
ecg	NN	O	O
.	.	.	.

antifungals	NNS	G	G
:	:	O	O
in	FW	O	O
vitro	FW	O	O
and/or	CC	O	O
in	FW	O	O
vivo	FW	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
fluconazole	NN	D	D
","	","	O	O
itraconazole	NN	D	D
","	","	O	O
and	CC	O	O
oral	JJ	O	O
ketoconazole	NN	D	D
markedly	RB	O	O
inhibit	VBP	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
cisapride	NN	D	D
","	","	O	O
which	WDT	O	O
can	MD	O	O
result	VB	O	O
in	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
cisapride	NN	D	D
levels	NNS	O	O
and	CC	O	O
prolongation	NN	O	O
of	IN	O	O
the	DT	O	O
qt	NNP	O	O
interval	NN	O	O
on	IN	O	O
the	DT	O	O
ecg	NN	O	O
.	.	.	.

human	JJ	O	O
pharmacokinetic	JJ	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
oral	JJ	O	O
ketoconazole	NN	D	D
markedly	RB	O	O
inhibits	VBZ	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
cisapride	NN	D	D
","	","	O	O
resulting	VBG	O	O
in	IN	O	O
a	DT	O	O
mean	NN	O	O
eight-fold	JJ	O	O
increase	NN	O	O
in	IN	O	O
auc	NN	O	O
of	IN	O	O
cisapride	NN	D	D
.	.	.	.

a	DT	O	O
study	NN	O	O
in	IN	O	O
14	CD	O	O
normal	JJ	O	O
male	NN	O	O
and	CC	O	O
female	JJ	O	O
volunteers	NNS	O	O
suggests	VBZ	O	O
that	IN	O	O
coadministration	NN	O	O
of	IN	O	O
cisapride	NN	D	D
and	CC	O	O
ketoconazole	NN	D	D
can	MD	O	O
result	VB	O	O
in	IN	O	O
prolongation	NN	O	O
of	IN	O	O
the	DT	O	O
qt	NNP	O	O
interval	NN	O	O
on	IN	O	O
the	DT	O	O
ecg	NN	O	O
.	.	.	.

h2	NN	O	O
receptor	NN	O	O
antagonists	NNS	O	O
:	:	O	O
cimetidine	NN	D	D
coadministration	NN	O	O
leads	VBZ	O	O
to	TO	O	O
an	DT	O	O
increased	VBN	O	O
peak	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
and	CC	O	O
auc	NN	O	O
of	IN	O	O
cisapride	NN	D	D
","	","	O	O
there	EX	O	O
is	VBZ	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
cisapride	NN	D	D
absorption	NN	O	O
when	WRB	O	O
it	PRP	O	O
is	VBZ	O	O
coadministered	VBN	O	O
with	IN	O	O
ranitidine	NN	D	D
.	.	.	.

the	DT	O	O
gastrointestinal	JJ	O	O
absorption	NN	O	O
of	IN	O	O
cimetidine	NN	D	D
and	CC	O	O
ranitidine	NN	D	D
is	VBZ	O	O
accelerated	VBN	O	O
when	WRB	O	O
they	PRP	O	O
are	VBP	O	O
coadministered	VBN	O	O
with	IN	O	O
cisapride	NN	D	D
.	.	.	.

protease	NN	O	O
inhibitors	NNS	O	O
:	:	O	O
in	FW	O	O
vitro	FW	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
indinavir	NN	D	D
and	CC	O	O
ritonavir	NN	D	D
markedly	RB	O	O
inhibit	VBP	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
cisapride	NN	D	D
which	WDT	O	O
can	MD	O	O
result	VB	O	O
in	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
cisapride	NN	D	D
levels	NNS	O	O
and	CC	O	O
prolongation	NN	O	O
of	IN	O	O
the	DT	O	O
qt	NNP	O	O
interval	NN	O	O
on	IN	O	O
the	DT	O	O
ecg	NN	O	O
.	.	.	.

other	JJ	O	O
:	:	O	O
coadministration	NN	O	O
of	IN	O	O
grapefruit	NN	O	O
juice	NN	O	O
with	IN	O	O
cisapride	NN	D	D
increases	VBZ	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
cisapride	NN	D	D
and	CC	O	O
concomitant	JJ	O	O
use	NN	O	O
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
.	.	.	.

cisapride	NNP	D	D
should	MD	O	O
not	RB	O	O
be	VB	O	O
used	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
known	VBN	O	O
to	TO	O	O
prolong	VB	O	O
the	DT	O	O
qt	NNP	O	O
interval	NN	O	O
:	:	O	O
certain	JJ	O	O
antiarrhythmics	NNS	G	G
","	","	O	O
including	VBG	O	O
those	DT	O	O
of	IN	O	O
class	NNP	O	O
ia	NNP	O	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
quinidine	NN	D	D
and	CC	O	O
procainamide	NN	D	D
-rrb-	-RRB-	O	O
and	CC	O	O
class	NN	O	O
iii	CD	O	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
sotalol	NN	D	O
-rrb-	-RRB-	O	O
.	.	.	.

tricyclic	JJ	O	O
antidepressants	NNS	G	G
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
amitriptyline	NNP	D	B
-rrb-	-RRB-	O	O
.	.	.	.

certain	JJ	O	O
tetracyclic	JJ	O	O
antidepressants	NNS	G	G
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
maprotiline	NN	D	O
-rrb-	-RRB-	O	O
.	.	.	.

certain	JJ	O	O
antipsychotic	JJ	O	O
medications	NNS	O	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
sertindole	NN	D	O
-rrb-	-RRB-	O	O
.	.	.	.

astemizole	NN	D	D
","	","	O	O
bepridil	NN	D	D
","	","	O	O
sparfloxacin	NN	D	D
","	","	O	O
and	CC	O	O
terodiline	NN	D	D
.	.	.	.

the	DT	O	O
preceding	VBG	O	O
lists	NNS	O	O
of	IN	O	O
drugs	NNS	D	D
are	VBP	O	O
not	RB	O	O
comprehensive	JJ	O	O
.	.	.	.

the	DT	O	O
acceleration	NN	O	O
of	IN	O	O
gastric	JJ	O	O
emptying	NN	O	O
by	IN	O	O
cisapride	NN	D	D
could	MD	O	O
affect	VB	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
absorption	NN	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
.	.	.	.

patients	NNS	O	O
receiving	VBG	O	O
narrow	JJ	O	O
therapeutic	JJ	O	O
ratio	NN	O	O
drugs	NNS	D	D
or	CC	O	O
other	JJ	O	O
drugs	NNS	D	D
that	WDT	O	O
require	VBP	O	O
careful	JJ	O	O
titration	NN	O	O
should	MD	O	O
be	VB	O	O
followed	VBN	O	O
closely	RB	O	O
;	:	O	O
.	.	.	.

if	IN	O	O
plasma	NN	O	O
levels	NNS	O	O
are	VBP	O	O
being	VBG	O	O
monitored	VBN	O	O
","	","	O	O
they	PRP	O	O
should	MD	O	O
be	VB	O	O
reassessed	VBN	O	O
.	.	.	.

administration	NN	O	O
of	IN	O	O
0.1-mg	JJ	O	O
/	:	O	O
kg	NN	O	O
-lrb-	-LRB-	O	O
2	CD	O	O
x	CC	O	O
ed95	NN	O	O
-rrb-	-RRB-	O	O
nimbex	NN	B	D
at	IN	O	O
10	CD	O	O
%	NN	O	O
or	CC	O	O
95	CD	O	O
%	NN	O	O
recovery	NN	O	O
following	VBG	O	O
an	DT	O	O
intubating	VBG	O	O
dose	NN	O	O
of	IN	O	O
succinylcholine	NN	D	D
-lrb-	-LRB-	O	O
1	CD	O	O
mg/kg	NN	O	O
-rrb-	-RRB-	O	O
produced	VBD	O	O
95	CD	O	O
%	NN	O	O
neuromuscular	JJ	O	O
block	NN	O	O
.	.	.	.

the	DT	O	O
time	NN	O	O
to	TO	O	O
onset	NN	O	O
of	IN	O	O
maximum	NN	O	O
block	NN	O	O
following	VBG	O	O
nimbex	NNP	B	B
is	VBZ	O	O
approximately	RB	O	O
2	CD	O	O
minutes	NNS	O	O
faster	RBR	O	O
with	IN	O	O
prior	JJ	O	O
administration	NN	O	O
of	IN	O	O
succinylcholine	NN	D	D
.	.	.	.

prior	RB	O	O
administration	NN	O	O
of	IN	O	O
succinylcholine	NN	D	D
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
duration	NN	O	O
of	IN	O	O
neuromuscular	JJ	O	O
block	NN	O	O
following	VBG	O	O
initial	JJ	O	O
or	CC	O	O
maintenance	NN	O	O
bolus	NN	O	O
doses	NNS	O	O
of	IN	O	O
nimbex	NNP	B	B
.	.	.	.

infusion	NN	O	O
requirements	NNS	O	O
of	IN	O	O
nimbex	NNP	B	B
in	IN	O	O
patients	NNS	O	O
administered	VBN	O	O
succinylcholine	NN	D	D
prior	RB	O	O
to	TO	O	O
infusions	NNS	O	O
of	IN	O	O
nimbex	NNP	B	B
were	VBD	O	O
comparable	JJ	O	O
to	TO	O	O
or	CC	O	O
slightly	RB	O	O
greater	JJR	O	O
than	IN	O	O
when	WRB	O	O
succinylcholine	NN	D	D
was	VBD	O	O
not	RB	O	O
administered	VBN	O	O
.	.	.	.

the	DT	O	O
use	NN	O	O
of	IN	O	O
nimbex	NN	B	O
before	IN	O	O
succinylcholine	NN	D	D
to	TO	O	O
attenuate	VB	O	O
some	DT	O	O
of	IN	O	O
the	DT	O	O
side	JJ	O	O
effects	NNS	O	O
of	IN	O	O
succinylcholine	NN	D	D
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
.	.	.	.

although	IN	O	O
not	RB	O	O
studied	VBN	O	O
systematically	RB	O	O
in	IN	O	O
clinical	JJ	O	O
trials	NNS	O	O
","	","	O	O
no	DT	O	O
drug	NN	D	O
interactions	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
when	WRB	O	O
vecuronium	NN	D	D
","	","	O	O
pancuronium	NN	D	D
","	","	O	O
or	CC	O	O
atracurium	NN	D	D
were	VBD	O	O
administered	VBN	O	O
following	VBG	O	O
varying	VBG	O	O
degrees	NNS	O	O
of	IN	O	O
recovery	NN	O	O
from	IN	O	O
single	JJ	O	O
doses	NNS	O	O
or	CC	O	O
infusions	NNS	O	O
of	IN	O	O
nimbex	NNP	B	B
.	.	.	.

isoflurane	NN	D	D
or	CC	O	O
enflurane	NN	D	D
administered	VBN	O	O
with	IN	O	O
nitrous	JJ	O	O
oxide/oxygen	NN	O	O
to	TO	O	O
achieve	VB	O	O
1.25	CD	O	O
mac	NNP	O	O
-lsb-	-LRB-	O	O
minimum	NNP	O	O
alveolar	JJ	O	O
concentration	NN	O	O
-rsb-	-RRB-	O	O
may	MD	O	O
prolong	VB	O	O
the	DT	O	O
clinically	RB	O	O
effective	JJ	O	O
duration	NN	O	O
of	IN	O	O
action	NN	O	O
of	IN	O	O
initial	JJ	O	O
and	CC	O	O
maintenance	NN	O	O
doses	NNS	O	O
of	IN	O	O
nimbex	NNP	B	B
and	CC	O	O
decrease	VB	O	O
the	DT	O	O
required	VBN	O	O
infusion	NN	O	O
rate	NN	O	O
of	IN	O	O
nimbex	NNP	B	B
.	.	.	.

the	DT	O	O
magnitude	NN	O	O
of	IN	O	O
these	DT	O	O
effects	NNS	O	O
may	MD	O	O
depend	VB	O	O
on	IN	O	O
the	DT	O	O
duration	NN	O	O
of	IN	O	O
administration	NN	O	O
of	IN	O	O
the	DT	O	O
volatile	JJ	O	O
agents	NNS	O	O
.	.	.	.

fifteen	CD	O	O
to	TO	O	O
30	CD	O	O
minutes	NNS	O	O
of	IN	O	O
exposure	NN	O	O
to	TO	O	O
1.25	CD	O	O
mac	NNP	O	O
isoflurane	NN	D	O
or	CC	O	O
enflurane	NN	D	D
had	VBD	O	O
minimal	JJ	O	O
effects	NNS	O	O
on	IN	O	O
the	DT	O	O
duration	NN	O	O
of	IN	O	O
action	NN	O	O
of	IN	O	O
initial	JJ	O	O
doses	NNS	O	O
of	IN	O	O
nimbex	NNP	B	B
and	CC	O	O
therefore	RB	O	O
","	","	O	O
no	DT	O	O
adjustment	NN	O	O
to	TO	O	O
the	DT	O	O
initial	JJ	O	O
dose	NN	O	O
should	MD	O	O
be	VB	O	O
necessary	JJ	O	O
when	WRB	O	O
nimbex	NNP	B	B
is	VBZ	O	O
administered	VBN	O	O
shortly	RB	O	O
after	IN	O	O
initiation	NN	O	O
of	IN	O	O
volatile	JJ	O	O
agents	NNS	O	O
.	.	.	.

in	IN	O	O
long	JJ	O	O
surgical	JJ	O	O
procedures	NNS	O	O
during	IN	O	O
enflurane	NN	D	D
or	CC	O	O
isoflurane	NN	D	D
anesthesia	NN	D	O
","	","	O	O
less	JJR	O	O
frequent	JJ	O	O
maintenance	NN	O	O
dosing	NN	O	O
","	","	O	O
lower	JJR	O	O
maintenance	NN	O	O
doses	NNS	O	O
","	","	O	O
or	CC	O	O
reduced	VBN	O	O
infusion	NN	O	O
rates	NNS	O	O
of	IN	O	O
nimbex	NNP	B	B
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
.	.	.	.

the	DT	O	O
average	JJ	O	O
infusion	NN	O	O
rate	NN	O	O
requirement	NN	O	O
may	MD	O	O
be	VB	O	O
decreased	VBN	O	O
by	IN	O	O
as	RB	O	O
much	JJ	O	O
as	IN	O	O
30	CD	O	O
%	NN	O	O
to	TO	O	O
40	CD	O	O
%	NN	O	O
.	.	.	.

in	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
propofol	NN	D	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
duration	NN	O	O
of	IN	O	O
action	NN	O	O
or	CC	O	O
dosing	NN	O	O
requirements	NNS	O	O
for	IN	O	O
nimbex	NNP	B	O
.	.	.	.

other	JJ	O	O
drugs	NNS	D	D
which	WDT	O	O
may	MD	O	O
enhance	VB	O	O
the	DT	O	O
neuromuscular	JJ	O	O
blocking	VBG	O	O
action	NN	O	O
of	IN	O	O
nondepolarizing	JJ	O	O
agents	NNS	O	O
such	JJ	O	O
as	IN	O	O
nimbex	NNP	B	B
include	VBP	O	O
certain	JJ	O	O
antibiotics	NNS	G	G
-lrb-	-LRB-	O	O
e.	FW	O	O
g.	FW	O	O
","	","	O	O
aminoglycosides	NNS	G	G
","	","	O	O
tetracyclines	NNS	G	G
","	","	O	O
bacitracin	NN	D	G
","	","	O	O
polymyxins	NNS	G	G
","	","	O	O
lincomycin	NN	D	D
","	","	O	O
clindamycin	NN	D	D
","	","	O	O
colistin	NN	D	D
","	","	O	O
and	CC	O	O
sodium	NN	O	O
colistemethate	NN	O	O
-rrb-	-RRB-	O	O
","	","	O	O
magnesium	NN	D	D
salts	NNS	O	O
","	","	O	O
lithium	NN	D	D
","	","	O	O
local	JJ	O	O
anesthetics	NNS	G	G
","	","	O	O
procainamide	NN	D	D
","	","	O	O
and	CC	O	O
quinidine	NN	D	D
.	.	.	.

resistance	NN	O	O
to	TO	O	O
the	DT	O	O
neuromuscular	JJ	O	O
blocking	VBG	O	O
action	NN	O	O
of	IN	O	O
nondepolarizing	JJ	O	O
neuromuscular	JJ	O	O
blocking	VBG	O	O
agents	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
demonstrated	VBN	O	O
in	IN	O	O
patients	NNS	O	O
chronically	RB	O	O
administered	VBN	O	O
phenytoin	NN	D	D
or	CC	O	O
carbamazepine	NN	D	D
.	.	.	.

while	IN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
chronic	JJ	O	O
phenytoin	NN	D	D
or	CC	O	O
carbamazepine	NN	D	D
therapy	NN	O	O
on	IN	O	O
the	DT	O	O
action	NN	O	O
of	IN	O	O
nimbex	NNP	B	B
are	VBP	O	O
unknown	JJ	O	O
","	","	O	O
slightly	RB	O	O
shorter	JJR	O	O
durations	NNS	O	O
of	IN	O	O
neuromuscular	JJ	O	O
block	NN	O	O
may	MD	O	O
be	VB	O	O
anticipated	VBN	O	O
and	CC	O	O
infusion	NN	O	O
rate	NN	O	O
requirements	NNS	O	O
may	MD	O	O
be	VB	O	O
higher	JJR	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
none	NN	O	O
known	VBN	O	O
.	.	.	.

plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
anticonvulsant	JJ	O	G
agents	NNS	O	O
may	MD	O	O
become	VB	O	O
subtherapeutic	JJ	O	O
during	IN	O	O
cisplatin	NN	D	D
therapy	NN	O	O
.	.	.	.

central	NNP	O	O
nervous	JJ	O	O
system	NN	O	O
depressant	NN	O	O
-lrb-	-LRB-	O	O
cns	NN	O	O
-rrb-	-RRB-	O	O
drugs	NNS	D	D
including	VBG	O	O
alcohol	NN	D	D
","	","	O	O
antidepressants	NNS	G	G
","	","	O	O
antihistamines	NNS	G	G
","	","	O	O
antipsychotics	NNS	G	G
","	","	O	O
blood	NN	O	O
pressure	NN	O	O
medications	NNS	O	O
-lrb-	-LRB-	O	O
reserpine	NN	D	D
","	","	O	O
methyldopa	NN	D	D
","	","	O	O
beta-blockers	NNS	G	G
-rrb-	-RRB-	O	O
","	","	O	O
motion	NN	O	O
sickness	NN	O	O
medications	NNS	O	O
","	","	O	O
muscle	NN	O	O
relaxants	NNS	O	O
","	","	O	O
narcotics	NNS	G	G
","	","	O	O
sedatives	NNS	G	G
","	","	O	O
sleeping	VBG	O	O
pills	NNS	O	O
and	CC	O	O
tranquilizer	NN	O	O
.	.	.	.

there	EX	O	O
are	VBP	O	O
no	RB	O	O
known	VBN	O	O
drug	NN	D	O
interactions	NNS	O	O
with	IN	O	O
leustatin	NNP	B	B
injection	NN	O	O
.	.	.	.

caution	NN	O	O
should	MD	O	O
be	VB	O	O
exercised	VBN	O	O
if	IN	O	O
leustatin	NNP	B	B
injection	NN	O	O
is	VBZ	O	O
administered	VBN	O	O
before	RB	O	O
","	","	O	O
after	IN	O	O
","	","	O	O
or	CC	O	O
in	IN	O	O
conjunction	NN	O	O
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
known	VBN	O	O
to	TO	O	O
cause	VB	O	O
immunosuppression	NN	O	O
or	CC	O	O
myelosuppression	NN	O	O
.	.	.	.

the	DT	O	O
concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
allopurinol	NN	D	D
and	CC	O	O
ampicillin	NN	D	D
increases	NNS	O	O
substantially	RB	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
rashes	NNS	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
both	CC	O	O
drugs	NNS	D	D
as	IN	O	O
compared	VBN	O	O
to	TO	O	O
patients	NNS	O	O
receiving	VBG	O	O
ampicillin	NN	D	D
alone	RB	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
whether	IN	O	O
this	DT	O	O
potentiation	NN	O	O
of	IN	O	O
ampicillin	NN	D	O
rashes	NNS	O	O
is	VBZ	O	O
due	JJ	O	O
to	TO	O	O
allopurinol	NN	D	D
or	CC	O	O
the	DT	O	O
hyperuricemia	NN	O	O
present	JJ	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	.	.

in	IN	O	O
controlled	JJ	O	O
clinical	JJ	O	O
trials	NNS	O	O
of	IN	O	O
augmentin	NNP	O	D
xr	NNP	O	O
","	","	O	O
22	CD	O	O
patients	NNS	O	O
received	VBD	O	O
concomitant	JJ	O	O
allopurinol	NN	D	D
and	CC	O	O
augmentin	NNP	O	O
xr	NNP	O	O
.	.	.	.

no	DT	O	O
rashes	NNS	O	O
were	VBD	O	O
reported	VBN	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
this	DT	O	O
sample	NN	O	O
size	NN	O	O
is	VBZ	O	O
too	RB	O	O
small	JJ	O	O
to	TO	O	O
allow	VB	O	O
for	IN	O	O
any	DT	O	O
conclusions	NNS	O	O
to	TO	O	O
be	VB	O	O
drawn	VBN	O	O
regarding	VBG	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
rashes	NNS	O	O
with	IN	O	O
concomitant	JJ	O	O
augmentin	NNP	O	B
xr	NN	O	O
and	CC	O	O
allopurinol	NN	D	D
use	NN	O	O
.	.	.	.

in	IN	O	O
common	JJ	O	O
with	IN	O	O
other	JJ	O	O
broad-spectrum	JJ	O	O
antibiotics	NNS	G	G
","	","	O	O
augmentin	NNP	O	O
xr	NNP	O	O
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
efficacy	NN	O	O
of	IN	O	O
oral	JJ	O	O
contraceptive	NN	O	G
.	.	.	.

additive	JJ	O	O
cns	NN	O	O
depression	NN	O	O
may	MD	O	O
occur	VB	O	O
when	WRB	O	O
antihistamines	NNS	G	G
are	VBP	O	O
administered	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
other	JJ	O	O
cns	NN	O	O
depressants	NNS	O	O
including	VBG	O	O
barbiturates	NNS	G	G
","	","	O	O
tranquilizers	NNS	G	G
","	","	O	O
and	CC	O	O
alcohol	NN	D	D
.	.	.	.

patients	NNS	O	O
receiving	VBG	O	O
antihistamines	NNS	G	G
should	MD	O	O
be	VB	O	O
advised	VBN	O	O
against	IN	O	O
the	DT	O	O
concurrent	JJ	O	O
use	NN	O	O
of	IN	O	O
other	JJ	O	O
cns	NNS	O	O
depressant	NN	O	O
drugs	NNS	D	D
.	.	.	.

monoamine	NN	O	O
oxidase	NN	O	O
-lrb-	-LRB-	O	O
mao	NN	O	O
-rrb-	-RRB-	O	O
inhibitors	NNS	O	O
prolong	VB	O	O
and	CC	O	O
intensify	VB	O	O
the	DT	O	O
anticholinergic	JJ	G	G
effects	NNS	O	O
of	IN	O	O
antihistamines	NNS	G	G
.	.	.	.

amantadine	NNP	D	D
","	","	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
","	","	O	O
and	CC	O	O
maois	NNS	G	G
may	MD	O	O
increase	VB	O	O
anticholinergic	JJ	G	G
effect	NN	O	O
of	IN	O	O
clidinium	NN	D	D
.	.	.	.

clidinium	NNP	D	D
may	MD	O	O
decrease	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
phenothiazines	NNS	G	G
","	","	O	O
levodopa	NN	D	D
","	","	O	O
and	CC	O	O
ketoconazole	NN	D	D
.	.	.	.

clindamycin	NNP	D	D
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
have	VB	O	O
neuromuscular	JJ	O	O
blocking	VBG	O	O
properties	NNS	O	O
that	WDT	O	O
may	MD	O	O
enhance	VB	O	O
the	DT	O	O
action	NN	O	O
of	IN	O	O
other	JJ	O	O
neuromuscular	JJ	O	O
blocking	VBG	O	O
agents	NNS	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
it	PRP	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
caution	NN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
such	JJ	O	O
agents	NNS	O	O
.	.	.	.

antagonism	NN	O	O
has	VBZ	O	O
been	VBN	O	O
demonstrated	VBN	O	O
between	IN	O	O
clindamycin	NN	D	D
and	CC	O	O
erythromycin	NN	D	D
in	FW	O	O
vitro	FW	O	O
.	.	.	.

because	IN	O	O
of	IN	O	O
possible	JJ	O	O
clinical	JJ	O	O
significance	NN	O	O
","	","	O	O
these	DT	O	O
two	CD	O	O
drugs	NNS	D	D
should	MD	O	O
not	RB	O	O
be	VB	O	O
administered	VBN	O	O
concurrently	RB	O	O
.	.	.	.

alcohol	NN	D	D
-lrb-	-LRB-	O	O
increases	NNS	O	O
bioavailability	NN	O	O
by	IN	O	O
50	CD	O	O
%	NN	O	O
-rrb-	-RRB-	O	O
","	","	O	O
cimetidine	NN	D	D
","	","	O	O
and	CC	O	O
valproates	NNS	O	G
.	.	.	.

no	DT	O	O
separate	JJ	O	O
information	NN	O	O
available	JJ	O	O
.	.	.	.

although	IN	O	O
no	DT	O	O
clinical	JJ	O	O
drug-drug	JJ	O	O
interaction	NN	O	O
studies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
conducted	VBN	O	O
to	TO	O	O
date	NN	O	D
","	","	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
the	DT	O	O
in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
","	","	O	O
cytochrome	NN	O	O
p450	NN	O	O
inhibitors	NNS	O	O
and	CC	O	O
inducers	NNS	O	O
are	VBP	O	O
unlikely	JJ	O	O
to	TO	O	O
affect	VB	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
clofarabine	NN	D	D
.	.	.	.

the	DT	O	O
effect	NN	O	O
of	IN	O	O
clofarabine	NN	D	D
on	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
substrates	NNS	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
studied	VBN	O	O
.	.	.	.

drug/laboratory	NNP	O	O
tests	NNP	O	O
interactions	NNS	O	O
there	EX	O	O
are	VBP	O	O
no	DT	O	O
known	JJ	O	O
clinically	RB	O	O
significant	JJ	O	O
interactions	NNS	O	O
of	IN	O	O
clolar	NN	B	B
with	IN	O	O
other	JJ	O	O
medications	NNS	O	O
or	CC	O	O
laboratory	NN	O	O
tests	NNS	O	O
.	.	.	.

no	DT	O	O
formal	JJ	O	O
drug/laboratory	JJ	O	O
test	NN	O	O
interaction	NN	O	O
studies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
conducted	VBN	O	O
with	IN	O	O
clolar	NN	B	B
.	.	.	.

preliminary	JJ	O	O
data	NNS	O	O
which	WDT	O	O
suggest	VBP	O	O
that	IN	O	O
dapsone	NN	D	D
may	MD	O	O
inhibit	VB	O	O
the	DT	O	O
anti-inflammatory	JJ	O	G
activity	NN	O	O
of	IN	O	O
lamprene	NNP	B	D
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
confirmed	VBN	O	O
.	.	.	.

if	IN	O	O
leprosy-associated	JJ	O	O
inflammatory	JJ	O	O
reactions	NNS	O	O
develop	VBP	O	O
in	IN	O	O
patients	NNS	O	O
being	VBG	O	O
treated	VBN	O	O
with	IN	O	O
dapsone	NN	D	D
and	CC	O	O
clofazimine	NN	D	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
still	RB	O	O
advisable	JJ	O	O
to	TO	O	O
continue	VB	O	O
treatment	NN	O	O
with	IN	O	O
both	CC	O	O
drugs	NNS	D	D
.	.	.	.

caution	NN	O	O
should	MD	O	O
be	VB	O	O
exercised	VBN	O	O
when	WRB	O	O
anticoagulants	NNS	G	G
are	VBP	O	O
given	VBN	O	O
in	IN	O	O
conjunction	NN	O	O
with	IN	O	O
atromid-s	NN	B	D
.	.	.	.

usually	RB	O	O
","	","	O	O
the	DT	O	O
dosage	NN	O	O
of	IN	O	O
the	DT	O	O
anticoagulant	NN	G	G
should	MD	O	O
be	VB	O	O
reduced	VBN	O	O
by	IN	O	O
one-half	NN	O	O
-lrb-	-LRB-	O	O
depending	VBG	O	O
on	IN	O	O
the	DT	O	O
individual	JJ	O	O
case	NN	O	O
-rrb-	-RRB-	O	O
to	TO	O	O
maintain	VB	O	O
the	DT	O	O
prothrombin	NN	O	O
time	NN	O	O
at	IN	O	O
the	DT	O	O
desired	VBN	O	O
level	NN	O	O
to	TO	O	O
prevent	VB	O	O
bleeding	JJ	O	O
complications	NNS	O	O
.	.	.	.

frequent	JJ	O	O
prothrombin	NN	O	O
determinations	NNS	O	O
are	VBP	O	O
advisable	JJ	O	O
until	IN	O	O
it	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
determined	VBN	O	O
definitely	RB	O	O
that	IN	O	O
the	DT	O	O
prothrombin	NN	O	O
level	NN	O	O
has	VBZ	O	O
been	VBN	O	O
stabilized	VBN	O	O
.	.	.	.

atromid-s	NN	B	D
may	MD	O	O
displace	VB	O	O
acidic	JJ	O	O
drugs	NNS	D	D
such	JJ	O	O
as	IN	O	O
phenytoin	NN	D	D
or	CC	O	O
tolbutamide	NN	D	D
from	IN	O	O
their	PRP$	O	O
binding	NN	O	O
sites	NNS	O	O
.	.	.	.

caution	NN	O	O
should	MD	O	O
be	VB	O	O
exercised	VBN	O	O
when	WRB	O	O
treating	VBG	O	O
patients	NNS	O	O
with	IN	O	O
either	DT	O	O
of	IN	O	O
these	DT	O	O
drugs	NNS	D	D
or	CC	O	O
other	JJ	O	O
highly	RB	O	O
protein-bound	JJ	O	O
drugs	NNS	D	D
and	CC	O	O
atromid-s	NN	B	O
.	.	.	.

the	DT	O	O
hypoglycemic	JJ	O	O
effect	NN	O	O
of	IN	O	O
tolbutamide	NN	D	D
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
increase	VB	O	O
when	WRB	O	O
atromid-s	NN	B	D
is	VBZ	O	O
given	VBN	O	O
concurrently	RB	O	O
.	.	.	.

fulminant	JJ	O	O
rhabdomyolysis	NN	O	O
has	VBZ	O	O
been	VBN	O	O
seen	VBN	O	O
as	IN	O	O
early	JJ	O	O
as	IN	O	O
three	CD	O	O
weeks	NNS	O	O
after	IN	O	O
initiation	NN	O	O
of	IN	O	O
combined	JJ	O	O
therapy	NN	O	O
with	IN	O	O
another	DT	O	O
fibrate	NN	G	O
and	CC	O	O
lovastatin	NN	D	D
but	CC	O	O
may	MD	O	O
be	VB	O	O
seen	VBN	O	O
after	IN	O	O
several	JJ	O	O
months	NNS	O	O
.	.	.	.

for	IN	O	O
these	DT	O	O
reasons	NNS	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
felt	VBN	O	O
that	IN	O	O
","	","	O	O
in	IN	O	O
most	JJS	O	O
subjects	NNS	O	O
who	WP	O	O
have	VBP	O	O
had	VBD	O	O
an	DT	O	O
unsatisfactory	JJ	O	O
lipid	NN	O	O
response	NN	O	O
to	TO	O	O
either	CC	O	O
drug	NN	D	O
alone	RB	O	O
","	","	O	O
the	DT	O	O
possible	JJ	O	O
benefits	NNS	O	O
of	IN	O	O
combined	JJ	O	O
therapy	NN	O	O
with	IN	O	O
lovastatin	NN	D	D
and	CC	O	O
a	DT	O	O
fibrate	NN	G	O
do	VBP	O	O
not	RB	O	O
outweigh	VB	O	O
the	DT	O	O
risks	NNS	O	O
of	IN	O	O
severe	JJ	O	O
myopathy	NN	O	O
","	","	O	O
rhabdomyolysis	NN	O	O
","	","	O	O
and	CC	O	O
acute	JJ	O	O
renal	JJ	O	O
failure	NN	O	O
.	.	.	.

while	IN	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
whether	IN	O	O
this	DT	O	O
interaction	NN	O	O
occurs	VBZ	O	O
with	IN	O	O
fibrates	NNS	G	O
other	JJ	O	O
than	IN	O	O
gemfibrozil	NN	D	D
","	","	O	O
myopathy	NN	O	O
and	CC	O	O
rhabdomyolysis	NN	O	O
have	VBP	O	O
occasionally	RB	O	O
been	VBN	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
fibrates	NNS	G	G
alone	RB	O	O
","	","	O	O
including	VBG	O	O
clofibrate	NN	D	D
.	.	.	.

therefore	RB	O	O
","	","	O	O
the	DT	O	O
combined	VBN	O	O
use	NN	O	O
of	IN	O	O
lovastatin	NN	D	D
with	IN	O	O
fibrates	NNS	G	G
should	MD	O	O
generally	RB	O	O
be	VB	O	O
avoided	VBN	O	O
.	.	.	.

drug	NN	O	O
interactions	NNS	O	O
with	IN	O	O
clomiphene	NN	O	O
citrate	NN	O	O
tablets	NNS	O	O
usp	NNP	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
documented	VBN	O	O
.	.	.	.

the	DT	O	O
risks	NNS	O	O
of	IN	O	O
using	VBG	O	O
anafranil	NNP	B	D
in	IN	O	O
combination	NN	O	O
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
systematically	RB	O	O
evaluated	VBN	O	O
.	.	.	.

given	VBN	O	O
the	DT	O	O
primary	JJ	O	O
cns	NN	O	O
effects	NNS	O	O
of	IN	O	O
anafranil	NNP	B	B
","	","	O	O
caution	NN	O	O
is	VBZ	O	O
advised	VBN	O	O
in	IN	O	O
using	VBG	O	O
it	PRP	O	O
concomitantly	RB	O	O
with	IN	O	O
other	JJ	O	O
cns-active	JJ	O	O
drugs	NNS	D	D
.	.	.	.

anafranil	NNP	B	B
should	MD	O	O
not	RB	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
mao	NN	O	O
inhibitors	NNS	O	O
.	.	.	.

close	JJ	O	O
supervision	NN	O	O
and	CC	O	O
careful	JJ	O	O
adjustment	NN	O	O
of	IN	O	O
dosage	NN	O	O
are	VBP	O	O
required	VBN	O	O
when	WRB	O	O
anafranil	NNP	B	B
is	VBZ	O	O
administered	VBN	O	O
with	IN	O	O
anticholinergic	JJ	G	G
or	CC	O	O
sympathomimetic	JJ	D	G
drugs	NNS	D	D
.	.	.	.

several	JJ	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
block	VB	O	O
the	DT	O	O
pharmacologic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
guanethidine	NN	D	D
","	","	O	O
clonidine	NN	D	D
","	","	O	O
or	CC	O	O
similar	JJ	O	O
agents	NNS	O	O
","	","	O	O
and	CC	O	O
such	PDT	O	O
an	DT	O	O
effect	NN	O	O
may	MD	O	O
be	VB	O	O
anticipated	VBN	O	O
with	IN	O	O
cmi	NN	D	D
because	IN	O	O
of	IN	O	O
its	PRP$	O	O
structural	JJ	O	O
similarity	NN	O	O
to	TO	O	O
other	JJ	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
.	.	.	.

the	DT	O	O
plasma	NN	O	O
concentration	NN	O	O
of	IN	O	O
cmi	NNP	D	B
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
be	VB	O	O
increased	VBN	O	O
by	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
haloperidol	NN	D	D
.	.	.	.

plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
several	JJ	O	O
closely	RB	O	O
related	JJ	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
be	VB	O	O
increased	VBN	O	O
by	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
methylphenidate	NN	D	D
or	CC	O	O
hepatic	JJ	O	O
enzyme	NN	O	O
inhibitors	NNS	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
cimetidine	NN	D	D
","	","	O	O
fluoxetine	NN	D	D
-rrb-	-RRB-	O	O
and	CC	O	O
decreased	VBN	O	O
by	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
hepatic	JJ	O	O
enzyme	NN	O	O
inducers	NNS	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
barbiturates	NNS	G	G
","	","	O	O
phenytoin	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
and	CC	O	O
such	PDT	O	O
an	DT	O	O
effect	NN	O	O
may	MD	O	O
be	VB	O	O
anticipated	VBN	O	O
with	IN	O	O
cmi	NNP	D	B
as	RB	O	O
well	RB	O	O
.	.	.	.

administration	NN	O	O
of	IN	O	O
cmi	NNP	D	B
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
increase	VB	O	O
the	DT	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
phenobarbital	NN	D	D
","	","	O	O
if	IN	O	O
given	VBN	O	O
concomitantly	RB	O	O
.	.	.	.

drugs	NNS	O	O
metabolized	VBN	O	O
by	IN	O	O
p450	NN	O	O
2d6	NN	O	O
:	:	O	O
the	DT	O	O
biochemical	JJ	O	O
activity	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	D	O
metabolizing	VBG	O	O
isozyme	NN	O	O
cytochrome	NN	O	O
p450	NN	O	O
2d6	NN	O	O
-lrb-	-LRB-	O	O
debrisoquin	NN	D	D
hydroxylase	NN	O	O
-rrb-	-RRB-	O	O
is	VBZ	O	O
reduced	VBN	O	O
in	IN	O	O
a	DT	O	O
subset	NN	O	O
of	IN	O	O
the	DT	O	O
aucasian	JJ	O	O
population	NN	O	O
-lrb-	-LRB-	O	O
about	IN	O	O
7	CD	O	O
%	NN	O	O
-10	CD	O	O
%	NN	O	O
of	IN	O	O
caucasians	NNPS	O	O
are	VBP	O	O
so-called	JJ	O	O
poor	JJ	O	O
metabolizers	NNS	O	O
-rrb-	-RRB-	O	O
;	:	O	O
.	.	.	.

reliable	JJ	O	O
estimates	NNS	O	O
of	IN	O	O
the	DT	O	O
prevalence	NN	O	O
of	IN	O	O
reduced	VBN	O	O
p450	NN	O	O
2d6	NN	O	O
isozyme	NN	O	O
activity	NN	O	O
among	IN	O	O
asian	JJ	O	O
","	","	O	O
african	JJ	O	O
and	CC	O	O
other	JJ	O	O
populations	NNS	O	O
are	VBP	O	O
not	RB	O	O
yet	RB	O	O
available	JJ	O	O
.	.	.	.

poor	NNP	O	O
metabolizers	NNS	O	O
have	VBP	O	O
higher	JJR	O	O
than	IN	O	O
expected	VBN	O	O
lasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
-lrb-	-LRB-	O	O
tcas	NNS	G	G
-rrb-	-RRB-	O	O
when	WRB	O	O
given	VBN	O	O
usual	JJ	O	O
doses	NNS	O	O
.	.	.	.

depending	VBG	O	O
on	IN	O	O
the	DT	O	O
fraction	NN	O	O
of	IN	O	O
drug	NN	D	O
metabolized	VBN	O	O
by	IN	O	O
p450	NN	O	O
2d6	NN	O	O
","	","	O	O
the	DT	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
concentration	NN	O	O
may	MD	O	O
be	VB	O	O
small	JJ	O	O
","	","	O	O
or	CC	O	O
quite	RB	O	O
large	JJ	O	O
-lrb-	-LRB-	O	O
8	CD	O	O
fold	JJ	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
auc	NN	O	O
of	IN	O	O
the	DT	O	O
tca	NNP	G	G
-rrb-	-RRB-	O	O
.	.	.	.

in	IN	O	O
addition	NN	O	O
","	","	O	O
certain	JJ	O	O
drugs	NNS	D	D
inhibit	VBP	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
this	DT	O	O
isozyme	NN	O	O
and	CC	O	O
make	VB	O	O
normal	JJ	O	O
metabolizers	NNS	O	O
resemble	VBP	O	O
poor	JJ	O	O
metabolizers	NNS	O	O
.	.	.	.

an	DT	O	O
individual	NN	O	O
who	WP	O	O
is	VBZ	O	O
stable	JJ	O	O
on	IN	O	O
a	DT	O	O
given	VBN	O	O
dose	NN	O	O
of	IN	O	O
tcamay	NN	O	D
become	VBP	O	O
abruptly	RB	O	O
toxic	JJ	O	O
when	WRB	O	O
given	VBN	O	O
one	CD	O	O
of	IN	O	O
these	DT	O	O
inhibiting	VBG	O	O
drugs	NNS	D	D
as	IN	O	O
concomitant	JJ	O	O
therapy	NN	O	O
.	.	.	.

the	DT	O	O
drugs	NNS	D	D
that	WDT	O	O
inhibit	VBP	O	O
cytochrome	NN	O	O
p450	NN	O	O
2d6	NN	O	O
include	VBP	O	O
some	DT	O	O
that	WDT	O	O
are	VBP	O	O
not	RB	O	O
metabolized	VBN	O	O
by	IN	O	O
the	DT	O	O
enzyme	NN	O	O
-lrb-	-LRB-	O	O
quinidine	NN	D	D
.	.	.	.

cimetidine	NN	D	D
-rrb-	-RRB-	O	O
and	CC	O	O
many	JJ	O	O
that	WDT	O	O
are	VBP	O	O
substrates	NNS	O	O
for	IN	O	O
p450	NN	O	O
2d6	NN	O	O
-lrb-	-LRB-	O	O
many	JJ	O	O
other	JJ	O	O
antidepressants	NNS	G	G
","	","	O	O
phenothiazines	NNS	G	G
","	","	O	O
and	CC	O	O
the	DT	O	O
type	NN	O	O
1c	NN	O	O
antiarrhythmics	NNS	G	G
propafenone	NN	D	D
and	CC	O	O
flecainide	NN	D	D
-rrb-	-RRB-	O	O
.	.	.	.

while	IN	O	O
all	PDT	O	O
the	DT	O	O
selective	JJ	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NNS	O	O
-lrb-	-LRB-	O	O
ssris	NNS	G	G
-rrb-	-RRB-	O	O
","	","	O	O
e.g.	FW	O	O
","	","	O	O
fluoxetine	NN	D	D
","	","	O	O
sertraline	NN	D	D
","	","	O	O
paroxetine	NN	D	D
","	","	O	O
and	CC	O	O
fluvoxamine	NN	D	D
","	","	O	O
inhibit	VBP	O	O
p450	NN	O	O
2d6	NN	O	O
","	","	O	O
they	PRP	O	O
may	MD	O	O
vary	VB	O	O
in	IN	O	O
the	DT	O	O
extent	NN	O	O
of	IN	O	O
inhibition	NN	O	O
.	.	.	.

fluvoxamine	NNP	D	D
has	VBZ	O	O
also	RB	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
inhibit	VB	O	O
p450	NN	O	O
1a2	NN	O	O
","	","	O	O
an	DT	O	O
isoform	NN	O	O
also	RB	O	O
involved	VBN	O	O
in	IN	O	O
tcametabolism	NN	O	O
.	.	.	.

the	DT	O	O
extent	NN	O	O
to	TO	O	O
which	WDT	O	O
ssri-tcainteractions	NNS	O	O
may	MD	O	O
pose	VB	O	O
clinical	JJ	O	O
problems	NNS	O	O
will	MD	O	O
depend	VB	O	O
on	IN	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
inhibition	NN	O	O
and	CC	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
the	DT	O	O
ssri	NNP	G	G
involved	VBN	O	O
.	.	.	.

nevertheless	RB	O	O
","	","	O	O
caution	NN	O	O
is	VBZ	O	O
indicated	VBN	O	O
in	IN	O	O
the	DT	O	O
co-administration	NN	O	O
of	IN	O	O
tcas	NNS	G	G
with	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
ssris	NNS	G	G
and	CC	O	O
also	RB	O	O
in	IN	O	O
switching	NN	O	O
from	IN	O	O
one	CD	O	O
class	NN	O	O
to	TO	O	O
the	DT	O	O
other	JJ	O	O
.	.	.	.

of	IN	O	O
particular	JJ	O	O
importance	NN	O	O
","	","	O	O
sufficient	JJ	O	O
time	NN	O	O
must	MD	O	O
elapse	VB	O	O
before	IN	O	O
initiating	VBG	O	O
tcatreatment	NN	O	O
in	IN	O	O
a	DT	O	O
patient	NN	O	O
being	VBG	O	O
withdrawn	VBN	O	O
from	IN	O	O
fluoxetine	NN	D	D
","	","	O	O
given	VBN	O	O
the	DT	O	O
long	JJ	O	O
half-life	NN	O	O
of	IN	O	O
the	DT	O	O
parent	NN	O	O
and	CC	O	O
active	JJ	O	O
metabolite	NN	O	O
-lrb-	-LRB-	O	O
at	IN	O	O
least	JJS	O	O
5	CD	O	O
weeks	NNS	O	O
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
-rrb-	-RRB-	O	O
.	.	.	.

concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
agents	NNS	O	O
in	IN	O	O
the	DT	O	O
tricyclic	JJ	O	G
antidepressant	JJ	O	G
class	NN	O	O
-lrb-	-LRB-	O	O
which	WDT	O	O
includes	VBZ	O	O
anafranil	NNP	B	O
-rrb-	-RRB-	O	O
with	IN	O	O
drugs	NNS	D	D
that	WDT	O	O
can	MD	O	O
inhibit	VB	O	O
cytochrome	NN	O	O
p450	NN	O	O
2d6	NN	O	O
may	MD	O	O
require	VB	O	O
lower	JJR	O	O
doses	NNS	O	O
than	IN	O	O
usually	RB	O	O
prescribed	VBN	O	O
for	IN	O	O
either	CC	O	O
the	DT	O	O
tricyclic	JJ	O	G
antidepressant	JJ	O	G
agent	NN	O	O
or	CC	O	O
the	DT	O	O
other	JJ	O	O
drug	NN	D	O
.	.	.	.

furthermore	RB	O	O
","	","	O	O
whenever	WRB	O	O
one	CD	O	O
of	IN	O	O
these	DT	O	O
drugs	NNS	D	D
is	VBZ	O	O
withdrawn	VBN	O	O
from	IN	O	O
co-therapy	JJ	O	O
","	","	O	O
an	DT	O	O
increased	VBN	O	O
dose	NN	O	O
of	IN	O	O
tricyclic	JJ	O	G
antidepressant	JJ	O	G
agent	NN	O	O
may	MD	O	O
be	VB	O	O
required	VBN	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
desirable	JJ	O	O
to	TO	O	O
monitor	VB	O	O
tcaplasma	NN	O	O
levels	NNS	O	O
whenever	WRB	O	O
an	DT	O	O
agent	NN	O	O
of	IN	O	O
the	DT	O	O
tricyclic	JJ	O	G
antidepressant	JJ	O	G
class	NN	O	O
including	VBG	O	O
anafranil	NNP	B	B
is	VBZ	O	O
going	VBG	O	O
to	TO	O	O
be	VB	O	O
co-administered	VBN	O	O
with	IN	O	O
another	DT	O	O
drug	NN	D	O
known	VBN	O	O
to	TO	O	O
be	VB	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
p450	NN	O	O
2d6	NN	O	O
-lrb-	-LRB-	O	O
and/or	CC	O	O
p450	NN	O	O
1a2	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

because	IN	O	O
anafranil	NNP	B	B
is	VBZ	O	O
highly	RB	O	O
bound	VBN	O	O
to	TO	O	O
serum	NN	O	O
protein	NN	O	O
","	","	O	O
the	DT	O	O
administration	NN	O	O
of	IN	O	O
anafranil	NNP	B	B
to	TO	O	O
patients	NNS	O	O
taking	VBG	O	O
other	JJ	O	O
drugs	NNS	D	D
that	WDT	O	O
are	VBP	O	O
highly	RB	O	O
bound	VBN	O	O
to	TO	O	O
protein	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
warfarin	NN	D	D
","	","	O	O
digoxin	NN	D	D
-rrb-	-RRB-	O	O
may	MD	O	O
cause	VB	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
these	DT	O	O
drugs	NNS	D	D
","	","	O	O
potentially	RB	O	O
resulting	VBG	O	O
in	IN	O	O
adverse	JJ	O	O
effects	NNS	O	O
.	.	.	.

conversely	RB	O	O
","	","	O	O
adverse	JJ	O	O
effects	NNS	O	O
may	MD	O	O
result	VB	O	O
from	IN	O	O
displacement	NN	O	O
of	IN	O	O
protein-bound	JJ	O	O
anafranil	NNP	B	B
by	IN	O	O
other	JJ	O	O
highly	RB	O	O
bound	VBN	O	O
drugs	NNS	D	D
.	.	.	.

effect	NN	O	O
of	IN	O	O
clonazepam	NNP	D	B
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	O	D
:	:	O	O
clonazepam	NN	D	D
does	VBZ	O	O
not	RB	O	O
appear	VB	O	O
to	TO	O	O
alter	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
phenytoin	NN	D	D
","	","	O	O
carbamazepine	NN	D	D
","	","	O	O
or	CC	O	O
phenobarbital	NN	D	D
.	.	.	.

the	DT	O	O
effect	NN	O	O
of	IN	O	O
clonazepam	NN	D	D
on	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
investigated	VBN	O	O
.	.	.	.

effect	NN	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	O	D
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
clonazepam	NNP	D	D
:	:	O	O
literature	NNP	O	O
reports	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
ranitidine	NN	D	D
","	","	O	O
an	DT	O	O
agent	NN	O	O
that	WDT	O	O
decreases	VBZ	O	O
stomach	NN	O	O
acidity	NN	O	O
","	","	O	O
does	VBZ	O	O
not	RB	O	O
greatly	RB	O	O
alter	VB	O	O
clonazepam	NN	D	D
pharmacokinetics	NNS	O	O
.	.	.	.

in	IN	O	O
a	DT	O	O
study	NN	O	O
in	IN	O	O
which	WDT	O	O
the	DT	O	O
2	CD	O	O
mg	NN	O	O
clonazepam	NN	D	O
orally	RB	O	O
disintegrating	VBG	O	O
tablet	NN	O	D
was	VBD	O	O
administered	VBN	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
propantheline	NN	D	D
-lrb-	-LRB-	O	O
an	DT	O	O
anticholinergic	JJ	G	G
agent	NN	O	O
with	IN	O	O
multiple	JJ	O	O
effects	NNS	O	O
on	IN	O	O
the	DT	O	O
gi	NN	O	O
tract	NN	O	O
-rrb-	-RRB-	O	O
to	TO	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
","	","	O	O
the	DT	O	O
auc	NN	O	O
of	IN	O	O
clonazepam	NN	D	D
was	VBD	O	O
10	CD	O	O
%	NN	O	O
lower	JJR	O	O
and	CC	O	O
the	DT	O	O
cmax	NN	O	O
of	IN	O	O
clonazepam	NN	D	D
was	VBD	O	O
20	CD	O	O
%	NN	O	O
lower	JJR	O	O
when	WRB	O	O
the	DT	O	O
orally	RB	O	O
disintegrating	VBG	O	O
tablet	NN	O	D
was	VBD	O	O
given	VBN	O	O
with	IN	O	O
propantheline	NN	D	D
compared	VBN	O	O
to	TO	O	O
when	WRB	O	O
it	PRP	O	O
was	VBD	O	O
given	VBN	O	O
alone	RB	O	O
.	.	.	.

fluoxetine	NN	D	D
does	VBZ	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
clonazepam	NN	D	D
.	.	.	.

cytochrome	NN	O	O
p-450	NN	O	O
inducers	NNS	O	O
","	","	O	O
such	JJ	O	O
as	IN	O	O
phenytoin	NN	D	D
","	","	O	O
carbamazepine	NN	D	D
and	CC	O	O
phenobarbital	NN	D	D
","	","	O	O
induce	VBP	O	O
clonazepam	NN	D	O
metabolism	NN	O	O
","	","	O	O
causing	VBG	O	O
an	DT	O	O
approximately	RB	O	O
30	CD	O	O
%	NN	O	O
decrease	NN	O	O
in	IN	O	O
plasma	NN	O	O
clonazepam	NN	D	O
levels	NNS	O	O
.	.	.	.

although	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
performed	VBN	O	O
","	","	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
the	DT	O	O
cytochrome	NN	O	O
p-450	NN	O	O
3a	NN	O	O
family	NN	O	O
in	IN	O	O
clonazepam	NN	D	O
metabolism	NN	O	O
","	","	O	O
inhibitors	NNS	O	O
of	IN	O	O
this	DT	O	O
enzyme	NN	O	O
system	NN	O	O
","	","	O	O
notably	RB	O	O
oral	JJ	O	O
antifungal	JJ	O	G
agents	NNS	O	O
","	","	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
cautiously	RB	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
clonazepam	NN	D	D
.	.	.	.

pharmacodynamic	JJ	O	O
interactions	NNS	O	O
:	:	O	O
the	DT	O	O
cns-depressant	JJ	O	O
action	NN	O	O
of	IN	O	O
the	DT	O	O
benzodiazepine	NN	G	O
class	NN	O	O
of	IN	O	O
drugs	NNS	D	D
may	MD	O	O
be	VB	O	O
potentiated	VBN	O	O
by	IN	O	O
alcohol	NN	D	D
","	","	O	O
narcotics	NNS	G	G
","	","	O	O
barbiturates	NNS	G	G
","	","	O	O
nonbarbiturate	JJ	O	O
hypnotics	NNS	O	O
","	","	O	O
antianxiety	JJ	O	O
agents	NNS	O	O
","	","	O	O
the	DT	O	O
phenothiazines	NNS	G	G
","	","	O	O
thioxanthene	NN	O	D
and	CC	O	O
butyrophenone	NN	O	O
classes	NNS	O	O
of	IN	O	O
antipsychotic	JJ	O	O
agents	NNS	O	O
","	","	O	O
monoamine	NN	O	O
oxidase	NN	O	O
inhibitors	NNS	O	O
and	CC	O	O
the	DT	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
","	","	O	O
and	CC	O	O
by	IN	O	O
other	JJ	O	O
anticonvulsant	JJ	O	G
drugs	NNS	D	D
.	.	.	.

tablet	NNP	O	O
if	IN	O	O
a	DT	O	O
patient	NN	O	O
receiving	VBG	O	O
clonidine	NN	D	D
hydrochloride	NN	O	O
is	VBZ	O	O
also	RB	O	O
taking	VBG	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
","	","	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
clonidine	NN	D	D
may	MD	O	O
be	VB	O	O
reduced	VBN	O	O
","	","	O	O
thus	RB	O	O
necessitating	VBG	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
dosage	NN	O	O
.	.	.	.

clonidine	NN	D	D
hydrochloride	NN	O	O
may	MD	O	O
enhance	VB	O	O
the	DT	O	O
cns-depressive	JJ	O	O
effects	NNS	O	O
of	IN	O	O
alcohol	NN	D	D
","	","	O	O
barbiturates	NNS	G	G
or	CC	O	O
other	JJ	O	O
sedatives	NNS	G	G
.	.	.	.

amitriptyline	NNP	D	D
in	IN	O	O
combination	NN	O	O
with	IN	O	O
clonidine	NN	D	D
enhances	VBZ	O	O
the	DT	O	O
manifestation	NN	O	O
of	IN	O	O
corneal	NN	O	O
lesions	NNS	O	O
in	IN	O	O
rats	NNS	O	O
epidural	JJ	O	O
injection	NN	O	O
clonidine	NN	D	O
may	MD	O	O
potentiate	VB	O	O
the	DT	O	O
cns-depressive	JJ	O	O
effect	NN	O	O
of	IN	O	O
alcohol	NN	D	D
","	","	O	O
barbiturates	NNS	G	G
or	CC	O	O
other	JJ	O	O
sedating	VBG	O	O
drugs	NNS	D	D
.	.	.	.

narcotic	JJ	O	O
analgesics	NNS	G	G
may	MD	O	O
potentiate	VB	O	O
the	DT	O	O
hypotensive	JJ	O	O
effects	NNS	O	O
of	IN	O	O
clonidine	NN	D	D
.	.	.	.

tricyclic	JJ	O	O
antidepressants	NNS	G	G
may	MD	O	O
antagonize	VB	O	O
the	DT	O	O
hypotensive	JJ	O	O
effects	NNS	O	O
of	IN	O	O
clonidine	NN	D	D
.	.	.	.

the	DT	O	O
effects	NNS	O	O
of	IN	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
on	IN	O	O
clonidines	NNS	O	O
analgesic	JJ	O	O
actions	NNS	O	O
are	VBP	O	O
not	RB	O	O
known	VBN	O	O
.	.	.	.

beta	NN	O	O
blockers	NNS	O	O
may	MD	O	O
exacerbate	VB	O	O
the	DT	O	O
hypertensive	JJ	O	O
response	NN	O	O
seen	VBN	O	O
with	IN	O	O
clonidine	NN	D	D
withdrawl	NN	O	O
.	.	.	.

also	RB	O	O
","	","	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
potential	NN	O	O
for	IN	O	O
additive	JJ	O	O
effects	NNS	O	O
such	JJ	O	O
as	IN	O	O
bradycardia	NN	O	O
and	CC	O	O
av	NN	O	O
block	NN	O	O
","	","	O	O
caution	NN	O	O
is	VBZ	O	O
warranted	VBN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
clonidine	NN	D	D
with	IN	O	O
agents	NNS	O	O
known	VBN	O	O
to	TO	O	O
affect	VB	O	O
sinus	NN	O	O
node	NN	O	O
function	NN	O	O
or	CC	O	O
av	NN	O	O
nodal	JJ	O	O
conduction	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
digitalis	NN	G	G
","	","	O	O
calcium	NN	D	D
channel	NN	O	O
blockers	NNS	O	O
","	","	O	O
and	CC	O	O
beta-blockers	NNS	G	G
.	.	.	.

there	EX	O	O
is	VBZ	O	O
one	CD	O	O
reported	VBD	O	O
case	NN	O	O
of	IN	O	O
a	DT	O	O
patient	NN	O	O
with	IN	O	O
acute	JJ	O	O
delirium	NN	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
simultaneous	JJ	O	O
use	NN	O	O
of	IN	O	O
fluphenazine	NN	D	D
and	CC	O	O
oral	JJ	O	O
clonidine	NN	D	D
.	.	.	.

symptoms	NNS	O	O
resolved	VBN	O	O
when	WRB	O	O
clonidine	NN	D	D
was	VBD	O	O
withdrawn	VBN	O	O
and	CC	O	O
recurred	VBN	O	O
when	WRB	O	O
the	DT	O	O
patient	NN	O	O
was	VBD	O	O
rechallenged	VBN	O	O
with	IN	O	O
clonidine	NN	D	D
.	.	.	.

epidural	JJ	O	O
clonidine	NN	D	O
may	MD	O	O
prolong	VB	O	O
the	DT	O	O
duration	NN	O	O
of	IN	O	O
pharmacologic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
epidural	JJ	O	O
local	JJ	O	O
anesthetics	NNS	G	G
","	","	O	O
including	VBG	O	O
both	DT	O	O
sensory	JJ	O	O
and	CC	O	O
motor	NN	O	O
blockade	NN	O	O
.	.	.	.

aspirin	NN	B	B
","	","	O	O
warfarin	NN	D	D
","	","	O	O
heparin	NN	D	D
","	","	O	O
nsaid	NN	O	O
if	IN	O	O
tranxene	NN	B	D
is	VBZ	O	O
to	TO	O	O
be	VB	O	O
combined	VBN	O	O
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
acting	VBG	O	O
on	IN	O	O
the	DT	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
","	","	O	O
careful	JJ	O	O
consideration	NN	O	O
should	MD	O	O
be	VB	O	O
given	VBN	O	O
to	TO	O	O
the	DT	O	O
pharmacology	NN	O	O
of	IN	O	O
the	DT	O	O
agents	NNS	O	O
to	TO	O	O
be	VB	O	O
employed	VBN	O	O
.	.	.	.

animal	NN	O	O
experience	NN	O	O
indicates	VBZ	O	O
that	IN	O	O
clorazepate	NN	O	O
dipotassium	NN	O	O
prolongs	VBZ	O	O
the	DT	O	O
sleeping	VBG	O	O
time	NN	O	O
after	IN	O	O
hexobarbital	JJ	D	O
or	CC	O	O
after	IN	O	O
ethyl	NN	O	O
alcohol	NN	D	D
","	","	O	O
increases	VBZ	O	O
the	DT	O	O
inhibitory	JJ	O	O
effects	NNS	O	O
of	IN	O	O
chlorpromazine	NN	D	D
","	","	O	O
but	CC	O	O
does	VBZ	O	O
not	RB	O	O
exhibit	VB	O	O
monoamine	NN	O	O
oxidase	NN	O	O
inhibition	NN	O	O
.	.	.	.

clinical	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
increased	VBN	O	O
sedation	NN	O	O
with	IN	O	O
concurrent	JJ	O	O
hypnotic	JJ	O	O
medications	NNS	O	O
.	.	.	.

the	DT	O	O
actions	NNS	O	O
of	IN	O	O
the	DT	O	O
benzodiazepines	NNS	G	G
may	MD	O	O
be	VB	O	O
potentiated	VBN	O	O
by	IN	O	O
barbiturates	NNS	G	G
","	","	O	O
narcotics	NNS	G	G
","	","	O	O
phenothiazines	NNS	G	G
","	","	O	O
monoamine	NN	O	O
oxidase	NN	O	O
inhibitors	NNS	O	O
or	CC	O	O
other	JJ	O	O
antidepressants	NNS	G	G
.	.	.	.

if	IN	O	O
tranxene	NN	B	D
tablets	NNS	O	O
are	VBP	O	O
used	VBN	O	O
to	TO	O	O
treat	VB	O	O
anxiety	NN	O	O
associated	VBN	O	O
with	IN	O	O
somatic	JJ	O	O
disease	NN	O	O
states	NNS	O	O
","	","	O	O
careful	JJ	O	O
attention	NN	O	O
must	MD	O	O
be	VB	O	O
paid	VBN	O	O
to	TO	O	O
possible	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
with	IN	O	O
concomitant	JJ	O	O
medication	NN	O	O
.	.	.	.

in	IN	O	O
bioavailability	NN	O	O
studies	NNS	O	O
with	IN	O	O
normal	JJ	O	O
subjects	NNS	O	O
","	","	O	O
the	DT	O	O
concurrent	JJ	O	O
administration	NN	O	O
of	IN	O	O
antacids	NNS	G	G
at	IN	O	O
therapeutic	JJ	O	O
levels	NNS	O	O
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
influence	VB	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
tranxene	NNP	B	B
tablets	NNS	O	O
.	.	.	.

the	DT	O	O
risks	NNS	O	O
of	IN	O	O
using	VBG	O	O
clozapine	NNP	D	D
in	IN	O	O
combination	NN	O	O
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
systematically	RB	O	O
evaluated	VBN	O	O
.	.	.	.

pharmacodynamic-related	JJ	O	O
interactions	NNS	O	O
:	:	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
clozapine	NN	D	D
induced	VBD	O	O
agranulocytosis	NN	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	.	.

nonetheless	RB	O	O
","	","	O	O
the	DT	O	O
possibility	NN	O	O
that	IN	O	O
causative	JJ	O	O
factors	NNS	O	O
may	MD	O	O
interact	VB	O	O
synergistically	RB	O	O
to	TO	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
and/or	CC	O	O
severity	NN	O	O
of	IN	O	O
bone	NN	O	O
marrow	NN	O	O
suppression	NN	O	O
warrants	NNS	O	O
consideration	NN	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
clozapine	NNP	D	B
should	MD	O	O
not	RB	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
other	JJ	O	O
agents	NNS	O	O
having	VBG	O	O
a	DT	O	O
well-known	JJ	O	O
potential	NN	O	O
to	TO	O	O
suppress	VB	O	O
bone	NN	O	O
marrow	NN	O	O
function	NN	O	O
.	.	.	.

given	VBN	O	O
the	DT	O	O
primary	JJ	O	O
cns	NN	O	O
effects	NNS	O	O
of	IN	O	O
clozapine	NNP	D	B
","	","	O	O
caution	NN	O	O
is	VBZ	O	O
advised	VBN	O	O
in	IN	O	O
using	VBG	O	O
it	PRP	O	O
concomitantly	RB	O	O
with	IN	O	O
other	JJ	O	O
cns-active	JJ	O	O
drugs	NNS	D	D
or	CC	O	O
alcohol	NN	D	D
.	.	.	.

orthostatic	JJ	O	O
hypotension	NN	O	O
in	IN	O	O
patients	NNS	O	O
taking	VBG	O	O
clozapine	NN	D	D
can	MD	O	O
","	","	O	O
in	IN	O	O
rare	JJ	O	O
cases	NNS	O	O
-lrb-	-LRB-	O	O
approximately	RB	O	O
1	CD	O	O
case	NN	O	O
per	IN	O	O
"3,000"	CD	O	O
patients	NNS	O	O
-rrb-	-RRB-	O	O
","	","	O	O
be	VB	O	O
accompanied	VBN	O	O
by	IN	O	O
profound	JJ	O	O
collapse	NN	O	O
and	CC	O	O
respiratory	JJ	O	O
and/or	CC	O	O
cardiac	JJ	O	O
arrest	NN	O	O
.	.	.	.

some	DT	O	O
of	IN	O	O
the	DT	O	O
cases	NNS	O	O
of	IN	O	O
collapse/respiratory	JJ	O	O
arrest/cardiac	JJ	O	O
arrest	NN	O	O
during	IN	O	O
initial	JJ	O	O
treatment	NN	O	O
occurred	VBD	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
were	VBD	O	O
being	VBG	O	O
administered	VBN	O	O
benzodiazepines	NNS	G	G
.	.	.	.

similar	JJ	O	O
events	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
patients	NNS	O	O
taking	VBG	O	O
other	JJ	O	O
psychotropic	JJ	O	O
drugs	NNS	D	D
or	CC	O	O
even	RB	O	O
clozapine	NNP	D	O
by	IN	O	O
itself	PRP	O	O
.	.	.	.

although	IN	O	O
it	PRP	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
established	VBN	O	O
that	IN	O	O
there	EX	O	O
is	VBZ	O	O
an	DT	O	O
interaction	NN	O	O
between	IN	O	O
clozapine	NNP	D	B
and	CC	O	O
benzodiazepines	NNS	G	G
or	CC	O	O
other	JJ	O	O
psychotropics	NNS	G	O
","	","	O	O
caution	NN	O	O
is	VBZ	O	O
advised	VBN	O	O
when	WRB	O	O
clozapine	NN	D	B
is	VBZ	O	O
initiated	VBN	O	O
in	IN	O	O
patients	NNS	O	O
taking	VBG	O	O
a	DT	O	O
benzodiazepine	NN	G	O
or	CC	O	O
any	DT	O	O
other	JJ	O	O
psychotropic	JJ	O	O
drug	NN	D	O
.	.	.	.

clozapine	NNP	D	B
may	MD	O	O
potentiate	VB	O	O
the	DT	O	O
hypotensive	JJ	O	O
effects	NNS	O	O
of	IN	O	O
antihypertensive	JJ	O	G
drugs	NNS	D	D
and	CC	O	O
the	DT	O	O
anticholinergic	JJ	G	G
effects	NNS	O	O
of	IN	O	O
atropine-type	JJ	O	O
drugs	NNS	D	D
.	.	.	.

the	DT	O	O
administration	NN	O	O
of	IN	O	O
epinephrine	NN	D	D
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
drug	NN	D	O
induced	VBD	O	O
hypotension	NN	O	O
because	IN	O	O
of	IN	O	O
a	DT	O	O
possible	JJ	O	O
reverse	JJ	O	O
epinephrine	NN	D	D
effect	NN	O	O
.	.	.	.

pharmacokinetic-related	JJ	O	O
interactions	NNS	O	O
:	:	O	O
clozapine	NNP	D	D
is	VBZ	O	O
a	DT	O	O
substrate	NN	O	O
for	IN	O	O
many	JJ	O	O
cyp	NN	O	O
450	CD	O	O
isozymes	NNS	O	O
","	","	O	O
in	IN	O	O
particular	JJ	O	O
1a2	NN	O	O
","	","	O	O
2d6	NN	O	O
","	","	O	O
and	CC	O	O
3a4	NN	O	O
.	.	.	.

the	DT	O	O
risk	NN	O	O
of	IN	O	O
metabolic	JJ	O	O
interactions	NNS	O	O
caused	VBN	O	O
by	IN	O	O
an	DT	O	O
effect	NN	O	O
on	IN	O	O
an	DT	O	O
individual	JJ	O	O
isoform	NN	O	O
is	VBZ	O	O
therefore	RB	O	O
minimized	VBN	O	O
.	.	.	.

nevertheless	RB	O	O
","	","	O	O
caution	NN	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
concomitant	JJ	O	O
treatment	NN	O	O
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
that	WDT	O	O
are	VBP	O	O
either	DT	O	O
inhibitors	NNS	O	O
or	CC	O	O
inducers	NNS	O	O
of	IN	O	O
these	DT	O	O
enzymes	NNS	O	O
.	.	.	.

concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
drugs	NNS	D	D
known	VBN	O	O
to	TO	O	O
induce	VB	O	O
cytochrome	NN	O	O
p450	NN	O	O
enzymes	NNS	O	O
may	MD	O	O
decrease	VB	O	O
the	DT	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
clozapine	NN	D	D
.	.	.	.

phenytoin	NNP	D	D
","	","	O	O
nicotine	NN	D	D
","	","	O	O
and	CC	O	O
rifampin	NN	D	D
may	MD	O	O
decrease	VB	O	O
clozapine	NNP	D	B
plasma	NN	O	O
levels	NNS	O	O
","	","	O	O
resulting	VBG	O	O
in	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
effectiveness	NN	O	O
of	IN	O	O
a	DT	O	O
previously	RB	O	O
effective	JJ	O	O
clozapine	NNP	D	B
dose	NN	O	O
.	.	.	.

concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
drugs	NNS	D	D
known	VBN	O	O
to	TO	O	O
inhibit	VB	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
isozymes	NNS	O	O
may	MD	O	O
increase	VB	O	O
the	DT	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
clozapine	NN	D	D
.	.	.	.

cimetidine	NNP	D	D
","	","	O	O
caffeine	NN	D	D
","	","	O	O
and	CC	O	O
erythromycin	NN	D	D
may	MD	O	O
increase	VB	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
clozapine	NNP	D	B
","	","	O	O
potentially	RB	O	O
resulting	VBG	O	O
in	IN	O	O
adverse	JJ	O	O
effects	NNS	O	O
.	.	.	.

although	IN	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
clozapine	NNP	D	B
and	CC	O	O
carbamazepine	NN	D	D
is	VBZ	O	O
not	RB	O	O
recommended	VBN	O	O
","	","	O	O
it	PRP	O	O
should	MD	O	O
be	VB	O	O
noted	VBN	O	O
that	IN	O	O
discontinuation	NN	O	O
of	IN	O	O
concomitant	JJ	O	O
carbamazepine	NN	D	D
administration	NN	O	O
may	MD	O	O
result	VB	O	O
in	IN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
clozapine	NNP	D	B
plasma	NN	O	O
levels	NNS	O	O
.	.	.	.

in	IN	O	O
a	DT	O	O
study	NN	O	O
of	IN	O	O
schizophrenic	JJ	O	O
patients	NNS	O	O
who	WP	O	O
received	VBD	O	O
clozapine	NN	D	O
under	IN	O	O
steady	JJ	O	O
state	NN	O	O
conditions	NNS	O	O
","	","	O	O
fluvoxamine	NN	D	D
or	CC	O	O
paroxetine	NN	D	D
was	VBD	O	O
added	VBN	O	O
in	IN	O	O
16	CD	O	O
and	CC	O	O
14	CD	O	O
patients	NNS	O	O
","	","	O	O
respectively	RB	O	O
.	.	.	.

after	IN	O	O
14	CD	O	O
days	NNS	O	O
of	IN	O	O
co-administration	NN	O	O
","	","	O	O
mean	VB	O	O
trough	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
clozapine	NN	D	D
and	CC	O	O
its	PRP$	O	O
metabolites	NNS	O	O
","	","	O	O
n-desmethylclozapine	NN	D_n	O
and	CC	O	O
clozapine	NN	D	O
n-oxide	NN	O	O
","	","	O	O
were	VBD	O	O
elevated	JJ	O	O
with	IN	O	O
fluvoxamine	NN	D	D
by	IN	O	O
about	IN	O	O
three-fold	JJ	O	O
compared	VBN	O	O
to	TO	O	O
baseline	NN	O	O
concentrations	NNS	O	O
.	.	.	.

paroxetine	NNP	D	D
produced	VBD	O	O
only	RB	O	O
minor	JJ	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
levels	NNS	O	O
of	IN	O	O
clozapine	NN	D	D
and	CC	O	O
its	PRP$	O	O
metabolites	NNS	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
other	JJ	O	O
published	VBN	O	O
reports	NNS	O	O
describe	VBP	O	O
modest	JJ	O	O
elevations	NNS	O	O
-lrb-	-LRB-	O	O
less	JJR	O	O
than	IN	O	O
two-fold	JJ	O	O
-rrb-	-RRB-	O	O
of	IN	O	O
clozapine	NN	D	D
and	CC	O	O
metabolite	NN	O	O
concentrations	NNS	O	O
when	WRB	O	O
clozapine	NN	D	D
was	VBD	O	O
taken	VBN	O	O
with	IN	O	O
paroxetine	NN	D	D
","	","	O	O
fluoxetine	NN	D	D
","	","	O	O
and	CC	O	O
sertraline	NN	D	D
.	.	.	.

therefore	RB	O	O
","	","	O	O
such	JJ	O	O
combined	JJ	O	O
treatment	NN	O	O
should	MD	O	O
be	VB	O	O
approached	VBN	O	O
with	IN	O	O
caution	NN	O	O
and	CC	O	O
patients	NNS	O	O
should	MD	O	O
be	VB	O	O
monitored	VBN	O	O
closely	RB	O	O
when	WRB	O	O
clozapine	NNP	D	B
is	VBZ	O	O
combined	VBN	O	O
with	IN	O	O
these	DT	O	O
drugs	NNS	D	D
","	","	O	O
particularly	RB	O	O
with	IN	O	O
fluvoxamine	NN	D	D
.	.	.	.

a	DT	O	O
reduced	VBN	O	O
clozapine	NNP	D	B
dose	NN	O	O
should	MD	O	O
be	VB	O	O
considered	VBN	O	O
.	.	.	.

a	DT	O	O
subset	NN	O	O
-lrb-	-LRB-	O	O
3	CD	O	O
%	NN	O	O
-10	CD	O	O
%	NN	O	O
-rrb-	-RRB-	O	O
of	IN	O	O
the	DT	O	O
population	NN	O	O
has	VBZ	O	O
reduced	VBN	O	O
activity	NN	O	O
of	IN	O	O
certain	JJ	O	O
drug	NN	D	O
metabolizing	VBG	O	O
enzymes	NNS	O	O
such	JJ	O	O
as	IN	O	O
the	DT	O	O
cytochrome	NN	O	O
p450	NN	O	O
isozyme	NN	O	O
p450	NN	O	O
2d6	NN	O	O
.	.	.	.

such	JJ	O	O
individuals	NNS	O	O
are	VBP	O	O
referred	VBN	O	O
to	TO	O	O
as	IN	O	O
poor	JJ	O	O
metabolizers	NNS	O	O
of	IN	O	O
drugs	NNS	D	D
such	JJ	O	O
as	IN	O	O
debrisoquin	NN	D	D
","	","	O	O
dextromethorphan	NN	D	D
","	","	O	O
the	DT	O	O
tricyclic	JJ	O	G
antidepressants	NNS	G	G
","	","	O	O
and	CC	O	O
clozapine	NN	D	D
.	.	.	.

these	DT	O	O
individuals	NNS	O	O
may	MD	O	O
develop	VB	O	O
higher	JJR	O	O
than	IN	O	O
expected	VBN	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
clozapine	NN	D	D
when	WRB	O	O
given	VBN	O	O
usual	JJ	O	O
doses	NNS	O	O
.	.	.	.

in	IN	O	O
addition	NN	O	O
","	","	O	O
certain	JJ	O	O
drugs	NNS	D	D
that	WDT	O	O
are	VBP	O	O
metabolized	VBN	O	O
by	IN	O	O
this	DT	O	O
isozyme	NN	O	O
","	","	O	O
including	VBG	O	O
many	JJ	O	O
antidepressants	NNS	G	G
-lrb-	-LRB-	O	O
clozapine	NN	D	D
","	","	O	O
selective	JJ	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
and	CC	O	O
others	NNS	O	O
-rrb-	-RRB-	O	O
","	","	O	O
may	MD	O	O
inhibit	VB	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
this	DT	O	O
isozyme	NN	O	O
","	","	O	O
and	CC	O	O
thus	RB	O	O
may	MD	O	O
make	VB	O	O
normal	JJ	O	O
metabolizers	NNS	O	O
resemble	VBP	O	O
poor	JJ	O	O
metabolizers	NNS	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
concomitant	JJ	O	O
therapy	NN	O	O
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
metabolized	VBN	O	O
by	IN	O	O
this	DT	O	O
enzyme	NN	O	O
system	NN	O	O
","	","	O	O
leading	VBG	O	O
to	TO	O	O
drug	NN	D	O
interaction	NN	O	O
.	.	.	.

concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
clozapine	NN	D	D
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
metabolized	VBN	O	O
by	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
2d6	NN	O	O
may	MD	O	O
require	VB	O	O
lower	JJR	O	O
doses	NNS	O	O
than	IN	O	O
usually	RB	O	O
prescribed	VBN	O	O
for	IN	O	O
either	CC	O	O
clozapine	NN	D	O
or	CC	O	O
the	DT	O	O
other	JJ	O	O
drug	NN	D	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
co-administration	NN	O	O
of	IN	O	O
clozapine	NN	D	D
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
that	WDT	O	O
are	VBP	O	O
metabolized	VBN	O	O
by	IN	O	O
this	DT	O	O
isozyme	NN	O	O
","	","	O	O
including	VBG	O	O
antidepressants	NNS	G	G
","	","	O	O
phenothiazines	NNS	G	G
","	","	O	O
carbamazepine	NN	D	D
","	","	O	O
and	CC	O	O
type	NN	O	O
1c	NN	O	O
antiarrhythmics	NNS	G	G
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
propafenone	NN	D	D
","	","	O	O
flecainide	NN	D	D
and	CC	O	O
encainide	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
or	CC	O	O
that	IN	O	O
inhibit	VBP	O	O
this	DT	O	O
enzyme	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
quinidine	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
should	MD	O	O
be	VB	O	O
approached	VBN	O	O
with	IN	O	O
caution	NN	O	O
.	.	.	.

the	DT	O	O
risk	NN	O	O
of	IN	O	O
a	DT	O	O
potential	JJ	O	O
interaction	NN	O	O
between	IN	O	O
novoseven	NNP	B	B
and	CC	O	O
coagulation	NN	O	O
factor	NN	O	O
concentrates	VBZ	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
adequately	RB	O	O
evaluated	VBN	O	O
in	IN	O	O
preclinical	JJ	O	O
or	CC	O	O
clinical	JJ	O	O
studies	NNS	O	O
.	.	.	.

simultaneous	JJ	O	O
use	NN	O	O
of	IN	O	O
activated	VBN	O	O
prothrombin	NN	O	O
complex	NN	O	O
concentrates	VBZ	O	O
or	CC	O	O
prothrombin	NN	O	O
complex	NN	O	O
concentrates	VBZ	O	O
should	MD	O	O
be	VB	O	O
avoided	VBN	O	O
.	.	.	.

although	IN	O	O
the	DT	O	O
specific	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
was	VBD	O	O
not	RB	O	O
studied	VBN	O	O
in	IN	O	O
a	DT	O	O
clinical	JJ	O	O
trial	NN	O	O
","	","	O	O
there	EX	O	O
have	VBP	O	O
been	VBN	O	O
more	JJR	O	O
than	IN	O	O
50	CD	O	O
episodes	NNS	O	O
of	IN	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
antifibrinolytic	JJ	O	O
therapies	NNS	O	O
-lrb-	-LRB-	O	O
i.e.	FW	O	O
","	","	O	O
tranexamic	JJ	O	O
acid	NN	O	O
","	","	O	O
aminocaproic	JJ	O	O
acid	NN	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
novoseven	NNP	B	O
.	.	.	.

novoseven	NNP	B	B
should	MD	O	O
not	RB	O	O
be	VB	O	O
mixed	VBN	O	O
with	IN	O	O
infusion	NN	O	O
solutions	NNS	O	O
until	IN	O	O
clinical	JJ	O	O
data	NNS	O	O
are	VBP	O	O
available	JJ	O	O
to	TO	O	O
direct	VB	O	O
this	DT	O	O
use	NN	O	O
.	.	.	.

codeine	NNP	D	D
in	IN	O	O
combination	NN	O	O
with	IN	O	O
other	JJ	O	O
narcotic	JJ	G	O
analgesics	NNS	G	G
","	","	O	O
general	JJ	O	O
anesthetics	NNS	G	G
","	","	O	O
phenothiazines	NNS	G	G
","	","	O	O
tranquilizers	NNS	G	G
","	","	O	O
sedative-hypnotics	NNS	G	G
","	","	O	O
or	CC	O	O
other	JJ	O	O
cns	NN	O	O
depressants	NNS	O	O
-lrb-	-LRB-	O	O
including	VBG	O	O
alcohol	NN	D	D
-rrb-	-RRB-	O	O
has	VBZ	O	O
additive	JJ	O	O
depressant	NN	O	O
effects	NNS	O	O
.	.	.	.

when	WRB	O	O
s.c.	NN	O	O
combination	NN	O	O
therapy	NN	O	O
is	VBZ	O	O
contemplated	VBN	O	O
","	","	O	O
the	DT	O	O
dosage	NN	O	O
of	IN	O	O
one	CD	O	O
or	CC	O	O
both	DT	O	O
agents	NNS	O	O
should	MD	O	O
be	VB	O	O
reduced	VBN	O	O
.	.	.	.

colchicine	NNP	D	D
is	VBZ	O	O
inhibited	VBN	O	O
by	IN	O	O
acidifying	VBG	O	O
agents	NNS	O	O
.	.	.	.

the	DT	O	O
action	NN	O	O
of	IN	O	O
colchicine	NN	D	D
is	VBZ	O	O
potentiated	VBN	O	O
by	IN	O	O
alkalinizing	VBG	O	O
agents	NNS	O	O
.	.	.	.

colchicine	NNP	D	D
may	MD	O	O
increase	VB	O	O
sensitivity	NN	O	O
to	TO	O	O
the	DT	O	O
cns	NN	O	O
depressants	NNS	O	O
.	.	.	.

response	NN	O	O
to	TO	O	O
sympathomimetic	JJ	D	G
agents	NNS	O	O
may	MD	O	O
be	VB	O	O
enhanced	VBN	O	O
by	IN	O	O
colchicine	NN	D	O
.	.	.	.

welchol	NNP	B	D
has	VBZ	O	O
been	VBN	O	O
studied	VBN	O	O
in	IN	O	O
several	JJ	O	O
human	JJ	O	O
drug	NN	D	O
interaction	NN	O	O
studies	NNS	O	O
in	IN	O	O
which	WDT	O	O
it	PRP	O	O
was	VBD	O	O
administered	VBN	O	O
with	IN	O	O
a	DT	O	O
meal	NN	O	O
and	CC	O	O
the	DT	O	O
test	NN	O	O
drug	NN	D	O
.	.	.	.

welchol	NNP	B	D
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
no	DT	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
digoxin	NN	D	D
","	","	O	O
lovastatin	NN	D	D
","	","	O	O
metoprolol	NN	D	D
","	","	O	O
quinidine	NN	D	D
","	","	O	O
valproic	JJ	O	O
acid	NN	O	O
","	","	O	O
and	CC	O	O
warfarin	NN	D	D
.	.	.	.

welchol	NNP	B	D
decreased	VBD	O	O
the	DT	O	O
cmax	NN	O	O
and	CC	O	O
auc	NN	O	O
of	IN	O	O
sustained-release	JJ	O	O
verapamil	NN	D	O
-lrb-	-LRB-	O	O
calan	JJ	O	O
sr	NN	O	O
-rrb-	-RRB-	O	O
by	IN	O	O
approximately	RB	O	O
31	CD	O	O
%	NN	O	O
and	CC	O	O
11	CD	O	O
%	NN	O	O
","	","	O	O
respectively	RB	O	O
.	.	.	.

since	IN	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
high	JJ	O	O
degree	NN	O	O
of	IN	O	O
variability	NN	O	O
in	IN	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
verapamil	NN	D	D
","	","	O	O
the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
this	DT	O	O
finding	NN	O	O
is	VBZ	O	O
unclear	JJ	O	O
.	.	.	.

increased	VBN	O	O
phenytoin	NNP	D	D
levels	NNP	O	O
should	MD	O	O
be	VB	O	O
treated	VBN	O	O
with	IN	O	O
appropriate	JJ	O	O
dosage	NN	O	O
adjustment	NN	O	O
.	.	.	.

it	PRP	O	O
may	MD	O	O
be	VB	O	O
necessary	JJ	O	O
to	TO	O	O
adjust	VB	O	O
the	DT	O	O
dosage	NN	O	O
of	IN	O	O
oral	JJ	O	O
anticoagulants	NNS	G	G
upon	IN	O	O
beginning	VBG	O	O
or	CC	O	O
stopping	VBG	O	O
disulfiram	NN	D	D
.	.	.	.

since	IN	O	O
disulfiram	NN	D	D
may	MD	O	O
prolong	VB	O	O
prothrombin	NN	O	O
time	NN	O	O
.	.	.	.

patients	NNS	O	O
taking	VBG	O	O
isoniazid	NN	D	D
when	WRB	O	O
disulfiram	NN	D	D
is	VBZ	O	O
given	VBN	O	O
should	MD	O	O
be	VB	O	O
observed	VBN	O	O
for	IN	O	O
the	DT	O	O
appearance	NN	O	O
of	IN	O	O
unsteady	JJ	O	O
gait	NN	O	O
or	CC	O	O
marked	JJ	O	O
changes	NNS	O	O
in	IN	O	O
mental	JJ	O	O
status	NN	O	O
.	.	.	.

the	DT	O	O
disulfiram	NN	D	O
should	MD	O	O
be	VB	O	O
discontinued	VBN	O	O
if	IN	O	O
such	JJ	O	O
signs	NNS	O	O
appear	VBP	O	O
.	.	.	.

in	IN	O	O
rats	NNS	O	O
","	","	O	O
simultaneous	JJ	O	O
ingestion	NN	O	O
of	IN	O	O
disulfiram	NN	D	D
and	CC	O	O
nitrite	NN	D	O
in	IN	O	O
the	DT	O	O
diet	NN	O	O
for	IN	O	O
78	CD	O	O
weeks	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
cause	VB	O	O
tumors	NNS	O	O
","	","	O	O
and	CC	O	O
it	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
suggested	VBN	O	O
that	IN	O	O
disulfiram	NN	D	D
may	MD	O	O
react	VB	O	O
with	IN	O	O
nitrites	NNS	G	O
in	IN	O	O
the	DT	O	O
rat	NN	O	O
stomach	NN	O	O
to	TO	O	O
form	VB	O	O
a	DT	O	O
nitrosamine	NN	O	O
","	","	O	O
which	WDT	O	O
is	VBZ	O	O
tumorigenic	JJ	O	O
.	.	.	.

disulfiram	NNP	D	D
alone	RB	O	O
in	IN	O	O
the	DT	O	O
rat	NN	O	O
s	VBZ	O	O
diet	NN	O	O
did	VBD	O	O
not	RB	O	O
lead	VB	O	O
to	TO	O	O
such	JJ	O	O
tumors	NNS	O	O
.	.	.	.

the	DT	O	O
relevance	NN	O	O
of	IN	O	O
this	DT	O	O
finding	NN	O	O
to	TO	O	O
humans	NNS	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
at	IN	O	O
this	DT	O	O
time	NN	O	O
.	.	.	.

animal	NN	O	O
studies	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
dobutamine	NN	D	D
may	MD	O	O
be	VB	O	O
ineffective	JJ	O	O
if	IN	O	O
the	DT	O	O
patient	NN	O	O
has	VBZ	O	O
recently	RB	O	O
received	VBN	O	O
a	DT	O	O
b-blocking	NN	O	O
drug	NN	D	O
.	.	.	.

in	IN	O	O
such	PDT	O	O
a	DT	O	O
case	NN	O	O
","	","	O	O
the	DT	O	O
peripheral	JJ	O	O
vascular	JJ	O	O
resistance	NN	O	O
may	MD	O	O
increase	VB	O	O
.	.	.	.

preliminary	JJ	O	O
studies	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
dobutamine	NN	D	D
and	CC	O	O
nitroprusside	JJ	D	O
results	NNS	O	O
in	IN	O	O
a	DT	O	O
higher	JJR	O	O
cardiac	JJ	O	O
output	NN	O	O
and	CC	O	O
","	","	O	O
usually	RB	O	O
","	","	O	O
a	DT	O	O
lower	JJR	O	O
pulmonary	JJ	O	O
wedge	NN	O	O
pressure	NN	O	O
than	IN	O	O
when	WRB	O	O
either	CC	O	O
drug	NN	D	O
is	VBZ	O	O
used	VBN	O	O
alone	RB	O	O
.	.	.	.

there	EX	O	O
was	VBD	O	O
no	DT	O	O
evidence	NN	O	O
of	IN	O	O
drug	NN	D	O
interactions	NNS	O	O
in	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
in	IN	O	O
which	WDT	O	O
dobutamine	NN	D	O
was	VBD	O	O
administered	VBN	O	O
concurrently	RB	O	O
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
","	","	O	O
including	VBG	O	O
digitalis	NN	G	G
preparations	NNS	O	O
","	","	O	O
furosemide	NN	D	D
","	","	O	O
spironolactone	NN	D	D
","	","	O	O
lidocaine	NN	D	D
","	","	O	O
glyceryl	NN	O	O
trinitrate	NN	O	O
","	","	O	O
isosorbide	NN	O	O
dinitrate	NN	O	O
","	","	O	O
morphine	NN	D	D
","	","	O	O
atropine	NN	D	D
","	","	O	O
heparin	NN	D	D
","	","	O	O
protamine	NN	D	O
","	","	O	O
potassium	NN	D	D
chloride	NN	O	O
","	","	O	O
folic	JJ	O	O
acid	NN	O	O
","	","	O	O
and	CC	O	O
acetaminophen	NN	D	D
.	.	.	.

there	EX	O	O
have	VBP	O	O
been	VBN	O	O
no	DT	O	O
formal	JJ	O	O
clinical	JJ	O	O
studies	NNS	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
drug	NN	D	O
interactions	NNS	O	O
of	IN	O	O
taxotere	NN	B	B
with	IN	O	O
other	JJ	O	O
medications	NNS	O	O
.	.	.	.

in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
docetaxel	NN	D	D
may	MD	O	O
be	VB	O	O
modified	VBN	O	O
by	IN	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
compounds	NNS	O	O
that	WDT	O	O
induce	VBP	O	O
","	","	O	O
inhibit	VBP	O	O
","	","	O	O
or	CC	O	O
are	VBP	O	O
metabolized	VBN	O	O
by	IN	O	O
cytochrome	NN	O	O
p450	NN	O	O
3a4	NN	O	O
","	","	O	O
such	JJ	O	O
as	IN	O	O
cyclosporine	NN	D	D
","	","	O	O
terfenadine	NN	D	D
","	","	O	O
ketoconazole	NN	D	D
","	","	O	O
erythromycin	NN	D	D
","	","	O	O
and	CC	O	O
troleandomycin	NN	D	D
.	.	.	.

caution	NN	O	O
should	MD	O	O
be	VB	O	O
exercised	VBN	O	O
with	IN	O	O
these	DT	O	O
drugs	NNS	D	D
when	WRB	O	O
treating	VBG	O	O
patients	NNS	O	O
receiving	VBG	O	O
taxotere	NN	B	O
as	IN	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
potential	NN	O	O
for	IN	O	O
a	DT	O	O
significant	JJ	O	O
interaction	NN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
none	NN	O	O
known	VBN	O	O
.	.	.	.

drug-drug	NNP	O	O
interactions	NNS	O	O
cimetidine	NNP	D	D
:	:	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
cimetidine	NN	D	D
is	VBZ	O	O
contraindicated	VBN	O	O
.	.	.	.

cimetidine	NN	D	D
at	IN	O	O
400	CD	O	O
mg	NN	O	O
bid	NNP	O	O
-lrb-	-LRB-	O	O
the	DT	O	O
usual	JJ	O	O
prescription	NN	O	O
dose	NN	O	O
-rrb-	-RRB-	O	O
co-administered	JJ	O	O
with	IN	O	O
tikosyn	NN	B	D
-lrb-	-LRB-	O	O
500	CD	O	O
mcg	NN	O	O
bid	NNP	O	O
-rrb-	-RRB-	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
increase	VB	O	O
dofetilide	NN	D	D
plasma	NN	O	O
levels	NNS	O	O
by	IN	O	O
58	CD	O	O
%	NN	O	O
.	.	.	.

cimetidine	NN	D	D
at	IN	O	O
doses	NNS	O	O
of	IN	O	O
100	CD	O	O
mg	NN	O	O
bid	NNP	O	O
-lrb-	-LRB-	O	O
otc	NNP	O	O
dose	NN	O	O
-rrb-	-RRB-	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
13	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
dofetilide	NN	D	D
plasma	NN	O	O
levels	NNS	O	O
-lrb-	-LRB-	O	O
500	CD	O	O
mcg	NN	O	O
single	JJ	O	O
dose	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

no	DT	O	O
studies	NNS	O	O
have	VBP	O	O
been	VBN	O	O
conducted	VBN	O	O
at	IN	O	O
intermediate	JJ	O	O
doses	NNS	O	O
of	IN	O	O
cimetidine	NN	D	D
.	.	.	.

if	IN	O	O
a	DT	O	O
patient	NN	O	O
requires	VBZ	O	O
tikosyn	NNP	B	O
and	CC	O	O
anti-ulcer	JJ	G	O
therapy	NN	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
suggested	VBN	O	O
that	IN	O	O
omeprazole	NN	D	D
","	","	O	O
ranitidine	NN	D	D
","	","	O	O
or	CC	O	O
antacids	NNS	G	G
-lrb-	-LRB-	O	O
aluminum	NN	D	D
and	CC	O	O
magnesium	NN	D	D
hydroxides	NNS	O	O
-rrb-	-RRB-	O	O
be	VB	O	O
used	VBN	O	O
as	IN	O	O
alternatives	NNS	O	O
to	TO	O	O
cimetidine	NN	D	D
","	","	O	O
as	IN	O	O
these	DT	O	O
agents	NNS	O	O
have	VBP	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
pharmacokinetic	JJ	O	O
profile	NN	O	O
of	IN	O	O
tikosyn	NNP	B	B
.	.	.	.

verapamil	NNP	D	D
:	:	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
verapamil	NN	D	D
is	VBZ	O	O
contraindicated	VBN	O	O
.	.	.	.

co-administration	NN	O	O
of	IN	O	O
tikosyn	NN	B	D
with	IN	O	O
verapamil	NN	D	D
resulted	VBD	O	O
in	IN	O	O
increases	NNS	O	O
in	IN	O	O
dofetilide	NN	D	O
peak	NN	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
42	CD	O	O
%	NN	O	O
","	","	O	O
although	IN	O	O
overall	JJ	O	O
exposure	NN	O	O
to	TO	O	O
dofetilide	NN	D	D
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
increased	VBN	O	O
.	.	.	.

in	IN	O	O
an	DT	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
supraventricular	JJ	O	O
arrhythmia	NN	O	O
and	CC	O	O
diamond	NN	O	O
patient	NN	O	O
populations	NNS	O	O
","	","	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
verapamil	NN	D	D
with	IN	O	O
dofetilide	NN	D	D
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
higher	JJR	O	O
occurrence	NN	O	O
of	IN	O	O
torsade	FW	O	O
de	FW	O	O
pointes	FW	O	O
.	.	.	.

ketoconazole	NN	D	D
:	:	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
ketoconazole	NN	D	D
is	VBZ	O	O
contraindicated	VBN	O	O
.	.	.	.

ketoconazole	NN	D	D
at	IN	O	O
400	CD	O	O
mg	NN	O	O
daily	JJ	O	O
-lrb-	-LRB-	O	O
the	DT	O	O
maximum	NN	O	O
approved	VBD	O	O
prescription	NN	O	D
dose	NN	O	O
-rrb-	-RRB-	O	O
co-administered	JJ	O	O
with	IN	O	O
tikosyn	NN	B	D
-lrb-	-LRB-	O	O
500	CD	O	O
mcg	NN	O	O
bid	NNP	O	O
-rrb-	-RRB-	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
increase	VB	O	O
dofetilide	NN	D	D
cmax	NN	O	O
by	IN	O	O
53	CD	O	O
%	NN	O	O
in	IN	O	O
males	NNS	O	O
and	CC	O	O
97	CD	O	O
%	NN	O	O
in	IN	O	O
females	NNS	O	O
","	","	O	O
and	CC	O	O
auc	NN	O	O
by	IN	O	O
41	CD	O	O
%	NN	O	O
in	IN	O	O
males	NNS	O	O
and	CC	O	O
69	CD	O	O
%	NN	O	O
in	IN	O	O
females	NNS	O	O
.	.	.	.

trimethoprim	NNP	D	D
alone	RB	O	O
or	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
sulfamethoxazole	NNP	D	B
:	:	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
trimethoprim	NN	D	D
alone	RB	O	O
or	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
sulfamethoxazole	NN	D	D
is	VBZ	O	O
contraindicated	VBN	O	O
.	.	.	.

hydrochlorothiazide	NN	D	D
-lrb-	-LRB-	O	O
hctz	NN	D	D
-rrb-	-RRB-	O	O
alone	RB	O	O
or	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
triamterene	NN	D	D
:	:	O	O
concomitant	JJ	O	O
use	NN	O	O
of	IN	O	O
hctz	NN	D	D
alone	RB	O	O
or	CC	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
triamterene	NN	D	D
is	VBZ	O	O
contraindicated	VBN	O	O
.	.	.	.

hctz	NN	D	D
50	CD	O	O
mg	NN	O	O
qd	NN	O	O
or	CC	O	O
hctz/triamterene	NN	O	D
50/100	CD	O	O
mg	NN	O	O
qd	NN	O	O
was	VBD	O	O
co-administered	VBN	O	O
with	IN	O	O
tikosyn	NN	B	D
-lrb-	-LRB-	O	O
500	CD	O	O
mcg	NN	O	O
bid	NNP	O	O
-rrb-	-RRB-	O	O
for	IN	O	O
5	CD	O	O
days	NNS	O	O
-lrb-	-LRB-	O	O
following	VBG	O	O
2	CD	O	O
days	NNS	O	O
of	IN	O	O
diuretic	JJ	G	G
use	NN	O	O
at	IN	O	O
half	NN	O	D
dose	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
hctz	NN	D	D
alone	RB	O	O
","	","	O	O
dofetilide	NN	D	O
auc	NN	O	O
increased	VBN	O	O
by	IN	O	O
27	CD	O	O
%	NN	O	O
and	CC	O	O
cmax	NN	O	O
by	IN	O	O
21	CD	O	O
%	NN	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
the	DT	O	O
pharmacodynamic	JJ	O	O
effect	NN	O	O
increased	VBN	O	O
by	IN	O	O
197	CD	O	O
%	NN	O	O
-lrb-	-LRB-	O	O
qtc	NN	O	O
increase	NN	O	O
over	IN	O	O
time	NN	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
by	IN	O	O
95	CD	O	O
%	NN	O	O
-lrb-	-LRB-	O	O
maximum	NN	O	O
qtc	NN	O	O
increase	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
the	DT	O	O
pharmacodynamic	JJ	O	O
effect	NN	O	O
increased	VBN	O	O
by	IN	O	O
190	CD	O	O
%	NN	O	O
-lrb-	-LRB-	O	O
qtc	NN	O	O
increase	NN	O	O
over	IN	O	O
time	NN	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
by	IN	O	O
84	CD	O	O
%	NN	O	O
-lrb-	-LRB-	O	O
maximum	NNP	O	O
qtc	NNP	O	O
increase	NN	O	O
-rrb-	-RRB-	O	O
.	.	.	.

the	DT	O	O
pharmacodynamic	JJ	O	O
effects	NNS	O	O
can	MD	O	O
be	VB	O	O
explained	VBN	O	O
by	IN	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
the	DT	O	O
increase	NN	O	O
in	IN	O	O
dofetilide	NN	D	O
exposure	NN	O	O
and	CC	O	O
the	DT	O	O
reductions	NNS	O	O
in	IN	O	O
serum	NN	O	O
potassium	NN	D	D
.	.	.	.

in	IN	O	O
the	DT	O	O
diamond	NN	O	O
trials	NNS	O	O
","	","	O	O
1252	CD	O	O
patients	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
tikosyn	NN	B	D
and	CC	O	O
diuretics	NNS	G	G
concomitantly	RB	O	O
of	IN	O	O
whom	WP	O	O
493	CD	O	O
died	VBD	O	O
compared	VBN	O	O
to	TO	O	O
508	CD	O	O
deaths	NNS	O	O
among	IN	O	O
the	DT	O	O
1248	CD	O	O
patients	NNS	O	O
receiving	VBG	O	O
placebo	NN	O	O
and	CC	O	O
diuretics	NNS	G	G
.	.	.	.

of	IN	O	O
the	DT	O	O
229	CD	O	O
patients	NNS	O	O
who	WP	O	O
had	VBD	O	O
potassium	NN	D	D
depleting	VBG	O	O
diuretics	NNS	G	G
added	VBD	O	O
to	TO	O	O
their	PRP$	O	O
concomitant	JJ	O	O
medications	NNS	O	O
in	IN	O	O
the	DT	O	O
diamond	NN	O	O
trials	NNS	O	O
","	","	O	O
the	DT	O	O
patients	NNS	O	O
on	IN	O	O
tikosyn	NNP	B	B
had	VBD	O	O
a	DT	O	O
non-significantly	JJ	O	O
reduced	VBN	O	O
relative	JJ	O	O
risk	NN	O	O
for	IN	O	O
death	NN	O	O
of	IN	O	O
0.68	CD	O	O
-lrb-	-LRB-	O	O
95	CD	O	O
%	NN	O	O
ci	NN	O	O
0.376	CD	O	O
","	","	O	O
1.23	CD	O	O
-rrb-	-RRB-	O	O
.	.	.	.

potential	JJ	O	O
drug	NN	O	O
interactions	NNS	O	O
dofetilide	NNP	D	B
is	VBZ	O	O
eliminated	VBN	O	O
in	IN	O	O
the	DT	O	O
kidney	NN	O	O
by	IN	O	O
cationic	JJ	O	O
secretion	NN	O	O
.	.	.	.

inhibitors	NNS	O	O
of	IN	O	O
renal	JJ	O	O
cationic	JJ	O	O
secretion	NN	O	O
are	VBP	O	O
contraindicated	VBN	O	O
with	IN	O	O
tikosyn	NN	B	O
.	.	.	.

in	IN	O	O
addition	NN	O	O
","	","	O	O
drugs	NNS	D	D
that	WDT	O	O
are	VBP	O	O
actively	RB	O	O
secreted	VBN	O	O
via	IN	O	O
this	DT	O	O
route	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
triamterene	NN	D	D
","	","	O	O
metformin	NN	D	D
and	CC	O	O
amiloride	NN	D	D
-rrb-	-RRB-	O	O
should	MD	O	O
be	VB	O	O
co-administered	VBN	O	O
with	IN	O	O
care	NN	O	O
as	IN	O	O
they	PRP	O	O
might	MD	O	O
increase	VB	O	O
dofetilide	NN	D	O
levels	NNS	O	O
.	.	.	.

dofetilide	NNP	D	D
is	VBZ	O	O
metabolized	VBN	O	O
to	TO	O	O
a	DT	O	O
small	JJ	O	O
extent	NN	O	O
by	IN	O	O
the	DT	O	O
cyp3a4	NN	D	D
isoenzyme	NN	O	O
of	IN	O	O
the	DT	O	O
cytochrome	NN	O	O
p450	NN	O	O
system	NN	O	O
.	.	.	.

inhibitors	NNS	O	O
of	IN	O	O
the	DT	O	O
cyp3a4	NN	D	D
isoenzyme	NN	O	O
could	MD	O	O
increase	VB	O	O
systemic	JJ	O	O
dofetilide	NN	D	O
exposure	NN	O	O
.	.	.	.

inhibitors	NNS	O	O
of	IN	O	O
this	DT	O	O
isoenzyme	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
macrolide	NN	O	O
antibiotics	NNS	G	G
","	","	O	O
azole	JJ	O	O
antifungal	JJ	O	O
agents	NNS	O	O
","	","	O	O
protease	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
amiodarone	NN	D	D
","	","	O	O
cannabinoids	NNS	G	G
","	","	O	O
diltiazem	NN	D	D
","	","	O	O
grapefruit	NN	O	O
juice	NN	O	O
","	","	O	O
nefazadone	NN	D	D
","	","	O	O
norfloxacin	NN	D	D
","	","	O	O
quinine	NN	D	D
","	","	O	O
zafirlukast	NN	D	D
-rrb-	-RRB-	O	O
should	MD	O	O
be	VB	O	O
cautiously	RB	O	O
coadministered	VBN	O	O
with	IN	O	O
tikosyn	NN	B	O
as	IN	O	O
they	PRP	O	O
can	MD	O	O
potentially	RB	O	O
increase	VB	O	O
dofetilide	NN	D	D
levels	NNS	O	O
.	.	.	.

dofetilide	NNP	D	D
is	VBZ	O	O
not	RB	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
cyp3a4	NN	D	D
nor	CC	O	O
of	IN	O	O
other	JJ	O	O
cytochrome	NN	O	O
p450	NN	O	O
isoenzymes	NNS	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
cyp2c9	NN	D	O
","	","	O	O
cyp2d6	NN	D	O
-rrb-	-RRB-	O	O
and	CC	O	O
is	VBZ	O	O
not	RB	O	O
expected	VBN	O	O
to	TO	O	O
increase	VB	O	O
levels	NNS	O	O
of	IN	O	O
drugs	NNS	D	D
metabolized	VBN	O	O
by	IN	O	O
cyp3a4	NN	D	D
.	.	.	.

other	JJ	O	O
drug	NN	O	O
interaction	NN	O	O
information	NN	O	O
digoxin	NNP	D	O
:	:	O	O
studies	NNS	O	O
in	IN	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
tikosyn	NN	B	D
does	VBZ	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
digoxin	NN	D	D
.	.	.	.

in	IN	O	O
patients	NNS	O	O
","	","	O	O
the	DT	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
digoxin	NN	D	D
with	IN	O	O
dofetilide	NN	D	D
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
higher	JJR	O	O
occurrence	NN	O	O
of	IN	O	O
torsade	FW	O	O
de	FW	O	O
pointes	FW	O	O
.	.	.	.

it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
clear	JJ	O	O
whether	IN	O	O
this	DT	O	O
represents	VBZ	O	O
an	DT	O	O
interaction	NN	O	O
with	IN	O	O
tikosyn	NN	B	D
or	CC	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
more	RBR	O	O
severe	JJ	O	O
structural	JJ	O	O
heart	NN	O	O
disease	NN	O	O
in	IN	O	O
patients	NNS	O	O
on	IN	O	O
digoxin	NN	D	D
.	.	.	.

structural	JJ	O	O
heart	NN	O	O
disease	NN	O	O
is	VBZ	O	O
a	DT	O	O
known	JJ	O	O
risk	NN	O	O
factor	NN	O	O
for	IN	O	O
arrhythmia	NN	O	O
.	.	.	.

no	DT	O	O
increase	NN	O	O
in	IN	O	O
mortality	NN	O	D
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
patients	NNS	O	O
taking	VBG	O	O
digoxin	NN	D	D
as	IN	O	O
concomitant	JJ	O	O
medication	NN	O	O
.	.	.	.

other	JJ	O	O
drugs	NNS	O	O
:	:	O	O
in	IN	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
","	","	O	O
amlodipine	NN	D	D
","	","	O	O
phenytoin	NN	D	D
","	","	O	O
glyburide	NN	D	D
","	","	O	O
ranitidine	NN	D	D
","	","	O	O
omeprazole	NN	D	D
","	","	O	O
hormone	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
-lrb-	-LRB-	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
conjugated	VBN	O	O
estrogens	NNS	G	G
and	CC	O	O
medroxyprogesterone	NN	D	D
-rrb-	-RRB-	O	O
","	","	O	O
antacid	NN	G	G
-lrb-	-LRB-	O	O
aluminum	NN	D	D
and	CC	O	O
magnesium	NN	D	D
hydroxides	NNS	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
theophylline	NN	D	D
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
tikosyn	NN	B	D
.	.	.	.

in	IN	O	O
addition	NN	O	O
","	","	O	O
studies	NNS	O	O
in	IN	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
tikosyn	NN	B	D
does	VBZ	O	O
not	RB	O	O
affect	VB	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
or	CC	O	O
pharmacodynamics	NNS	O	O
of	IN	O	O
warfarin	NN	D	D
","	","	O	O
or	CC	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
propranolol	NN	D	D
-lrb-	-LRB-	O	O
40	CD	O	O
mg	NN	O	O
twice	RB	O	O
daily	RB	O	O
-rrb-	-RRB-	O	O
","	","	O	O
phenytoin	NN	D	D
","	","	O	O
theophylline	NN	D	D
","	","	O	O
or	CC	O	O
oral	JJ	O	O
contraceptives	NNS	G	G
.	.	.	.

population	NNP	O	O
pharmacokinetic	JJ	O	O
analyses	NNS	O	O
were	VBD	O	O
conducted	VBN	O	O
on	IN	O	O
plasma	NN	O	O
concentration	NN	O	O
data	NNS	O	O
from	IN	O	O
1445	CD	O	O
patients	NNS	O	O
in	IN	O	O
clinical	JJ	O	O
trials	NNS	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
concomitant	JJ	O	O
medications	NNS	O	O
on	IN	O	O
clearance	NN	O	O
or	CC	O	O
volume	NN	O	O
of	IN	O	O
distribution	NN	O	O
of	IN	O	O
dofetilide	NN	D	O
.	.	.	.

concomitant	JJ	O	O
medications	NNS	O	O
were	VBD	O	O
grouped	VBN	O	O
as	IN	O	O
ace	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
oral	JJ	O	O
anticoagulants	NNS	G	G
","	","	O	O
calcium	NN	D	D
channel	NN	O	O
blockers	NNS	O	O
","	","	O	O
beta	NN	O	O
blockers	NNS	O	O
","	","	O	O
cardiac	JJ	O	O
glycosides	NNS	O	G
","	","	O	O
inducers	NNS	O	O
of	IN	O	O
cyp3a4	NN	D	D
","	","	O	O
substrates	NNS	O	O
and	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
cyp3a4	NN	D	D
","	","	O	O
substrates	NNS	O	O
and	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
p-glycoprotein	NN	O	O
","	","	O	O
nitrates	NNS	G	G
","	","	O	O
sulphonylureas	NNS	G	G
","	","	O	O
loop	NN	O	O
diuretics	NNS	G	G
","	","	O	O
potassium	NN	D	D
sparing	VBG	O	O
diuretics	NNS	G	G
","	","	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
","	","	O	O
substrates	NNS	O	O
and	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
tubular	JJ	O	O
organic	JJ	O	O
cation	NN	O	O
transport	NN	O	O
","	","	O	O
and	CC	O	O
qtc-prolonging	JJ	O	O
drugs	NNS	D	D
.	.	.	.

differences	NNS	O	O
in	IN	O	O
clearance	NN	O	O
between	IN	O	O
patients	NNS	O	O
on	IN	O	O
these	DT	O	O
medications	NNS	O	O
-lrb-	-LRB-	O	O
at	IN	O	O
any	DT	O	O
occasion	NN	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
-rrb-	-RRB-	O	O
and	CC	O	O
those	DT	O	O
off	IN	O	O
medications	NNS	O	O
varied	VBD	O	O
between	IN	O	O
-16	CD	O	O
%	NN	O	O
and	CC	O	O
3	CD	O	O
%	NN	O	O
.	.	.	.

the	DT	O	O
mean	NN	O	O
clearances	NNS	O	O
of	IN	O	O
dofetilide	NN	D	O
were	VBD	O	O
16	CD	O	O
%	NN	O	O
and	CC	O	O
15	CD	O	O
%	NN	O	O
lower	JJR	O	O
in	IN	O	O
patients	NNS	O	O
on	IN	O	O
thiazide	JJ	O	G
diuretics	NNS	G	G
and	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
tubular	JJ	O	O
organic	JJ	O	O
cation	NN	O	O
transport	NN	O	O
","	","	O	O
respectively	RB	O	O
.	.	.	.

the	DT	O	O
potential	NN	O	O
for	IN	O	O
clinically	RB	O	O
significant	JJ	O	O
drug-drug	JJ	O	O
interactions	NNS	O	O
posed	VBN	O	O
by	IN	O	O
dolasetron	NN	D	D
and	CC	O	O
hydrodolasetron	NN	D_n	D
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
low	JJ	O	O
for	IN	O	O
drugs	NNS	D	D
commonly	RB	O	O
used	VBN	O	O
in	IN	O	O
chemotherapy	NN	O	O
or	CC	O	O
surgery	NN	O	D
","	","	O	O
because	IN	O	O
hydrodolasetron	NN	D_n	D
is	VBZ	O	O
eliminated	VBN	O	O
by	IN	O	O
multiple	JJ	O	O
routes	NNS	O	O
.	.	.	.

blood	NN	O	O
levels	NNS	O	O
of	IN	O	O
hydrodolasetron	NN	D_n	D
increased	VBD	O	O
24	CD	O	O
%	NN	O	O
when	WRB	O	O
dolasetron	NN	D	D
was	VBD	O	O
coadministered	VBN	O	O
with	IN	O	O
cimetidine	NN	D	D
-lrb-	-LRB-	O	O
nonselective	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p-450	NN	O	O
-rrb-	-RRB-	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
","	","	O	O
and	CC	O	O
decreased	VBD	O	O
28	CD	O	O
%	NN	O	O
with	IN	O	O
coadministration	NN	O	O
of	IN	O	O
rifampin	NN	D	D
-lrb-	-LRB-	O	O
potent	JJ	O	O
inducer	NN	O	O
of	IN	O	O
cytochrome	NN	O	O
p-450	NN	O	O
-rrb-	-RRB-	O	O
for	IN	O	O
7	CD	O	O
days	NNS	O	O
.	.	.	.

dolasetron	NNP	D	D
has	VBZ	O	O
been	VBN	O	O
safely	RB	O	O
coadministered	VBN	O	O
with	IN	O	O
drugs	NNS	D	D
used	VBN	O	O
in	IN	O	O
chemotherapy	NN	O	O
and	CC	O	O
surgery	NN	O	O
.	.	.	.

this	DT	O	O
observed	VBN	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
fexofenadine	NN	D	D
may	MD	O	O
be	VB	O	O
due	JJ	O	O
to	TO	O	O
transport-related	JJ	O	O
effects	NNS	O	O
","	","	O	O
such	JJ	O	O
as	IN	O	O
p-glycoprotein	NN	O	O
.	.	.	.

in	FW	O	O
vivo	FW	O	O
animal	NN	O	O
studies	NNS	O	O
also	RB	O	O
suggest	VBP	O	O
that	IN	O	O
in	IN	O	O
addition	NN	O	O
to	TO	O	O
enhancing	VBG	O	O
absorption	NN	O	O
","	","	O	O
ketoconazole	NN	D	D
decreases	VBZ	O	O
fexofenadine	NN	D	D
gastrointestinal	JJ	O	O
secretion	NN	O	O
","	","	O	O
while	IN	O	O
erythromycin	NN	D	D
may	MD	O	O
also	RB	O	O
decrease	VB	O	O
biliary	JJ	O	O
excretion	NN	O	O
.	.	.	.

drug	NN	O	O
interactions	NNS	O	O
with	IN	O	O
antacids	NNPS	G	G
administration	NNP	O	O
of	IN	O	O
120	CD	O	O
mg	NN	O	O
of	IN	O	O
fexofenadine	NN	D	D
hydrochloride	NN	O	O
-lrb-	-LRB-	O	O
2	CD	O	O
x	CC	O	O
60	CD	O	O
mg	NN	O	O
capsule	NN	O	O
-rrb-	-RRB-	O	O
within	IN	O	O
15	CD	O	O
minutes	NNS	O	O
of	IN	O	O
an	DT	O	O
aluminum	NN	D	D
and	CC	O	O
magnesium	NN	D	D
containing	VBG	O	O
antacid	NN	G	G
-lrb-	-LRB-	O	O
maalox	NNP	B	B
-rrb-	-RRB-	O	O
decreased	VBD	O	O
fexofenadine	NN	D	D
auc	NN	O	O
by	IN	O	O
41	CD	O	O
%	NN	O	O
and	CC	O	O
cmax	NN	O	O
by	IN	O	O
43	CD	O	O
%	NN	O	O
.	.	.	.

allegra	NNP	B	B
should	MD	O	O
not	RB	O	O
be	VB	O	O
taken	VBN	O	O
closely	RB	O	O
in	IN	O	O
time	NN	O	O
with	IN	O	O
aluminum	NN	D	D
and	CC	O	O
magnesium	NN	D	D
containing	VBG	O	O
antacids	NNS	G	G
.	.	.	.

interactions	NNS	O	O
with	IN	O	O
fruit	NNP	O	O
juices	NNP	O	O
fruit	NNP	O	O
juices	NNS	O	O
such	JJ	O	O
as	IN	O	O
grapefruit	NN	O	O
","	","	O	O
orange	NN	O	O
and	CC	O	O
apple	NN	O	D
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
bioavailability	NN	O	O
and	CC	O	O
exposure	NN	O	O
of	IN	O	O
fexofenadine	NN	D	D
.	.	.	.

this	DT	O	O
is	VBZ	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
results	NNS	O	O
from	IN	O	O
3	CD	O	O
clinical	JJ	O	O
studies	NNS	O	O
using	VBG	O	O
histamine	NN	D	D
induced	VBD	O	O
skin	NN	O	O
wheals	NNS	O	O
and	CC	O	O
flares	NNS	O	O
coupled	VBN	O	O
with	IN	O	O
population	NN	O	O
pharmacokinetic	JJ	O	O
analysis	NN	O	O
.	.	.	.

the	DT	O	O
size	NN	O	O
of	IN	O	O
wheal	NN	O	D
and	CC	O	O
flare	NN	O	D
were	VBD	O	O
significantly	RB	O	O
larger	JJR	O	O
when	WRB	O	O
fexofenadine	NN	D	D
hydrochloride	NN	O	O
was	VBD	O	O
administered	VBN	O	O
with	IN	O	O
either	CC	O	O
grapefruit	NN	O	O
or	CC	O	O
orange	JJ	O	O
juices	NNS	O	O
compared	VBN	O	O
to	TO	O	O
water	NN	O	D
.	.	.	.

based	VBN	O	O
on	IN	O	O
the	DT	O	O
literature	NN	O	O
reports	NNS	O	O
","	","	O	O
the	DT	O	O
same	JJ	O	O
effects	NNS	O	O
may	MD	O	O
be	VB	O	O
extrapolated	VBN	O	O
to	TO	O	O
other	JJ	O	O
fruit	NN	O	O
juices	NNS	O	O
such	JJ	O	O
as	IN	O	O
apple	NN	O	O
juice	NN	O	O
.	.	.	.

the	DT	O	O
clinical	JJ	O	O
significance	NN	O	O
of	IN	O	O
these	DT	O	O
observations	NNS	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	.	.

in	IN	O	O
addition	NN	O	O
","	","	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
population	NN	O	O
pharmacokinetics	NNS	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
combined	JJ	O	O
data	NNS	O	O
from	IN	O	O
grapefruit	NN	O	O
and	CC	O	O
orange	JJ	O	O
juices	NNS	O	O
studies	NNS	O	O
with	IN	O	O
the	DT	O	O
data	NNS	O	O
from	IN	O	O
a	DT	O	O
bioequivalence	NN	O	O
study	NN	O	O
","	","	O	O
the	DT	O	O
bioavailability	NN	O	O
of	IN	O	O
fexofenadine	NN	D	D
was	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
36	CD	O	O
%	NN	O	O
.	.	.	.

therefore	RB	O	O
","	","	O	O
to	TO	O	O
maximize	VB	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
fexofenadine	NN	D	D
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
recommended	VBN	O	O
that	IN	O	O
allegra	NNP	B	B
should	MD	O	O
be	VB	O	O
taken	VBN	O	O
with	IN	O	O
wate	NN	O	O
.	.	.	.

drug	NN	O	O
interactions	NNS	O	O
between	IN	O	O
neupogen	NNP	B	B
and	CC	O	O
other	JJ	O	O
drugs	NNS	D	D
have	VBP	O	O
not	RB	O	O
been	VBN	O	O
fully	RB	O	O
evaluated	VBN	O	O
.	.	.	.

drugs	NNS	O	O
which	WDT	O	O
may	MD	O	O
potentiate	VB	O	O
the	DT	O	O
release	NN	O	O
of	IN	O	O
neutrophils	NNS	O	G
","	","	O	O
such	JJ	O	O
as	IN	O	O
lithium	NN	D	D
","	","	O	O
should	MD	O	O
be	VB	O	O
used	VBN	O	O
with	IN	O	O
caution	NN	O	O
.	.	.	.

no	DT	O	O
drug	NN	D	O
interactions	NNS	O	O
of	IN	O	O
clinical	JJ	O	O
importance	NN	O	O
have	VBP	O	O
been	VBN	O	O
identified	VBN	O	O
.	.	.	.

finasteride	NN	D	D
does	VBZ	O	O
not	RB	O	O
appear	VB	O	O
to	TO	O	O
affect	VB	O	O
the	DT	O	O
cytochrome	NN	O	O
p450-linked	JJ	O	O
drug-metabolizing	JJ	O	O
enzyme	NN	O	O
system	NN	O	O
.	.	.	.

compounds	NNS	O	O
that	WDT	O	O
have	VBP	O	O
been	VBN	O	O
tested	VBN	O	O
in	IN	O	O
man	NN	O	O
include	VBP	O	O
antipyrine	NN	D	D
","	","	O	O
digoxin	NN	D	D
","	","	O	O
propranolol	NN	D	D
","	","	O	O
theophylline	NN	D	D
","	","	O	O
and	CC	O	O
warfarin	NN	D	D
and	CC	O	O
no	DT	O	O
clinically	RB	O	O
meaningful	JJ	O	O
interactions	NNS	O	O
were	VBD	O	O
found	VBN	O	O
.	.	.	.

other	JJ	O	O
concomitant	JJ	O	O
therapy	NN	O	O
although	IN	O	O
specific	JJ	O	O
interaction	NN	O	O
studies	NNS	O	O
were	VBD	O	O
not	RB	O	O
performed	VBN	O	O
","	","	O	O
finasteride	NN	D	O
doses	NNS	O	O
of	IN	O	O
1	CD	O	O
mg	NN	O	O
or	CC	O	O
more	JJR	O	O
were	VBD	O	O
concomitantly	RB	O	O
used	VBN	O	O
in	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
with	IN	O	O
acetaminophen	NN	D	D
","	","	O	O
acetylsalicylic	JJ	O	O
acid	NN	O	O
","	","	O	O
a-blockers	NNS	O	G
","	","	O	O
analgesics	NNS	G	G
","	","	O	O
angiotensin-converting	JJ	O	O
enzyme	NN	O	O
-lrb-	-LRB-	O	O
ace	NN	O	O
-rrb-	-RRB-	O	O
inhibitors	NNS	O	O
","	","	O	O
anticonvulsants	NNS	G	G
","	","	O	O
benzodiazepines	NNS	G	G
","	","	O	O
beta	NN	O	O
blockers	NNS	O	O
","	","	O	O
calcium-channel	JJ	O	O
blockers	NNS	O	O
","	","	O	O
cardiac	JJ	O	O
nitrates	NNS	G	G
","	","	O	O
diuretics	NNS	G	G
","	","	O	O
h2	NN	O	O
antagonists	NNS	O	O
","	","	O	O
hmg-coa	NN	O	O
reductase	NN	O	O
inhibitors	NNS	O	O
","	","	O	O
prostaglandin	NN	O	O
synthetase	NN	O	O
inhibitors	NNS	O	O
-lrb-	-LRB-	O	O
also	RB	O	O
referred	VBN	O	O
to	TO	O	O
as	IN	O	O
nsaids	NNS	G	G
-rrb-	-RRB-	O	O
","	","	O	O
and	CC	O	O
quinolone	NN	G	O
anti-infectives	NNS	O	O
without	IN	O	O
evidence	NN	O	O
of	IN	O	O
clinically	RB	O	O
significant	JJ	O	O
adverse	JJ	O	O
interactions	NNS	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
finasteride	NNP	D	D
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
circulating	VBG	O	O
levels	NNS	O	O
of	IN	O	O
cortisol	NN	O	O
","	","	O	O
thyroid-stimulating	JJ	O	O
hormone	NN	O	O
","	","	O	O
or	CC	O	O
thyroxine	NN	D	D
","	","	O	O
nor	CC	O	O
did	VBD	O	O
it	PRP	O	O
affect	VB	O	O
the	DT	O	O
plasma	NN	O	O
lipid	NN	O	O
profile	NN	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
total	JJ	O	O
cholesterol	NN	O	O
","	","	O	O
low-density	JJ	O	O
lipoproteins	NNS	O	O
","	","	O	O
high-density	JJ	O	O
lipoproteins	NNS	O	O
and	CC	O	O
triglycerides	NNS	O	O
-rrb-	-RRB-	O	O
or	CC	O	O
bone	NN	O	O
mineral	NN	O	O
density	NN	O	O
.	.	.	.

in	IN	O	O
studies	NNS	O	O
with	IN	O	O
finasteride	NN	D	D
","	","	O	O
no	DT	O	O
clinically	RB	O	O
meaningful	JJ	O	O
changes	NNS	O	O
in	IN	O	O
luteinizing	VBG	O	O
hormone	NN	O	O
-lrb-	-LRB-	O	O
lh	NN	O	B
-rrb-	-RRB-	O	O
","	","	O	O
follicle-stimulating	JJ	O	O
hormone	NN	O	O
-lrb-	-LRB-	O	O
fsh	NN	O	O
-rrb-	-RRB-	O	O
or	CC	O	O
prolactin	NN	O	O
were	VBD	O	O
detected	VBN	O	O
.	.	.	.

in	IN	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
","	","	O	O
treatment	NN	O	O
with	IN	O	O
finasteride	NN	D	B
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
the	DT	O	O
response	NN	O	O
of	IN	O	O
lh	NN	O	D
and	CC	O	O
fsh	NN	O	O
to	TO	O	O
gonadotropin-releasing	NN	O	O
hormone	NN	O	O
indicating	VBG	O	O
that	IN	O	O
the	DT	O	O
hypothalamic-pituitary-testicular	JJ	O	O
axis	NN	O	O
was	VBD	O	O
not	RB	O	O
affected	VBN	O	O
.	.	.	.

in	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
with	IN	O	O
propecia	NN	B	B
-lrb-	-LRB-	O	O
finasteride	NN	D	D
","	","	O	O
1	CD	O	O
mg	NN	O	O
-rrb-	-RRB-	O	O
in	IN	O	O
men	NNS	O	O
18-41	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
","	","	O	O
the	DT	O	O
mean	JJ	O	O
value	NN	O	O
of	IN	O	O
serum	NN	O	O
prostate-specific	JJ	O	O
antigen	NN	O	O
-lrb-	-LRB-	O	O
psa	NN	O	O
-rrb-	-RRB-	O	O
decreased	VBD	O	O
from	IN	O	O
0.7	CD	O	O
ng/ml	NN	O	O
at	IN	O	O
baseline	NN	O	O
to	TO	O	O
0.5	CD	O	O
ng/ml	NN	O	O
at	IN	O	O
month	NNP	O	O
12	CD	O	O
.	.	.	.

further	RB	O	O
","	","	O	O
in	IN	O	O
clinical	JJ	O	O
studies	NNS	O	O
with	IN	O	O
proscar	NN	B	B
-lrb-	-LRB-	O	O
finasteride	NN	D	D
","	","	O	O
5	CD	O	O
mg	NN	O	O
-rrb-	-RRB-	O	O
when	WRB	O	O
used	VBN	O	O
in	IN	O	O
older	JJR	O	O
men	NNS	O	O
who	WP	O	O
have	VBP	O	O
benign	JJ	O	O
prostatic	JJ	O	O
hyperplasia	NN	O	O
-lrb-	-LRB-	O	O
bph	NNP	O	B
-rrb-	-RRB-	O	O
","	","	O	O
psa	NN	O	O
levels	NNS	O	O
are	VBP	O	O
decreased	VBN	O	O
by	IN	O	O
approximately	RB	O	O
50	CD	O	O
%	NN	O	O
.	.	.	.

these	DT	O	O
findings	NNS	O	O
should	MD	O	O
be	VB	O	O
taken	VBN	O	O
into	IN	O	O
account	NN	O	O
for	IN	O	O
proper	JJ	O	O
interpretation	NN	O	O
of	IN	O	O
serum	NN	O	O
psa	NN	O	O
when	WRB	O	O
evaluating	VBG	O	O
men	NNS	O	O
treated	VBN	O	O
with	IN	O	O
finasteride	NN	D	D
.	.	.	.

drug	NN	O	O
interactions	NNS	O	O
.	.	.	.

tambocor	NN	B	D
has	VBZ	O	O
been	VBN	O	O
administered	VBN	O	O
to	TO	O	O
patients	NNS	O	O
receiving	VBG	O	O
digitalis	NN	G	G
preparations	NNS	O	O
or	CC	O	O
beta-adrenergic	JJ	O	O
blocking	VBG	O	O
agents	NNS	O	O
without	IN	O	O
adverse	JJ	O	O
effects	NNS	O	O
.	.	.	.

during	IN	O	O
administration	NN	O	O
of	IN	O	O
multiple	JJ	O	O
oral	JJ	O	O
doses	NNS	O	O
of	IN	O	O
tambocor	NN	B	D
to	TO	O	O
healthy	JJ	O	O
subjects	NNS	O	O
stabilized	VBD	O	O
on	IN	O	O
a	DT	O	O
maintenance	NN	O	O
dose	NN	O	O
of	IN	O	O
digoxin	NN	D	D
","	","	O	O
a	DT	O	O
13	CD	O	O
%	NN	O	O
-19	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
plasma	NN	O	O
digoxin	NN	D	D
levels	NNS	O	O
occurred	VBD	O	O
at	IN	O	O
six	CD	O	O
hours	NNS	O	O
postdose	NN	O	O
.	.	.	.

in	IN	O	O
a	DT	O	O
study	NN	O	O
involving	VBG	O	O
healthy	JJ	O	O
subjects	NNS	O	O
receiving	VBG	O	O
tambocor	NN	B	D
and	CC	O	O
propranolol	NN	D	D
concurrently	RB	O	O
","	","	O	O
plasma	NN	O	O
flecainide	NN	D	D
levels	NNS	O	O
were	VBD	O	O
increased	VBN	O	O
about	RB	O	O
20	CD	O	O
%	NN	O	O
and	CC	O	O
propranolol	NN	D	D
levels	NNS	O	O
were	VBD	O	O
increased	VBN	O	O
about	IN	O	O
30	CD	O	O
%	NN	O	O
compared	VBN	O	O
to	TO	O	O
control	VB	O	O
values	NNS	O	O
.	.	.	.

in	IN	O	O
this	DT	O	O
formal	JJ	O	O
interaction	NN	O	O
study	NN	O	O
","	","	O	O
tambocor	NN	B	O
and	CC	O	O
propranolol	NN	D	D
were	VBD	O	O
each	DT	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
negative	JJ	O	O
inotropic	JJ	O	O
effects	NNS	O	O
.	.	.	.

when	WRB	O	O
the	DT	O	O
drugs	NNS	D	D
were	VBD	O	O
administered	VBN	O	O
together	RB	O	O
","	","	O	O
the	DT	O	O
effects	NNS	O	O
were	VBD	O	O
additive	JJ	O	O
.	.	.	.

the	DT	O	O
effects	NNS	O	O
of	IN	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
tambocor	NN	B	D
and	CC	O	O
propranolol	NN	D	D
on	IN	O	O
the	DT	O	O
pr	NN	O	O
interval	NN	O	O
were	VBD	O	O
less	JJR	O	O
than	IN	O	O
additive	JJ	O	O
.	.	.	.

in	IN	O	O
tambocor	NN	B	O
clinical	JJ	O	O
trials	NNS	O	O
","	","	O	O
patients	NNS	O	O
who	WP	O	O
were	VBD	O	O
receiving	VBG	O	O
beta	NN	O	O
blockers	NNS	O	O
concurrently	RB	O	O
did	VBD	O	O
not	RB	O	O
experience	VB	O	O
an	DT	O	O
increased	VBN	O	O
incidence	NN	O	O
of	IN	O	O
side	JJ	O	O
effects	NNS	O	O
.	.	.	.

nevertheless	RB	O	O
","	","	O	O
the	DT	O	O
possibility	NN	O	O
of	IN	O	O
additive	JJ	O	O
negative	JJ	O	O
inotropic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
beta	NN	O	O
blockers	NNS	O	O
and	CC	O	O
flecainide	NN	D	D
should	MD	O	O
be	VB	O	O
recognized	VBN	O	O
.	.	.	.

flecainide	NNP	D	D
is	VBZ	O	O
not	RB	O	O
extensively	RB	O	O
bound	VBN	O	O
to	TO	O	O
plasma	NN	O	O
proteins	NNS	O	O
.	.	.	.

in	FW	O	O
vitro	FW	O	O
studies	NNS	O	O
with	IN	O	O
several	JJ	O	O
drugs	NNS	D	D
which	WDT	O	O
may	MD	O	O
be	VB	O	O
administered	VBN	O	O
concomitantly	RB	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
extent	NN	O	O
of	IN	O	O
flecainide	NN	D	D
binding	NN	O	O
to	TO	O	O
human	JJ	O	O
plasma	NN	O	O
proteins	NNS	O	O
is	VBZ	O	O
either	CC	O	O
unchanged	JJ	O	O
or	CC	O	O
only	RB	O	O
slightly	RB	O	O
less	RBR	O	O
.	.	.	.

consequently	RB	O	O
","	","	O	O
interactions	NNS	O	O
with	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
which	WDT	O	O
are	VBP	O	O
highly	RB	O	O
protein	NN	O	O
bound	VBD	O	O
-lrb-	-LRB-	O	O
e.g.	FW	O	O
","	","	O	O
anticoagulants	NNS	G	G
-rrb-	-RRB-	O	O
would	MD	O	O
not	RB	O	O
be	VB	O	O
expected	VBN	O	O
.	.	.	.

tambocor	NN	B	D
has	VBZ	O	O
been	VBN	O	O
used	VBN	O	O
in	IN	O	O
a	DT	O	O
large	JJ	O	O
number	NN	O	O
of	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
diuretics	NNS	G	G
without	IN	O	O
apparent	JJ	O	O
interaction	NN	O	O
.	.	.	.

limited	JJ	O	O
data	NNS	O	O
in	IN	O	O
patients	NNS	O	O
receiving	VBG	O	O
known	JJ	O	O
enzyme	NN	O	O
inducers	NNS	O	O
-lrb-	-LRB-	O	O
phenytoin	NN	D	D
","	","	O	O
phenobarbital	NN	D	D
","	","	O	O
carbamazepine	NN	D	D
-rrb-	-RRB-	O	O
indicate	VBP	O	O
only	RB	O	O
a	DT	O	O
30	CD	O	O
%	NN	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
flecainide	NN	D	D
elimination	NN	O	O
.	.	.	.

in	IN	O	O
healthy	JJ	O	O
subjects	NNS	O	O
receiving	VBG	O	O
cimetidine	NN	D	D
-lrb-	-LRB-	O	O
1	CD	O	O
gm	NN	O	O
daily	JJ	O	O
-rrb-	-RRB-	O	O
for	IN	O	O
one	CD	O	O
week	NN	O	O
","	","	O	O
plasma	NN	O	O
flecainide	NN	D	O
levels	NNS	O	O
increased	VBN	O	O
by	IN	O	O
about	IN	O	O
30	CD	O	O
%	NN	O	O
and	CC	O	O
half-life	NN	O	O
increased	VBN	O	O
by	IN	O	O
about	RB	O	O
10	CD	O	O
%	NN	O	O
.	.	.	.

when	WRB	O	O
amiodarone	NN	D	D
is	VBZ	O	O
added	VBN	O	O
to	TO	O	O
flecainide	NN	D	D
therapy	NN	O	O
","	","	O	O
plasma	NN	O	O
flecainide	NN	D	D
levels	NNS	O	O
may	MD	O	O
increase	VB	O	O
two-fold	RB	O	O
or	CC	O	O
more	RBR	O	O
in	IN	O	O
some	DT	O	O
patients	NNS	O	O
","	","	O	O
if	IN	O	O
flecainide	NN	D	D
dosage	NN	O	O
is	VBZ	O	O
not	RB	O	O
reduced	VBN	O	O
.	.	.	.

drugs	NNS	O	O
that	WDT	O	O
inhibit	VBP	O	O
cytochrome	NN	O	O
p450iid6	NN	O	O
","	","	O	O
such	JJ	O	O
as	IN	O	O
quinidine	NN	D	D
","	","	O	O
might	MD	O	O
increase	VB	O	O
the	DT	O	O
plasma	NN	O	O
concentrations	NNS	O	O
of	IN	O	O
flecainide	NN	D	D
in	IN	O	O
patients	NNS	O	O
that	WDT	O	O
are	VBP	O	O
on	IN	O	O
chronic	JJ	O	O
flecainide	NN	D	D
therapy	NN	O	O
.	.	.	.

especially	RB	O	O
if	IN	O	O
these	DT	O	O
patients	NNS	O	O
are	VBP	O	O
extensive	JJ	O	O
metabolizers	NNS	O	O
.	.	.	.

there	EX	O	O
has	VBZ	O	O
been	VBN	O	O
little	JJ	O	O
experience	NN	O	O
with	IN	O	O
the	DT	O	O
coadministration	NN	O	O
of	IN	O	O
tambocor	NN	B	D
and	CC	O	O
either	CC	O	O
disopyramide	NN	D	D
or	CC	O	O
verapamil	NN	D	D
.	.	.	.

because	IN	O	O
both	DT	O	O
of	IN	O	O
these	DT	O	O
drugs	NNS	D	D
have	VBP	O	O
negative	JJ	O	O
inotropic	JJ	O	O
properties	NNS	O	O
and	CC	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
coadministration	NN	O	O
with	IN	O	O
tambocor	NN	B	D
are	VBP	O	O
unknown	JJ	O	O
","	","	O	O
neither	CC	O	O
disopyramide	NN	D	D
nor	CC	O	O
verapamil	NN	D	D
should	MD	O	O
be	VB	O	O
administered	VBN	O	O
concurrently	RB	O	O
with	IN	O	O
tambocor	NN	B	D
unless	IN	O	O
","	","	O	O
in	IN	O	O
the	DT	O	O
judgment	NN	O	O
of	IN	O	O
the	DT	O	O
physician	NN	O	O
","	","	O	O
the	DT	O	O
benefits	NNS	O	O
of	IN	O	O
this	DT	O	O
combination	NN	O	O
outweigh	VBP	O	O
the	DT	O	O
risks	NNS	O	O
.	.	.	.

there	EX	O	O
has	VBZ	O	O
been	VBN	O	O
too	RB	O	O
little	JJ	O	O
experience	NN	O	O
with	IN	O	O
the	DT	O	O
coadministration	NN	O	O
of	IN	O	O
tambocor	NN	B	D
with	IN	O	O
nifedipine	NN	D	D
or	CC	O	O
diltiazem	NN	D	D
to	TO	O	O
recommend	VB	O	O
concomitant	JJ	O	O
use	NN	O	O
.	.	.	.

combination	NN	O	O
therapy	NN	O	O
:	:	O	O
any	DT	O	O
form	NN	O	O
of	IN	O	O
therapy	NN	O	O
which	WDT	O	O
adds	VBZ	O	O
to	TO	O	O
the	DT	O	O
stress	NN	O	O
of	IN	O	O
the	DT	O	O
patient	NN	O	O
","	","	O	O
interferes	VBZ	O	O
with	IN	O	O
nutrition	NN	O	D
or	CC	O	O
depresses	VBZ	O	O
bone	NN	O	O
marrow	NN	O	O
function	NN	O	O
will	MD	O	O
increase	VB	O	O
the	DT	O	O
toxicity	NN	O	O
of	IN	O	O
floxuridine	NN	D	D
.	.	.	.

cytosine	NN	O	O
arabinoside	NN	O	O
","	","	O	O
a	DT	O	O
cytostatic	JJ	O	O
agent	NN	O	O
","	","	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
to	TO	O	O
inactivate	VB	O	O
the	DT	O	O
antifungal	JJ	O	O
activity	NN	O	O
of	IN	O	O
flucytosine	NN	D	O
by	IN	O	O
competitive	JJ	O	O
inhibition	NN	O	O
.	.	.	.

drugs	NNS	O	O
which	WDT	O	O
impair	VBP	O	O
glomerular	JJ	O	O
filtration	NN	O	O
may	MD	O	O
prolong	VB	O	O
the	DT	O	O
biological	JJ	O	O
half-life	NN	O	O
of	IN	O	O
flucytosine	NN	D	D
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
:	:	O	O
measurement	NN	O	O
of	IN	O	O
serum	NN	O	O
creatinine	NN	O	O
levels	NNS	O	O
should	MD	O	O
be	VB	O	O
determined	VBN	O	O
by	IN	O	O
the	DT	O	O
jaffe	NNP	O	O
reaction	NN	O	O
","	","	O	O
since	IN	O	O
ancobon	NNP	B	B
does	VBZ	O	O
not	RB	O	O
interfere	VB	O	O
with	IN	O	O
the	DT	O	O
determination	NN	O	O
of	IN	O	O
creatinine	NN	O	O
values	NNS	O	O
by	IN	O	O
this	DT	O	O
method	NN	O	O
.	.	.	.

most	JJS	O	O
automated	JJ	O	O
equipment	NN	O	O
for	IN	O	O
measurement	NN	O	O
of	IN	O	O
creatinine	NN	O	O
makes	VBZ	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
jaffe	NNP	O	O
reaction	NN	O	O
.	.	.	.

the	DT	O	O
use	NN	O	O
of	IN	O	O
fludara	NNP	B	D
for	IN	O	O
injection	NNP	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
pentostatin	NN	D	D
is	VBZ	O	O
not	RB	O	O
recommended	VBN	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
severe	JJ	O	O
pulmonary	JJ	O	O
toxicity	NN	O	O
.	.	.	.

when	WRB	O	O
administered	VBN	O	O
concurrently	RB	O	O
","	","	O	O
the	DT	O	O
following	VBG	O	O
drugs	NNS	D	D
may	MD	O	O
interact	VB	O	O
with	IN	O	O
adrenal	JJ	O	O
corticosteroids	NNS	G	G
.	.	.	.

amphotericin	NN	O	D
b	NN	O	O
or	CC	O	O
potassium-depleting	JJ	O	O
diuretics	NNS	G	G
-lrb-	-LRB-	O	O
benzothiadiazines	NNS	G	G
and	CC	O	O
related	JJ	O	O
drugs	NNS	D	D
","	","	O	O
ethacrynic	JJ	O	O
acid	NN	O	O
and	CC	O	O
furosemide	NN	D	D
-rrb-	-RRB-	O	O
enhanced	VBD	O	O
hypokalemia	NN	O	O
.	.	.	.

check	VB	O	O
serum	NN	O	O
potassium	NN	D	D
levels	NNS	O	O
at	IN	O	O
frequent	JJ	O	O
intervals	NNS	O	O
;	:	O	O
.	.	.	.

use	NN	O	O
potassium	NN	D	D
supplements	NNS	O	O
if	IN	O	O
necessary	JJ	O	O
.	.	.	.

digitalis	NN	G	G
glycosides	NNS	O	G
enhanced	VBD	O	O
possibility	NN	O	O
of	IN	O	O
arrhythmias	NNS	O	O
or	CC	O	O
digitalis	NN	G	G
toxicity	NN	O	O
associated	VBN	O	O
with	IN	O	O
hypokalemia	NN	O	O
.	.	.	.

monitor	NNP	O	O
serum	NN	O	O
potassium	NN	D	D
levels	NNS	O	O
;	:	O	O
.	.	.	.

use	NN	O	O
potassium	NN	D	D
supplements	NNS	O	O
if	IN	O	O
necessary	JJ	O	O
.	.	.	.

oral	JJ	O	O
anticoagulants	NNS	G	G
decreased	VBD	O	O
prothrombin	NN	O	O
time	NN	O	O
response	NN	O	O
.	.	.	.

monitor	NNP	O	O
prothrombin	NN	O	O
levels	NNS	O	O
and	CC	O	O
adjust	VBP	O	O
anticoagulant	JJ	G	G
dosage	NN	O	O
accordingly	RB	O	O
.	.	.	.

antidiabetic	JJ	O	O
drugs	NNS	D	D
-lrb-	-LRB-	O	O
oral	JJ	O	O
agents	NNS	O	O
and	CC	O	O
insulin	NN	D	D
-rrb-	-RRB-	O	O
diminished	VBD	O	O
antidiabetic	JJ	O	O
effect	NN	O	O
.	.	.	.

monitor	NNP	O	O
for	IN	O	O
symptoms	NNS	O	O
of	IN	O	O
hyperglycemia	NN	O	O
;	:	O	O
.	.	.	.

adjust	VBP	O	O
dosage	NN	O	O
of	IN	O	O
antidiabetic	JJ	O	D
drug	NN	D	O
upward	RB	O	O
if	IN	O	O
necessary	JJ	O	O
.	.	.	.

aspirin	NN	B	B
increased	VBD	O	O
ulcerogenic	JJ	O	O
effect	NN	O	O
.	.	.	.

decreased	VBN	O	O
pharmacologic	JJ	O	O
effect	NN	O	O
of	IN	O	O
aspirin	NN	B	B
.	.	.	.

rarely	RB	O	O
salicylate	NN	G	G
toxicity	NN	O	O
may	MD	O	O
occur	VB	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
discontinue	VBP	O	O
steroids	NNS	G	G
after	IN	O	O
concurrent	JJ	O	O
high-dose	JJ	O	O
aspirin	NN	B	B
therapy	NN	O	O
.	.	.	.

monitor	NNP	O	O
salicylate	NN	G	G
levels	NNS	O	O
or	CC	O	O
the	DT	O	O
therapeutic	JJ	O	O
effect	NN	O	O
for	IN	O	O
which	WDT	O	O
aspirin	NN	B	B
is	VBZ	O	O
given	VBN	O	O
.	.	.	.

adjust	VBP	O	O
salicylate	NN	G	G
dosage	NN	O	O
accordingly	RB	O	O
if	IN	O	O
effect	NN	O	O
is	VBZ	O	O
altered	VBN	O	O
.	.	.	.

barbiturates	NNP	G	G
","	","	O	O
phenytoin	NN	D	D
","	","	O	O
or	CC	O	O
rifampin	NN	D	D
increased	VBD	O	O
metabolic	JJ	O	O
clearance	NN	O	O
of	IN	O	O
fludrocortisone	NN	O	O
acetate	NN	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
induction	NN	O	O
of	IN	O	O
hepatic	JJ	O	O
enzymes	NNS	O	O
.	.	.	.

observe	VB	O	O
the	DT	O	O
patient	NN	O	O
for	IN	O	O
possible	JJ	O	O
diminished	JJ	O	O
effect	NN	O	O
of	IN	O	O
steroid	NN	G	D
and	CC	O	O
increase	VB	O	O
the	DT	O	O
steroid	NN	G	G
dosage	NN	O	O
accordingly	RB	O	O
.	.	.	.

anabolic	JJ	O	O
steroids	NNS	G	G
-lrb-	-LRB-	O	O
particularly	RB	O	O
c-17	JJ	O	O
alkylated	VBN	O	O
androgens	NNS	G	G
such	JJ	O	O
as	IN	O	O
oxymetholone	NN	D	D
","	","	O	O
methandrostenolone	NN	D	D
","	","	O	O
norethandrolone	NN	D	D
","	","	O	O
and	CC	O	O
similar	JJ	O	O
compounds	NNS	O	O
-rrb-	-RRB-	O	O
enhanced	VBD	O	O
tendency	NN	O	O
toward	IN	O	O
edema	NN	O	O
.	.	.	.

use	NNP	O	O
caution	NN	O	O
when	WRB	O	O
giving	VBG	O	O
these	DT	O	O
drugs	NNS	D	D
together	RB	O	O
","	","	O	O
especially	RB	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
hepatic	JJ	O	O
or	CC	O	O
cardiac	JJ	O	O
disease	NN	O	O
.	.	.	.

vaccines	NNS	G	G
neurological	JJ	O	O
complications	NNS	O	O
and	CC	O	O
lack	NN	O	O
of	IN	O	O
antibody	NN	O	O
response	NN	O	O
.	.	.	.

estrogen	NN	G	D
increased	VBD	O	O
levels	NNS	O	O
of	IN	O	O
corticosteroid-binding	JJ	O	O
globulin	NN	O	O
","	","	O	O
thereby	RB	O	O
increasing	VBG	O	O
the	DT	O	O
bound	VBN	O	O
-lrb-	-LRB-	O	O
inactive	JJ	O	O
-rrb-	-RRB-	O	O
fraction	NN	O	O
.	.	.	.

this	DT	O	O
effect	NN	O	O
is	VBZ	O	O
at	IN	O	O
least	JJS	O	O
balanced	VBN	O	O
by	IN	O	O
decreased	VBN	O	O
metabolism	NN	O	O
of	IN	O	O
corticosteroids	NNS	G	G
.	.	.	.

when	WRB	O	O
estrogen	NN	G	G
therapy	NN	O	O
is	VBZ	O	O
initiated	VBN	O	O
","	","	O	O
a	DT	O	O
reduction	NN	O	O
in	IN	O	O
corticosteroid	NN	G	G
dosage	NN	O	O
may	MD	O	O
be	VB	O	O
required	VBN	O	O
","	","	O	O
and	CC	O	O
increased	VBD	O	O
amounts	NNS	O	O
may	MD	O	O
be	VB	O	O
required	VBN	O	O
when	WRB	O	O
estrogen	NN	G	D
is	VBZ	O	O
terminated	VBN	O	O
.	.	.	.

drug/laboratory	JJ	O	O
test	NN	O	O
interactions	NNS	O	O
corticosteroids	NNS	G	O
may	MD	O	O
affect	VB	O	O
the	DT	O	O
nitrobluetetrazolium	JJ	O	O
test	NN	O	O
for	IN	O	O
bacterial	JJ	O	O
infection	NN	O	O
and	CC	O	O
produce	VBP	O	O
false-negative	JJ	O	O
result	NN	O	O
.	.	.	.

interaction	NN	O	O
with	IN	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
depressants	NNS	O	O
other	JJ	O	O
than	IN	O	O
benzodiazepines	NNS	G	G
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
specifically	RB	O	O
studied	VBN	O	O
.	.	.	.

however	RB	O	O
","	","	O	O
no	DT	O	O
deleterious	JJ	O	O
interactions	NNS	O	O
were	VBD	O	O
seen	VBN	O	O
when	WRB	O	O
romazicon	NNP	B	B
was	VBD	O	O
administered	VBN	O	O
after	IN	O	O
narcotics	NNS	G	G
","	","	O	O
inhalational	JJ	O	O
anesthetics	NNS	G	G
","	","	O	O
muscle	NN	O	O
relaxants	NNS	O	O
and	CC	O	O
muscle	NN	O	O
relaxant	NN	O	O
antagonists	NNS	O	O
administered	VBN	O	O
in	IN	O	O
conjunction	NN	O	O
with	IN	O	O
sedation	NN	O	D
or	CC	O	O
anesthesia	NN	D	O
.	.	.	.

particular	JJ	O	O
caution	NN	O	O
is	VBZ	O	O
necessary	JJ	O	O
when	WRB	O	O
using	VBG	O	O
romazicon	NNP	B	B
in	IN	O	O
cases	NNS	O	O
of	IN	O	O
mixed	JJ	O	O
drug	NN	D	O
overdosage	NN	O	O
since	IN	O	O
the	DT	O	O
toxic	JJ	O	O
effects	NNS	O	O
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
convulsions	NNS	O	G
and	CC	O	O
cardiac	JJ	O	O
dysrhythmias	NNS	O	O
-rrb-	-RRB-	O	O
of	IN	O	O
other	JJ	O	O
drugs	NNS	D	D
taken	VBN	O	O
in	IN	O	O
overdose	NN	O	O
-lrb-	-LRB-	O	O
especially	RB	O	O
cyclic	JJ	O	O
antidepressants	NNS	G	G
-rrb-	-RRB-	O	O
may	MD	O	O
emerge	VB	O	O
with	IN	O	O
the	DT	O	O
reversal	NN	O	O
of	IN	O	O
the	DT	O	O
benzodiazepine	NN	G	O
effect	NN	O	O
by	IN	O	O
flumazenil	NN	D	D
.	.	.	.

the	DT	O	O
use	NN	O	O
of	IN	O	O
romazicon	NNP	B	B
is	VBZ	O	O
not	RB	O	O
recommended	VBN	O	O
in	IN	O	O
epileptic	JJ	O	O
patients	NNS	O	O
who	WP	O	O
have	VBP	O	O
been	VBN	O	O
receiving	VBG	O	O
benzodiazepine	NN	G	D
treatment	NN	O	O
for	IN	O	O
a	DT	O	O
prolonged	JJ	O	O
period	NN	O	O
.	.	.	.

although	IN	O	O
romazicon	NN	B	D
exerts	VBZ	O	O
a	DT	O	O
slight	JJ	O	O
intrinsic	JJ	O	O
anticonvulsant	JJ	O	O
effect	NN	O	O
","	","	O	O
its	PRP$	O	O
abrupt	JJ	O	O
suppression	NN	O	O
of	IN	O	O
the	DT	O	O
protective	JJ	O	O
effect	NN	O	O
of	IN	O	O
a	DT	O	O
benzodiazepine	NN	G	O
agonist	NN	O	O
can	MD	O	O
give	VB	O	O
rise	VB	O	O
to	TO	O	O
convulsions	NNS	O	O
in	IN	O	O
epileptic	JJ	O	O
patients	NNS	O	O
.	.	.	.

romazicon	NN	B	D
blocks	VBZ	O	O
the	DT	O	O
central	JJ	O	O
effects	NNS	O	O
of	IN	O	O
benzodiazepines	NNS	G	G
by	IN	O	O
competitive	JJ	O	O
interaction	NN	O	O
at	IN	O	O
the	DT	O	O
receptor	NN	D	O
level	NN	O	O
.	.	.	.

the	DT	O	O
effects	NNS	O	O
of	IN	O	O
nonbenzodiazepine	JJ	O	O
agonists	NNS	O	O
at	IN	O	O
benzodiazepine	NN	G	O
receptors	NNS	O	O
","	","	O	O
such	JJ	O	O
as	IN	O	O
zopiclone	NN	D	D
","	","	O	O
triazolopyridazines	NNS	O	O
and	CC	O	O
others	NNS	O	O
","	","	O	O
are	VBP	O	O
also	RB	O	O
blocked	VBN	O	O
by	IN	O	O
romazicon	NN	B	O
.	.	.	.

the	DT	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
benzodiazepines	NNS	G	G
are	VBP	O	O
unaltered	JJ	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
flumazenil	NN	D	D
and	CC	O	O
vice	NN	O	D
versa	RB	O	O
.	.	.	.

there	EX	O	O
is	VBZ	O	O
no	DT	O	O
pharmacokinetic	JJ	O	O
interaction	NN	O	O
between	IN	O	O
ethanol	NN	D	D
and	CC	O	O
flumazenil	NN	D	O
.	.	.	.

use	NN	O	O
in	IN	O	O
ambulatory	JJ	O	O
patients	NNS	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
romazicon	NN	B	D
may	MD	O	O
wear	VB	O	O
off	RP	O	O
before	IN	O	O
a	DT	O	O
long-acting	JJ	O	O
benzodiazepine	NN	G	O
is	VBZ	O	O
completely	RB	O	O
cleared	VBN	O	O
from	IN	O	O
the	DT	O	O
body	NN	O	O
.	.	.	.

in	IN	O	O
general	JJ	O	O
","	","	O	O
if	IN	O	O
a	DT	O	O
patient	NN	O	O
shows	VBZ	O	O
no	DT	O	O
signs	NNS	O	O
of	IN	O	O
sedation	NN	O	O
within	IN	O	O
2	CD	O	O
hours	NNS	O	O
after	IN	O	O
a	DT	O	O
1-mg	JJ	O	O
dose	NN	O	O
of	IN	O	O
flumazenil	NN	D	O
","	","	O	O
serious	JJ	O	O
resedation	NN	O	O
at	IN	O	O
a	DT	O	O
later	JJ	O	O
time	NN	O	O
is	VBZ	O	O
unlikely	JJ	O	O
.	.	.	.

an	DT	O	O
adequate	JJ	O	O
period	NN	O	O
of	IN	O	O
observation	NN	O	D
must	MD	O	O
be	VB	O	O
provided	VBN	O	O
for	IN	O	O
any	DT	O	O
patient	NN	O	O
in	IN	O	O
whom	WP	O	O
either	CC	O	O
long-acting	JJ	O	O
benzodiazepines	NNS	G	G
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
diazepam	NN	D	D
-rrb-	-RRB-	O	O
or	CC	O	O
large	JJ	O	O
doses	NNS	O	O
of	IN	O	O
short-acting	JJ	O	O
benzodiazepines	NNS	G	G
-lrb-	-LRB-	O	O
such	JJ	O	O
as	IN	O	O
10	CD	O	O
mg	NN	O	O
of	IN	O	O
midazolam	NN	D	D
-rrb-	-RRB-	O	O
have	VBP	O	O
been	VBN	O	O
used	VBN	O	O
.	.	.	.

because	IN	O	O
of	IN	O	O
the	DT	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
adverse	JJ	O	O
reactions	NNS	O	O
in	IN	O	O
patients	NNS	O	O
who	WP	O	O
have	VBP	O	O
been	VBN	O	O
taking	VBG	O	O
benzodiazepines	NNS	G	G
on	IN	O	O
a	DT	O	O
regular	JJ	O	O
basis	NN	O	O
","	","	O	O
it	PRP	O	O
is	VBZ	O	O
particularly	RB	O	O
important	JJ	O	O
that	IN	O	O
physicians	NNS	O	O
query	NN	O	O
patients	NNS	O	O
or	CC	O	O
their	PRP$	O	O
guardians	NNS	O	O
carefully	RB	O	O
about	IN	O	O
benzodiazepine	NN	G	O
","	","	O	O
alcohol	NN	D	D
and	CC	O	O
sedative	NN	G	D
use	VBP	O	O
as	IN	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
history	NN	O	O
prior	RB	O	O
to	TO	O	O
any	DT	O	O
procedure	NN	O	O
in	IN	O	O
which	WDT	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
romazicon	NNP	B	B
is	VBZ	O	O
planned	VBN	O	O
.	.	.	.

no	DT	O	O
information	NN	O	O
available	JJ	O	O
.	.	.	.

do	VB	O	O
not	RB	O	O
take	VB	O	O
this	DT	O	O
medicine	NN	O	O
with	IN	O	O
thioridizine	NN	O	D
","	","	O	O
or	CC	O	O
within	IN	O	O
5	CD	O	O
weeks	NNS	O	O
of	IN	O	O
taking	VBG	O	O
fluoxetine	NN	D	D
.	.	.	.

talk	NN	O	O
to	TO	O	O
your	PRP$	O	O
doctor	NN	O	O
if	IN	O	O
you	PRP	O	O
are	VBP	O	O
taking	VBG	O	O
certain	JJ	O	O
antibiotics	NNS	G	G
such	JJ	O	O
as	IN	O	O
erythromycin	NN	D	D
","	","	O	O
clarithromycin	NN	D	D
or	CC	O	O
azithromycin	NN	D	D
.	.	.	.

this	DT	O	O
medicine	NN	O	O
should	MD	O	O
not	RB	O	O
be	VB	O	O
taken	VBN	O	O
with	IN	O	O
mao	NN	O	O
inhibitors	NNS	O	O
.	.	.	.

caution	NN	O	O
should	MD	O	O
be	VB	O	O
exercised	VBN	O	O
when	WRB	O	O
taking	VBG	O	O
this	DT	O	O
medicine	NN	O	O
certain	JJ	O	O
antibiotics	NNS	G	G
","	","	O	O
such	JJ	O	O
as	IN	O	O
erythromycin	NN	D	D
","	","	O	O
clarithromycin	NN	D	D
","	","	O	O
or	CC	O	O
azithromycin	NN	D	D
.	.	.	.

this	DT	O	O
medicine	NN	O	O
should	MD	O	O
not	RB	O	O
be	VB	O	O
taken	VBN	O	O
with	IN	O	O
mao	NN	O	O
inhibitors	NNS	O	O
.	.	.	.

if	IN	O	O
you	PRP	O	O
think	VBP	O	O
you	PRP	O	O
are	VBP	O	O
taking	VBG	O	O
an	DT	O	O
mao	NNP	O	O
inhibitor	NN	O	O
talk	NN	O	O
to	TO	O	O
your	PRP$	O	O
doctor	NN	O	O
or	CC	O	O
pharmacist	NN	O	O
.	.	.	.

do	VB	O	O
not	RB	O	O
take	VB	O	O
this	DT	O	O
medicine	NN	O	O
with	IN	O	O
st.	NNP	O	O
johns	NNP	O	O
wort	NNP	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
additive	JJ	O	O
effects	NNS	O	O
of	IN	O	O
sertonin	NN	O	D
.	.	.	.

this	DT	O	O
medication	NN	O	O
should	MD	O	O
not	RB	O	O
be	VB	O	O
taken	VBN	O	O
with	IN	O	O
mao	NN	O	O
inhibitors	NNS	O	O
.	.	.	.

your	PRP$	O	O
doctor	NN	O	O
or	CC	O	O
pharmacist	NN	O	O
can	MD	O	O
give	VB	O	O
you	PRP	O	O
more	JJR	O	O
information	NN	O	O
on	IN	O	O
mao	NN	O	O
inhibitors	NNS	O	O
.	.	.	.

wait	VB	O	O
5	CD	O	O
weeks	NNS	O	O
after	IN	O	O
stopping	VBG	O	O
escitalopram	NN	D	O
before	IN	O	O
starting	VBG	O	O
a	DT	O	O
non-selective	JJ	O	O
mao	NNP	O	O
inhibitor	NN	O	O
.	.	.	.

wait	VB	O	O
2	CD	O	O
weeks	NNS	O	O
after	IN	O	O
stopping	VBG	O	O
an	DT	O	O
mao	NNP	O	O
inhibitor	NN	O	O
before	IN	O	O
starting	VBG	O	O
escitalopram	NN	D	D

